<SEC-DOCUMENT>0001140361-23-023920.txt : 20230510
<SEC-HEADER>0001140361-23-023920.hdr.sgml : 20230510
<ACCEPTANCE-DATETIME>20230510170046
ACCESSION NUMBER:		0001140361-23-023920
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230510
DATE AS OF CHANGE:		20230510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		23907484

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>brhc20052583_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:adma="http://admabiologics.com/20230331" xmlns="http://www.w3.org/1999/xhtml">
<head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_2e64117d18464d49aecdd898b33655bd" contextRef="c20230101to20230331" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_3048083e6df1471d98b6ea583393e433" contextRef="c20230101to20230331" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_201f815237e24e2bb0cbb6492bd63806" contextRef="c20230101to20230331">2023</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_cb89b750ba74428abca9019a30e62ec9" contextRef="c20230101to20230331">Q1</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_d7c5e0f25d8342ca84c2245f7a32857c" contextRef="c20230101to20230331">0001368514</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_4342de1675c9405cb8dc40be8462b988" contextRef="c20230101to20230331_RangeAxis_MinimumMember">P3Y</ix:nonNumeric><ix:nonFraction name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="Fact_5ecb5c13cda94b628b0011be8e172a1f" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U008" decimals="INF">5</ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_9109aae765d343688bd225ff5a0745fd" contextRef="c20230331" unitRef="U002" xsi:nil="true"></ix:nonFraction><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_cd2a31ec8a274e85bda554fc0b8b2bc8" contextRef="c20221231" unitRef="U002" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="adma-20230331.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20230101to20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_TypeOfArrangementAxis_BiotestLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20261001to20261231_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_StatementScenarioAxis_ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-10-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220621_PlanNameAxis_Two022CompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:Two022CompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20160101to20160131_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:InternationalCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:InternationalCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ProductOrServiceAxis_BIVIGAMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20121219to20121219_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-19</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20121219to20121219_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-19</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ProductOrServiceAxis_BIVIGAMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220331_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>adma:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>adma:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>adma:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>adma:Term</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>adma:Center</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />
      <div>
        <div style="text-align: center; font-weight: bold;"><span style="font-size: 14pt;">UNITED STATES<br />
          </span></div>

        <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

        <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_a0d9e94c759448c09df2bc1351396d8c" contextRef="c20230101to20230331">10-Q</ix:nonNumeric></div>

        <div>(Mark One)</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_b53cb21a99644ac4b9204b3b460c13ad" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric><br />
              </td>

    <td style="width: auto; vertical-align: top;">
                <div>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
<div>
        &#160;&#160;&#160; For the quarterly period ended <span style="text-decoration: underline;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_ce58c97ebbcb4fcea326afe3780ddae3" contextRef="c20230101to20230331" format="ixt:date-monthname-day-year-en">March 31, 2023</ix:nonNumeric></span></div>

        <div style="text-align: center;">OR</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_d85353686fbe48bf8e7878419b56f8ae" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
              </td>

    <td style="width: auto; vertical-align: top;">
                <div>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
<div><span style="width: 9pt; font-size: 1px; display: inline-block;" class="HorizontalTab"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</span>
        For the transition period from ________ to ________
        </div>
<div style="text-align: center;">Commission file number <span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_859779f71d204f3798e344b5e49be48b" contextRef="c20230101to20230331">001-36728</ix:nonNumeric></span></div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_82b3a17aa92149bb84de1feff5b8c57c" contextRef="c20230101to20230331">ADMA BIOLOGICS, INC.</ix:nonNumeric><br />
          </span></div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Exact Name of Registrant as Specified in Its Charter)</div>

        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_b28ddabe7c884ea6b9a2f113c7e08a6b" contextRef="c20230101to20230331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
                  </span></div>
              </td>

    <td style="width: 2%; vertical-align: top;">
                <div style="margin-left: 9pt">&#160;</div>
              </td>

    <td style="width: 49%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_4a217cad01224ff2aa08e144ce21933b" contextRef="c20230101to20230331">56-2590442</ix:nonNumeric><br />
                  </span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(State or Other Jurisdiction of Incorporation or Organization)</div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_45757d4814314793b088f54205f44d05" contextRef="c20230101to20230331">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_7e236f72d44a4e27853e1438eaa465bd" contextRef="c20230101to20230331">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_d9cb8bb1b42f4e20a9b3dbab349bed9f" contextRef="c20230101to20230331" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></span></div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_e7ab623e44b84a8088674e45263ccdd8" contextRef="c20230101to20230331">07446</ix:nonNumeric><br />
                  </span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
              </td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_8a402689f3a74b43935688aff4a2ae50" contextRef="c20230101to20230331">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_e1300f532a5446569ff2d35af10bf003" contextRef="c20230101to20230331">478-5552</ix:nonNumeric></span></div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
              </td>

    <td style="width: 30%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
              </td>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
              </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_e4972f0dbab549bb8e505344fb693cb8" contextRef="c20230101to20230331">Common Stock</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 30%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_ac6430b6bc59416e9fda32973cc3d616" contextRef="c20230101to20230331">ADMA</ix:nonNumeric><br />
                </div>
              </td>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_931b5bd883384f379da9cc5695705e29" contextRef="c20230101to20230331" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric><br />
                </div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
          such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_809cb7bbffaa41d7b65263f51cbc291f" contextRef="c20230101to20230331">Yes</ix:nonNumeric> &#9746;&#160; &#160; No &#9744;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter)
          during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_e8acb1809c6c46b1bacf6022a51d02bb" contextRef="c20230101to20230331">Yes</ix:nonNumeric> &#9746;&#160; &#160; No &#9744;</div>

        <div style="text-align: justify;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
          definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Large accelerated filer&#160; &#160; &#9744;</div>
              </td>

    <td style="width: 35%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Accelerated filer&#160; &#160; &#9744;</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_6a96681819934be289daf11217252615" contextRef="c20230101to20230331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric>&#160; &#160; </span>&#9746;</div>
              </td>

    <td style="width: 35%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Smaller reporting company&#160; &#160; <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_6f5313fab06c4d629f1a90897bbc09ae" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;" colspan="1">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Emerging growth company&#160; &#160; </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_1895b40d8e2546a1af8881b6b76362f2" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
          provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#160; Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_3b5c972b64d64c658153a4a1362a7945" contextRef="c20230101to20230331" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; &#160; No &#9746;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt;">As of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">May 5, 2023</span></span>, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_4002b2b468c14c6d9d0e621bba575953" contextRef="c20230505" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">222,272,962</ix:nonFraction> shares of the issuer&#8217;s common stock
          outstanding.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br />
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after:always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

        </div>

        <!--PROfilePageNumberReset%LCR%1%%%--> </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

    <div>&#160;</div>

    <div style="text-align: center; font-weight: bold;"><a id="INDEX"><!--Anchor--></a>INDEX</div>

    <div><br /></div>

    <table cellspacing="0" cellpadding="0" border="0" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse;">


  <tr>

    <td style="vertical-align: top;" colspan="3">
            <div>PART I FINANCIAL INFORMATION</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" rowspan="1" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;">
            <div style="text-align: center;">Item 1.</div>
          </td>

    <td style="width: 82%; vertical-align: top;">
            <div>Financial Statements</div>
          </td>

    <td style="width: 6%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#BALANCESHEETS">Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">1</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#STATEMENTSOFOPERATIONS">Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2023 and 2022</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">2</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#STOCKHOLDERSEQUITY">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) for the Three Months Ended March 31, 2023 and 2022</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">3</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#CASHFLOWS">Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2023 and 2022</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">4</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#NOTES">Notes to Unaudited Condensed Consolidated Financial Statements</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">5</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; text-align: center; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 2.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#ManagementsDiscussionandA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">21</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 3.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">33</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 4.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#ControlsandProcedures.">Controls and Procedures.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">33</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">
            <div><a href="#PARTII">PART II OTHER INFORMATION</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">34</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" rowspan="1" colspan="2">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 1.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#LegalProceedings.">Legal Proceedings.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">34</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 1A.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#RiskFactors">Risk Factors.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">34</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 2.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#UnregisteredSalesofEquity">Unregistered Sales of Equity Securities and Use of Proceeds.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">64</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 3.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#DefaultsUponSeniorSecurit">Defaults Upon Senior Securities.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">64</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 4.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#MineSafetyDisclosures.">Mine Safety Disclosures.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">64</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 5.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#OtherInformation.">Other Information.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">64</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: center;">Item 6.</div>
          </td>

    <td style="width: 82%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#Exhibits">Exhibits.</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">64</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 82%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 6%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="2">
            <div><a href="#SIGNATURES">SIGNATURES</a></div>
          </td>

    <td style="width: 6%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;">65</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="color: rgb(0, 0, 0); text-indent: 36pt;">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#8482;</sup>,&#8221;
      &#8220;Nabi-HB<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>&#8221; and &#8220;BIVIGAM<sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>,&#8221; which are protected under applicable intellectual property
      laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the <sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#174;</sup>, <sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">&#8482;</sup> or <sup style="line-height: 1; font-size: smaller; vertical-align: text-top;">SM</sup> symbols, but such references are not
      intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other
      parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div>

    <div style="color: rgb(0, 0, 0); text-indent: 36pt;"> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">i</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
            </a></div>

        </div>

      </div>

    </div>

    <div style="text-align: center; font-weight: bold;">Special Note Regarding Forward-Looking Statements</div>

    <div><br />
    </div>

    <div style="color: rgb(0, 0, 0); text-indent: 36pt;">Some of the information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
      Securities and Exchange Act of 1934, as amended. These statements include, among others, statements about:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our ability to manufacture BIVIGAM and ASCENIV on a commercial scale and further commercialize these products as a result of their approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in 2019;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the labeling or nature of any such approvals;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our dependence upon our third-party customers and vendors and their compliance with applicable regulatory requirements;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our belief that we have addressed the delays experienced with final drug product Current Good Manufacturing Practices (&#8220;cGMP&#8221;) release testing by our third-party vendors by adding additional release testing laboratories to our FDA-approved
              consortium listed in our drug approval documents;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our plans to increase our supplies of source plasma, which include plasma collection center expansion, our ability to obtain and maintain regulatory compliance and receive FDA approvals of new plasma collection centers and reliance on
              third-party supply agreements as well as any extensions to such agreements;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>the potential indications for our products and product candidates;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>potential investigational new product applications;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>the acceptability of any of our products, including BIVIGAM, ASCENIV and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or payers;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>concurrence by the FDA with our conclusions concerning our products and product candidates;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>the comparability of results of our hyperimmune and immune globulin (&#8220;IG&#8221;) products to other comparably run hyperimmune and immune globulin clinical trials;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>t<span style="font-family: 'Times New Roman';">he potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with <span style="font-size: 10pt; color: rgb(0, 0, 0);">Primary Humoral Immunodeficiency
                  (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity,</span> or other immune deficiencies or any other condition for which the products may be prescribed or evaluated</span>;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">ii</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
            </a></div>

        </div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful revenues from this product;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV or other future pipeline product candidates;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our plans related to the expansion and efficiencies of our manufacturing capacity, yield improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and other collaborative agreements and the success of such
              endeavors;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>our estimates regarding revenues, expenses, capital requirements, timing to profitability and positive cash flows and the need for and availability of additional financing;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>possible or likely reimbursement levels for our currently marketed products;</div>
          </td>

  </tr>


</table>
    <div style="text-indent: -18pt; margin-left: 36pt;"><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>effects of the coronavirus COVID-19 pandemic and other potential pandemics on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted prior
              to the macroeconomic effects of the COVID-19 pandemic and other potential pandemics; and</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>future domestic and global economic conditions including, but not limited to, supply chain constraints, inflationary pressures or performance.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="color: rgb(0, 0, 0); text-indent: 36pt;">These statements may be found under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections of this Quarterly Report on Form 10-Q.
      Forward-looking statements&#160; may be identified by the use of terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or &#8220;should&#8221; or the negative thereof or other
      variations thereof or comparable terminology. Our actual results could differ materially from those contained in the forward-looking statements due to the factors described in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and
      Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022 and in this Quarterly Report on Form 10-Q for the quarter ended March 31, 2023. Any forward-looking statement
      included or incorporated by reference in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions related to our operations, industry and future
      growth. These forward-looking statements speak only as of the dates such statements are made and we undertake no obligation to publicly update any forward-looking statements or to publicly announce revisions to any of the forward-looking statements,
      unless otherwise required by the federal securities laws.</div>

    <div style="color: rgb(0, 0, 0); text-indent: 36pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">iii</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
            </a></div>

        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%1%%%-->
  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor-->PART I</div>

        <div style="text-align: center; font-weight: bold;">FINANCIAL INFORMATION</div>

        <div> <br />
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top;"><span style="font-weight: bold;">Item 1<!--Anchor-->.</span></td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;"><!--Anchor-->Financial Statements.</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <!--Anchor-->
        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED
          <!--Anchor--><!--Anchor--><a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS<!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">&#160;March 31,</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">&#160;December 31,</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023 </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2022 </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">ASSETS</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center;">(Unaudited)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2433aaa0f77c4c2088cd8707941d7e68" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,204,163</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_9cbd99f142bc49918de54d35b82c9d7f" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">86,521,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts receivable, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_a65a3741507a430fb1245c9c1f8d85e2" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">26,518,495</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_86347a9c044b48f19dc559a37403ea87" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">15,505,048</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Inventories</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_9142fbb79b634d9da8f751e35db17e72" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">163,984,873</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_c733c840f9854e208bc854b08f2bbeeb" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">163,280,047</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,378,681</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_9177520ab36c49ea97cd19a1c968df92" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,095,146</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">264,086,212</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f45b3271b441455cb2105680565b129e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">270,401,783</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Property and equipment, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,370,783</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_c7aaf9819ea84e03bf8722ce95af85af" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">58,261,481</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Intangible assets, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_f17de370315f4091b0f89c2e84d973d1" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">834,577</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_0514a0e23bdc4d0ea5e717bdf3754926" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,013,415</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Goodwill</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_769d5f0c97eb4064bdb43ac410530a21" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,529,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,529,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Right to use assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_bbc32b4cc98043e9a94ba4f7220fb722" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,247,700</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_6dd902973f4846a4bb1c1594e27f8f57" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,485,447</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,718,761</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_a50743018b6247889bc69ddeeb66ade6" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,770,246</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL ASSETS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_c2f9187a8f1347b180e4de1c4e0650a0" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">340,787,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">348,461,881</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_7dde0dfcef624d98a7c818296df97379" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,956,486</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_79f8959f51c440058a2b2ae73dcbf97b" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,229,390</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued expenses and other current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_dd0f579f43084bb2aa500ce0cc36df30" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,672,464</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_0e9ccf6016784da8a8b04f3a1af923c3" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,989,349</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of deferred revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_717f5016a22d44e788a7623ed89d02dc" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,834</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_f9a0da175433427abcd2517ac58e7ac3" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,834</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of lease obligations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_e15d10dae4084e71835cb788dda3105c" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">956,045</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">905,369</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_e040cd8f2ecf4ad193d82978ff855ac5" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,727,829</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_df082a6c52ae4c43b80203fb015af4c8" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">39,266,942</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Senior notes payable, net of discount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_5dbbafa983e447648edea5d160779986" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">144,300,930</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_a253f9727f7042bdb255854fc1f4cc07" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,833,063</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred revenue, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c6a34d215f70489cb00ad0517bb21b35" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,797,323</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c686e6297dea4e4d93efce7816cca250" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,833,031</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;">End of term fee<br />
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_4d410e2a246640308a098f9cd7fdd048" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_a0a3d9326c654effa015cbfada21a58e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease obligations, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_67604891dc8248dba7f483ed9d867778" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,468,109</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,704,176</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other non-current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_1425725201a64a6b81c6061265b988a6" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">338,731</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_019efd73590a4e5fb4700d5a202f9ba9" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">350,454</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_4b09c740ef954edab33c4b39d9ffc56e" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">195,132,922</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_95d12ad8d1e64b189d1268bbd917203d" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">196,487,666</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">COMMITMENTS AND CONTINGENCIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;"><span style="-sec-ix-hidden:Fact_9109aae765d343688bd225ff5a0745fd"> </span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;"><span style="-sec-ix-hidden:Fact_cd2a31ec8a274e85bda554fc0b8b2bc8"> </span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Preferred Stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_4b322bc4ff9047ada11d276fba00f032" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546" contextRef="c20230331" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_c51731a3209d45bc9c438cd58e2594ec" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6460774f302542369b031f1439c51371" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_7357d7c8b24b4172b404e8fb73377a70" contextRef="c20221231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_6a23abbcd48d427490a73e11ae49d3bd" contextRef="c20230331" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_985ef26e70de4d438886de20409f6e62" contextRef="c20221231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_65817be99e324befbc84fa32051df194" contextRef="c20230331" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span>
                  shares issued and outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_32421b2e655449bc95407ba53997b2dd" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_1b0624f0760d4befb7bf3f49d8cdc325" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Common Stock - voting, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_772895fcdb8948edaa197e1a3cbda00b" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_0b9116e5ffd647cd91be96bc28d8ec95" contextRef="c20230331" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_a6da05b44012449790cf1f8fefcf0523" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_e17fd8ff3db44d0db345255c9de5d29c" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_be2280b446274185893dcebcbf2be1f3" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_a47a04445e0a40c0ac5864df134f7b0a" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">222,262,588</ix:nonFraction></ix:nonFraction></span>
                  and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6acdb1cf62784deea606e18a567d8916" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_4889dba395554041a519d29516e511d1" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,816,930</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_58134c88742643e59d1016963f21fc5a" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,226</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a9deedc4c75a4eca9914e129648a18c2" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,182</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_c293fe47874d4c80ae1b7165eead05cc" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">630,437,880</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_393b6c347b684f7c93234fece20c7a2e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">629,968,704</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accumulated deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46" contextRef="c20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">484,805,486</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a" contextRef="c20221231" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">478,016,671</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1a6712ef74b145788070fef039c2ef2d" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">145,654,620</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3acf9855c6604de4b9fef2d7902b6e9c" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,974,215</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_b55ab3549e7148a98c2fb93694e5d4ad" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">340,787,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_cceb9a747e2849a3a60625fde7c5ccf2" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">348,461,881</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div style="text-align: justify;"><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br />
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED <a id="STATEMENTSOFOPERATIONS"><!--Anchor--></a>STATEMENTS OF
            <!--Anchor-->OPERATIONS</div>

          <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

          <div style="text-align: center; font-weight: bold;"> <br />
          </div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-weight: bold;">Three Months Ended March 31,</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">2023<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">2022<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">REVENUES</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e1a7bf1ebf4940a9ac52031b4c09a220" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,913,534</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6b5d3f97463c401a87c32670456c3435" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,103,093</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" rowspan="1">Cost of product revenue</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_54ecfb1fca31461f8721b04faf5e7414" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,400,544</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_af6c05a9f3024b4391ad85666edd8a66" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,441,046</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                  <div style="margin-left: 9pt;">
                    <div style="margin-left: 9pt; font-weight: bold;">Gross profit<br />
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_dbecef88bfea4621a31c61eaf0c420bb" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">16,512,990</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_08e2ddd1f7c44aa7a6dd24b4768fdbd1" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,662,047</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OPERATING EXPENSES:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_615dea589ffb4335b67030347f30a99e" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">855,351</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_77fdf3e87b344c129c955fd6ab5a8f35" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">624,111</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Plasma center operating expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_bab9b38c1d2f492b8af3f48d7277931b" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,780,463</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_ce7e63f3d9944cad8002dcc0a7838249" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,974,589</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Amortization of intangible assets</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_f38461586708484abff1ba3bcbf27632" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">178,838</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_59646d8e9d9f4993a493e59764cb973a" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">178,838</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Selling, general and administrative</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_8309a23ecae0401582dad9aa52200854" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,511,656</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_6d1aebc0edf747a8a862967456b523bd" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,699,575</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Total operating expenses</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_825cd8cce1eb49ef98f0fc3183a63e80" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,326,308</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_40366600d6b1473f888d814c6b9af5b3" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,477,113</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LOSS FROM OPERATIONS</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_a9d19c3dc40a448d962464e0e9595d92" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">813,318</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_f9a09c65f0fa4802b39a57cea8cc63bb" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">14,815,066</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OTHER INCOME (EXPENSE):</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest income</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_974134faa6a64a578613db71d029091a" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">166,971</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_bd144782dbb743568eaefb57b6253e69" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,068</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_69a47bd0a77143c1b4d83d79922787a9" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,115,484</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_8cfce7d67ef447bda059c26df59959d2" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,389,038</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                  <div style="margin-left: 9pt;">Loss on extinguishment of debt</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_16d2a88ce7ef411382fc61ae9a260ab4" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_5ef7ff9cfb3643079fd29eedf459a70a" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,669,941</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Other expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_03381f8457df47f783cd742e63a14267" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">26,984</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_e6163902b75c42e6b186529957d79cb3" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">166,880</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_18e76cd651af46308b002f0fda03523e" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,975,497</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_fcb8c0059fd642f78f92174435ea2ef2" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">10,192,791</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">NET LOSS</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b61a3cd5083041568d8f9f2b65d6a19b" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,788,815</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_032522af1eea4b4bb8be8ed607d36873" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,007,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">BASIC AND DILUTED LOSS PER COMMON SHARE</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_6f12964ec58f4ee4b944dbcaf88ca639" contextRef="c20230101to20230331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2490adcca0ce4b4b9fb500d82d60a0d6" contextRef="c20230101to20230331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.03</ix:nonFraction></ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_8346916284f042e79bb7fb835ced2ee9" contextRef="c20220101to20220331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_7fe7614164aa439a80e6048fb7a3df80" contextRef="c20220101to20220331" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.13</ix:nonFraction></ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-weight: bold;">Basic and Diluted</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_72538301662d490499d94942ed29f5de" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_189471ab7a1343b7879585c1a633996f" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,921,750</ix:nonFraction></ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_8abba748112d400f858988b59d813858" contextRef="c20220101to20220331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_059b576bade5410dbe0737e32c1c183e" contextRef="c20220101to20220331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">195,871,932</ix:nonFraction></ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div><br />
          </div>

          <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

          <div style="text-align: center;"> <br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div>
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div>
        <div>
          <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</div>

          <div style="text-align: center; font-weight: bold;"><a id="STOCKHOLDERSEQUITY"><!--Anchor--></a>STOCKHOLDERS&#8217;
            <!--Anchor-->EQUITY (Unaudited) </div>

          <div><br />
          </div>

          <div style="text-align: center; font-weight: bold;">For the Three Months Ended March 31, 2023</div>

          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="6">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2"> Additional</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2"> Total</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-weight: bold;"> Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Paid-in</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Accumulated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Amount</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Capital</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Deficit</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Equity</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at December 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a62f749fd1664bca8c6adbbfa5588954" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,816,930</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_ee83ffd3663847a59cd370d5bda40ef6" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,182</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0a6b44af90004426a8f294edf299950d" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">629,968,704</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9a6c2292e6684b2490ad5c92b8e1aef4" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">478,016,671</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c0a1b6000dfb4ca5bbee90933e9c0425" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,974,215</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6587a89ac47f4696832b56606c3095c1" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_c332687a9e504b96984768e306bb356d" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,110,166</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_c4c2621be76b4dbd863076582d033d7b" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_10a99c1fa49446c79d5365a2444fabab" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,110,166</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Vesting of Restricted Stock Units, net of shares withheld for taxes<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" id="Fact_bec0e3ba2b49431f8e6f5fd0e709d6ad" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">443,215</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_b5f7f04cc7074cccae7a1e3e924e6c06" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">44</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_d8aea68e63a345edb705675a05049cac" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">640,990</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_af6e11e186e24992a4141639daeb9f99" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_31287449ee1e43079a950abf3fca2614" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">640,946</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercise of stock options</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_6677a165ddff41bb8a3a3cb9fc262fa3" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,443</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_91b1dfa7002d4ebebbd03a312fe6889b" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_3920e3f9effa48f4b6e9389e4dfc4d1a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_35b9411fde6b46868f022f98e42d349f" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_262e390c1a644219800014c0ad1a957d" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d72d92fa55c2487db85fd407ede3e976" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6b0b40f5e72a454d89879ad7eac300b7" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3569a30027e84def80f3e99b71692ba5" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,788,815</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b5175c9db7354a63b37c9eedf7cb6414" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,788,815</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Balance at March 31, <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a0aed09d0df84d75a1f0df353f6c7ffb" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">222,262,588</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_525af4fdcf7c44b6b537ca5ffcd9f2e0" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,226</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aadcb5bf1094428686dee5e620a2ed17" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">630,437,880</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d4893889d68f4a5281c440b9104bf27e" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">484,805,486</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e954c6a864264c98ac4a960c9ca3abe0" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">145,654,620</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div><br />
          </div>

          <div style="text-align: center; font-weight: bold;">For the Three Months Ended March 31, 2022</div>

          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="6">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2"> Additional</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2"> Total</td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                  <div style="text-align: center; font-weight: bold;"> Common Stock</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Paid-in</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Accumulated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Amount</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Capital</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"> Deficit</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;">Equity</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Balance at December 31, <span style="text-indent: 0pt;">2021</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_ec44f0d1ba5a43078f4539332440aca1" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">195,813,817</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_eea7468bf242442b9080e37d9ea4e64c" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,581</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_5d6ff8b442ac477d9237640c161cbedb" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">553,265,706</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_00d3de036ac74e2ba85b466425d52038" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">412,112,721</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4149bd8a07914db3b171faaa195732af" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">141,172,566</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Warrants issued in connection with notes payable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_397fa125fadf4dc795659a5ace38a204" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_9c93139521444a7eabaaea4036fe96a4" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,569,604</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_11a92a4ebdb64053ba221055cd91d4cf" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_c741d2e617cf45a88160b06d80fb55df" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,569,604</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Stock-based compensation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_2ad8790f46e7423394ff4abbcd958a97" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_1ba6f3ce039e458894c0d5ec7ae6dad0" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,641,388</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_882704c07b6849348d45a123adc9dab7" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_ef3d75afc3a343ef9291cc6b52d85bae" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,641,388</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;" rowspan="1">
                  <div style="text-indent: -9pt; margin-left: 9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" id="Fact_08b9170314564933aa0a2e4acbddfb91" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">533,712</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_479f03bcf3914d87bf32fd4c1c121d71" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">54</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_64b69570bf5744a7a2b3db3977639922" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">442,690</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_eb32e8d428c24cba8f95e2525e0b593f" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="Fact_7a44f5d4a8ed400da35805f4e985c69f" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">442,636</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Net loss</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7025cf294da1491698a1ea040c60f93e" contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_05a1ad779e704642a286f47d38dc2e28" contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_00eae54f7e1f46919a6253785e3f4455" contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,007,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b106ffb9d0b04e8bb7813315001ccb6d" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,007,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px;">
                  <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Balance at March 31, <span style="text-indent: 0pt;">2022</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_fad7ceda95614b4da079d0981f4dadc6" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">196,347,529</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_42f5e4ede4e54c8dbbd4b4ed6a333051" contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,635</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2a052e1527054a168c68425e82de9544" contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">564,034,008</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_36e7d75bd73a4ed0a0dba9310659d7e6" contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">437,120,578</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div>$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4e615f2a583f409a8e87fd68ae41a730" contextRef="c20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">126,933,065</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          <div><br />
          </div>

          <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

          <div style="text-align: center;"> <br />
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

            <div style="page-break-after:always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div>
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
                  </a></div>

              </div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF<!--Anchor--><a id="CASHFLOWS"><!--Anchor--></a>
          <!--Anchor--><!--Anchor-->CASH FLOWS<!--Anchor--><!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

        <div style="text-align: center; font-weight: bold;"> <br />
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                <div style="text-align: center; font-weight: bold;">Three Months Ended March 31,</div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2023<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <div style="text-align: center; font-weight: bold;">2022<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Net loss</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_606e384999c44b89a2f45b44d9be2517" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,788,815</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_554cda1cba654604bbccaaebde7db98c" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,007,857</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Adjustments to reconcile net loss to net cash used in operating activities: </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Depreciation and amortization</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_83080cccdd6c41ebbae85287f51e38d5" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,032,965</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_ca7370b0b19e46f99b974659c5ad04e6" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,590,217</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Loss on disposal of fixed assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_515262ae94b843ba8af2bd8952c28fa5" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">18,096</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_68fa0d6ea69d4931b29a903cca06f2d5" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">2,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-indent: 18pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">Interest paid in kind</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_a7a703ba8e0641b5a8eb820d496f2cb7" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">979,978</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_d8e180512f2644cf831d6f64ad829e56" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8d5c2bb295224d419c3420694af40e45" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,110,166</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_670daf81ec0e4ae59184cfe715be7bcc" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,641,388</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of debt discount</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_fd92d9f44d34479786a5d68a3983d2af" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">487,889</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_f13bdc7f5a914f4084b4953436f3654d" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">584,842</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" rowspan="1">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Loss on extinguishment of debt</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_8b1568f9e4594e87bbace8ab3717b33c" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_92904d881f344c8f93453ce44c45aef8" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,669,941</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of license revenue</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_3e57e53903a545c1ac13b4b75ab07fce" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">35,708</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_89a9d124aac042ee93e9b2e64f0875e0" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">35,708</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Changes in operating assets and liabilities:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts receivable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_1dd109c39b304e7c91c47847eb964c36" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,013,446</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_9b8f4c75f5734cdc85490f66d98fe227" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">2,947,233</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Inventories</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_264d1acc9c834f019a733c35d2177df8" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">704,826</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_a9b6140c5d234afdb8706bbbf1d75f35" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,422,219</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_f5acef387bce4b40a96171dd2a65c78a" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">716,465</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_c77b61709a1d49c7b5267b2f15dde1bc" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,180,056</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_b1d73d329b954767897f8f303d9ffebf" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">289,232</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,397,672</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_3f886d78219940d3ae9eb541eb90c632" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">272,904</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_5bbf598ffc494351b32f0efe70ce5fee" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,685,724</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_40dbe8521d1446c6936e91f772fa3bf3" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,353,815</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,775,526</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Other current and non-current liabilities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_f25bbf8593734543b01b1dfd3ea1038e" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">187,551</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">111,064</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in operating activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6cfe9408e8844ab9b40d95553100bcca" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">14,722,274</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_a0dea6324de24915a75e5abd788855e6" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">26,013,413</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Purchase of property and equipment</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_b1f5fe8caf7047798637405d4650fbb9" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,944,596</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_4e1c44f0ac144022bf9d800076d23a3a" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,842,085</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in investing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_8b1af39671aa45ceb09f7ef327d9e32a" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">1,944,596</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_d8843976a13c448cafd94324f9287089" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">2,842,085</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Principal payments on notes payable</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_3e5c9553ac2b423384ae3a9c73edfe26" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_a2ae51b9989a401c98d739f9f793d1be" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="margin-left: 18pt;">Payment of debt refinancing fees<br />
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="adma:PaymentOfDebtRefinancingFees" id="Fact_e1a434839c5c4e438182727f622e3fb7" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:PaymentOfDebtRefinancingFees" id="Fact_946f591d558d46f9bea90b6cd5f7f278" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,000,000</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                <div style="margin-left: 18pt;">Proceeds from issuance of note payable</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_927b588459b84c0d9a76a6fbdf5630cf" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_4ab5374da80148589efe2ba7ac99535c" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,750,000</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Taxes paid on vested Restricted Stock Units</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">640,946</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_f2f6799b325341b3a9d32f52e87bc068" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">91,367</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Payments on finance lease obligations</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_32e891ca8de644d3b4189b5bb7913221" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,563</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,941</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" rowspan="1">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Payment of deferred financing fees</div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" id="Fact_748f6b7e930442dc979dc2c05008d02f" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" id="Fact_b63adce01c9d440bb05114c85e487919" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,378,366</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash (used in) provided by financing activities</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_69272294317744fcbfbcc384392b85ee" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">650,509</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">47,271,326</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net (decrease) increase in cash and cash equivalents</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_45c3b87b315a4c698252bde2791e3307" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">17,317,379</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>)</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_79454785ed50456da17cfe72739aa946" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,415,828</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - beginning of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b2be9221ca3942a0b45e4f329506aeb1" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">86,521,542</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2bd75314b7494603aa085ca7d4edf16b" contextRef="c20211231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">51,089,118</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - end of period</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_ab8dcca17d114290a2011513bb272e45" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,204,163</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div>$</div>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e" contextRef="c20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">69,504,946</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
        <div><br />
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br />
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

          <div class="BRPFPageBreak" style="page-break-after:always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a><a href="#INDEX"><br />
                </a></div>

            </div>

          </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><a id="NOTES"><!--Anchor--></a>NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br />
          </div>

          <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_014177761dc640798f373cc359e0df61" contextRef="c20230101to20230331" escape="true" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d1">
<div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                  </td>

  </tr>


</table>
          </div>
</ix:nonNumeric>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d1" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d2" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d3">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d3" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d4">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical
            company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted
            patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d4" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d5" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d6">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d6" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d7" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d8">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters
              Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#8220;BPC&#8221; and,
              together with Biotest AG, &#8220;Biotest&#8221;) on June 6, 2017. The acquisition included certain assets of BTBU, including the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma
              fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;). BTBU had previously been the Company&#8217;s third-party contract manufacturer. ADMA BioCenters is the Company&#8217;s source plasma
              collection business with</span><span style="font-size: 10pt; font-family: 'Times New Roman';"> <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="Fact_031fdfc61f444092b07221fedfa54d04" contextRef="c20230101to20230331" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> plasma collection facilities
              located throughout the U.S., <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_5b60fa18617a487692f8cc703f2d5d9a" contextRef="c20230101to20230331" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction> <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of which hold an approved license with the FDA.</span></span> </div>
</ix:continuation>
          <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d8" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d9">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> <span style="font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d9" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d10">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d10" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d11">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has <ix:nonFraction name="adma:NumberOfFDAApprovedProduct" id="Fact_53446129f2e5474f80608ef59aff3c5e" contextRef="c20230101to20230331" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the
              treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in
              August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October
              2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its
              commercially available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin
              production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at
              risk for certain infectious diseases.</div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d11" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d12">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br />
              </span> </div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d12" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d13">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d13" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d14">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of March 31, 2023, the Company had working capital of $<ix:nonFraction name="adma:WorkingCapital" id="Fact_4c06658812404b328b80d471b74113fc" contextRef="c20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">227.4</ix:nonFraction> million, including $<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" id="Fact_e65765eb0cfc4a08a4f5865223f909f6" contextRef="c20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">69.2</ix:nonFraction> </span>million of cash and cash
              equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s management currently
              believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, through the end of the second quarter of 2024, by which time the Company believes it
              will have begun generating positive cash flow from operations. These estimates may change based upon several factors, including the success of the Company&#8217;s commercial efforts with respect to the sale of its products, whether or not the
              assumptions underlying the Company&#8217;s projected revenues and expenses are correct and the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers. There can be no assurance that the Company&#8217;s approved products will
              be commercially viable, or that plant capacity expansion or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the
              biologics, biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
              personnel, inflationary pressures, supply chain constraints, protection of proprietary technology and compliance with FDA and other governmental regulations and approval requirements.</div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d14" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d15">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br />
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d15" continuedAt="Text_1317ea7d7374482f96dcde90dcd05e8d16">
<div><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_1317ea7d7374482f96dcde90dcd05e8d16">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;">T<span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">he
                Company continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The exploration of value-creating opportunities remains a top corporate priority for ADMA.</span><br />
            </div>
</ix:continuation>
<div>
             <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="font-variant: normal; text-transform: none;"> </span></span></div>

            <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>

            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                  </a></div>

                <a href="#INDEX"></a>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>

            <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> <span style="font-variant: normal; text-transform: none;"> </span> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_de030162bc8b448998134934872398f9" contextRef="c20230101to20230331" escape="true" continuedAt="Text_ab69e61320f34336a241913cd033f5cf1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf1" continuedAt="Text_ab69e61320f34336a241913cd033f5cf2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf2" continuedAt="Text_ab69e61320f34336a241913cd033f5cf3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf3" continuedAt="Text_ab69e61320f34336a241913cd033f5cf4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf4" continuedAt="Text_ab69e61320f34336a241913cd033f5cf5"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_1b842d491338428ea527247b3dcb683e" contextRef="c20230101to20230331" escape="true" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a71">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf5" continuedAt="Text_ab69e61320f34336a241913cd033f5cf6"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a71" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a72">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf6" continuedAt="Text_ab69e61320f34336a241913cd033f5cf7"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a72" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a73">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> </span><br />
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf7" continuedAt="Text_ab69e61320f34336a241913cd033f5cf8"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a73" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a74">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf8" continuedAt="Text_ab69e61320f34336a241913cd033f5cf9"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a74" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a75">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf9" continuedAt="Text_ab69e61320f34336a241913cd033f5cf10"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a75" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a76">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf10" continuedAt="Text_ab69e61320f34336a241913cd033f5cf11"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a76" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a77">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2022 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 23, 2023.&#160; The accompanying consolidated balance sheet as of December 31,
              2022 was derived from the audited financial statements as of and for the year ended December 31, 2022. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8
              of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have
              been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and
              assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2023 and its results of operations, changes in stockholders&#8217; equity and cash flows for the three months
              ended March 31, 2023 and 2022.</span></div>
</ix:continuation></ix:continuation>
          <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf11" continuedAt="Text_ab69e61320f34336a241913cd033f5cf12"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a77" continuedAt="Text_af4d56c8d1bb45b3b89ecf46697807a78">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br /></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf12" continuedAt="Text_ab69e61320f34336a241913cd033f5cf13"><ix:continuation id="Text_af4d56c8d1bb45b3b89ecf46697807a78">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts
              presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf13" continuedAt="Text_ab69e61320f34336a241913cd033f5cf14">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf14" continuedAt="Text_ab69e61320f34336a241913cd033f5cf15">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf15" continuedAt="Text_ab69e61320f34336a241913cd033f5cf16"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8dc991838e454edf8db537076279b401" contextRef="c20230101to20230331" escape="true" continuedAt="Text_f67f998905c8464fa0c6a70e1fc272381">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf16" continuedAt="Text_ab69e61320f34336a241913cd033f5cf17"><ix:continuation id="Text_f67f998905c8464fa0c6a70e1fc272381" continuedAt="Text_f67f998905c8464fa0c6a70e1fc272382">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf17" continuedAt="Text_ab69e61320f34336a241913cd033f5cf18"><ix:continuation id="Text_f67f998905c8464fa0c6a70e1fc272382" continuedAt="Text_f67f998905c8464fa0c6a70e1fc272383">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf18" continuedAt="Text_ab69e61320f34336a241913cd033f5cf19"><ix:continuation id="Text_f67f998905c8464fa0c6a70e1fc272383" continuedAt="Text_f67f998905c8464fa0c6a70e1fc272384">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf19" continuedAt="Text_ab69e61320f34336a241913cd033f5cf20"><ix:continuation id="Text_f67f998905c8464fa0c6a70e1fc272384" continuedAt="Text_f67f998905c8464fa0c6a70e1fc272385">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf20" continuedAt="Text_ab69e61320f34336a241913cd033f5cf21"><ix:continuation id="Text_f67f998905c8464fa0c6a70e1fc272385">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
              granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf21" continuedAt="Text_ab69e61320f34336a241913cd033f5cf22">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf22" continuedAt="Text_ab69e61320f34336a241913cd033f5cf23">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf23" continuedAt="Text_ab69e61320f34336a241913cd033f5cf24"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_960edfd623ae41ecbb40cabb46d04a99" contextRef="c20230101to20230331" escape="true" continuedAt="Text_818651a002c04b96b13af717395eb80f1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf24" continuedAt="Text_ab69e61320f34336a241913cd033f5cf25"><ix:continuation id="Text_818651a002c04b96b13af717395eb80f1" continuedAt="Text_818651a002c04b96b13af717395eb80f2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf25" continuedAt="Text_ab69e61320f34336a241913cd033f5cf26"><ix:continuation id="Text_818651a002c04b96b13af717395eb80f2" continuedAt="Text_818651a002c04b96b13af717395eb80f3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf26" continuedAt="Text_ab69e61320f34336a241913cd033f5cf27"><ix:continuation id="Text_818651a002c04b96b13af717395eb80f3" continuedAt="Text_818651a002c04b96b13af717395eb80f4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf27" continuedAt="Text_ab69e61320f34336a241913cd033f5cf28"><ix:continuation id="Text_818651a002c04b96b13af717395eb80f4" continuedAt="Text_818651a002c04b96b13af717395eb80f5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf28" continuedAt="Text_ab69e61320f34336a241913cd033f5cf29"><ix:continuation id="Text_818651a002c04b96b13af717395eb80f5">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf29" continuedAt="Text_ab69e61320f34336a241913cd033f5cf30">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf30" continuedAt="Text_ab69e61320f34336a241913cd033f5cf31">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf31" continuedAt="Text_ab69e61320f34336a241913cd033f5cf32"><ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" id="Text_1d7ad30ef88342e895d372c263a22966" contextRef="c20230101to20230331" escape="true" continuedAt="Text_f5eacf131ac642e99efa42e6d196a2711">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf32" continuedAt="Text_ab69e61320f34336a241913cd033f5cf33"><ix:continuation id="Text_f5eacf131ac642e99efa42e6d196a2711" continuedAt="Text_f5eacf131ac642e99efa42e6d196a2712">
<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br />
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span></span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf33" continuedAt="Text_ab69e61320f34336a241913cd033f5cf34"><ix:continuation id="Text_f5eacf131ac642e99efa42e6d196a2712" continuedAt="Text_f5eacf131ac642e99efa42e6d196a2713">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf34" continuedAt="Text_ab69e61320f34336a241913cd033f5cf35"><ix:continuation id="Text_f5eacf131ac642e99efa42e6d196a2713">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts in
            the amount of $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_cfab2d27358740db9a85eae8e0318f0a" contextRef="c20221231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_9fbbea8fa36e46c5a460641570a41692" contextRef="c20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction> million at March<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> 31</span>, 2023 and December 31, 2022, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The



              Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an
              ongoing basis.</span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_78bf5fdf2a604699a853f57695ffc0dc" contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> customers accounted for an aggregate of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_0af5136c7efb412ebc55f2f32a88e933" contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction>% of the Company&#8217;s total accounts receivable, and at December 31, 2022, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_fa9f45706d4b4a6590bcd0cf4e417a27" contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_c5bb4b08114e4ff7a9e41821281f6bee" contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">92</ix:nonFraction>% of the Company&#8217;s total
            accounts receivable.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf35" continuedAt="Text_ab69e61320f34336a241913cd033f5cf36">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf36" continuedAt="Text_ab69e61320f34336a241913cd033f5cf37">
<div><br /></div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                  </a></div>

                <a href="#INDEX"></a>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>
<ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf37" continuedAt="Text_ab69e61320f34336a241913cd033f5cf38"><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="Text_a6c7a7396fa04bec80b800afedb33d14" contextRef="c20230101to20230331" escape="true" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f71">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf38" continuedAt="Text_ab69e61320f34336a241913cd033f5cf39"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f71" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f72">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf39" continuedAt="Text_ab69e61320f34336a241913cd033f5cf40"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f72" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f73">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf40" continuedAt="Text_ab69e61320f34336a241913cd033f5cf41"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f73" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f74">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf41" continuedAt="Text_ab69e61320f34336a241913cd033f5cf42"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f74" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f75">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf42" continuedAt="Text_ab69e61320f34336a241913cd033f5cf43"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f75" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f76">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct
              and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable
              supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square
              footage of the facility.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf43" continuedAt="Text_ab69e61320f34336a241913cd033f5cf44"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f76" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f77">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf44" continuedAt="Text_ab69e61320f34336a241913cd033f5cf45"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f77" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f78">
<div style="display:none;"><br /></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf45" continuedAt="Text_ab69e61320f34336a241913cd033f5cf46"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f78" continuedAt="Text_ca78702dd3a44fd2a2c327333da956f79">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf46" continuedAt="Text_ab69e61320f34336a241913cd033f5cf47"><ix:continuation id="Text_ca78702dd3a44fd2a2c327333da956f79">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of
              conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf47" continuedAt="Text_ab69e61320f34336a241913cd033f5cf48">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf48" continuedAt="Text_ab69e61320f34336a241913cd033f5cf49">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf49" continuedAt="Text_ab69e61320f34336a241913cd033f5cf50"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Text_0213f3d0f66b495f8215943a938312e6" contextRef="c20230101to20230331" escape="true" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd1">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf50" continuedAt="Text_ab69e61320f34336a241913cd033f5cf51"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd1" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf51" continuedAt="Text_ab69e61320f34336a241913cd033f5cf52"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd2" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf52" continuedAt="Text_ab69e61320f34336a241913cd033f5cf53"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd3" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf53" continuedAt="Text_ab69e61320f34336a241913cd033f5cf54"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd4" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf54" continuedAt="Text_ab69e61320f34336a241913cd033f5cf55"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd5" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160; Goodwill
              at <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and December 31, 2022 was $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_f79119270e7845dd876b490ea8c3034b" contextRef="c20221231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_8fb2c4dc9bee48798bb21997549153e0" contextRef="c20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction></ix:nonFraction> million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to the Biotest
              Transaction.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf55" continuedAt="Text_ab69e61320f34336a241913cd033f5cf56"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd6" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf56" continuedAt="Text_ab69e61320f34336a241913cd033f5cf57"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd7" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf57" continuedAt="Text_ab69e61320f34336a241913cd033f5cf58"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd8" continuedAt="Text_d78ba61ab4c84908b08d2a51f5364bfd9">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf58" continuedAt="Text_ab69e61320f34336a241913cd033f5cf59"><ix:continuation id="Text_d78ba61ab4c84908b08d2a51f5364bfd9">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
              goodwill impairment test as of October 1, 2022 did not result in a goodwill impairment charge, and the Company did <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_3c189550ae83447e817a2fe8093be0f5" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_bc7b74c485e04e909989644e60dd9b1f" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three months
                ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf59" continuedAt="Text_ab69e61320f34336a241913cd033f5cf60">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf60" continuedAt="Text_ab69e61320f34336a241913cd033f5cf61">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf61" continuedAt="Text_ab69e61320f34336a241913cd033f5cf62"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Text_545ada14f0fa4349907835c9c9451111" contextRef="c20230101to20230331" escape="true" continuedAt="Text_55d66b99729242d9a9fd7f18a2ea2e9a1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf62" continuedAt="Text_ab69e61320f34336a241913cd033f5cf63"><ix:continuation id="Text_55d66b99729242d9a9fd7f18a2ea2e9a1" continuedAt="Text_55d66b99729242d9a9fd7f18a2ea2e9a2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf63" continuedAt="Text_ab69e61320f34336a241913cd033f5cf64"><ix:continuation id="Text_55d66b99729242d9a9fd7f18a2ea2e9a2" continuedAt="Text_55d66b99729242d9a9fd7f18a2ea2e9a3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf64" continuedAt="Text_ab69e61320f34336a241913cd033f5cf65"><ix:continuation id="Text_55d66b99729242d9a9fd7f18a2ea2e9a3" continuedAt="Text_55d66b99729242d9a9fd7f18a2ea2e9a4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf65" continuedAt="Text_ab69e61320f34336a241913cd033f5cf66"><ix:continuation id="Text_55d66b99729242d9a9fd7f18a2ea2e9a4" continuedAt="Text_55d66b99729242d9a9fd7f18a2ea2e9a5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf66" continuedAt="Text_ab69e61320f34336a241913cd033f5cf67"><ix:continuation id="Text_55d66b99729242d9a9fd7f18a2ea2e9a5">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022, the Company
              determined that there was <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_f65f3194e4f3411c821464e58b6f7048" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_cc9222cb585d436b901d2321f2d48ec2" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> impairment of its long-lived assets.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf67" continuedAt="Text_ab69e61320f34336a241913cd033f5cf68">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf68" continuedAt="Text_ab69e61320f34336a241913cd033f5cf69">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                  </a></div>

                <a href="#INDEX"></a>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>
<ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf69" continuedAt="Text_ab69e61320f34336a241913cd033f5cf70"><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Text_3fb205bcaf1f40118c3c5793f85cc5d1" contextRef="c20230101to20230331" escape="true" continuedAt="Text_51c6bb88e839494e9de90f1aae4673361">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf70" continuedAt="Text_ab69e61320f34336a241913cd033f5cf71"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673361" continuedAt="Text_51c6bb88e839494e9de90f1aae4673362">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf71" continuedAt="Text_ab69e61320f34336a241913cd033f5cf72"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673362" continuedAt="Text_51c6bb88e839494e9de90f1aae4673363">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf72" continuedAt="Text_ab69e61320f34336a241913cd033f5cf73"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673363" continuedAt="Text_51c6bb88e839494e9de90f1aae4673364">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf73" continuedAt="Text_ab69e61320f34336a241913cd033f5cf74"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673364" continuedAt="Text_51c6bb88e839494e9de90f1aae4673365">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf74" continuedAt="Text_ab69e61320f34336a241913cd033f5cf75"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673365" continuedAt="Text_51c6bb88e839494e9de90f1aae4673366">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023</span>
                and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the
                Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the
                out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance
                with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a
                period of approximately <ix:nonNumeric name="adma:DeferredRevenueRemainingAmortizationPeriod" id="Fact_a821e18e7c8d4e27add102e33df431e0" contextRef="c20230101to20230331_TypeOfArrangementAxis_BiotestLicenseAgreementMember" format="ixt-sec:duryear">22</ix:nonNumeric> years.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf75" continuedAt="Text_ab69e61320f34336a241913cd033f5cf76"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673366" continuedAt="Text_51c6bb88e839494e9de90f1aae4673367">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf76" continuedAt="Text_ab69e61320f34336a241913cd033f5cf77"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673367" continuedAt="Text_51c6bb88e839494e9de90f1aae4673368">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf77" continuedAt="Text_ab69e61320f34336a241913cd033f5cf78"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673368" continuedAt="Text_51c6bb88e839494e9de90f1aae4673369">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based
              on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin
              products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other
              wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates,
              control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf78" continuedAt="Text_ab69e61320f34336a241913cd033f5cf79"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae4673369" continuedAt="Text_51c6bb88e839494e9de90f1aae46733610">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf79" continuedAt="Text_ab69e61320f34336a241913cd033f5cf80"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733610" continuedAt="Text_51c6bb88e839494e9de90f1aae46733611">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf80" continuedAt="Text_ab69e61320f34336a241913cd033f5cf81"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733611" continuedAt="Text_51c6bb88e839494e9de90f1aae46733612">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf81" continuedAt="Text_ab69e61320f34336a241913cd033f5cf82"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733612" continuedAt="Text_51c6bb88e839494e9de90f1aae46733613">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf82" continuedAt="Text_ab69e61320f34336a241913cd033f5cf83"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733613" continuedAt="Text_51c6bb88e839494e9de90f1aae46733614">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf83" continuedAt="Text_ab69e61320f34336a241913cd033f5cf84"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733614" continuedAt="Text_51c6bb88e839494e9de90f1aae46733615">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf84" continuedAt="Text_ab69e61320f34336a241913cd033f5cf85"><ix:continuation id="Text_51c6bb88e839494e9de90f1aae46733615">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the three months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_4b251da8bcd647d0b7f165f5bb4402d1" contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> customers represented an aggregate of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_a811fd670ab54d42b8312414824f25ea" contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">76</ix:nonFraction>% of the Company&#8217;s consolidated revenues. For the three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2022, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_b178290194c84c27b8790aad16d6bb57" contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> customers represented an aggregate
              of <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_95a4e52f604b4c3885bcc11c83e1be0d" contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">83</ix:nonFraction>% of the Company&#8217;s consolidated revenues.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf85" continuedAt="Text_ab69e61320f34336a241913cd033f5cf86">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf86" continuedAt="Text_ab69e61320f34336a241913cd033f5cf87">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf87" continuedAt="Text_ab69e61320f34336a241913cd033f5cf88"><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="Text_6ca79cd1448e48568dbd38122f71c2fe" contextRef="c20230101to20230331" escape="true" continuedAt="Text_553e948d4cca4ca984d395112ad6229e1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf88" continuedAt="Text_ab69e61320f34336a241913cd033f5cf89"><ix:continuation id="Text_553e948d4cca4ca984d395112ad6229e1" continuedAt="Text_553e948d4cca4ca984d395112ad6229e2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf89" continuedAt="Text_ab69e61320f34336a241913cd033f5cf90"><ix:continuation id="Text_553e948d4cca4ca984d395112ad6229e2" continuedAt="Text_553e948d4cca4ca984d395112ad6229e3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf90" continuedAt="Text_ab69e61320f34336a241913cd033f5cf91"><ix:continuation id="Text_553e948d4cca4ca984d395112ad6229e3" continuedAt="Text_553e948d4cca4ca984d395112ad6229e4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf91" continuedAt="Text_ab69e61320f34336a241913cd033f5cf92"><ix:continuation id="Text_553e948d4cca4ca984d395112ad6229e4" continuedAt="Text_553e948d4cca4ca984d395112ad6229e5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf92" continuedAt="Text_ab69e61320f34336a241913cd033f5cf93"><ix:continuation id="Text_553e948d4cca4ca984d395112ad6229e5">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products,
              intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the
              activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf93" continuedAt="Text_ab69e61320f34336a241913cd033f5cf94">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf94" continuedAt="Text_ab69e61320f34336a241913cd033f5cf95">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf95" continuedAt="Text_ab69e61320f34336a241913cd033f5cf96"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_daa896e121f44c169299ec74eac4e54f" contextRef="c20230101to20230331" escape="true" continuedAt="Text_3a4c440e15374e6db3e01e43dca043351">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf96" continuedAt="Text_ab69e61320f34336a241913cd033f5cf97"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043351" continuedAt="Text_3a4c440e15374e6db3e01e43dca043352">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss Per Common Share</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf97" continuedAt="Text_ab69e61320f34336a241913cd033f5cf98"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043352" continuedAt="Text_3a4c440e15374e6db3e01e43dca043353">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf98" continuedAt="Text_ab69e61320f34336a241913cd033f5cf99"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043353" continuedAt="Text_3a4c440e15374e6db3e01e43dca043354">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf99" continuedAt="Text_ab69e61320f34336a241913cd033f5cf100"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043354" continuedAt="Text_3a4c440e15374e6db3e01e43dca043355">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf100" continuedAt="Text_ab69e61320f34336a241913cd033f5cf101"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043355" continuedAt="Text_3a4c440e15374e6db3e01e43dca043356">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the
                weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if
                any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock
                options and warrants, using the treasury stock method, as well as Restricted Stock Units (&#8220;RSUs&#8221;). Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be
                anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported
                a net loss for all periods presented. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_ab7f841969c94f449bf078e68e34cc98" contextRef="c20230101to20230331" escape="true" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a1"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">For the three months ended </span></ix:nonNumeric></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a1" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a2"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">March 31</span></ix:continuation></span><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a2" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a3"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;">, 2023</span></ix:continuation></span></span></span></span><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a3" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a4"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"> and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></ix:continuation></span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf101" continuedAt="Text_ab69e61320f34336a241913cd033f5cf102"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043356" continuedAt="Text_3a4c440e15374e6db3e01e43dca043357"><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a4" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a5">
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf102" continuedAt="Text_ab69e61320f34336a241913cd033f5cf103"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043357" continuedAt="Text_3a4c440e15374e6db3e01e43dca043358"><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a5" continuedAt="Text_4995a8332f2649e8a1f3e29fb1fbdb7a6">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf103" continuedAt="Text_ab69e61320f34336a241913cd033f5cf104"><ix:continuation id="Text_3a4c440e15374e6db3e01e43dca043358"><ix:continuation id="Text_4995a8332f2649e8a1f3e29fb1fbdb7a6">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For the Three Months Ended March 31,</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_bf5a3c7624b0421294b6356dfb118016" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">9,945,703</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f056fa61cab34068b74393112340514a" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,686,068</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b4756af683ed4195aed24751abbfb8d9" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,875,464</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2ecb69dec99547d39716a1aec878c546" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,729,758</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_45736de5d542415aa1154fa3c6b401fa" contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,525,148</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_e615d86f57ae41aa9826f425d451538d" contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,631,207</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_0dcbd75585ae49d3bb1506f1132bb62f" contextRef="c20230101to20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">28,346,315</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_c42349cd4ca2490caba90853bcf504ed" contextRef="c20220101to20220331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">27,047,033</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf104" continuedAt="Text_ab69e61320f34336a241913cd033f5cf105">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf105" continuedAt="Text_ab69e61320f34336a241913cd033f5cf106">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span></div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                  </a></div>

                <a href="#INDEX"></a>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>


            <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_a536cdb4a1e2457ebf1b43140fa12824" contextRef="c20230101to20230331" escape="true" continuedAt="Text_b5bd0782a63e478e98b426c87b8521771"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf106" continuedAt="Text_ab69e61320f34336a241913cd033f5cf107">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>
</ix:continuation></ix:nonNumeric>
            <ix:continuation id="Text_b5bd0782a63e478e98b426c87b8521771" continuedAt="Text_b5bd0782a63e478e98b426c87b8521772"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf107" continuedAt="Text_ab69e61320f34336a241913cd033f5cf108">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b5bd0782a63e478e98b426c87b8521772" continuedAt="Text_b5bd0782a63e478e98b426c87b8521773"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf108" continuedAt="Text_ab69e61320f34336a241913cd033f5cf109">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b5bd0782a63e478e98b426c87b8521773" continuedAt="Text_b5bd0782a63e478e98b426c87b8521774"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf109" continuedAt="Text_ab69e61320f34336a241913cd033f5cf110">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_b5bd0782a63e478e98b426c87b8521774"><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf110" continuedAt="Text_ab69e61320f34336a241913cd033f5cf111">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is
              generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_475316ece6474ec7a06853b791a13749" contextRef="c20230101to20230331" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period and a term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_1ac80000485044f4aa252591c1129398" contextRef="c20230101to20230331" format="ixt-sec:duryear">10</ix:nonNumeric>
              years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
              related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf111" continuedAt="Text_ab69e61320f34336a241913cd033f5cf112">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf112" continuedAt="Text_ab69e61320f34336a241913cd033f5cf113">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation><ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf113" continuedAt="Text_ab69e61320f34336a241913cd033f5cf114"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_4e76a2f0cb524e40a7bd3220a1b1553c" contextRef="c20230101to20230331" escape="true" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d71">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf114" continuedAt="Text_ab69e61320f34336a241913cd033f5cf115"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d71" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d72">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf115" continuedAt="Text_ab69e61320f34336a241913cd033f5cf116"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d72" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d73">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf116" continuedAt="Text_ab69e61320f34336a241913cd033f5cf117"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d73" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d74">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf117" continuedAt="Text_ab69e61320f34336a241913cd033f5cf118"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d74" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d75">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf118" continuedAt="Text_ab69e61320f34336a241913cd033f5cf119"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d75" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d76">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2018 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf119" continuedAt="Text_ab69e61320f34336a241913cd033f5cf120"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d76" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d77">
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf120" continuedAt="Text_ab69e61320f34336a241913cd033f5cf121"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d77" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d78">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf121" continuedAt="Text_ab69e61320f34336a241913cd033f5cf122"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d78" continuedAt="Text_480c2ffcc2504854b38911ffe1e699d79">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_ab69e61320f34336a241913cd033f5cf122"><ix:continuation id="Text_480c2ffcc2504854b38911ffe1e699d79">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by
                the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is
                greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company
                has determined that it has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_3c6f65c7c92e49fbabc14928d484db1f" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_7f358321ebd84922853fd1abcc000f10" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t incurred any liability for unrecognized tax benefits as of March 31, 2023 and December 31,
                2022, and during the three months ended March 31, 2023 and 2022, the Company recognized</span><span style="font-size: 10pt;"> <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" id="Fact_e942c2c5233d44339db919ed6f249e6e" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" id="Fact_5ab2eab5db4640c0a4c1ce853db1b06a" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>
                adjustments for uncertain tax positions.</span></div>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

            <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
              </span> </div>

            <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" id="Text_b0ac280d826c42309d29f504917785df" contextRef="c20230101to20230331" escape="true" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc1" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc2" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc3" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc4" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc5"><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Text_bf83d86f9e0a4222991cdbebd88801ef" contextRef="c20230101to20230331" escape="true" continuedAt="Text_72a1f002d9c04421851ad7305480a1851">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc5" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc6"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1851" continuedAt="Text_72a1f002d9c04421851ad7305480a1852">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc6" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc7"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1852" continuedAt="Text_72a1f002d9c04421851ad7305480a1853">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc7" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc8"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1853" continuedAt="Text_72a1f002d9c04421851ad7305480a1854">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc8" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc9"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1854" continuedAt="Text_72a1f002d9c04421851ad7305480a1855">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc9" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc10"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1855" continuedAt="Text_72a1f002d9c04421851ad7305480a1856">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_2d34d457b6124f25b65b906e1d6a3b96" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">55,747,754</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_521767692cd54c1791539f8b12b3b5d3" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">48,644,527</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_49f2133999b84ab093232b2701426613" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">62,087,760</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_93477d87adf649a19d47496f71eb41fe" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,170,853</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_042a02e65df74d36aaf611d3b9a896b0" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">46,149,359</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_d6497a5b9f85488c9d8e9f886b1f02e7" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">58,464,667</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_980f682de67e4587a8c03ea0526072ef" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">163,984,873</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_b72d8c93d4cb4f2c92132f52742a7a50" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">163,280,047</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc10" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc11"><ix:continuation id="Text_72a1f002d9c04421851ad7305480a1856">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc11" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc12" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc13" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc14">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit. All other activities and materials associated with the production of
            inventories used in research and development activities are expensed as incurred.</div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc14" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc15">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc15" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc16">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc16" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc17">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s
            immunoglobulin products. </div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc17" continuedAt="Text_43ded41e7eb641569a9ab0fe4d4f77bc18">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_43ded41e7eb641569a9ab0fe4d4f77bc18">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Text_f46b388b3a2a480ca88f823b8eb2cec7" contextRef="c20230101to20230331" escape="true" continuedAt="Text_b622ffaba6df496198e22fa4482aba401">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba401" continuedAt="Text_b622ffaba6df496198e22fa4482aba402">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba402" continuedAt="Text_b622ffaba6df496198e22fa4482aba403">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba403" continuedAt="Text_b622ffaba6df496198e22fa4482aba404">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_b622ffaba6df496198e22fa4482aba404" continuedAt="Text_b622ffaba6df496198e22fa4482aba405"><ix:nonNumeric name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="Text_198a34bb24c64972a597f9e24fef66c1" contextRef="c20230101to20230331" escape="true" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69831">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba405" continuedAt="Text_b622ffaba6df496198e22fa4482aba406"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69831" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69832">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba406" continuedAt="Text_b622ffaba6df496198e22fa4482aba407"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69832" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69833">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba407" continuedAt="Text_b622ffaba6df496198e22fa4482aba408"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69833" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69834">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba408" continuedAt="Text_b622ffaba6df496198e22fa4482aba409"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69834" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69835">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba409" continuedAt="Text_b622ffaba6df496198e22fa4482aba4010"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69835" continuedAt="Text_fe586999eb2a4c7f9af46a77a7bb69836">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;Accumulated</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;Accumulated</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_b142be7350dc46018989319caa2d1951" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,100,046</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_6c470f7e0b5b4990a4686a3e6a68ca9f" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,416,706</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_598b71b281fc4100834e3b762665f564" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">683,340</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_af30414e56764200b4a622796ed1b64e" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,100,046</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_2e08ae71786b411ab93439db67e89543" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,270,276</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_5c065f733c7c47d79071b687d9de2e7a" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">829,770</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_de6ece799bdf4966bf8cf65088951c65" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">907,421</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_f7ba28f86ba44f6ab88bb969791826aa" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">756,184</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_0578913d955a4388aaa8d526f1a8450b" contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">151,237</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_3870bc08ca464369b992f87f26e9f4ef" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">907,421</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_7d88f316f6824144a34cf1d77dc7f80f" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">723,776</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_eed44b0536ce45a69e167c819f42fdb5" contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">183,645</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_234a57eeb3d048cd86051b403d6e5621" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,007,467</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_758873bdcb3f4cf687d50a95e0b99abb" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,172,890</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_44efd124cf7d477cb9c5d8821f93c955" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">834,577</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_1a797a3450c147479fa8fa7872060bec" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,007,467</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_6f19060c80e1410290899b776b18fd53" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,994,052</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_5be46883f3d645729f059bbfe124e986" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,013,415</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4010" continuedAt="Text_b622ffaba6df496198e22fa4482aba4011"><ix:continuation id="Text_fe586999eb2a4c7f9af46a77a7bb69836">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4011" continuedAt="Text_b622ffaba6df496198e22fa4482aba4012">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation><ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4012" continuedAt="Text_b622ffaba6df496198e22fa4482aba4013"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Text_4116e731c5374a47a052e2a92e8e2c69" contextRef="c20230101to20230331" escape="true" continuedAt="Text_2fbaea01adbd491397b269f77de2308a1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4013" continuedAt="Text_b622ffaba6df496198e22fa4482aba4014"><ix:continuation id="Text_2fbaea01adbd491397b269f77de2308a1" continuedAt="Text_2fbaea01adbd491397b269f77de2308a2">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization expense
              related to these intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_65a7bc614d9040c6b6a3c9fcdc3baebf" contextRef="c20220101to20220331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_4b3e6aff8c2b4408b8f4bf75481aa17c" contextRef="c20230101to20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction> million for the three months ended March 31, 2023 and 2022. Estimated future
              aggregate amortization expense is expected to be as follows:</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4014" continuedAt="Text_b622ffaba6df496198e22fa4482aba4015"><ix:continuation id="Text_2fbaea01adbd491397b269f77de2308a2" continuedAt="Text_2fbaea01adbd491397b269f77de2308a3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4015" continuedAt="Text_b622ffaba6df496198e22fa4482aba4016"><ix:continuation id="Text_2fbaea01adbd491397b269f77de2308a3" continuedAt="Text_2fbaea01adbd491397b269f77de2308a4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4016" continuedAt="Text_b622ffaba6df496198e22fa4482aba4017"><ix:continuation id="Text_2fbaea01adbd491397b269f77de2308a4" continuedAt="Text_2fbaea01adbd491397b269f77de2308a5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b622ffaba6df496198e22fa4482aba4017"><ix:continuation id="Text_2fbaea01adbd491397b269f77de2308a5">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span><br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" id="Fact_f940e9f5d5894e4e9e3c5f65b0b4dff7" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">536,514</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" id="Fact_02501b664c4649f285d8ea7164f950b3" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">298,063</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_c58c1d3b3a2e40808b659d66e69f3c99" contextRef="c20230101to20230331" escape="true" continuedAt="Text_52d3536218474b2ebb141aea1a3345c71">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c71" continuedAt="Text_52d3536218474b2ebb141aea1a3345c72">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c72" continuedAt="Text_52d3536218474b2ebb141aea1a3345c73">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c73" continuedAt="Text_52d3536218474b2ebb141aea1a3345c74">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c74" continuedAt="Text_52d3536218474b2ebb141aea1a3345c75"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_593a680e06f44efe9f78af2c2597bdb7" contextRef="c20230101to20230331" escape="true" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5021">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c75" continuedAt="Text_52d3536218474b2ebb141aea1a3345c76"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5021" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5022">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c76" continuedAt="Text_52d3536218474b2ebb141aea1a3345c77"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5022" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5023">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c77" continuedAt="Text_52d3536218474b2ebb141aea1a3345c78"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5023" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5024">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c78" continuedAt="Text_52d3536218474b2ebb141aea1a3345c79"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5024" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5025">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c79" continuedAt="Text_52d3536218474b2ebb141aea1a3345c710"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5025" continuedAt="Text_1f2c08eb67df457fb28aac96064cb5026">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_4381ec9eb69146a7b6ded74b8862a92a" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,828,570</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c01caccf89d34729a8ff2c9a8cb90cfd" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,767,807</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_aedd1b1a3adf4ea7a03017bcf30bf182" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,939,060</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_3f513f6217484aafa0bd921692b4c4ae" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,318,669</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_283eea153dc043e08551cdbf652e961f" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,662,407</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_6e75c54251264674af56251ab8ead733" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,109,898</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_e500159dd50d4f799deb69fa59591632" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,515,267</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_95f5a0118f9a4fb68139ee4b1ca494c7" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,726,995</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a347a7edc2604a1abb3cd9f39655549d" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">20,514,697</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_9c6faa54c0364f2b8eb9a2050d265e4a" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">17,930,905</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_b68d9c63283247e8b19af5c866fe181a" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,339,441</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a22589e4dad1465a8c12ca444d4b3d26" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,339,441</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_6644f2a91a1843199a929973020c21e9" contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,856,505</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_83da68f762f74c529fcfee12c54ec639" contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,544,307</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_8c1b574ebceb466c91533ca010853c96" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">78,655,947</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_c62855bfb4a940d19484f97925c3ec33" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">77,738,022</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_c7a4df061f7e4e128948669f3300c241" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">21,285,164</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_0ce41a39c07c461b9de62a208a07c978" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">19,476,541</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property, plant and equipment, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_7aa94e8510a44158a2b209a0661a95ff" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">57,370,783</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_20f890a061d446d0bbd7c407105293c0" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">58,261,481</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c710" continuedAt="Text_52d3536218474b2ebb141aea1a3345c711"><ix:continuation id="Text_1f2c08eb67df457fb28aac96064cb5026">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c711" continuedAt="Text_52d3536218474b2ebb141aea1a3345c712">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c712" continuedAt="Text_52d3536218474b2ebb141aea1a3345c713">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c713" continuedAt="Text_52d3536218474b2ebb141aea1a3345c714">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_7a90c5724662448dac546b240cdf9e1b" contextRef="c20230101to20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingMember" format="ixt-sec:duryear">30</ix:nonNumeric>
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_4342de1675c9405cb8dc40be8462b988">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_5dab68a3af58417694a9f3e8a202739b" contextRef="c20230101to20230331_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c714" continuedAt="Text_52d3536218474b2ebb141aea1a3345c715">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c715" continuedAt="Text_52d3536218474b2ebb141aea1a3345c716">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_52d3536218474b2ebb141aea1a3345c716">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recorded depreciation expense on property and equipment for the three
              months ended March 31, 2023 and 2022 of $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_44dce707cb694a1f995df3dcde8a7d31" contextRef="c20230101to20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction> million and $</span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_1e9e1cd910984b8b9d475e03f82e97dd" contextRef="c20220101to20220331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.4</ix:nonFraction><span style="color: rgb(0, 0, 0);"> million, respectively.<br />
              </span></span></div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div> <br />
          </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_ba86dceeeabc4c1dba19c743f8d13860" contextRef="c20230101to20230331" escape="true" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76281">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76281" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76282">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76282" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76283">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76283" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76284">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76284" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76285"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_6310a76925dc44908412817c735f99a4" contextRef="c20230101to20230331" escape="true" continuedAt="Text_2de4a777c36b4c06b3b0260e43a017cc1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76285" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76286"><ix:continuation id="Text_2de4a777c36b4c06b3b0260e43a017cc1" continuedAt="Text_2de4a777c36b4c06b3b0260e43a017cc2">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 are as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76286" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76287"><ix:continuation id="Text_2de4a777c36b4c06b3b0260e43a017cc2" continuedAt="Text_2de4a777c36b4c06b3b0260e43a017cc3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76287" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76288"><ix:continuation id="Text_2de4a777c36b4c06b3b0260e43a017cc3" continuedAt="Text_2de4a777c36b4c06b3b0260e43a017cc4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76288" continuedAt="Text_5d7ce6f5f3514a6cba463d49498e76289"><ix:continuation id="Text_2de4a777c36b4c06b3b0260e43a017cc4" continuedAt="Text_2de4a777c36b4c06b3b0260e43a017cc5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_5d7ce6f5f3514a6cba463d49498e76289"><ix:continuation id="Text_2de4a777c36b4c06b3b0260e43a017cc5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_2d8d6ef258404312be938ac34bf0addd" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,129,902</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_da6545af9b834d399a86744f1a09ea77" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,436,484</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_1f7c338b74294c4182143601e4448804" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,406,033</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_3aaadfb6cc5a4618b73884d645def646" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,166,896</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_0f62571a884541d3b182a3379d5ffeff" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,179,600</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_c460a945127c40ef8d3eab26304a9250" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,193,919</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_236e06b899cd4a4e97e28bec8a12fdaa" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">169,825</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_3b19311eed7043d182b46a1632ebc3e0" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">309,867</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br />
                  </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_56bab8a0ca744761a118592cea38fb92" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,745,245</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_d44067eb37304808af273609f6319689" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,086,379</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_8ed8710b20cf4e688dbdad8c2d713072" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,041,859</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_c20ccd0344c8496a89b4a1a148bddcae" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,795,804</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_d9ee88aba9574787b61abd43b04a9e8b" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,672,464</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_d646dc143942428a8cc7c4d07f0a6b39" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,989,349</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>

          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" id="Text_c8c0406143ff4d4fa3adaf8468c4a17c" contextRef="c20230101to20230331" escape="true" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd1" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd2" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd3" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd4" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd5"><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" id="Text_113038a69c3c4b0e9deb47d766fca208" contextRef="c20230101to20230331" escape="true" continuedAt="Text_2ef51718a44045e6b56b481fb6793ad11">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd5" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd6"><ix:continuation id="Text_2ef51718a44045e6b56b481fb6793ad11" continuedAt="Text_2ef51718a44045e6b56b481fb6793ad12">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd6" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd7"><ix:continuation id="Text_2ef51718a44045e6b56b481fb6793ad12" continuedAt="Text_2ef51718a44045e6b56b481fb6793ad13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd7" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd8"><ix:continuation id="Text_2ef51718a44045e6b56b481fb6793ad13" continuedAt="Text_2ef51718a44045e6b56b481fb6793ad14">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd8" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd9"><ix:continuation id="Text_2ef51718a44045e6b56b481fb6793ad14" continuedAt="Text_2ef51718a44045e6b56b481fb6793ad15">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd9" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd10"><ix:continuation id="Text_2ef51718a44045e6b56b481fb6793ad15">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_fcb36d3c9d95436cb714320f28004118" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">155,727,724</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_c47c7a5145544370ba72ba371849f1aa" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">154,747,746</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_e49189797899423686b8b3938c7fb42f" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,426,794</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_a95400604367415ea7e3ffd314aceb1e" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,914,683</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_c16a548d11dd4edd99ed6a6ec9e004e8" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">144,300,930</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_49d61dd3ca5c4a358b7b5d13a9a0de31" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">142,833,063</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd10" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd11">
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd11" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation>
          <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd12" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd13">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On March 23,&#160;2022 (the &#8220;Hayfin Closing Date&#8221;), the Company and all of its subsidiaries entered into a Credit and Guaranty Agreement (the &#8220;Hayfin Credit Agreement&#8221;) with Hayfin
                Services LLP (&#8220;Hayfin&#8221;). The Hayfin Credit Agreement provides for a senior secured term loan facility in a principal amount of up to $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_a9641ae020244e5da4847a57ffc293f4" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">175.0</ix:nonFraction>
                million (the &#8220;Hayfin Credit Facility&#8221;), composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_1cde708ded3641e88f10932f96e87c0a" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction>
                million (the &#8220;Hayfin Closing Date Loan&#8221;), and (ii) a delayed draw term loan in the principal amount of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_ebf3fb1b78c8491e87ae171a65fcb083" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction> million (the &#8220;Hayfin
                Delayed Draw Loan&#8221; and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans&#8221;). The obligation of the lenders to make the Hayfin Delayed Draw Loan was to have expired on <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_78b0dcc7209b4c0d913d4ab786f2ae15" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember" format="ixt:date-monthname-day-year-en">March 22, 2023</ix:nonNumeric> and is subject to the satisfaction of certain conditions, including, but not limited to, the Company&#8217;s meeting certain 12-month revenue targets as set
                forth in the Hayfin Credit Agreement. The Hayfin Credit Facility has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_b8dd537d34f349c18c39d3244efe7c61" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember" format="ixt:date-monthname-day-year-en">March 23, 2027</ix:nonNumeric> (the &#8220;Hayfin Maturity
                Date&#8221;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement). </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On March 22, 2023, the Company and Hayfin entered into an amendment to the Hayfin Credit Agreement whereby the lenders&#8217; obligation to
                make the Hayfin Delayed Draw Loan was extended to June 30, 2023.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd13" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd14">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd14" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd15">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On the Hayfin Closing Date, the Company used $<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_d1e68345a7db439193b393c68a29b784" contextRef="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction> million of
                the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previously existing credit facility (the &#8220;Perceptive Credit Facility&#8221;) with Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;).
                The Company also used $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedPremium" id="Fact_16383f29eb5d481891afd14a04e94164" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used
                approximately $<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_ac50e8813f4c4fef9dfe5f3f939e9470" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with
                this transaction. In addition, a $<ix:nonFraction name="adma:DebtInstrumentUpfrontFeePaidInKind" id="Fact_ac99ee091f704bea9013683e53b1f172" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction> million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding
                principal balance in accordance with the terms of the Hayfin Credit Agreement. In connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt
                in the amount of $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_150377055ead4b22a544db11793d89fd" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">6.7</ix:nonFraction> million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the
                redemption premium paid to Perceptive.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd15" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd16">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd16" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd17">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the Hayfin Credit Agreement bear interest, at the Company&#8217;s election, at either (a) a base rate (equal to the highest of (i) the rate of interest per annum
                last quoted by The Wall Street Journal as the &#8220;Prime Rate&#8221; in the United States, (ii) the federal funds rate in effect on such day plus <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_45f895148fb84101817f7c6ad3d951dd" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">0.50</ix:nonFraction>%
                and (iii) adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_8f8b66f0cb5e49899ba112a3b5a6280d" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" format="ixt-sec:durwordsen">one-month</ix:nonNumeric> tenor in effect on such day plus <ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" id="Fact_f1dfcc79263941a3bb20782bd24c26cb" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.00</ix:nonFraction>%), plus an applicable margin of <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_a4500fc57c9347a4a167d14455c5f402" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%,
                or (b) adjusted Term SOFR for either a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_d87e9e34443d430b9e2f596596745b98" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" format="ixt-sec:durwordsen">one-month</ix:nonNumeric> or <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_fda2f9efe7194d2f97edde559195e333" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> tenor, as elected by the Company, and subject to a floor of <ix:nonFraction name="adma:DebtInstrumentFloorInterestRate" id="Fact_d0bef17cd8294ce3a8e10f2fa2677aea" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.25</ix:nonFraction>%,
                plus an applicable margin of <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_76064f1e6e1f4f69956fb70e1e3efb4b" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.5</ix:nonFraction>% (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an
                Event of Default, the Applicable Margin increases by an additional <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_58655071fdfb4015b3851747c518593d" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% per annum. On the last day of each calendar month or
                quarter during the term of the Hayfin Credit Facility, the Company will pay accrued interest to Hayfin. The rate of interest in effect as of March 31,2023 and December 31, 2022&#160; was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_d43820058cb14f37b3d613c89f129df4" contextRef="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">14.4</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_83e68a911c3f4e189b1bcb271d50f1b8" contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.9</ix:nonFraction>%, respectively. The Company is also
                permitted to pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly or quarterly interest period in an amount equal to <ix:nonFraction name="adma:DebtInstrumentInterestAmountToBePayInKind" id="Fact_f3fba596db074f2c99098c82999923d2" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>%
                per annum, which is added to the principal amount of the outstanding debt under the Hayfin Credit Facility. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For</span> the three months ending March 31,2023, approximately $<ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_81a2b8669d0141bb8b2f4a322c0bfd5c" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd17" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd18">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

                <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                  </a></div>

                <a href="#INDEX"></a>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>

            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd18" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd19">
<div style="display:none;"><br /></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On the Hayfin Maturity Date, the Company will pay Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as
                well as an exit fee of <ix:nonFraction name="adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" id="Fact_b7d7483c6757441bb6107f3f4e1d8176" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the outstanding principal amount being paid. This exit fee is recorded separately as a
                non-current liability on the accompanying consolidated balance sheets as of March 31,2023 and December 31,2022. Prior to the Hayfin Maturity Date, there are <ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" id="Fact_3e17b499c53446489c2059d44f848ae3" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> scheduled principal payments on the Hayfin Loans. The Company may prepay outstanding principal on the Hayfin Loans at any time and from time to time upon <span style="-sec-ix-hidden:Fact_5ecb5c13cda94b628b0011be8e172a1f">five</span> business days&#8217; prior written notice, subject to the payment to Hayfin of, (A) any accrued but unpaid interest on the prepaid principal amount plus (B) an early
                prepayment fee in the amount equal to (i) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_1eb80172398b447d960459a2852ce6dd" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.0</ix:nonFraction>% of the prepaid principal amount, if prepaid on or prior to the first anniversary
                of the Hayfin Closing Date, (ii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_759fcbb0fe47407cb4dc631898bbb604" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the prepaid principal amount, if prepaid after the first anniversary of the Hayfin
                Closing Date and on or prior to the second anniversary of the Hayfin Closing Date, or (iii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_f3974a5b12564abfa57b2bc5ac1d8f88" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the prepaid principal
                amount, if prepaid after the second anniversary of the Hayfin Closing Date and on or prior to the third anniversary of the Hayfin Closing Date. In addition, for any prepayments of principal or payment of principal on the Hayfin Maturity
                Date, the Company is also required to pay the exit fee.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd19" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd20">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd20" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd21">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">All of the Company&#8217;s obligations under the Hayfin Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible
                and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Hayfin Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and
                conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin
                Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain
                Investments or Restricted Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">other </span>indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that
                have the impact of restricting the Company&#8217;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company is required (i) at all times prior to the Maturity Date to maintain a minimum cash balance of $<ix:nonFraction name="us-gaap:Cash" id="Fact_7a9dc232ae404931b5b587e15f8ca3c5" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that
                exceed the amounts set forth in the Hayfin Credit Agreement, which range from $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_64b18c68f468478eb1977f96000cefef" contextRef="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction> million for the fiscal quarter ended June
                30,&#160;2022 to $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_74ff21d9ac2c47eab9c170e93fcad207" contextRef="c20261001to20261231_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_StatementScenarioAxis_ScenarioForecastMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">250.0</ix:nonFraction> million for the fiscal quarter ended December 31,&#160;2026. As of March 31,&#160;2023, the Company was in compliance
                with all of the covenants contained in the Hayfin Credit Agreement.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd21" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd22">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd22" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd23">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As consideration for the Hayfin Credit Agreement, the Company issued to various entities affiliated with Hayfin, on the Hayfin Closing Date, warrants to purchase an aggregate
                of <ix:nonFraction name="adma:SharesIssuedUponExerciseOfWarrants" id="Fact_f9c543c53ef84ecaa7e33e494d71fdc5" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">9,103,047</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Hayfin Warrants&#8221;). The Hayfin Warrants have an exercise price equal to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_72404f5ccbd047ff8182de4ead9e4b7d" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">1.6478</ix:nonFraction> per share, which is equal to the trailing <ix:nonNumeric name="adma:TrailingPeriodForVolumeWeightedAveragePrice" id="Fact_f344dbea5a2c4dd3aec9029fda8ac4b2" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" format="ixt-sec:durday">30</ix:nonNumeric>-day
                Volume Weighted-average Price of the Company&#8217;s common stock on the business day immediately prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_524515b3c29c4b1ea760e7de8280b193" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction> million as of the Hayfin Closing Date and have an expiration date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_c074ac2f22004c1e883b0fcce021ea04" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" format="ixt:date-monthname-day-year-en">March 23, 2029</ix:nonNumeric>.</span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd23" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd24">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd24" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd25">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and the value of the Hayfin
                Warrants, the Company recognized an aggregate discount on the Hayfin Loans in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_2a4ed928ded0448a874422150b3a24f4" contextRef="c20220323" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.9</ix:nonFraction> million. The Company records
                debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Hayfin Warrants and the aggregate amount
                of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the Hayfin Loans as of March 31,2023 and December 31,&#160;2022 was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_9971d5f1e8304944a23a89a764162457" contextRef="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">16.6</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_90beff2c86b24c29b9c843b52535255c" contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">16.1</ix:nonFraction>%, respectively.</span> </div>
</ix:continuation>
            <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd25" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd26">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation>
            <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
              <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd26" continuedAt="Text_da7e0de0cc994213832f31d4b10e45bd27">
<div style="display:none;"><br /></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; margin-left: 27pt; text-indent: 9pt;">See Note 14 for discussion of an additional amendment to the Hayfin Credit Facility.</div>
</ix:continuation>
              <ix:continuation id="Text_da7e0de0cc994213832f31d4b10e45bd27">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></div>

            </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
        <div>
          <div>
            <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_5ecaf0c606624acda2de24059b4958ef" contextRef="c20230101to20230331" escape="true" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c1">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                  </td>

  </tr>


</table>
</ix:nonNumeric>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c1" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c2" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c3">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c3" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c4" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c5">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to <ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_6148f1619d4d4af8866241695b9e89fd" contextRef="c20221231" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_2cc258f189594bd1bfdfbefcee2aa432" contextRef="c20230331" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction> million shares of preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_e266a99f1b614d429d1c4a39756f751b" contextRef="c20230331" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_3f0785c459d84156a90607d414818e93" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>, par value per share.
              There were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_407b812d081740ee83ec7aa2358211c6" contextRef="c20230331" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_3f0f3064d1b14c959dcb73ca5523d2ad" contextRef="c20221231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at March 31, 2023 and December 31, 2022.</div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c5" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c6">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c6" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c7">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c7" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c8">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br />
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c8" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c9">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of March 31, 2023 and December 31, 2022, the Company was authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_a046785ef18a437198ed297a9d5b7db8" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_3b9e44eb949042d2ae26365247588421" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction> shares of its common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_66f73f0e4eb3476393c5d4095002c914" contextRef="c20230331" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_50fec3bead3a4ca7a88ed6e40c49194e" contextRef="c20221231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
              par value per share, and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_441f449bd9ac48e4ad39a873bda7f2b6" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">222,262,588</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_2c6accfe3e0d4da3b6d9344e407213a9" contextRef="c20221231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,816,930</ix:nonFraction> shares of common stock were outstanding as of March 31, 2023 and December 31, 2022, respectively. After giving effect to the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_727f47289d314df8921bbd058ddffb77" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">48,356,592</ix:nonFraction> shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of March 31, 2023
              there were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_82baa76c618a428fad8740745caf2e7f" contextRef="c20230331" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">29,380,820</ix:nonFraction> shares of common stock available for issuance.<br />
              <br />
            </div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c9" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c10">
<div><span style="font-style: italic;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</span></span></span></div>
</ix:continuation>
          <div><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c10" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c11">
<div> &#160; <br /></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c11" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c12">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the Hayfin Credit Agreement that the Company entered into on March 23, 2022 (see Note 7), the
              Company issued the Hayfin Warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_f428b0ea7b534a4196d7b030cd4dab8d" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">9,103,047</ix:nonFraction> shares of the Company&#8217;s common stock. The Hayfin Warrants were valued at
              $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_8335c214c487470ab23e3680a7e50d5c" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction> million using the Black-Scholes option-pricing model assuming an expected term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_42f0e33974714447b220b4e846accef7" contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>, a volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_8fdf8ce1691a498482cca65b0a7b0862" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">68.1</ix:nonFraction>%, a dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_a0c5c5cf2cd8452696c515e71704f320" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% and a risk-free rate of interest of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_e69854533be24024b1ac02d3e1437b52" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.36</ix:nonFraction>%.
              At March 31, 2023 and December 31,2022, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_c9f00ccef15e493d800f48de7609fdc4" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_8604e95ee0184bd09bf477fc3d5b72e7" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">13,525,148</ix:nonFraction></ix:nonFraction> shares of
              common stock, with a weighted-average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_cfc2b564eb4344d18277a08a980b6321" contextRef="c20230331" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_63b91e2af63a4861ab46d42a6fcf46fb" contextRef="c20221231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.99</ix:nonFraction></ix:nonFraction> per share with expiration dates ranging between May 2023 and
              December 2030 (see Note 14).</div>
</ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c12" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             &#160; <br /></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c13" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c14">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c14" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c15">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c15" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c16">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under the Company&#8217;s equity incentive plans was determined on the
                date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition,
                option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of
                traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_91b9573094e44c8f81d6558493652ebe" contextRef="c20230101to20230331" escape="true" continuedAt="Text_2694f530bdbb42628aaf3c5cbd15e06c1"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2023 and 2022:</span></ix:nonNumeric></span></div>
</ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c16" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c17"><ix:continuation id="Text_2694f530bdbb42628aaf3c5cbd15e06c1" continuedAt="Text_2694f530bdbb42628aaf3c5cbd15e06c2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
            &#160; <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span></div>
</ix:continuation></ix:continuation></div>

          <div>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c17" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c18"><ix:continuation id="Text_2694f530bdbb42628aaf3c5cbd15e06c2">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br />
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br />
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_473ac0f0030843c29a48fe34c056128f" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_4b4b926eb239435c92ad52d7be99b429" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_a7d8abb2dd2d4764b0c3a81e823cc8bd" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_a4734cfb5d014ec48b8be311a9601004" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_6821d8848d6c4f039848cf5721df3d0e" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">%</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_8823310d38ba4e259e1451f2d5cc7e9f" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">%</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_38140635326c4da9ac4a72fdc1432b7e" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction><br />
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_f4953db0b85a4a90ac70dae5ff6f2294" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction><br />
                      </span></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_43174049f52a4cc59d32b04cd55da070" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.20</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_172b5386ff5a41babb48025d4999dc22" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.24</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_3e9df7be035d41f788a4d5a3749f1e45" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.72</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_1ce561a689e34c36b160d4e7653fa3be" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.73</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c18" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c19">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>&#160; <br /></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c19" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c20">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">On June 21, 2022, the
                Company&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#8220;2022 Equity Plan&#8221;), which replaced the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan.&#160; Approval of the 2022 Equity Plan resulted in
                approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_b3c7212a503a4445bf12af8c988b5ec5" contextRef="c20220621_PlanNameAxis_Two022CompensationPlanMember" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction> million additional shares of the Company&#8217;s common stock being reserved for future awards. </span>During the
              three months ended March 31, 2023 and 2022, the Company granted options to purchase an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_06f01f65f4e44445ac037a4ef76d98f1" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,727,510</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_04afc859757d4c06baf6ecf37c9aeef8" contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,194,032</ix:nonFraction> shares of common stock, respectively, to its directors and employees.&#160; The weighted average remaining contractual life of stock options
              outstanding and expected to vest at March 31, 2023 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_ec77ed4127b04edb99b57f1faf82a8cb" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_b2bd3c79df8b4333a5ec2522d5fb5ba8" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.6</ix:nonNumeric></ix:nonNumeric> years. The weighted average remaining contractual life of stock
              options exercisable at March 31, 2023 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_f401657979dc4ee8b4bf72fd035a1f4c" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.3</ix:nonNumeric> years. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">During
                the three months ended March 31, 2023, options to purchase <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_14a2ed725dc84076889a7954444b8e99" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,416</ix:nonFraction> shares of common stock were exercised in a cashless transaction
                resulting in the issuance of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_4488de17cbd247ee98cde51e112076c2" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,443</ix:nonFraction> shares of common stock.</span></div>
</ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c20" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c21">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span> </div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c21" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c22"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_619c0196e81947b1af4e026299b00e41" contextRef="c20230101to20230331" escape="true" continuedAt="Text_ddcf193c427446b4ad8a90d65d8687dc1">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
              follows:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c22" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c23"><ix:continuation id="Text_ddcf193c427446b4ad8a90d65d8687dc1" continuedAt="Text_ddcf193c427446b4ad8a90d65d8687dc2">
<div>
            &#160;</div>
</ix:continuation></ix:continuation></div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <div>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c23" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c24"><ix:continuation id="Text_ddcf193c427446b4ad8a90d65d8687dc2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;"> Weighted </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;"> Average </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_25e7337318414c89a428e1b19b42b681" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,256,211</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_3319708b964d406e9b1e5a4535a95319" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.37</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_f6489c7676fb4ddf9cc09c13a2792787" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">15,555</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_2f1f43aeb041426791db13b4878ecf14" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.29</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_a7fa45effef1422cb5dfc931ba325f49" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">17,047</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_56c8a4f324e34217a6f797e9316b5e83" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.06</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_c5b88ccb8eec493aa8b33637d1911eb2" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,727,510</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_f1e9f901cef4414bbda6b9ac0e5be636" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.35</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_5016699cc900467ba5d927a12cf12385" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,416</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">$ <br />
                  </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_eea81ecb589649abbafc1fe30bb274c6" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.08</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_eb2597933319447fba5ff42635e0fd81" contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">9,945,703</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_bd6e25cb95a14cfa89698d85c74f5e9d" contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.36</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_5bc64833a0c1493ba7c44101723a051a" contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">6,660,313</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_1a9db572936b44f1aa32b2461a170cf8" contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.67</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c24" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c25">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c25" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c26">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of March 31, 2023, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_7ed2a0340a9a48e58b9be44815ff08c4" contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction> million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average
              period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_2e9d97e87a744b6f85fa18fc2cdef9ab" contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">3.0</ix:nonNumeric> years.</div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c26" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c27">
<div style="display:none;"><br /></div>
<div style="text-indent: -9pt; margin-left: 9pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> &#160; <br />
            </div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c27" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c28">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">During the three months ended March 31, 2023 and 2022, the Company granted RSUs representing an aggregate
                of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_42c7c49a3ea44c8b8de8390f2e73c9ec" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,666,260</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_46fadf1fefe14e3fa72bf32a2fefbca9" contextRef="c20220101to20220331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,059,266</ix:nonFraction>
                shares, respectively, to certain employees of the Company and to members of its Board of Directors</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">. These RSUs generally vest annually over a period<span style="font-variant: normal; text-transform: none;"> of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_a8e2c17260254c9c924f8af68977cc43" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric> for employees and semi-annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_7804c9f805744bfabcdbe7505cf5fe7b" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> for directors</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> During the <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">three months ended March 31, 2023</span>, an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_ec480c04c85d46c38b3fc005607426a2" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">628,283</ix:nonFraction>
                shares of common stock vested in connection with grants of RSUs. With respect to these vested RSUs, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_9922205a4b424dcca98bb0084b7e48b7" contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">185,068</ix:nonFraction> shares valued at
                approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_59e019bcd33e42e2b345f5fdb0cce604" contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million were withheld by the Company to cover employees&#8217; tax liabilities. These shares were no longer
                outstanding as of <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March
                    31, 2023</span></span>. <ix:nonNumeric name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="Text_71b5a908ff2b4457976debb0a68ec1ca" contextRef="c20230101to20230331" escape="true" continuedAt="Text_70ef9dd9a7f941b4b79dd79eb8c773be1"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">A
                summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span></ix:nonNumeric></span> </div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c28" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c29"><ix:continuation id="Text_70ef9dd9a7f941b4b79dd79eb8c773be1" continuedAt="Text_70ef9dd9a7f941b4b79dd79eb8c773be2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
              </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c29" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c30"><ix:continuation id="Text_70ef9dd9a7f941b4b79dd79eb8c773be2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" colspan="2">&#160;Weighted </td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="2">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" colspan="2">&#160;Average Grant</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_65f67c03386f4d369b00a49851dd37be" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,866,987</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_85905970f8dd4decaa82cc07ff786ce2" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.59</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_ca69bc415d7b47738a66578202a0f985" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,666,260</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_76431cc418784863896d14f84f14bf9a" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.35</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_0a727f5d64504bc68cbeec7bfb27a05c" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">628,283</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_1ef195ac4c084888b9f567078be07388" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.76</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_5fc0ea8813994a9a885df1baa3152643" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">29,500</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_8b30b82d06a142c4857578632d1b29fa" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.25</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_760bd1a1f22749cb925f25da6a242cbe" contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,875,464</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_84f337121311474d885f9cc13dbfcab1" contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.53</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c30" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c31">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c31" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c32">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></span>, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_821c5235207a4d4282868b95e36e92da" contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.0</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
              weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_d7c6246721de4dd392193caba756695b" contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">3.4</ix:nonNumeric> years.</div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c32" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c33">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Text_0cfebe5db0554c4a8d6b82f250a91866" contextRef="c20230101to20230331" escape="true" continuedAt="Text_c9cad7334f58437f97a895ee2d1270c71"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> </span></ix:nonNumeric></div>
</ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c33" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c34"><ix:continuation id="Text_c9cad7334f58437f97a895ee2d1270c71" continuedAt="Text_c9cad7334f58437f97a895ee2d1270c72">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
              months ended March 31, 2023 and 2022 is as follows:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c34" continuedAt="Text_5ac88991a2a44850b80e3f55259f6f2c35"><ix:continuation id="Text_c9cad7334f58437f97a895ee2d1270c72" continuedAt="Text_c9cad7334f58437f97a895ee2d1270c73">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_5ac88991a2a44850b80e3f55259f6f2c35"><ix:continuation id="Text_c9cad7334f58437f97a895ee2d1270c73">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="6">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br />
                      </span> </div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br />
                      </span> </div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_aedf9500aff549b7ad9ca08d0a685181" contextRef="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,385</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_93da4be6d8f44c7abb248d80d07698cd" contextRef="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,671</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 67.86%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_0b74025b985044469546e6ede8f892ec" contextRef="c20230101to20230331_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,055</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_ce16641e4b77464bbb8a55a8ce2b73ef" contextRef="c20220101to20220331_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">21,052</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_7a44d39cde314d6fbca2b4fbb90d3cf0" contextRef="c20230101to20230331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">978,124</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_366cfc8f370f4946a34ede7141df09c8" contextRef="c20220101to20220331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,517,602</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 67.86%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b57b7ad2a48e49869d45a09685b8dd40" contextRef="c20230101to20230331_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">103,602</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2d397230a3f542bf980e4871a9f1dead" contextRef="c20220101to20220331_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">98,063</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 67.86%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_3d15b40761384452b3f03c941ce9d3c1" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,110,166</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_08d3dd33248e4e6195db11a4ff5f2b12" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,641,388</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span></div>
 </div>

        </div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_c780bfd708e44e8fa86486118498f0cb" contextRef="c20230101to20230331" escape="true" continuedAt="Text_286fae793b6f4a23b2df188613874f0c1">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  </div>
</ix:nonNumeric>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c1" continuedAt="Text_286fae793b6f4a23b2df188613874f0c2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c2" continuedAt="Text_286fae793b6f4a23b2df188613874f0c3">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c3" continuedAt="Text_286fae793b6f4a23b2df188613874f0c4">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c4" continuedAt="Text_286fae793b6f4a23b2df188613874f0c5">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c5" continuedAt="Text_286fae793b6f4a23b2df188613874f0c6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;)
        pursuan<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">t to an agreement for services
          effective as of January 1, 2016, as amended from time to time<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and pays monthly rent on this facility in the amount of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_89da785ebbf342e7931b4ec9afeef58f" contextRef="c20160101to20160131_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> through December 31, 2026</span>. Rent expense for the three months ended March 31, 2023 and 2022 amounted to $<ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_281c722cca424cf3915d23ec0c4269b5" contextRef="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" id="Fact_104d285391014103b76b2b0386a39ccc" contextRef="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction></ix:nonFraction> (see</span> Note 12). Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the three months
        ended March 31, 2023 and 2022. </div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c6" continuedAt="Text_286fae793b6f4a23b2df188613874f0c7">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
            </a></div>

          <a href="#INDEX"></a>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

        </div>

      </div>

      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c7" continuedAt="Text_286fae793b6f4a23b2df188613874f0c8">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">three months ended March 31, 2023 and 2022, the Company purchased certain specialized medical equipment and
          services primarily related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#8220;Genesis&#8221;), aggregating to $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_723420fd7a9449be9c9b9b432233e5d5" contextRef="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_02a9473ca8c94c9281e72d6d39b5ab6c" contextRef="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">43,000</ix:nonFraction>, respectively. Genesis is owned by Dr.
          Grossman and Adam Grossman.<br />
        </span></div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c8" continuedAt="Text_286fae793b6f4a23b2df188613874f0c9">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c9" continuedAt="Text_286fae793b6f4a23b2df188613874f0c10">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c10" continuedAt="Text_286fae793b6f4a23b2df188613874f0c11">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_286fae793b6f4a23b2df188613874f0c11">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">See Note 7 for a discussion of the Company&#8217;s former credit facility and related
        transactions with Perceptive, a holder of more than <ix:nonFraction name="adma:MinimumPercentageOfCommonStockHeldByLender" id="Fact_38bf9630d6e44419af753fcf4a8b8099" contextRef="c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s common stock during<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> the three months ended March 31, 2022. There were no transactions with Perceptive
          during the three months ended March 31, 2023.</span><br class="Apple-interchange-newline" />
      </div>
</ix:continuation>

      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br />
        </span></div>

      <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_4473a060a68a403d939a6af745d8e9bf" contextRef="c20230101to20230331" escape="true" continuedAt="Text_22ca9f4269e743569383df04832bd7c91">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c91" continuedAt="Text_22ca9f4269e743569383df04832bd7c92">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c92" continuedAt="Text_22ca9f4269e743569383df04832bd7c93">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c93" continuedAt="Text_22ca9f4269e743569383df04832bd7c94">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c94" continuedAt="Text_22ca9f4269e743569383df04832bd7c95">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c95" continuedAt="Text_22ca9f4269e743569383df04832bd7c96">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c96" continuedAt="Text_22ca9f4269e743569383df04832bd7c97">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c97" continuedAt="Text_22ca9f4269e743569383df04832bd7c98">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c98" continuedAt="Text_22ca9f4269e743569383df04832bd7c99">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c99" continuedAt="Text_22ca9f4269e743569383df04832bd7c910">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection
            with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c910" continuedAt="Text_22ca9f4269e743569383df04832bd7c911">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c911" continuedAt="Text_22ca9f4269e743569383df04832bd7c912">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c912" continuedAt="Text_22ca9f4269e743569383df04832bd7c913">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c913" continuedAt="Text_22ca9f4269e743569383df04832bd7c914">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COVID-19 Pandemic</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c914" continuedAt="Text_22ca9f4269e743569383df04832bd7c915">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c915" continuedAt="Text_22ca9f4269e743569383df04832bd7c916">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c916" continuedAt="Text_22ca9f4269e743569383df04832bd7c917">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c917" continuedAt="Text_22ca9f4269e743569383df04832bd7c918">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the emergence of
            the Delta, Omicron and BA.2 variants and other resistant strains of the coronavirus, and its impacts to the Company&#8217;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement
            of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale. A substantial portion of such testing has
            historically been performed by contract laboratories outside the United States.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c918" continuedAt="Text_22ca9f4269e743569383df04832bd7c919">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c919" continuedAt="Text_22ca9f4269e743569383df04832bd7c920">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c920" continuedAt="Text_22ca9f4269e743569383df04832bd7c921">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Due to a combination of previously mandated state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus
            packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company at times experienced lower than normal donor collections at its FDA approved plasma collection centers <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">during 2021 and part of 2022. From time to time during 2021 and 2022, t</span>he Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as
            delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. In addition, the Company has been subject to supply chain delays as a
            result of certain of its suppliers diverting significant resources towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company has elected to carry more raw materials inventory than it has in the past. The
            COVID-19 pandemic previously impacted, to a certain degree, the Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel faced difficulties communicating directly with physicians and other healthcare
            professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c921" continuedAt="Text_22ca9f4269e743569383df04832bd7c922">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c922" continuedAt="Text_22ca9f4269e743569383df04832bd7c923">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c923" continuedAt="Text_22ca9f4269e743569383df04832bd7c924">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The pandemic could also impact the Company&#8217;s ability to interact with the FDA or other regulatory authorities and could result in delays in the conduct of inspections
              or review of pending applications or submissions. Although the Company has received <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">FDA approvals for <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" id="Fact_198cd67edccb4c8ca1bab6db0498e936" contextRef="c20230101to20230331" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> of its plasma collection centers since January 1, 2022 and</span> </span>received several other FDA approvals while <ix:nonFraction name="adma:NumberOfFDAInspections" id="Fact_eae5538634cf4fde9e72aa4704ccdfd2" contextRef="c20210101to20211231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> FDA inspections of the Boca Facility were completed during the year ended December 31, 2021, no assurances can be provided as to the timing for completion of any
              future regulatory submissions or applications that may be impacted by restrictions related to COVID-19.</span></div>
</ix:continuation>
          <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_22ca9f4269e743569383df04832bd7c924" continuedAt="Text_22ca9f4269e743569383df04832bd7c925">
<div><br /></div>
</ix:continuation>
            <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c925" continuedAt="Text_22ca9f4269e743569383df04832bd7c926">
<div style="display:none;"><br /></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, revenue attributable to international customers was
              approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_ab52f13454084277b4a14d6c31060815" contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction>% and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_3d6a4261879443e794c3a35b548ff4b9" contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">6</ix:nonFraction>%,
              respectively, of the Company&#8217;s total revenues. As the Company seeks to grow this aspect of its business, it may also be subject to the impacts of the COVID-19 pandemic in locations outside the United States.</div>
</ix:continuation>
            <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c926" continuedAt="Text_22ca9f4269e743569383df04832bd7c927">
<div><br /></div>
</ix:continuation>
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c927" continuedAt="Text_22ca9f4269e743569383df04832bd7c928">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s financial
            condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facilities have been significantly impacted by the COVID-19
            pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c928" continuedAt="Text_22ca9f4269e743569383df04832bd7c929">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c929" continuedAt="Text_22ca9f4269e743569383df04832bd7c930">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c930" continuedAt="Text_22ca9f4269e743569383df04832bd7c931">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and financial
            resources, because the Company is unable to determine the ultimate severity or duration of the COVID-19 pandemic or other pandemics or their long-term effects on, among other things, the global, national or local economies, the capital and
            credit markets or the Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 or other pandemics will have a material adverse impact on the Company&#8217;s business, financial condition,
            liquidity or results of operations.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c931" continuedAt="Text_22ca9f4269e743569383df04832bd7c932">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c932" continuedAt="Text_22ca9f4269e743569383df04832bd7c933">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c933" continuedAt="Text_22ca9f4269e743569383df04832bd7c934">
<div style="font-style: italic;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br />
            </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span><span style="font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c934" continuedAt="Text_22ca9f4269e743569383df04832bd7c935">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c935" continuedAt="Text_22ca9f4269e743569383df04832bd7c936">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase
            Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
            volume from BPC, but may also collect high-titer RSV plasma from up to <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilities" id="Fact_ce732eded190416dbdfc77722e4e6dff" contextRef="c20230101to20230331_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> wholly-owned ADMA plasma collection facilities. During
            2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its
            reach for raw material supply as it executes its commercialization plans for ASCENIV. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the <ix:nonNumeric name="adma:PlasmaPurchaseAgreementTerm" id="Fact_501ecfdcddaa474991fa1c349d30a1f7" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" format="ixt-sec:durwordsen">ten-year</ix:nonNumeric> anniversary of the closing date of the Biotest Transaction. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June
            2027, after which it may be renewed for <ix:nonFraction name="adma:NumberOfRenewalTerms" id="Fact_8347d0a47967428f861c361edf8658b4" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional <ix:nonNumeric name="adma:PlasmaPurchaseAgreementRenewalPeriod" id="Fact_c01546d85f4d47ccbbf445b78ba26355" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> periods if agreed to by the parties. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations
            Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing
            antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company could purchase RSV plasma from Grifols from the <ix:nonFraction name="adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" id="Fact_5acd5a659e6842959f033a3e4234348a" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>
            plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus <ix:nonFraction name="adma:PercentageOfPlasmaPurchasePriceEqualToCost" id="Fact_4d8d467429f5490bbdd4a5da986890af" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U007" decimals="2" scale="-2" format="ixt-sec:numwordsen">five </ix:nonFraction>percent (<ix:nonFraction name="adma:PercentageOfPlasmaPurchasePriceEqualToCost" id="Fact_4050a02fd1c94bb28345e9bedf0b9fd5" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>%) (without any additional increase due to inflation). Effective January 1, 2022, RSV plasma purchased from these <ix:nonFraction name="adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" id="Fact_c15d536757ea42e0b82c3479e024b7e0" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> plasma collection centers are subject to the pricing terms in effect for RSV plasma purchased from other plasma collection centers owned by
            Grifols.<br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c936" continuedAt="Text_22ca9f4269e743569383df04832bd7c937">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c937" continuedAt="Text_22ca9f4269e743569383df04832bd7c938">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c938" continuedAt="Text_22ca9f4269e743569383df04832bd7c939">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an
            exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric name="adma:PlasmaSupplyAgreementTerm" id="Fact_9a329f5292134d8b8f01ce4bd8f701fd" contextRef="c20230101to20230331" format="ixt-sec:duryear">10</ix:nonNumeric>-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c939" continuedAt="Text_22ca9f4269e743569383df04832bd7c940">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c940" continuedAt="Text_22ca9f4269e743569383df04832bd7c941">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c941" continuedAt="Text_22ca9f4269e743569383df04832bd7c942">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c942" continuedAt="Text_22ca9f4269e743569383df04832bd7c943">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase Agreement&#8221;),
            pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among
            other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC.
            Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years 2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts,
            provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA
            BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to
            supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c943" continuedAt="Text_22ca9f4269e743569383df04832bd7c944">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c944" continuedAt="Text_22ca9f4269e743569383df04832bd7c945">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c945" continuedAt="Text_22ca9f4269e743569383df04832bd7c946">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement whereby, among other things, the term of the agreement was
              extended through December 31, 2022, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">however Grifols&#8217; commitment
                to supply the Company with NSP under this agreement was not satisfied until March of 2023</span>. In order to maintain a reliable supply of raw material plasma thereafter, the Company has executed additional agreements with multiple
              third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement. The Company has also increased its number of planned plasma collection center buildouts such that the Company expects to have <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilities" id="Fact_78dfde90b4e74057bcec1e23690d6c06" contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> FDA-approved plasma collection centers in operation by the end of 2023, while also continuing to increase its plasma collection capabilities
              at its ADMA BioCenters plasma collection centers business segment.</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c946" continuedAt="Text_22ca9f4269e743569383df04832bd7c947">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c947" continuedAt="Text_22ca9f4269e743569383df04832bd7c948">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c948" continuedAt="Text_22ca9f4269e743569383df04832bd7c949">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c949" continuedAt="Text_22ca9f4269e743569383df04832bd7c950">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Through December 31, 2022, the</span>
            Company purchased substantially all of its raw material plasma from Grifols. For the three months ended March 31, 2023, plasma purchases from Grifols totaled $<ix:nonFraction name="adma:PlasmaPurchased" id="Fact_e4c3bfd3b6734ef09677e8ee45ed7c9b" contextRef="c20230101to20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.6</ix:nonFraction> million, or approximately <ix:nonFraction name="adma:PercentageOfInventoryPurchases" id="Fact_7553125fb9c34038a49a31fc63f98be9" contextRef="c20230101to20230331" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">40</ix:nonFraction>% of the Company&#8217;s total inventory
            purchases. For the three months ended March 31, 2022, plasma purchases from Grifols totaled approximately $<ix:nonFraction name="adma:PlasmaPurchased" id="Fact_7defc904079541e8aaa61f9587d5d124" contextRef="c20220101to20220331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.5</ix:nonFraction> million, representing
            approximately <ix:nonFraction name="adma:PercentageOfInventoryPurchases" id="Fact_e3350024fc7a4d0c89a3ddd6a47de8df" contextRef="c20220101to20220331" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% of the Company&#8217;s total inventory purchases.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c950" continuedAt="Text_22ca9f4269e743569383df04832bd7c951">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c951" continuedAt="Text_22ca9f4269e743569383df04832bd7c952">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c952" continuedAt="Text_22ca9f4269e743569383df04832bd7c953">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-Marketing Commitments</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c953" continuedAt="Text_22ca9f4269e743569383df04832bd7c954">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c954" continuedAt="Text_22ca9f4269e743569383df04832bd7c955">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"><br />
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c955" continuedAt="Text_22ca9f4269e743569383df04832bd7c956">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the approval of the BLA for BIVIGAM, on December 19, 2012, Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a
            post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The pediatric study for BIVIGAM has been completed, and the safety study has been completed pending a clinical study report to
              the FDA</span>. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. For the three months ended March 31, 2023 and 2022, the Company incurred expenses
            related to these studies of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_d5166901d9d94b9e9c36a0bce66d8f35" contextRef="c20230101to20230331_ProductOrServiceAxis_BIVIGAMMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_b2e9ce47e2644275aa4ba8acdbc030d8" contextRef="c20220101to20220331_ProductOrServiceAxis_BIVIGAMMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction></ix:nonFraction> million. The Company currently expects to incur expenses of&#160; approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_58515ccbc51142c087e9b17417b66ebf" contextRef="c20121219to20121219_RangeAxis_MinimumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million to $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_cb29b92ea0bb4432b14f538cd1990e2c" contextRef="c20121219to20121219_RangeAxis_MaximumMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million to
            complete the safety study, which is required to be completed by June of 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c956" continuedAt="Text_22ca9f4269e743569383df04832bd7c957">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c957" continuedAt="Text_22ca9f4269e743569383df04832bd7c958">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2023 and 2022, the Company
            incurred expenses related to these studies in the amount of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_b7f5ecd39e5a46b7a7ae9ea86a6c3816" contextRef="c20230101to20230331_ProductOrServiceAxis_ASCENIVMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_adbe550f099146c4b9039cfc9b44130f" contextRef="c20220101to20220331_ProductOrServiceAxis_ASCENIVMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million, respectively. The Company expects to incur expenses of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_bdabb02754b941b588085acdb0f068a2" contextRef="c20190401to20190401" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million to complete this study, which is currently required to be completed by June of 2023. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company has submitted an extension request to the FDA.</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c958" continuedAt="Text_22ca9f4269e743569383df04832bd7c959">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c959" continuedAt="Text_22ca9f4269e743569383df04832bd7c960">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c960" continuedAt="Text_22ca9f4269e743569383df04832bd7c961">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment Contracts</span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c961" continuedAt="Text_22ca9f4269e743569383df04832bd7c962">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c962" continuedAt="Text_22ca9f4269e743569383df04832bd7c963">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c963" continuedAt="Text_22ca9f4269e743569383df04832bd7c964">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c964" continuedAt="Text_22ca9f4269e743569383df04832bd7c965">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has entered into employment agreements with Mr. Grossman and with Brian Lenz, its Executive Vice President,
            Chief Financial Officer and General Manager, ADMA BioCenters.<br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c965" continuedAt="Text_22ca9f4269e743569383df04832bd7c966">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c966" continuedAt="Text_22ca9f4269e743569383df04832bd7c967">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_22ca9f4269e743569383df04832bd7c967" continuedAt="Text_22ca9f4269e743569383df04832bd7c968">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span>
           <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c968" continuedAt="Text_22ca9f4269e743569383df04832bd7c969">
<div><span style="font-style: italic;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c969" continuedAt="Text_22ca9f4269e743569383df04832bd7c970">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: italic;"><span style="text-decoration: underline;">Other Commitments</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c970" continuedAt="Text_22ca9f4269e743569383df04832bd7c971">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="text-decoration: underline;"> <br />
              </span></span></div>
</ix:continuation>
          <ix:continuation id="Text_22ca9f4269e743569383df04832bd7c971">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is
            unknown as of March 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

    <div class="BRPFPageFooter" style="width: 100%;"></div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div>
      <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_8d577c5a49fb4883907c94d4289126da" contextRef="c20230101to20230331" escape="true" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406981">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406981" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406982">
<div><br /></div>
</ix:continuation>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406982" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406983">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The
          Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers segment consists of <ix:nonFraction name="adma:NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" id="Fact_35b721651aab431fab846eb589a872c5" contextRef="c20230101to20230331" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction><span style="color: rgb(0, 0, 0);"> operational plasma collection facilities located throughout the U.S., <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_02754c26802d4dd1ac4f66ceea59dfa6" contextRef="c20230101to20230331" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction> of which currently hold FDA</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0);">licenses</span></span>.
          The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze
          performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer. <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_60d8002bb1ba4c9dae45985bc0826d46" contextRef="c20230101to20230331" escape="true" continuedAt="Text_048243bfbed742b18a54d0ddbe2446051"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is shown in the following tables:</span></ix:nonNumeric></span> </div>
</ix:continuation>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406983" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406984"><ix:continuation id="Text_048243bfbed742b18a54d0ddbe2446051" continuedAt="Text_048243bfbed742b18a54d0ddbe2446052">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
        </span></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406984" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406985"><ix:continuation id="Text_048243bfbed742b18a54d0ddbe2446052" continuedAt="Text_048243bfbed742b18a54d0ddbe2446053">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2023</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"> ADMA</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;"> Plasma Collection</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c55eb74805d64ff2819a4629aba290c9" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">49,576,935</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b906122c1c0844f4851925fd57677283" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,300,891</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2048d782268d4bb9b931f485df12636d" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">35,708</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a310760096a9468882d3d78fb2536bc5" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,913,534</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_f0bc7941a21049069f1e5a7c311548d5" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">33,933,782</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_5ef41d8ca94c40e3ba73e665aa2a6e0d" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,466,762</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_5c111919d5634633ad1ca856ee9fcf53" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_6966b051cd7a484ba18a179e9fe090f2" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">40,400,544</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_2c49490e810743e2ae586fc8f71e76b2" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,476,441</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_b3ba2a7cc6904cc2b5316047a3000cf6" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">946,334</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0331bbc26bbb41f3bbdde436414311a8" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,343,425</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_6af9e88a051c44468a9821e6a63f3e67" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">813,318</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_fd7d366b5a9047dfbf476f31da57b583" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">23,779</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_8bd0923a77ae45f4b1067e0a93645422" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">227</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_22afae65e94749039ecf4929f3166042" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,951,491</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_2e7eeb0e259f49b48c22fe2156db8e96" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">5,975,497</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c654536d25014ac988e7f4fd1577f6db" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,452,662</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d48c5f4c909040458cdc0a6fca8b93a1" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">946,561</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_abe5e1bb770f4ceca49ce35c7a7b3216" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">11,294,916</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c2f7b73ef6394474b8e57c81d5bbf4a0" contextRef="c20230101to20230331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,788,815</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">Capital expenditures <br />
            </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_30be93c9d53b4854ac3118a6ba829ca9" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">452,032</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_ae98b8b7c13349abb69c76e4f498e9b7" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,492,564</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_aa4e0ffdadec4355895a3206107b0988" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_03d939784ac345c59badcf90f01776f3" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,944,596</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_5fa324bc0d01497ca5e41d8b784d24b9" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,292,608</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_f1d2cd6d3fd14b6691b2481a4583f3a1" contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">740,357</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_1fc144cc8544479dbf9b45f5da98d12a" contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_e25af2dd80ab4ea0adf42532f65abdae" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,032,965</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_901bd8aaeb374d4d8a2a46c7e6d7ae12" contextRef="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">234,894,891</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_9840e5d2c5e847d899afe4ff6e314b6b" contextRef="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">38,853,662</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_94dfb8f45b2040d5968d8330f4ad4f96" contextRef="c20230331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">67,038,989</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_46eab75f11d647af9abffb270f09b45f" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">340,787,542</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406985" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406986"><ix:continuation id="Text_048243bfbed742b18a54d0ddbe2446053" continuedAt="Text_048243bfbed742b18a54d0ddbe2446054">
<div><br /></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406986" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406987"><ix:continuation id="Text_048243bfbed742b18a54d0ddbe2446054">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2022</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"> ADMA </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;"> Plasma Collection </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7ce8d71b19e8430381e40b6c12e8d672" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,728,625</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0d360a26d94e4e518e385e886facab58" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,338,760</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ae58fe9a63f64ddb943d2ecc2f670100" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">35,708</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c4e64f6189274be397430f9455cb16ab" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,103,093</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_63258479b7684b58a82a8faa57923fa1" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">22,213,781</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_1c2bcec538cf42489f6c90fbb106a86d" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,227,265</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_9030a94d1b4942a2a767136e984f07c9" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_0cf291f1a46747a58126aa45c55b31a1" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">25,441,046</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_36ed2499f82f47798c893e1af8296ab8" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">4,442,684</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_d7db869e4bd5408bb37b6b1c30e95a6e" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">3,863,094</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_2f2aaed9af6a4675b577ec785a219739" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,509,288</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0e654d59f74a4834b6f9a95397193466" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">14,815,066</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_2cafeea62a354e85a19f99cda86edc6e" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">49,267</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_271834e4129b4275986e72beb1f24e99" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">729</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_c3688ad888ba470384ff2fc2016602c4" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">3,472,854</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:InterestAndOtherNonoperatingIncomeExpense" id="Fact_c88533a3708741549ef4b6db59d3a987" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">3,522,850</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; background-color: #CCEEFF; white-space: nowrap;">Loss on extinguishment of debt<br />
            </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_cbff0de3d37b4e0aa89c37227e14fd84" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_07c704f81b7543f2bca19b2ab7c50ae4" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_3a582a35a44c46b9859f894a7d05f860" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,669,941</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_9efcfa0c8f4e44d38cae34d2132d4a4f" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">6,669,941</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_466d99a5ae574142aa74b35f176c46ae" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">4,491,951</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c1411fd3e7b94e0da85f0460de263a5b" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">3,863,823</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d9f5143c2c9a479a8e242ec9806ae670" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">16,652,083</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a096e19498994fbe849ab7fd46bfd34d" contextRef="c20220101to20220331" unitRef="U002" decimals="0" sign="-" scale="0" format="ixt:num-dot-decimal">25,007,857</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">Capital expenditures </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_6d9da38483f54e70bbf2741e0117b4ff" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,310,379</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_b094387e2cf44e83bea143a6bce17efb" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,531,706</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_1caf2627137c4bc79326aff1b429022a" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_8128f2942f2f4f1c81174156d85257d7" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,842,085</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_6d2f46cffa244bb8bcb92c875822d286" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,111,951</ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_896d8abdea724e3d9ad17eca72264567" contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">477,503</ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_24af592968314ea1925475f659430fc3" contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">763</ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_2a2bfbd2c3b74a2f84dfa354ff4cbb40" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,590,217</ix:nonFraction><br />
              </div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_b2186393b1974c289384d2cefeb46e09" contextRef="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">214,150,322</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_7d797816588e4dc3860427afefd8427d" contextRef="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">32,568,911</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_051f815197b44be68b086586e8a4c221" contextRef="c20220331_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">61,313,259</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:Assets" id="Fact_113c873d836b41bcaf40535fd87aad69" contextRef="c20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">308,032,492</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

      <ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406987" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406988">
<div><br />
      </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

          <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
            </a></div>

          <a href="#INDEX"></a>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

        </div>

      </div>


      <ix:nonNumeric name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="Text_cb3457db51a845d5ad4ccf3d19e66190" contextRef="c20230101to20230331" escape="true" continuedAt="Text_0a85fbb2ef6040a984b002718be8447b1"><ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406988" continuedAt="Text_128f3d9ed5c44398ae33cb4511d406989">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>
</ix:continuation></ix:nonNumeric>
      <ix:continuation id="Text_0a85fbb2ef6040a984b002718be8447b1" continuedAt="Text_0a85fbb2ef6040a984b002718be8447b2"><ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d406989" continuedAt="Text_128f3d9ed5c44398ae33cb4511d4069810">
<div><br /></div>
</ix:continuation></ix:continuation>
      <ix:continuation id="Text_0a85fbb2ef6040a984b002718be8447b2"><ix:continuation id="Text_128f3d9ed5c44398ae33cb4511d4069810">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br />
                </span> </div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br />
                </span> </div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 70%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0b12dcd8893447519dafb472c230c362" contextRef="c20230101to20230331_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">52,694,723</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_70a098b5bec04ce0b38e504fbc0ded7c" contextRef="c20220101to20220331_StatementGeographicalAxis_US" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">27,316,151</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 70%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0cf14b2741724840ae7ed7de970ad42d" contextRef="c20230101to20230331_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,218,811</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_21fd3fb597d841a2839d2abb4c6f3003" contextRef="c20220101to20220331_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,786,942</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2323efd47254438f832ea8aeb803ebe9" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">56,913,534</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0e4a8f3a6f3a43a698e8f8c50c73851e" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">29,103,093</ix:nonFraction></div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
       <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span></div>
 </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_07c47f886b1349e5b405490a00370332" contextRef="c20230101to20230331" escape="true" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee1" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee2" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee3" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee4" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee5" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee6">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.</div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee6" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee7" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee8" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee9">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or
            less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease
            payments arising from the lease.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For all of its leases, the Company has elected and applies the practical expedient available to lessees to combine non-lease components with their related
                lease components and account for them as a single combined lease component.</span></span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include
            options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a
            straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense for the Company&#8217;s leases for the three months ended March 31, 2023 and 2022
            was approximately $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_9dcf8695c71f4f7db5e674e2fbf5b0f3" contextRef="c20230101to20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_8819e5ce7b984c79b27968018eeb2de4" contextRef="c20220101to20220331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>
            million, respectively. Cash paid for the Company&#8217;s leases for the three months ended March 31, 2023 and 2022 was approximately $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_b5b62b48619645a58510c7ee5149cd3c" contextRef="c20230101to20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction>
            million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_fe43622c7d86462ab118ba33645d09a1" contextRef="c20220101to20220331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, respectively. <br />
          </div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee9" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee10">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee10" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee11">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee11" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee12" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee13">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Including a finance lease the Company entered into in June 2018, the Company has aggregate lease
              liabilities of $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_de9c25558eda4c78b95fcd16a28ae7a6" contextRef="c20230331" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.4</ix:nonFraction> million and $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_48357cad25f64c6bb156da1348dcf02b" contextRef="c20221231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.6</ix:nonFraction>
              million as of March 31, 2023 and December 31, 2022, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin
              manufacturing operations.&#160; The Company&#8217;s operating leases have a weighted average remaining term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_4e486c3580ef42199c9a5adacb166b66" contextRef="c20230331" format="ixt-sec:duryear">8.3</ix:nonNumeric> years. <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_405210bb330f4623aeab49dce8f76c74" contextRef="c20230101to20230331" escape="true" continuedAt="Text_7486051f3d1d4f6fa9c88c31cd85ed901"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">Scheduled payments under the
              Company&#8217;s lease obligations are as follows:</span></ix:nonNumeric></span></div>
</ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee13" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee14"><ix:continuation id="Text_7486051f3d1d4f6fa9c88c31cd85ed901" continuedAt="Text_7486051f3d1d4f6fa9c88c31cd85ed902">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee14" continuedAt="Text_0aab711e90234def8ee8ae2e9a7a17ee15"><ix:continuation id="Text_7486051f3d1d4f6fa9c88c31cd85ed902" continuedAt="Text_7486051f3d1d4f6fa9c88c31cd85ed903">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0aab711e90234def8ee8ae2e9a7a17ee15"><ix:continuation id="Text_7486051f3d1d4f6fa9c88c31cd85ed903">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_612cda4c4f3b41a3aecc33a67d0bd827" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,805,644</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_f8402c9f05754531a2f762918b0d6ef2" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,343,314</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_00e2fd2caebf49349134462ca42d4025" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,366,432</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_600cdb5d9f704e53ba49347b8fc4fbcb" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,116,036</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2027</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_794fbef32f9d4855aef767d7bfa10e02" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,040,690</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2028</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_3dc6ff11ba774dfda1276d6642a8ef44" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,087,825</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_c5186f0c06994c8ea14527ce55ee369a" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,150,746</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_c6efbcfee0774faeaa9c6a48a365cbcf" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">18,910,687</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_970cb57242b8418480dfa6c6afb4aadb" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,486,533</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_53818766e4e84ac6983c20cedad7e4d7" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">956,045</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 4px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 74%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_6ac3fbf1c1a84c2fa55731dff151422e" contextRef="c20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,468,109</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <div><br />
          </div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">

    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Text_673ec408ded04a738b2e6188e9f26692" contextRef="c20230101to20230331" escape="true" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c61">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c61" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c62">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c62" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c63">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c63" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c64">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation><ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c64" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c65"><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="Text_35fb1c620ab44388bdc46b9d5e9dccc2" contextRef="c20230101to20230331" escape="true" continuedAt="Text_30791cfcf34d4b9e8642b9517ed86b0e1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c65" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c66"><ix:continuation id="Text_30791cfcf34d4b9e8642b9517ed86b0e1" continuedAt="Text_30791cfcf34d4b9e8642b9517ed86b0e2">
<div style="display:none;"><br /></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the three months ended March 31, 2023 and 2022 is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c66" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c67"><ix:continuation id="Text_30791cfcf34d4b9e8642b9517ed86b0e2" continuedAt="Text_30791cfcf34d4b9e8642b9517ed86b0e3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c67" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c68"><ix:continuation id="Text_30791cfcf34d4b9e8642b9517ed86b0e3" continuedAt="Text_30791cfcf34d4b9e8642b9517ed86b0e4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>
</ix:continuation></ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

              <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX"><br />
                </a></div>

              <a href="#INDEX"></a>
              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: normal;">NOTES TO (UNAUDITED) CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c68" continuedAt="Text_a6892b0bc6eb414db40bfb30fbbc72c69"><ix:continuation id="Text_30791cfcf34d4b9e8642b9517ed86b0e4" continuedAt="Text_30791cfcf34d4b9e8642b9517ed86b0e5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_a6892b0bc6eb414db40bfb30fbbc72c69"><ix:continuation id="Text_30791cfcf34d4b9e8642b9517ed86b0e5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br />
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_7002684da4844380b5c50aa5f72764df" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,639,283</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_2819a460546e47c7a3241f931dc14230" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,525,987</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_7cc46def58e442bebe794c59f7b2f17c" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">530,434</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_de6d1c57e82a452f915f8ca1ed6e778c" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,940,425</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" rowspan="1">
                  <div style="margin-left: 9pt;">Warrants issued in connection with notes payable<br />
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_6fc90e03e0654ad190e44990fcfd6621" contextRef="c20230101to20230331" unitRef="U002" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_18e26e2fd0cc4c9f87be7a9d78d68656" contextRef="c20220101to20220331" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,569,604</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br />
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

    <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" id="Text_96ad9ee9489b4607a5eadc16385dbcf3" contextRef="c20230101to20230331" escape="true" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e751">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUBSEQUENT EVENT<br />
              </span></div>
          </td>

  </tr>


</table>
</ix:nonNumeric>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e751" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e752">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span></div>
</ix:continuation>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e752" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e753">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On May 1, 2023, the Company entered into a second amendment (the &#8220;Hayfin Second Amendment&#8221;) to the
      Hayfin Credit Agreement (see Note 7) whereby the Applicable Margin for adjusted Term SOFR Loans was reduced from <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_dba2d970d6a24fd1926d60d126b52c1c" contextRef="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.5</ix:nonFraction>% to <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_9f7e3de86e1a43f1a9daeee801a8fcaf" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%. The Hayfin Second Amendment also extended the obligation of the lenders to make the Hayfin Delayed Draw Loan from June 30, 2023 to December 31,
      2023. </div>
</ix:continuation>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e753" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e754">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e754" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e755">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Under the terms of the Hayfin Second Amendment, in the event the Company elects to prepay all or any
      portion of the outstanding principal on the Hayfin Loans, the Company will be subject to an early prepayment fee in the amount equal to (i) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_c317fce6c4f24a5fbb8a6c50ea7e2e9f" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.0</ix:nonFraction>%
      of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Hayfin Second Amendment, (ii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_71309a42a94f41148e761d8b09551a8c" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">3.0</ix:nonFraction>% of the prepaid
      principal amount, if prepaid after the first anniversary of the Hayfin Second Amendment and on or prior to the second anniversary of the Hayfin Second Amendment, or (iii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_95009fba074444afb57a70e5ca0a0ddf" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the prepaid principal amount, if prepaid after the second anniversary of the Hayfin Second Amendment and on or prior to the third anniversary of the Hayfin Second Amendment. In
      addition, the Hayfin Second Amendment provides for a <ix:nonFraction name="adma:PercentageOfReductionPrepaymentFees" id="Fact_a93dce55a3cf42baae06a275e9558dab" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% reduction to the foregoing early prepayment fees if the Hayfin Loans are prepaid
      in connection with a change in control of the Company or other strategic transactions as further described in the Hayfin Second Amendment.<br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e755" continuedAt="Text_ff137ce2026b4c848ced05b2071f1e756">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
    </div>
</ix:continuation>
    <ix:continuation id="Text_ff137ce2026b4c848ced05b2071f1e756">
<div style="display:none;"><br /></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> In connection with the Hayfin Second Amendment, the Company issued&#160; additional warrants to the lenders
      to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_34940b2621ff4c139d449aab3407eb84" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,391,244</ix:nonFraction> shares of the Company&#8217;s common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_34919303ef094e48a9552305878c0b18" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">3.2619</ix:nonFraction> per share (&#8220;the Hayfin Second Amendment Warrants&#8221;). The Hayfin Second Amendment Warrants were valued at approximately $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_fb2c3b32e02e403490c5cf22c87b9568" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction> million and have an expiration date of May 1, 2030.  </div>
</ix:continuation>
    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>


  </div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <a id="ManagementsDiscussionandA"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-indent: 36pt; font-style: italic;">The following discussion of our financial condition and results of operations, which refers to our historical results, should be read in conjunction with the other sections of this Quarterly Report on
      Form 10-Q, including &#8220;Risk Factors&#8221; and our unaudited consolidated financial statements and the notes thereto appearing elsewhere herein, and in conjunction with the Management&#8217;s Discussion and Analysis of Financial Condition and Results of
      Operations set forth in our Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 23, 2023 (the &#8220;2022 10-K&#8221;). The various sections of this discussion contain a number of forward-looking statements, all of which are based on
      our current expectations and could be affected by the uncertainties and risk factors described throughout or referenced within this Quarterly Report on Form 10-Q. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;&#160; Our actual results may differ
      materially from our current expectations.</div>

    <div>&#160;</div>

    <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">OVERVIEW</span></div>

    <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;"> <br />
      </span></div>

    <div style="font-weight: bold;">Our Business</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the
      treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who
      may be immune-suppressed for medical reasons.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an
      Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, and for which we received FDA approval on May
      9, 2019 and commenced commercial sales in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first
      commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of
      plasma-derived therapeutics, including but not limited to, a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of <span style="font-style: italic;">S.
        pneumonia</span> infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of <span style="font-style: italic;">S. pneumoniae</span>. Our products and product candidates are intended to be used by
      physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual source plasma processing capability of up to 600,000 liters (the &#8220;Boca
      Facility&#8221;). Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce quantities of our immune globulin (&#8220;IG&#8221;) products
      representing annual revenues of $220 million or more in 2023, potentially more than $250 million in annual revenue in 2024 and potentially in excess of $300 million of annual revenue thereafter, as well as achieving profitability during the first
      quarter of 2024. At these revenue levels, we forecast achieving consolidated gross margins in the range of 40-50% and net income margins in the range of 20-30%. These assumptions translate to potential annual gross profit and net income in the range
      of $100-$150 million and $50-$100 million, respectively, during the 2024-2025 time period and beyond.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the U.S. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with
      substantially all of our blood plasma for the manufacture of our products, and also allows us to sell certain quantities of source plasma and certain other plasma products to third-party customers for further manufacturing. With respect to our
      operational plasma collection centers, eight plasma collection centers currently hold FDA licenses, with the remaining plasma collection centers anticipated to receive FDA approvals throughout 2023. In addition, three of our FDA-approved plasma
      collection centers also have approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. After giving effect to the supply chain robustness initiatives undertaken in 2021
      and 2022 as it pertains to our plasma collection network expansion, we remain on track to achieve our goal of having 10 FDA-licensed plasma collection centers by the end of 2023. A typical plasma collection center, such as those operated by ADMA
      BioCenters, can collect approximately 30,000 to 50,000 liters of source and hyperimmune plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale. Plasma
      collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221; market.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We sell plasma-derived intermediate fractions to certain customers, which are generated as part of our FDA-approved manufacturing process for IG and IVIG products. In January 2020, we announced our entry into a five-year
      manufacturing and supply agreement to produce and sell these intermediate by-products, which are used as the starting raw material to produce other plasma-derived biologics. In addition, from time to time we provide contract manufacturing and testing
      services for certain third-party clients. We also provide laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packaging services in light of the FDA approval of our in-house fill-finish
      capabilities.</div>

    <div><br />
    </div>

    <div style="font-weight: bold;">Our Products</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">BIVIGAM</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses, and help
        to protect PI patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not
        limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders.</span>&#160;<span style="color: #000000;">Based on recent estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</span></div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">On May 9, 2019, the FDA approved the Prior Approval Supplement (the &#8220;PAS&#8221;) for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the United
      States. We resumed production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The
      commercial re-launch and first commercial sales for this product commenced in August of 2019.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. This increased
      IVIG plasma pool scale, which allows us to produce BIVIGAM at an expanded capacity utilizing the same equipment, release testing assays and labor force, has had a favorable impact on our gross margins and operating results.</div>

    <div><br />
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">ASCENIV</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and prevent
      against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific-J-code for ASCENIV.&#160; Under the
      Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored
      plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to Respiratory Syncytial Virus (&#8220;RSV&#8221;) using our proprietary microneutralization testing assay. We are able to
      identify the high titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV with our patented testing methods and assay. This type of high titer plasma is typically found in less than 10% of the total donor
      collection samples we test.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">ASCENIV is approved for the treatment of Primary Immune Deficiency Disorder (&#8220;PIDD&#8221;), a class of inherited genetic disorders that causes a deficient or absent immune system in adults and
        adolescents (12 to 17 years of age). Our pivotal Phase III clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections (&#8220;SBI&#8221;) reported during 12 months of treatment. Secondary efficacy endpoints further
        demonstrated the benefits of ASCENIV in the low incidence of infection, therapeutic antibiotic use, days missed from work/school/daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA
        approval for the treatment of PIDD better positions ADMA to potentially further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens at an appropriate time. Due
        to the COVID-19 pandemic, our plans have been delayed.&#160; In the future however, we may work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient
        population. Commercial sales of ASCENIV commenced in October of 2019 and our commercial and medical education efforts are focused on the labeled indication of patients with PIDD. </span>ASCENIV&#8217;s prescriber and patient base continued to expand
      during the fourth quarter of 2022, which drove record utilization and pull-through for the product. These elevated demand trends have sustained into 2023, and ADMA currently expects that this product&#8217;s rapid growth will continue throughout 2023 and
      beyond.</div>

    <div style="text-indent: 36pt;"> <span style="font-size: 10pt;"><br />
      </span></div>

    <div>
      <p style="margin: 0px; text-indent: 27pt; font-size: 10pt;">The FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of the ASCEINV IVIG product. This increased IVIG
        plasma pool scale, which allows us to produce ASCENIV at an expanded capacity utilizing the same equipment, release testing assays and labor force, is expected to have a favorable impact on our gross margins and operating results. During the second
        quarter of 2023, ADMA successfully commenced manufacturing of ASCENIV at the 4,400 Liter production scale for the first time in corporate history. </p>
    </div>

    <div><span style="font-size: 10pt;"> </span></div>

    <div><span style="color: rgb(0, 0, 0); font-size: 10pt;"> </span><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Nabi-HB</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a
      Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with
      acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem. It can cause chronic infection and puts people at high
      risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.&#160; Production of Nabi-HB at the Boca Facility
      has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the U.S. and we continue to manufacture
      Nabi-HB under HHS License No. 2019.</div>

    <div><br />
    </div>

    <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">POTENTIAL IMPACT OF COVID-19</span></div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We continue to monitor the ongoing developments related to the COVID-19 pandemic, including the emergence of the Delta, Omicron and BA.2 variants and other resistant strains of the coronavirus, and its impacts to our
      commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug
      product that is required prior to its availability for commercial sale. A substantial portion of such testing has historically been performed by contract laboratories outside the United States.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Due to a combination of previously mandated state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, persisting social distancing measures and varying roll-outs of vaccinations by state, we
      experienced at times lower than normal donor collections at our FDA approved plasma collection centers during 2021 and part of 2022. From time to time during 2021 and 2022, we were also subject to delays in shipments of source plasma from our
      contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of our products. In addition, we have been subject
      to supply chain delays as a result of certain of our suppliers diverting significant resources towards the rapid development and distribution of COVID-19 vaccines and, as a result, we have elected to carry more raw materials inventory than we have in
      the past. The COVID-19 pandemic previously impacted, to a certain degree, our customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel faced difficulties communicating directly with physicians and other healthcare
      professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting our ability to communicate with potential customers.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">The pandemic could also impact our ability to interact with the FDA or other regulatory authorities and could result in delays in the conduct of inspections or review of pending applications or submissions. Although we
      have received FDA approvals for five of our plasma collection centers since January 1, 2022 and received several other FDA approvals while two FDA inspections of the Boca Facility were completed during the year ended December 31, 2021, no assurances
      can be provided as to the timing for completion of any future regulatory submissions or applications that may be impacted by restrictions related to COVID-19.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, our revenue attributable to international customers was approximately 7% and 6%, respectively, of our total revenues. As we seek to grow this aspect of our business,
      we may also be subject to the impacts of the COVID-19 pandemic in locations outside the United States.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on our financial condition or results of operations, and we do not believe that our production operations at the Boca Facility,
      our contract fill/finishers or our plasma collection facilities have been significantly impacted by the COVID-19 pandemic. As a result, we do not anticipate and have not experienced any material impairments with respect to any of our long-lived
      assets, including our property and equipment, goodwill or intangible assets.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Although the COVID-19 pandemic has not, to date, materially adversely impacted our capital and financial resources, because we are unable to determine the ultimate severity or duration of the pandemic or its long-term
      effects on, among other things, the global, national or local economies, the capital and credit markets or our workforce, customers or suppliers, at this time we are unable to predict whether COVID-19, or any known or future variant or government
      order, will have a material adverse impact on our business, financial condition, liquidity and results of operations. After the COVID-19 global pandemic has settled, we may continue to experience adverse impacts to our business as a result of
      evolving macroeconomic factors, including general economic uncertainty, unemployment rates, inflationary pressures and any actual economic recession that has occurred or may occur in the future.</div>

    <div><br />
    </div>

    <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">RESULTS OF OPERATIONS</span></div>

    <div><br />
    </div>

    <div style="font-weight: bold;">Critical Accounting Policies and Estimates</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed consolidated financial statements, which have been prepared in accordance with Accounting Principles
      Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and
      expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances.
      These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.
      Significant estimates include rebates and certain other deductions from gross revenues, impairment of long-lived assets, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards granted
      under our equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for our deferred tax assets.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Some of the estimates and assumptions we have to make under U.S. GAAP require difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, actual results could differ from
      those estimates. Due to the estimation processes involved, the following summary of accounting estimates and their application are considered to be critical to understanding our business operations, financial condition and results of operations. For
      a description of our significant accounting policies, see Note 2 to the Consolidated Financial Statements included in the 2022 10-K. Estimates and assumptions used in projecting future liquidity and capital requirements are described in Note 1 to the
      condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Revenues</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Our gross product revenues are subject to a variety of deductions, which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates, distribution fees,
      chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while other estimates require complex or
      subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Historically, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. However, two of our primary immunoglobulin products, ASCENIV and BIVIGAM,
      were only approved for commercial sale by the FDA in 2019, and as such our historical experience with rebates with respect to these products is limited. If any of our ratios, factors, assessments, experiences or judgments are not indicative or
      accurate estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment are those associated with U.S. Medicaid rebates because of the extensive time delay between the recording
      of the accrual and its ultimate settlement, an interval that can generally take up to several years or more. While our results of operations to date have not required any material adjustment due to this risk, the delay between when this obligation is
      initially recorded and ultimately settled could potentially materially impact our revenues and our results of operations in the future.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Stock-Based Compensation and Valuation of Warrants</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">All equity-based payments, including grants of stock options and Restricted Stock Units (&#8220;RSUs&#8221;) are recognized at their estimated fair value at the date of grant, and compensation expense is recognized on a
      straight-line basis over the grantee&#8217;s requisite vesting period. For the purpose of valuing stock options granted to our employees, directors and officers, we use the Black-Scholes option pricing model. The Black-Scholes option valuation model was
      developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options,
      and changes in the underlying Black-Scholes assumptions can materially affect the fair value estimate. To determine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with
      the expected term of our awards. The expected term of the options granted is in accordance with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletins 107 and 110 and is based on the average between vesting terms and contractual
      terms. The expected dividend yield reflects our current and expected future policy for dividends on our Common Stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our Common Stock
      since our Common Stock became publicly traded in the fourth quarter of 2013. We will continue to analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate.
      Any changes in the foregoing Black-Scholes assumptions, or if we were to elect to utilize an alternative method for valuing stock options granted to employees, directors and officers, could potentially impact our stock-based compensation expense and
      our results of operations.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We also use the Black-Scholes option valuation model for the purpose of estimating the fair value of warrants we issue from time to time in connection with the issuance of notes payable. Changes in our Black-Scholes
      assumptions, or if we were to utilize an alternative method for valuing warrants issued to our lenders, could impact our interest expense and results of operations.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">We assess the recoverability of our long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have
      occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded
      as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three months ended March 31, 2023 and 2022, we determined that there was no impairment of our long-lived assets. Examples of
      events or circumstances that may be indicative of impairment that would require the use of significant judgment by management include:</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>A significant adverse change in legal factors or in the business climate that could affect the value of the asset.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Significant and continued cash flow losses.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>A significant adverse change in the extent or manner in which an asset is used, such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability to manufacture our products using a particular asset.</div>
            </td>

  </tr>


</table>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>An expectation of losses or reduced profits associated with an asset. This could result, for example, from the introduction of a competitor&#8217;s product that impacts projected revenue growth, or a change in the&#160; acceptance of a product by
                patients, physicians and payers that results in an inability to sustain projected product revenues.</div>
            </td>

  </tr>


</table>
    </div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The testing of goodwill for impairment requires us to determine whether or not the fair value
      of the reporting unit associated with the goodwill is less than its carrying amount, including goodwill and other intangible assets. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value, with the
      impairment loss recognized not to exceed the total amount of goodwill allocated to that reporting unit. In order to determine the fair value of the reporting unit, we utilize the fair value of the Company as a whole, as determined by its market
      capitalization. Determination of the fair value and carrying value of each reporting unit, relative to the fair value of the Company, requires management to employ certain estimates, assumptions and judgment, which we believe are reasonable. However,
      any changes to these estimates and assumptions could impact our determination of whether or not our goodwill is impaired. We did not recognize any impairment charges related to goodwill for the three months ended March 31, 2023 and 2022.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Deferred Tax Assets</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">We maintain a full valuation allowance against all of our net deferred tax assets, and as a result have recorded no income tax benefit in the accompanying consolidated financial statements. This valuation allowance
      reflects our assessment of whether it is more likely than not that we will generate sufficient taxable income in the future to be able to utilize our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors
      such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred
      tax assets.&#160; We consider cumulative losses in recent years to be a significant type of negative evidence. Based on our history of losses, at this time we have not included future projected taxable income as a source of income to recognize our
      deferred tax assets.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-align: justify; font-weight: bold;">Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022</div>

    <div>&#160;</div>

    <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the three months ended March 31, 2023, our first fiscal quarter, compared to the three months ended March 31,
      2022:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1"></td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="10">
            <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended March 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; color: #000000; font-weight: bold;">Increase (Decrease)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Revenues</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">56,913,534</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">29,103,093</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">27,810,441</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cost of product revenue</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">40,400,544</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">25,441,046</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">14,959,498</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gross profit</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">16,512,990</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">3,662,047</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">12,850,943</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">855,351</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">624,111</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">231,240</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Plasma center operating expenses</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,780,463</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">3,974,589</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(2,194,126</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization of intangibles</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">178,838</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">178,838</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">-</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Selling, general and administrative expenses</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">14,511,656</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">13,699,575</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">812,081</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss from operations</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(813,318</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(14,815,066</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">14,001,748</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(6,115,484</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(3,389,038</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(2,726,446</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">-</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(6,669,941</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">6,669,941</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other income (expense), net</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">139,987</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(133,812</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">273,799</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(6,788,815</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(25,007,857</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">18,219,042</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Adjusted EBITDA *</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">2,469,800</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(11,717,273</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">14,187,073</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br />
    </div>

    <div>* - See Non-GAAP Financial Measures appearing at the end of this discussion </div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Revenues</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">We recorded total revenues of $56.9 million during the three months ended March 31, 2023, as compared to $29.1 million during the three months ended March 31, 2022, an increase of $27.8 million, or approximately 96%. The
      increase is primarily related to increased sales of our immunoglobulin products, mainly ASCENIV and BIVIGAM, generated by our Boca Facility manufacturing operations in 2023 of $23.8 million, as we continue to experience increased physician, payer and
      patient acceptance and utilization of ASCENIV and expand our customer base for BIVIGAM. We also benefitted from a substantial increase in sales of normal source plasma through our Plasma Collection Centers business segment of $4.0 million.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">During the first quarter of 2023, we fulfilled our entire commitment to supply normal source plasma to our third-party customer for fiscal 2023. As a result, we do not expect to generate comparable revenues from our
      Plasma Collection Centers during the remainder of 2023, as we anticipate using all of the plasma collected during that period to support our IVIG production operations.</div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue and Gross Profit</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Cost of product revenue was $40.4 million for the three months ended March 31, 2023, as compared to $25.4 million for the three months ended March 31, 2022. This increase is primarily attributable to volume-driven
      increases in product revenue costs related to the increased sales of our immunoglobulin products of $15.2 million and increased sales of normal source plasma by our Plasma Collection Centers business segment in the amount of $3.0 million. These
      increases were partially offset by a decrease in other manufacturing expenses of approximately $3.3 million in the first quarter of 2023 as compared to the same period of a year ago, mainly due to a shorter routine shutdown of the Boca Facility in
      2023 as compared to 2022.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">For the three months ended March 31, 2023, we had gross profit of $16.5 million, as compared to $3.7 million for the same period of a year ago. This gross profit improvement of approximately $12.9 million was primarily
      due to the revenue increases and the reduction in other manufacturing costs discussed above as we elected to extend our otherwise-routine plant shutdown in the first quarter of 2022 in order to complete certain projects. As a result, we achieved a
      gross margin of 29.0% in the first quarter of 2023 as compared to 12.6% in the first quarter of 2022.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Research and development (&#8220;R&amp;D&#8221;) expenses totaled $0.9 million for the first quarter of 2023, as compared to $0.6 million for the first quarter of 2022. The increase is primarily due to higher expenditures related to
      the BIVIGAM and ASCENIV post-marketing commitments we have with the FDA, which are required to be completed by June of 2023 (see Note 10 to the consolidated financial statements).</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Plasma Center Operating Expenses decreased from $4.0 million in the first quarter of 2022 to $1.8 million in the first quarter of 2023. As a result of our plasma center expansion initiatives, including three additional
      plasma collection facilities that opened subsequent to March 31, 2022, we experienced a significant increase in the number of liters of plasma collected in the first quarter of 2023 as compared to the first quarter of 2022. In addition, as a result
      of changes in the market price of normal source plasma and the impact on the net realizable value of our plasma inventory, the amount of plasma center costs we capitalized into inventory increased by approximately $10.6 million in the first quarter
      of 2023 as compared to the same period of a year ago. This amount was largely offset by increases in donor fees of $3.4 million, compensation and benefits of $1.1 million, softgoods and supplies of $1.3 million, donor testing expenses of $1.1
      million, depreciation of $0.3 million, temporary labor expenses of $0.3 million, software maintenance expense of $0.2 million, utilities and janitorial expense of $0.2 million, travel expenses of $0.1 million, transportation costs of $0.1 million,
      advertising expense of $0.1 million, repairs and maintenance expense of $0.1 million and rent of $0.1 million.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Amortization expense pertains to the amortization of intangible assets acquired in a 2017 acquisition transaction and was $0.2 million for the three months ended March 31, 2023 and 2022.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $14.5 million for the three months ended March 31, 2023, an increase of $0.8 million from the three months ended March 31, 2022. The increase reflects
      increases in data services and market intelligence fees in support of the continued ASCENIV and BIVIGAM commercialization efforts in the amount of $0.7 million, other professional services of $0.6 million, insurance expense of $0.2 million, employee
      recruiting of $0.2 million, software maintenance expense of&#160; $0.2 million, utilities and janitorial expense of $0.1 million, marketing expenses of $0.1 million and travel and entertainment costs of $0.1 million, partially offset by the non-recurring
      professional fees incurred in connection with the Morgan Stanley strategic alternatives process during the first quarter of 2022 in the amount of $1.4 million.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Loss from Operations</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Our operating loss was $0.8 million for the first quarter of 2023, as compared to $14.8 million for the first quarter of 2022. The $14.0 million decrease in operating loss was mainly due to the improved gross profit of
      $12.9 million and the reduction in Plasma Center Operating expenses of $2.2 million, partially offset by the increases in R&amp;D and SG&amp;A.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Interest expense for the three months ended March 31, 2023 was $6.1 million, as compared to $3.4 million for the three months ended March 31, 2022. The increase is mainly due to approximately $55.7 million of additional
      debt principal resulting from the refinancing of our senior credit facility on March 23, 2022 (see Note 7 to the consolidated financial statements and &#8220;Liquidity and Capital Resources&#8221;), including interest payments made &#8220;in kind&#8221; in the form of
      additional indebtedness of approximately $4.0 million, as well as an increase in the stated interest rate on our senior debt from 10.75% in 2022 to 14.1% in 2023.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Other Income (Expense), Net</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Other income, net, for the three months ended March 31, 2023 was $0.1 million, as compared to other expense, net, of $0.1 million for the three months ended March 31, 2022. The increase is mainly due to an increase in
      interest and other income of approximately $0.2 million in 2023, and to several non-recurring non-operational charges in 2022 of approximately $0.2 million.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Net Loss</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Our net loss was $6.8 million for the first quarter of 2023, as compared to $25.0 million for the first quarter of 2022. The $18.2 million decrease in net loss was mainly due to the narrowed operating loss of $14.0
      million attributable to the increased revenues and gross profit and the loss on extinguishment of debt of $6.7 million we recorded in the first quarter of 2022 in connection with the refinancing of our senior credit facility, partially offset by the
      increase in interest expense.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Non-GAAP Financial Measures</div>

    <div>&#160;</div>

    <div style="font-style: italic; font-weight: bold;">Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;) and Adjusted EBITDA</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">EBITDA and Adjusted EBITDA are important non-GAAP financial measures used by our management and board of directors to assess our operating performance. We use EBITDA and Adjusted EBITDA as key performance measures
      because we believe that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of
      Adjusted EBITDA, stock-based compensation or certain non-recurring items. In addition, we believe that EBITDA and Adjusted EBITDA and similar measures are widely used by investors, securities analysts, ratings agencies and other parties in evaluating
      companies in our industry as a measure of financial performance and debt-service capabilities. See below for a reconciliation of our EBITDA and Adjusted EBITDA to net income/loss, the most directly comparable financial measure calculated and
      presented in accordance with U.S. GAAP.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Because EBITDA and Adjusted EBITDA are measures not deemed to be in accordance with U.S. GAAP and are susceptible to varying calculations, our EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures
      of other companies, including companies in our industry, because other companies may calculate EBITDA and Adjusted EBITDA in a different manner than we calculate these measurements. <span style="color: #000000;">Although the Company uses Adjusted
        EBITDA as one of several financial measures to assess its operating performance, its use is limited as it excludes certain significant operating expenses. EBITDA and Adjusted EBITDA are not intended to represent cash flows for the periods
        presented, nor have they been presented as an alternative to operating income/loss, net income/loss or as an indicator of operating performance and should not be considered in isolation or as a substitute for measures of performance prepared in
        accordance with U.S. GAAP. The following table presents the reconciliation of net loss to EBITDA and Adjusted EBITDA for the three months ended March 31, 2023 and 2022:</span></div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; color: #000000; font-weight: bold;">Three Months Ended March 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net loss</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(6,788,815</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(25,007,857</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Depreciation</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,854,127</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,411,378</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">178,838</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">178,839</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">6,115,484</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">3,389,038</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">EBITDA</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,359,634</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(20,028,602</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Stock-based compensation</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,110,166</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">1,641,388</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div style="color: #000000;">-</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div style="color: #000000;">6,669,941</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Adjusted EBITDA</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">2,469,800</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">(11,717,273</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div style="color: #000000;">)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-indent: 36pt;">Adjusted EBITDA increased by $14.2 million for the three months ended March 31, 2023 as compared to the same period of a year ago. The improvement is driven primarily by the lower net loss attributable to increased sales
      and gross profit and, to a lesser extent, lower total operating expenses in 2023.</div>

    <div><br />
    </div>

    <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">LIQUIDITY AND CAPITAL RESOURCES</span></div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">At March 31, 2023, we had working capital of $227.4 million, primarily consisting of $164.0 million of inventory, cash and cash equivalents of $69.2 million and $26.5 million of accounts receivable, partially offset by
      current liabilities of $36.7 million, as compared to working capital at December 31, 2022 of $231.1 million, primarily consisting of $163.3 million of inventory, cash and cash equivalents of $86.5 million and accounts receivable of $15.5 million,
      partially offset by current liabilities of $39.3 million. We have incurred an accumulated deficit of $484.8 million since inception and had negative cash flows from operations of $14.7 million and $26.0 million for the three months ended March 31,
      2023 and 2022, respectively, and $59.5 million and $112.4 million for the years ended December 31, 2022 and 2021, respectively. We have funded our operations over the past few years primarily from the sale of our equity and debt securities. Our
      material cash requirements are primarily comprised of:</div>

    <div>&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The procurement of raw material plasma and other raw materials necessary to maintain and scale up our manufacturing operations;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Employee compensation and benefits;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Capital expenditures to complete the buildout for and maintain our plasma collection facilities and for equipment upgrades and capacity expansion at the Boca Facility;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Plasma donor fees and plasma center supplies;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Interest on our debt;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Marketing programs and continued commercialization efforts;</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Boca Facility maintenance, repairs and supplies; and</div>
          </td>

  </tr>


</table>
    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Conducting required post-marketing clinical trials for our FDA-approved products.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div>In addition, our end-to-end production cycle time from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial inventories of raw material plasma and
      other manufacturing materials and single use disposables.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024. We currently anticipate, based upon our projected revenue and expenditures, that
      our current cash, cash equivalents and accounts receivable will be sufficient to fund our operations, as currently conducted, through the end of the second quarter of 2024, by which time we believe we will begin to generate positive cash flow from
      operations. This time frame may change based on several factors, including the success of our commercial efforts with respect to the sale of our products and the acceptability of our immune globulin products by physicians, patients or payers, and
      whether or not the assumptions underlying our projected revenues and expenses are correct. If we are unable to achieve positive cash flow by the beginning of 2024, we may need to raise additional capital and if such capital is not available due to
      widespread liquidity constraints or significant market instability that could result from the COVID-19 pandemic, inflationary pressures or other factors beyond our control, we may have to delay, curtail or eliminate some of our commercialization
      efforts or product development activities. If we are unable to generate sufficient revenue to achieve positive cash flow by the beginning of 2024 and need to raise additional capital, we may decide to do so through public or private equity offerings
      or debt financings, or we may enter into a corporate collaboration or licensing arrangement.&#160; The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders and, in such event, the value and potential
      future market price of our common stock may decline.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">&#160;&#160;ADMA continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The exploration of value-creating opportunities remains a top corporate priority for ADMA.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">On March 23, 2022, (the &#8220;Hayfin Closing Date&#8221;) we and all of our subsidiaries entered into a Credit and Guaranty Agreement (the &#8220;Hayfin Credit Agreement&#8221;) with Hayfin Services LLP (&#8220;Hayfin&#8221;). The Hayfin
      Credit Agreement provides for a senior secured term loan facility in a principal amount of up to $175.0 million (the &#8220;Hayfin Credit Facility&#8221;), composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0 million (the
      &#8220;Hayfin Closing Date Loan&#8221;), and (ii) a delayed draw term loan in the principal amount of $25.0 million (the &#8220;Hayfin Delayed Draw Loan&#8221; and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans&#8221;). Pursuant to an amendment to the Hayfin
      Credit Agreement dated May 1, 2023 (the &#8220;Hayfin Second Amendment&#8221;), the obligation of the lenders to make the Hayfin Delayed Draw Loan expires on December 31, 2023, and was subject to the satisfaction of certain conditions, including, but not limited
      to, our meeting certain 12-month revenue targets as set forth in the Hayfin Credit Agreement which have been met. The Hayfin Credit Facility has a maturity date of March 23, 2027 (the &#8220;Hayfin Maturity Date&#8221;), subject to acceleration pursuant to the
      Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement).</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">On the Hayfin Closing Date, we used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under our previous senior credit facility with Perceptive
      (see Note 7 to the Consolidated Financial Statements). We also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay
      certain fees and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit
      Agreement. The remainder of the proceeds received or to be received from the Hayfin Loans are being used for working capital and other general corporate purposes.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">After giving effect to the Hayfin Second Amendment, borrowings under the Hayfin Credit Agreement currently bear interest at the adjusted Term SOFR for either a one-month or three-month tenor, as elected
      by us, and subject to a floor of 1.25%, plus an applicable margin of 8.5% (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin shall increase by an additional 3% per annum.
      We will also pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly or quarterly interest period in an amount equal to 2.5% per annum. Such interest paid &#8220;in kind&#8221; will reduce our quarterly cash interest obligation by
      approximately $1.0 million and will be added to the principal amount of the outstanding debt under the Hayfin Credit Facility. As a result, our outstanding debt principal on the Hayfin Loans will increase each month as long as we elect to continue to
      pay a portion of our interest obligation &#8220;in kind.&#8221; On the Hayfin Closing Date and as of March 31, 2023, the stated interest rate on the Hayfin Loans was 10.75% and 14.4%, respectively. On the last day of each calendar month or quarter during the
      term of the Hayfin Credit Facility, we are required to pay accrued interest to Hayfin of approximately $1.5 million per month or approximately $4.4 million per quarter based on current interest rates, after giving effect to the &#8220;in kind&#8221; interest of
      2.5% per annum, but without giving effect to the Hayfin Delayed Draw Loan, which we have yet to draw upon.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">On the Hayfin Maturity Date, we will pay Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as well as an exit fee of 1.0% of the outstanding principal
      amount being paid. Prior to the Hayfin Maturity Date, there are no scheduled principal payments on the Hayfin Loans. We may prepay outstanding principal on the Hayfin Loans at any time and from time to time upon five business days&#8217; prior written
      notice, subject to the payment to Hayfin of, (A) any accrued but unpaid interest on the prepaid principal amount plus (B) a prepayment fee in the amount equal to (i) 7.0% of the prepaid principal amount, if prepaid on or prior to the first
      anniversary of the Hayfin Second Amendment, (ii) 3.0% of the prepaid principal amount, if prepaid after the first anniversary of the Hayfin Second Amendment and on or prior to the second anniversary of the Hayfin Second Amendment, or (iii) 1.0% of
      the prepaid principal amount, if prepaid after the second anniversary of the Hayfin Second Amendment and on or prior to the third anniversary of the Hayfin Second Amendment. The Hayfin Second Amendment also provides for a 50% reduction to the
      foregoing early prepayment fees if the Hayfin Loans are prepaid under certain circumstances as defined in the Hayfin Second Amendment. In addition, for any prepayments of principal, we are required to pay the 1.0% exit fee for the amount of principal
      being paid.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">All of our obligations under the Hayfin Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual
      property and all of the equity interests in our subsidiaries. The Hayfin Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings.
      The negative covenants restrict or limit our ability and the ability of our subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin Credit Agreement, incur new indebtedness; create liens on assets; engage in
      certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Hayfin Credit Agreement); change our fiscal
      year; pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments under the Hayfin Credit
      Agreement. In addition, we are required (i) at all times prior to the Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing
      12-month period that exceed the amounts set forth in the Hayfin Credit Agreement, which range from $75.0 million for the fiscal quarter ending June 30, 2022 to $250.0 million for the fiscal quarter ending December 31, 2026 and each fiscal quarter
      thereafter. As of March 31, 2023, we were in compliance with all of the financial covenants contained in the Hayfin Credit Agreement.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">On December 9, 2022, we completed an underwritten public offering whereby we issued 24,125,873 shares of our common stock. Net proceeds after underwriting discounts and expenses associated with the offering were
      approximately $64.6 million and are being used to accelerate commercialization and production activities, complete plasma center buildouts and obtain FDA approvals, to conclude post&#8209;FDA marketing approval research and development projects, and for
      working capital, capital expenditures and general corporate purposes.</div>

    <div>
      <div><br />
      </div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div>
      <div style="text-indent: 36pt;">On September 3, 2021, we entered into a distribution agreement with Raymond James<span style="color: #000000;"> &amp; Associates, Inc., as agent (&#8220;Agent&#8221;), pursuant to which we may offer and sell, from time to time, at
          our option, through or to the Agent, up to an aggregate of $50 million of shares of our common stock (the &#8220;Distribution Agreement&#8221;). We currently intend to use any net proceeds from the sale of our common stock under the Distribution Agreement
          for general corporate purposes, including procurement of source plasma and other raw materials, supply chain initiatives and production expenditures, funding expansion of plasma collection centers, working capital, capital expenditures, expansion
          and resources for commercialization activities, and other potential research and development and business opportunities. We currently have approximately $42.8 million of shares available to sell under the Distribution Agreement.</span></div>

    </div>

    <div><br />
    </div>

    <div style="font-weight: bold;">Cash Flows</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">The following table sets forth a summary of our cash flows for the periods indicated:&#160;</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; font-weight: bold;">Three Months Ended March 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in operating activities</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(14,722,274</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(26,013,413</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in investing activities</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(1,944,596</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(2,842,085</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash (used in) provided by financing activities</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(650,509</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>47,271,326</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net change in cash and cash equivalents</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(17,317,379</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>18,415,828</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - beginning of period</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div>86,521,542</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div>51,089,118</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - end of period</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>69,204,163</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>69,504,946</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Net Cash Used in Operating Activities</div>

    <div style="font-style: italic; font-weight: bold;"> <br />
    </div>

    <div style="text-indent: 36pt;">Cash used in operations for the three months ended March 31, 2023 was $14.7 million, a decrease of $11.3 million from the same period of a year ago, mainly due to a lower net loss after non-cash items. The following
      table illustrates the primary components of and changes to our cash flows from operations:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="6">
            <div style="text-align: center; font-weight: bold;">Three Months Ended March 31,</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;"> 2023</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-weight: bold;">2022</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net loss</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(6,788,815</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(25,007,857</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-cash expenses, gains and losses</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>4,593,386</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>10,452,680</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts receivable</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(11,013,446</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>2,947,233</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in inventories</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(704,826</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(14,422,219</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in prepaid expenses and other current assets</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>716,465</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>(1,180,056</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts payable and accrued expenses</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(1,626,719</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
            <div>(89,802</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div>101,681</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">
            <div>1,286,608</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
            <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash used in operations</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div>(14,722,274</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div>$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
            <div>(26,013,413</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
            <div>)</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Net Cash Used in Investing Activities</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Net cash used in investing activities for the three months ended March 31, 2023 and 2022 was $1.9 million and $2.8 million, respectively, consisting of capital expenditures for the construction and buildout of new plasma
      collection centers and related equipment and capital expenditures at the Boca Facility. While we currently have no firm commitments for capital expenditures, we expect our total capital expenditures will be between $7.0 million and $9.0 million for
      the remainder of fiscal 2023, mainly for additional upgrades to the Boca Facility manufacturing operations and related systems.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Net Cash Provided by Financing Activities</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Cash used in financing activities was $0.7 million for the three months ended March 31, 2023, as compared to cash provided by financing activities was $47.3 million for the three months ended March 31, 2022 which mainly
      consisted of proceeds received from the Hayfin Credit Facility, net of payments to retire our previously existing credit facility with Perceptive (see Note 7 to the Consolidated Financial Statements).</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="color: #000000; font-weight: bold;">Effect of Inflation</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Inflation impacted a number of facets of our business during the three months ended March 31, 2023 and 2022 at both of our business segments. We experienced price increases for, among other items, certain raw materials,
      consumable supplies, services for repairs and maintenance of our facilities, utilities, shipping and freight charges, fuel surcharges and labor costs. We expect this trend to continue through 2023 and potentially longer, which could have a
      significant impact on our future results of operations. In addition, some of our plasma purchase agreements provide for annual price increases that are tied to various consumer price indices, which have resulted in higher than historical percentage
      price increases and has resulted in and is expected to continue to result in higher source plasma and other raw material and supplies costs in the remainder of 2023 and future periods.</div>

    <div><br />
    </div>

    <div style="font-weight: bold;">Off-Balance Sheet Arrangements</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt; color: #000000;">None.</div>

    <div style="text-indent: -72pt; margin-left: 72pt;"><br />
    </div>

    <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-indent: 36pt;">Not applicable.</div>

    <div><br />
    </div>

    <a id="ControlsandProcedures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Controls and Procedures.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">We designed our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), to provide reasonable assurance
      that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated and
      communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and
      procedures as of March 31, 2023. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures as of March 31, 2023 were functioning effectively to provide
      reasonable assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated
      and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosures.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">A control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide
        absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span> We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to prevent
      with certainty all errors and all fraud.</div>

    <div><br />
    </div>

    <div style="font-weight: bold;">Changes in Internal Control Over Financial Reporting</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over
      financial reporting.</div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <a id="PARTII"><!--Anchor--></a>
    <div style="text-align: center; font-weight: bold;">PART II</div>

    <div>&#160;</div>

    <div style="text-align: center; font-weight: bold;">OTHER INFORMATION</div>

    <div>&#160;</div>

    <a id="LegalProceedings."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Legal Proceedings.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-indent: 36pt;">We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that
      would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</div>

    <div><br />
    </div>

    <a id="RiskFactors"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 1A.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Risk Factors</div>
          </td>

  </tr>


</table>
    <div><span style="font-weight: bold;"> </span><br />
    </div>

    <div style="font-weight: bold;">Summary of Risk Factors</div>

    <div><br />
    </div>

    <div style="font-style: italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in
      this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Form 10-Q, the 2022 10-K and our other filings with the SEC,
      before making an investment decision regarding our common stock.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We have a history of losses and we may, in the future, need to raise additional capital to operate our business, which may not be available on favorable terms, if at all.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We are currently not profitable and may never become profitable.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The COVID-19 pandemic or other pandemics and efforts to reduce their spread has significantly affected worldwide economic conditions and could have a material adverse impact on our business, liquidity, financial condition and results of
              operations, as well as a change to the overall market size and potential for our products.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture. This reliance on third parties carries the risk that the services upon which we rely may not be performed in a timely
              manner or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to grow
              at similar rates, if at all.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Both of our business segments and our facilities are subject to periodic inspections by the FDA, which, depending on the outcome of such inspections, could result in certain FDA actions, including the issuance of observations, notices,
              citations or warning letters.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Business interruptions could adversely affect our business.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited and FDA could require clinical trials beyond what we
              may deem to be reasonable. Unless additional clinical trials are successfully conducted and the FDA approves a BLA or other required submission for review, we may not be authorized to market ASCENIV for any other indication.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>With the approval to market ASCENIV, BIVIGAM and Nabi-HB, there can be no assurance that we will be successful in further developing and expanding commercial operations or balancing our research and development activities with our
              commercialization activities.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, and such parties are outside of our control.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from the
              FDA.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we fail
              to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and
              financial condition.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing
              products, and if our business development efforts are not successful, our ability to achieve profitability may be adversely impacted.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Our ADMA BioCenters operations collect information from donors in the U.S. that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Our senior credit facility with Hayfin Services LLP (&#8220;Hayfin&#8221;) is subject to acceleration in specified circumstances, which may result in Hayfin taking possession and disposing of any collateral.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially
              damaged.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Cyberattacks and other security breaches could compromise our proprietary and confidential information, which could harm our business and reputation.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing processes against transmittable
              diseases.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw materials.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="font-weight: bold;">Risk Factors</div>

    <div>&#160;</div>

    <div style="font-style: italic;">Described below are various risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. You should recognize that other significant risks and uncertainties may
      arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or that
      are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial condition or results of operations could be materially and
      adversely affected. You should carefully consider the following risk factors and the section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; before you decide to invest in our securities.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-weight: bold;">Risks Relating to our Business</div>

    <div>&#160;</div>

    <div style="font-style: italic; font-weight: bold;">To date, we have a history of losses and have historically needed to raise, and in the future may be required to raise, additional capital to operate our business.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our long-term liquidity depends upon our ability to grow our commercial programs, expand our commercial operations at the Boca Facility, improve our supply-chain capabilities, improve production yields, continue to build
      out our commercial infrastructure and meet our ongoing obligations. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer,
      requiring substantial investments in raw material plasma and other manufacturing materials.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable will be sufficient to fund our operations, as currently conducted, through the
      end of the second quarter of 2024, by which time we believe we will begin to generate positive cash flow from operations. This time frame may change based upon how quickly we are able to execute on our commercialization efforts and operational
      initiatives and whether or not the assumptions underlying our projected revenues and expenses are correct. We anticipate that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024.
      If we are unable to generate sufficient positive cash flow in the first quarter of 2024 and cannot raise additional capital if needed, we may have to delay, curtail or eliminate our commercialization efforts as well as product development activities.
      Even if we are able to raise additional capital, such equity or debt financings may only be available on unattractive terms, resulting in significant dilution of stockholders&#8217; interests and, in such event, the value and potential future market price
      of our common stock may decline. In addition, if we raise additional funds through license arrangements or through the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or assets
      or grant licenses on terms that are not favorable to us.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We also continue to evaluate a variety of strategic alternatives through our ongoing engagement with Morgan Stanley. The exploration of value-creating opportunities remains a top corporate priority for ADMA.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Historically, the major source of our cash has been from proceeds from various public offerings of our common stock and the issuance of debt securities. The actual amount of additional cash that we may need, if any, is
      subject to many factors. There can be no assurances that additional financing will be available if needed or that management will be able to obtain financing on terms acceptable to us or that we will become profitable and generate positive operating
      cash flow.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We are currently not profitable and may never become profitable.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We have a history of losses and expect to incur substantial losses and negative operating cash flows in&#160; fiscal 2023, and we may never achieve or maintain profitability. For the years ended December 31, 2022 and 2021, we
      incurred net losses of $65.9 million and $71.6 million, respectively, and for the three months ended March 31, 2023 and 2022 we incurred net losses of $6.8 million and $25.0 million, respectively. From our inception in 2004 through March 31, 2023, we
      have incurred an accumulated deficit of $484.8 million. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and if we are unable to achieve positive cash flow we
      may need to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements. We also expect to continue to incur significant operating and capital expenditures and anticipate that as
      our business continues to grow our operating expenses will increase accordingly as we:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand commercialization and marketing efforts;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>implement additional internal systems, controls and infrastructure;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>hire additional personnel;</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand and build out our plasma center network; and</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>expand production capacity at the Boca Facility.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">As a result, we will need to generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">The COVID-19 pandemic and efforts to reduce its spread has significantly affected worldwide economic conditions, caused supply chain disruptions and could have a material adverse
      impact on our business, liquidity, financial condition and results of operations.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">The COVID-19 pandemic, including the Delta, Omicron and BA.2 variants and other resistant, mutating and emerging strains of the coronavirus, has the potential to adversely impact several aspects of each of our business
      segments, our commercial manufacturing operations and plasma collection facilities, including but not limited to potential disruptions to our supply-chain operations, including procurement of raw materials and packaging materials, a portion of which
      are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale.&#160; Such testing has historically been performed by contract laboratories outside the United States. While we do not
      believe that the COVID-19 pandemic has significantly affected operations and immunoglobulin production at our Boca Facility or our ADMA BioCenters plasma collection operations at this time, we may experience adverse effects in the future from the
      COVID-19 pandemic or future pandemics. For example, our employees becoming ill, the imposition of additional mandatory remote working environments and federal, state and local responses to the pandemic could materially affect the efficiency and pace
      of our operations and manufacturing at our Boca Facility. Employee or donor illness, if not properly managed, could also impact the availability of and quality of our products. Further, in certain instances and geographic regions, we may experience
      decreased customer engagement (for example, as a result of a temporary shutdown of a customer&#8217;s facilities or the continuation of no in-person meetings) could impact our results of operations. In addition, travel and other restrictions that were
      implemented in the United States or could be implemented in the future could impact our commercial efforts with respect to any of our products, including BIVIGAM and ASCENIV, as trade shows, industry and medical conferences and other events we had
      been planning to utilize and exhibit and attend with our staff to increase awareness of our products by physicians and payers were subject to limitations, rescheduling, virtual attendance or outright cancellation in response to the pandemic. Also,
      due to a combination of previous state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus packages, amongst other initiatives, we were experiencing, and may experience in the future, lower than expected donor collections at our
      FDA-licensed plasma collection centers. We are also subject to delays in shipments of source plasma from our contracted third-party suppliers, as well as delays in deliveries for personal protective equipment, reagents and other non-plasma raw
      materials and supplies used in the manufacture, testing and distribution of our products. We also experienced supply chain delays as a result of significant resources being diverted towards the rapid development and distribution of COVID-19 vaccines,
      which could result in our need to carry more inventory than we have in the past, which would put an additional strain on our cash resources. After the COVID-19 global pandemic has settled, we may continue to experience adverse impacts to our business
      as a result of evolving macroeconomic factors, including general economic uncertainty, unemployment rates, high inflation, recessionary pressures and any actual economic recession that has occurred or may occur in the future.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">In the future we may continue to experience pandemic-related challenges with respect to obtaining and manufacturing a sufficient amount of supplies, raw materials, and finished product to meet our need for commercial and
      clinical product supply.&#160; If we or any of our suppliers or manufacturers are adversely impacted by pandemics or the restrictions resulting from outbreaks, if they or we cannot obtain the necessary supplies, or if third parties need to prioritize
      other products or customers over us, including under the Defense Production Act, we may experience future delays or disruptions in our supply chain, which could have a material and adverse impact on our business. Moreover, we, our suppliers, and any
      third-party manufacturers may also need to implement measures and changes, or deviate from typical requirements, because of pandemics that may otherwise adversely impact our supply chains or the quality of the resulting products or supplies.
      Depending on the change, we may need to obtain FDA pre-approval or otherwise provide the FDA with a notification of the change.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">To the extent that we or our partners are conducting clinical trials, pandemics could cause delays or disruptions in these or future development programs. By example, the pandemic may result in slower enrollment, the
      need to suspend enrollment into studies, patient withdrawals, postponement of planned clinical or preclinical studies, redirection of site resources from studies, study modification, suspension, or termination, the introduction of remote study
      procedures and modified informed consent procedures, study site changes, direct delivery of investigational products to patient homes requiring state licensing, study deviations or noncompliance, and changes or delays in site monitoring.&#160; The
      foregoing could require that we consult with relevant review and ethics committees, IRBs, and the FDA. The foregoing could also impact the integrity of study data. The effects of&#160; pandemics may also increase the need for clinical trial patient
      monitoring and regulatory reporting of adverse effects.&#160; Pandemics could further impact our ability to interact with the FDA or other regulatory authorities and may result in delays in the conduct of inspections or review of pending applications or
      submissions. No assurances can be provided as to the timing for completion of any regulatory submissions or applications or other circumstances unknown to us presently or that are out of our direct control. Due to the potential impact of the COVID-19
      outbreak on clinical trials, drug development, and manufacturing, the FDA issued a number of guidances specifically concerning COVID-19, including guidance with respect to blood and blood components. The FDA&#8217;s guidance is continually evolving.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">The COVID-19 pandemic resulted in and future pandemics may also result in changes in laws and regulations.&#160; By example, in March 2020, the U.S. Congress passed the CARES Act, which includes various provisions regarding
      FDA drug shortage reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing. The CARES Act further included
      reporting requirements related to the volume of products produced over the course of the year.&#160; FDA issued guidance regarding this requirement. This and any future changes in law may require that we change our internal processes and procedures to
      ensure continued compliance. Additionally, the previous guidelines that were issued by public health authorities or any new or changing recommendations or guidelines may still impact the demand for or usage as well as the prescriptions of our IVIG
      products.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, operations, or financial condition, or on
      healthcare systems or the global economy as a whole. Although the COVID-19 pandemic has not adversely affected our capital and financial resources to date, the pandemic&#8217;s effects could have a material impact on our ability to access the capital
      markets as needed and on our operations and business, including those of the third parties on which we rely. Because we are unable to determine the ultimate severity or duration of the pandemic or its effects on, among other things, the global,
      national or local economies, the capital and credit markets, our workforce, our customers or our suppliers, at this time we are unable to predict whether COVID-19 will have a material adverse impact on our business, financial condition, liquidity and
      results of operations.</div>

    <div><br />
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">We contract with third parties for a portion of the filling, packaging, testing and labeling of the drug substance we manufacture. This reliance on third parties carries the risk that
      the services upon which we rely may not be performed in a timely manner or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">Third-party fill/finish providers may not perform as agreed or in accordance with FDA requirements. Any significant problem that our fill/finish providers experience could delay or interrupt our supply of
      finished drug product until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed fill/finish
      services meeting the necessary quality standards or at all could have a material and adverse effect on our products, business, financial condition and results from operations.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">Although we are utilizing our FDA-approved fill/finish suite that we built at the Boca Facility for a portion of our finished drug product, we also intend to continue to utilize third
        parties to supplement our fill/finish process for final drug product. Any failure by us, our contract fill/finishers, or other third parties involved in the process for producing our products or product candidates to comply with the applicable
        manufacturing, including manufacturing quality requirements, could place us and them </span>at risk of regulatory enforcement actions, recalls and other adverse consequences, could adversely impact our products, and could adversely impact patients
      receiving our products, which may negatively impact our business and our ability to produce and supply products to meet commercial and clinical needs.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt; color: #000000;">Our anticipated reliance on a limited number of third-party manufacturers exposes us to the following risks:</div>

    <div style="text-indent: 36pt; color: #000000;"> <br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>we may be unable to identify contract fill/finishers on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance
                as part of our marketing application;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the COVID-19 pandemic could adversely affect our contracted fill/finishers&#8217; operations, supply chain or workforce;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, and therefore they may require a significant amount of support from us in order to implement and maintain the infrastructure
                and processes required to deliver our finished drug product;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our third-party fill/finishers might be unable to timely provide finished drug product in sufficient quantity&#160;&#160; to meet our commercial needs;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>contract manufacturers may not be able to execute our inspection procedures and required tests appropriately;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>contract manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over third-party
                providers&#8217; compliance with these regulations;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>contract manufacturers may fail to comply with applicable regulatory requirements, placing them and us at risk of regulatory enforcement actions, recalls and other adverse consequences, which may negatively impact our business and their
                ability to supply products to meet our development, clinical and commercial needs;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our third-party fill/finishers could breach or terminate their agreements with us; and</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control, quality
                assurance and qualified personnel.</div>
            </td>

  </tr>


</table>
    </div>

    <div><br />
    </div>

    <div><span style="color: #000000;">Each of these risks could delay or prevent the completion of our finished drug product and the release of finished drug product by us or the FDA, which could result in higher costs or adversely impact our revenues.
        These risks could also result in the delay in obtaining clinical supplies, which would delay our development programs. In addition, our contract fill/finishers and our other third-party vendors may source their materials and supplies globally and
        are therefore subject to supply disruptions in the event of </span>fire, weather related events such as hurricanes, wind and rain, international conflicts, trade and sanction requirements and limits, other acts of God or force majeure events or
      global health occurrences and emergencies, including the COVID-19 pandemic.</div>

    <div><br />
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve
      the forecasted growth, our business could fail to grow at similar rates, if at all.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt; color: #000000;">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate, including as a result of changing
      circumstances during the ongoing COVID-19 pandemic. In particular, the size and growth of the overall U.S. IVIG and source plasma markets are subject to significant variables that can be difficult to measure, estimate or quantify. Our business
      depends on, among other things, successful commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there can be no assurance that we will be able to generate the
      revenue that we believe our products and plasma collection facilities are capable of generating. As a result, we may not be able to accurately forecast or predict revenue. For these reasons, the estimates and forecasts in our filings relating to
      revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates, if at all.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA, which, depending on the outcome of such inspections, could
      result in certain FDA actions, including the issuance of observations, notices, citations or warning letters.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">We and our suppliers and contractors may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements for commercial and
        clinical supply. </span>The FDA is authorized to perform inspections and remote regulatory assessments of our and our suppliers&#8217; facilities, including the Boca Facility. The FDA also may inspect and approve our and our third-parties&#8217; facilities
      before they may be used for commercial production. At the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause the FDA to not approve the use of the facility and cause us to modify certain
      activities identified during the inspection. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of regulatory significance of a warning letter. FDA
      guidelines also provide for the issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected to result in an enforcement action. FDA also may issue warning
      letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection. Depending on the seriousness of any findings, we or our suppliers may be subject to additional significant enforcement actions which could have a
      material impact on our business.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">In the event of any FDA enforcement actions, we and our third-party contractors would need to implement remedial actions which may be time-intensive or costly. We may not be able to timely resolve concerns raised by the
      FDA as a result of an inspection or without expending significant resources. We are unable to control the timing of FDA inspections, communications and actions, and will be required to respond to the FDA and make certain submissions within certain
      timeframes. We also do not know whether or not the FDA will change its requirements, guidance or expectations. If the FDA determines that we have not remediated the issues identified in a warning letter or any other inspection issues and
      deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of our commercialization efforts and could have a material adverse effect on our
      financial condition and operating results.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success
      of our business.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes.
      Our commercial manufacturing and any research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and
      wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption to our commercialization efforts, research and development efforts and business operations, environmental damage resulting in
      costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized internally and by our
      third-party manufacturers and service providers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental
      contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain
      materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our
      future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our commercial manufacturing,
      research and development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div><span style="font-weight: bold; font-style: italic;">Business interruptions could adversely affect our business</span><span style="font-weight: bold;">.</span></div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes, wind and rain,
      other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure, cyberattacks on our operations and information technology systems and breakdown, human error, employee issues, global health occurrences
      such as the COVID-19 pandemic, war, geopolitical conditions and emergencies, product liability claims and events beyond our control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of
      these risks, including replacing or rebuilding a part of our facilities, these policies are subject to the insurance carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our
      inventory, infrastructure, business income or our entire facility.&#160; In addition, our disaster recovery plans for our facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other
      manufacturers in the event of a casualty to or destruction of any of our facilities. If we are required to rebuild or relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited
      amount of business interruption insurance, which may not sufficiently compensate us for losses that may occur. As a result, any significant business interruption could adversely affect our business and results of operations.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or abandon
      development of such product, which would have a material adverse impact on our business.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to design and
      implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.<span style="font-weight: bold; font-style: italic;">&#160;</span>Human clinical trials are very
      expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur at any stage of the process, and we
      could encounter problems that cause us to abandon our product development programs and related INDs or BLAs, or to repeat clinical trials. The evolving COVID-19 pandemic may directly or indirectly affect the pace of enrollment in clinical trials as
      patients may be restricted in traveling to and accessing healthcare facilities and physicians&#8217; offices. Additionally, such healthcare facilities and offices have their limited resources directed towards treating patients with COVID-19 symptoms. The
      commencement and completion of clinical trials or ultimate product approval for any current or future development product candidate may be delayed by several factors, including:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>unforeseen safety issues;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>determination of dosing issues;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>lack of safety or effectiveness during clinical trials;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>slower than expected rates of patient recruitment;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>inability to monitor patients adequately during or after treatment; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>inability or unwillingness of medical investigators to follow our clinical protocols.</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

    </div>

    <div style="text-indent: 36pt;">We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our product
      candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase III) be demonstrated in two
      adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase III clinical trial results do not demonstrate a statistically significant, clinically meaningful benefit with an
      acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase III clinical trials in order to gain approval, we will incur significant additional development costs and commercialization of these products would be
      prevented or delayed and our business could be adversely affected.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">In addition, the FDA or an IRB may not permit us to commence a clinical trial, may require amendments to our clinical trial protocols, or may suspend our clinical trials at any time if it appears that we are exposing
      participants to unacceptable health risks or if the FDA or IRB finds deficiencies in our IND submissions or the conduct of these trials. Regulatory authorities may also not accept data from clinical trials if the trials are not conducted in
      accordance with the applicable regulatory requirements. Failure to comply with the applicable regulatory requirements may also result in enforcement actions. Therefore, we cannot provide any assurance or predict with certainty the schedule for future
      clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain regulatory approval to market and sell our product
      candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will increase.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon
      development of such product candidate altogether.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that later clinical
      trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay development of
      other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Other issues that may impact our clinical trials and that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, include:</div>

    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our CROs;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Regulators requiring us to perform additional or unanticipated clinical trials to obtain approval or becoming subject to additional post-marketing testing, surveillance, or REMS requirements to maintain regulatory approval;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Failure by our third-party contractors to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or our being required to engage in additional clinical
              trial site monitoring;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The cost of clinical trials of our product candidates being greater than we anticipate or our having insufficient funds for a clinical trial or to pay the substantial user fees required by FDA upon the filing of a marketing application;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Insufficient supply or inadequate quality of our product candidates or other materials necessary to conduct clinical trials;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Inability to achieve sufficient study enrollment, subjects dropping out or withdrawing from our studies, delays in adding new investigators or clinical trial sites or a withdrawal of clinical trial sites;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Flaws in our clinical trial design that are not discoverable until the clinical trial has progressed;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Disagreement by the FDA or comparable foreign regulatory authorities with our intended indications or study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials, finding that a product
              candidate&#8217;s benefits do not outweigh its safety risks or requiring that we conduct additional development or study work;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>The need to make changes to our product candidates that require additional testing or that cause our product candidates to perform differently than expected;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Global trade policies that may impact our ability to obtain raw materials and/or finished product for commercialization;</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>FDA or comparable regulatory authorities taking longer than we anticipate to make decisions on our products or product candidates; and</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
            <div>Potential inability to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</div>
          </td>

  </tr>


</table>
    <div><br />
    </div>

    <div style="text-indent: 36pt;">In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition, certain
      portions of our clinical trials and product testing for our product candidates may be performed outside of the U.S., and therefore, may not be performed in accordance with standards normally required by the FDA and other regulatory agencies.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make it
      difficult for us to recover the costs of researching and developing such product candidate.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">If we are not able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues, revenues generated
      from sales of our FDA-approved commercial products, revenues generated from new contract manufacturing arrangements with third parties and revenues generated from the sales of manufacturing intermediates. We cannot assure you that we will receive the
      approvals necessary to commercialize any product candidate we may acquire or develop in the future. In order to obtain FDA approval of any product candidate requiring FDA approval, our clinical development must demonstrate that the product candidate
      is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally requires significant research and testing, referred to as preclinical studies, as well
      as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity and novelty of the product candidate and requires substantial resources for research,
      development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and effective for indicated uses. The FDA has substantial discretion in the product approval
      process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies or may require additional CMC or other data and information, and the development and provision of this data and information may be
      time-consuming and expensive. The approval process may also be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining
      regulatory approvals may:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay commercialization of, and our ability to derive revenues from, our product candidates;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>impose costly procedures on us; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>diminish any competitive advantages that we may otherwise enjoy.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct further
      studies with more subjects. We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by
      leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate
      regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the FDA review, inspection and approval
      procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the U.S.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless
      additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The FDA and other governmental authorities strictly regulate and monitor marketing, labeling and the advertising and promotion of prescription drugs. These regulations include standards and restrictions for
      direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA does not allow drugs to be promoted for &#8220;off-label&#8221; uses&#8201;&#8212;&#8201;that is, uses that are
      not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. The FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new formulations, any
      new indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain FDA approval for any desired future
      indications for ASCENIV.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">While physicians in the U.S. may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in clinical studies and
      approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute an appropriate
      treatment for some patients in varied circumstances. Regulatory authorities in the U.S. generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict communications by pharmaceutical
      companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, these authorities. In addition,
      our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an approved product from the market,
      require a recall, require payment of civil fines or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, among other consequences, any of which could harm our reputation and our business.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations or balancing our research and development activities with
      our commercialization activities.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to successfully manage the
      balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing
      development of product candidates, which can include problems such as unanticipated issues related to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems
      related to managing manufacturing and supply, including supply chain constraints , reimbursement, marketing challenges, development of a comprehensive compliance program, and other related and additional costs. For example, the raw material plasma we
      collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors which contains high titer antibodies to RSV. This high titer plasma <span style="color: #000000;">which
        meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay </span>amounts to less than 10% of the total donor collection samples we test. As a result, we may experience an
      insufficient supply of this plasma.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the U.S. and other countries. In
      addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize any of our
      product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">We depend on third-party researchers, developers and vendors to develop, manufacture or test products and product candidates, as well as for other pre-and-post approval services, and such parties are,
      to some extent, outside of our control.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, CROs, contract manufacturers, contract fill/finishers and consultants to conduct our
      preclinical activities, clinical trials, CMC testing and other activities under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third
      parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. If outside collaborators fail to devote sufficient time and resources to our product-development
      programs, or if their performance is substandard or does not comply with the applicable regulatory standards, our trials may be repeated, extended, delayed, or terminated, the approval of our FDA application(s), if any, and our introduction of new
      products, if any, will be delayed. We or they may also be subject to regulatory enforcement actions and we may not be able to meet commercial demand. These collaborators may also have relationships with other commercial entities, some of whom may
      compete with us. If our collaborators assist our competitors at our expense, our competitive position would be harmed. Additionally, any change in the regulatory compliance status of any of our vendors may impede our ability to receive and maintain
      approval for our product candidates.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or</div>

    <div style="font-style: italic; font-weight: bold;">increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from the FDA.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">We currently anticipate expanding the manufacturing capacity of our Boca Facility by approximately 50% or more. We also anticipate expanding our production capabilities through the addition of our fill-finish machine at
      our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, such as our fill-finish machine, we will need to validate the expanded facility and equipment, make the necessary submissions to FDA,
      obtain any FDA required approvals and have it inspected by the FDA. Given the significant delays that may result during the validation process, we may experience a significant supply shortage of our products or our production capabilities may be
      limited until completion of and validation of our facility expansion and new manufacturing equipment.</div>

    <div><br />
    </div>

    <div style="text-align: justify; color: #000000; font-style: italic; font-weight: bold;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal
      from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as withdrawal from
      the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling and advertising and promotional activities for such products, among other things, are subject to ongoing regulatory compliance
      requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, adherence with
      labeling and promotional requirements and restrictions, requirements related to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding safeguarding the drug supply chain as
      well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our PAS to allow for the commercial relaunch of BIVIGAM, as well as the FDA&#8217;s approval of our BLA for ASCENIV, require us to conduct specified
      post-marketing studies related to our manufacturing controls and processes and submit specified post-marketing reports to the FDA. If, during the post-marketing period (after marketing approval) previously unknown adverse events, discovery that the
      product is less effective than previously thought, or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to comply with the numerous regulatory requirements to which we are
      subject, those circumstances may yield various results, including:</div>

    <div style="text-align: justify;"><span style="color: #000000;"> </span><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on such products or manufacturing processes;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on the labeling or marketing of a product;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on product distribution or use;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>clinical holds or termination of clinical trials;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>requirements to conduct further post-marketing studies or clinical trials, implement risk mitigation strategies,or to issue corrective information;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>warning letters or untitled letters;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>withdrawal of the products from the market;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>refusal to approve pending applications or supplements to approved applications that we submit;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>recall of products;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>restrictions on coverage by third-party payers;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>fines, restitution or disgorgement of profits or revenues;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>suspension or withdrawal of marketing approvals;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>refusal to permit the import or export of products;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>FDA debarment, suspension and debarment from government programs, refusal of orders under existing government contracts, exclusion from participation in federal healthcare programs, consent decrees, deferred or non-prosecution agreements
                or corporate integrity agreements;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>product seizure or detention; or</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 54pt;"><span style="color: #000000;"> </span><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#160;&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>injunctions or the imposition of civil penalties or criminal fines.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our
      business, results of operations and financial condition.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">For the three months ended March 31, 2023, three customers, BioCARE, Inc. (&#8220;BioCare&#8221;), Biolife Plasma Services, L.P., and Priority Healthcare Distribution, Inc. (&#8220;Curascript&#8221;), represented an aggregate of 76% of our
      consolidated revenues. For the year ended December 31, 2022, two customers BioCare and Curascript, represented an aggregate of 74% of our consolidated revenues.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">As of March 31, 2023, five customers, BioCare, Biolife, Healix Infusion Therapy, LLC (&#8220;Healix&#8221;), AmerisourceBergen Corporation and Reliance Life Sciences Pvt. Ltd. (&#8220;Reliance&#8221;), represented an aggregate of 98% of our
      consolidated accounts receivable. As of December 31, 2022, two customers, BioCare and Healix, represented an aggregate of 92% of our consolidated accounts receivable.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The loss of any key customers or a material change in the revenue generated by any of these customers could have a material adverse effect on our business, results of operations and financial condition. Moreover, we
      anticipate deriving increased revenue from some of these customers over the next few years. Factors that could influence our relationships with our customers include, among other things:</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to sell our products at competitive prices;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the impact of the ongoing COVID-19 pandemic and government responses thereto on our customers and their businesses, operations and financial condition.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div>Additionally, an adverse change in the financial condition of any of our key customers could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our business and results of operations.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and
      efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse inspection reports, warning
      letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, patient injury, refusal of a government to grant approvals and licenses,
      restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely manner may also cause negative publicity or a loss of customer
      confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully commercializing our current products and launching new products.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">In addition, as a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing process. As our
      biologics production levels increase, there may be normal course inventory losses or write-downs as we ensure product quality and compliance with cGMP, FDA, state and local regulations, or due to testing results not meeting specifications. As a
      result, our operating results are subject to potentially significant variability from one reporting period to the next should such normal course losses occur in any given period. However, because our products and product candidates are plasma-based
      products, not only are we subject to FDA&#8217;s drug and biologic cGMP requirements, but we are also subject to special requirements for the collection, testing, handling, storage, and use of blood products.&#160; This adds an extra level of compliance and
      complexity to our operations, which we may not be able to successfully meet.&#160; Failure to meet any regulatory quality standards could have an adverse impact on our business.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including, but not limited to:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>cost-effectiveness of our products relative to competing products;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>availability of reimbursement for our products from government or other healthcare payers; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div>The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">47</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates
      and label expansion of existing products, and if our business development efforts are not successful, our ability to achieve profitability may be adversely impacted.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our current product development portfolio consists primarily of label expansion activities for Nabi-HB, BIVIGAM and ASCENIV, as well as expanding our IP estate with patents issued for <span style="font-style: italic;">S.





        Pneumoniae</span> hyperimmune IG. We have initiated small scale preclinical activities to potentially expand our current portfolio through new product development efforts or to in-license or acquire additional products and product candidates. If we
      are not successful in developing or acquiring additional products and product candidates, we will have to depend on our ability to successfully commercialize ASCENIV, as well as our ability to generate revenue from Nabi-HB, BIVIGAM, contract
      manufacturing, intermediate fractions and plasma attributable to the operations of ADMA BioCenters, to support our operations.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our ADMA BioCenters operations collect information from donors in the U.S. that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to
      meet their requirements.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Consumer privacy is highly protected by federal and state law. The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health
      Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose, among other things, obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of protected health information
      (&#8220;PHI&#8221;) held by covered entities and business associates. A &#8220;covered entity&#8221; is the primary type of HIPAA-regulated entity.&#160; Health plans/insurers, healthcare providers engaging in standard transactions (i.e., insurance/health plan claims and
      encounters, payment and remittance advice, claims status, eligibility, enrollment/disenrollment, referrals and authorizations, coordination of benefits and premium payments), and healthcare clearinghouses (i.e., switches that convert data between
      standard and non-standard data sets) are covered entities. A &#8220;business associate&#8221; provides services to covered entities (directly or as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or
      transmitting PHI on a covered entity&#8217;s behalf.&#160; In order to legally provide access to PHI to service providers, covered entities and business associates must enter into a &#8220;business associate agreement&#8221; (&#8220;BAA&#8221;) with the service provider that receives
      PHI on behalf of the entity.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">While we are not a covered entity or business associate subject to HIPAA, even when HIPAA does not apply, according to the U.S. Federal Trade Commission (the &#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217;
      personal information secure constitutes unfair acts or practices in or affecting commerce may violate Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and
      appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data
      that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to, but prescriptive than, what is required by the HIPAA Security Rule. In addition, states impose a variety of laws protecting
      consumer information, with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened standards.&#160; In addition, federal and state privacy, data security, and breach notification laws, rules and regulations, and
      other laws apply to the collection, use and security of personal information, including social security number, driver&#8217;s license numbers, government identifiers, credit card and financial account numbers.&#160; Some state privacy and security laws apply
      more broadly than HIPAA and associated regulations. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;) was amended by the California Privacy Rights Act, effective January 1, 2023. The CCPA, among other things, imposes data privacy obligations
      for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data
      breaches, thereby potentially increasing risks associated with a data breach. It remains unclear what, if any, modifications will be made to this legislation through implementing regulations or how it will be interpreted and enforced. We could be
      subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws. Virginia, Colorado, Connecticut and Utah have also enacted privacy laws that become effective in 2023 and are similar in many respects
      to the CCPA.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">48</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">The Hayfin Credit Facility is subject to acceleration in specified circumstances, which may result in Hayfin taking possession and disposing of any collateral.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">On March 23, 2022 (the &#8220;Hayfin Closing Date&#8221;), we entered into the Hayfin Credit Agreement with Hayfin (see &#8220;Liquidity and Capital Resources&#8221;). The Hayfin Credit Agreement provides for a senior secured term loan facility
      in the principal amount of up to $175.0 million (the &#8220;Hayfin Credit Facility&#8221;), composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0 million (the &#8220;Hayfin Closing Date Loan&#8221;), (ii) a delayed draw term loan in
      the principal amount of $25.0 million (the &#8220;Hayfin Delayed Draw Loan&#8221; and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans&#8221;). The obligation of the lenders to make the Hayfin Delayed Draw Loan expires on December 31, 2023 and is subject
      to the satisfaction of certain conditions, including but not limited to, our meeting certain 12-month revenue targets as set forth in the Hayfin Credit Agreement which have been met. The Hayfin Credit Facility has a maturity date of March 23, 2027
      (the &#8220;Hayfin Maturity Date&#8221;). The Hayfin Loans are secured by substantially all of our assets, including our intellectual property. Events of Default include, among others, non-payment of principal, interest or fees, violation of covenants,
      inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. In addition to an increase in the rate of interest on the Hayfin
      Loans of 3% per annum, the occurrence of an Event of Default could result in, among other things, the termination of commitments under the Hayfin Credit Facility, the declaration that all outstanding Loans are immediately due and payable in whole or
      in part, and Hayfin taking immediate possession of, and selling, any collateral securing the Hayfin Loans.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Developments by competitors may render our products or technologies obsolete or non-competitive.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to compete with
      other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies in the U.S.
      and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater financial resources, larger research and development staffs and
      facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and parties for acquisitions,
      joint ventures or other collaborations.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and
      business prospects may be materially damaged.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">As we move forward in clinical development, we continue to discover novel technologies related to our products and we may draft patent applications directed to these technologies. We rely on a combination of patent
      rights, trade secrets and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance that our patents, trade secret policies and practices or other
      agreements will adequately protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts, the U.S. Patent and Trademark Office or foreign patent
      offices. Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition. The processes, systems, and/or security measures we use to preserve the integrity and confidentiality of our data and trade
      secrets may be breached, and we may not have adequate remedies as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. There can be no assurance that the
      confidentiality, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or
      any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently
      develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property
      owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">49</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">We could lose market exclusivity of a product earlier than expected.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the U.S. and in some other countries, when market
      exclusivity expires and generic or biosimilar versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on the availability
      of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, or limitations on the use or loss of such rights, could be material to us. In some countries, basic patent protections for our products
      may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable and the validity and
      enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be approved and marketed.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing approval or choose to
      launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly, time-consuming and no assurance can be given
      that we will prevail. In addition, any such litigation may divert our management&#8217;s attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a
      material and adverse effect on our business and prospects, regardless of the outcome.</div>

    <div>There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the full time period of the respective patent.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable terms or
      at all.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the development
      and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of products and competitors in our
      market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims. We cannot be certain that the conduct of
      our business does not and will not infringe intellectual property or other proprietary rights of others in the U.S. and in foreign jurisdictions. If our products, methods, processes and other technologies are found to infringe third-party patent
      rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the applicable third-party patent and pay royalties or are able to design around such patent. We may
      be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid infringement. Even if we are able to redesign our products or processes to avoid an infringement claim, our
      efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could cause us
      to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any
      infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating
      results. A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, or our customers from making, using, selling, offering to sell or importing one or more of our products or practicing our
      proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating results and financial condition.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">50</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">If we are unable to successfully manage our growth, our business may be harmed.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our success will depend on the expansion of our commercial and manufacturing activities, supply of plasma and overall operations and the effective management of our growth, which will place a significant strain on our
      management and on our administrative, operational and financial resources. To manage this growth, we must expand our facilities, augment our operational, financial and management systems and hire and train additional qualified personnel. Our ability
      to accomplish each of these objectives may be negatively impacted as a consequence of the COVID-19 pandemic. If we are unable to manage our growth effectively, our business could be harmed.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">The loss of one or more key members of our management team could adversely affect our business.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss of Adam S.
      Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment agreements with each of our
      executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms.
      The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and diversion of management resources.</div>

    <div><br />
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Cyberattacks and other security breaches could compromise our proprietary and confidential information, which could harm our business and reputation.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission of and access to
      this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other electronic
      communications. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment during the COVID-19 pandemic, the risk of cybersecurity attacks and data breaches, particularly through
      phishing attempts, may be increased as we and third parties with whom we interact leverage our IT infrastructure in unanticipated ways during the ongoing COVID-19 pandemic. In addition, an employee, contractor, or other third party with whom we do
      business may attempt to obtain such information and may purposefully or inadvertently cause a breach involving such information. While we have certain safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide
      cybersecurity policy, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, or employee error or malfeasance. Any such compromise of our data security and access to, or public
      disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information and subject us to additional costs which could adversely affect our
      business.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development, manufacturing operations,
      and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales, marketing, medical affairs, reimbursement,
      government regulation, formulation, quality control, manufacturing, finance, general and&#160; operational management and plasma collections. In particular, over the next 12-24 months, we expect to hire several new employees devoted to our plasma
      collection centers, commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, finance and general and operational management. Qualified individuals of the requisite caliber and number needed to fill
      these positions may be in short supply in some areas. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such individuals is intense, and we cannot assure you
      that our search for such personnel will be successful, particularly if the COVID-19 pandemic causes significant changes in the competitive market for such personnel, including but not limited to overall increases in the cost of labor or travel
      restrictions related to COVID-19, prevent us from being able to hire qualified personnel. If we are unable to hire and retain personnel capable of consistently performing at a high level, our business and operations could be materially adversely
      affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect on our business, financial condition or operating results.</div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">51</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">We currently collect human blood plasma at our ADMA BioCenters facilities, and if we cannot maintain FDA approval for these facilities or obtain FDA approval for additional facilities that we
      construct or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We intend to maintain FDA approval of our current and future ADMA BioCenters collection facilities for the collection of human blood plasma and we may seek other governmental and regulatory approvals for these
      facilities. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation, including compliance with current cGMP and blood standards and FDA and other governmental approvals, as
      applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our current or future facilities may result in enforcement actions, such as adverse inspection reports, warning or untitled letters, product
      recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of regulatory authority approvals and licenses, restrictions on operations or withdrawal of
      existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a material adverse effect on our ability to manufacture our products or offer for sale plasma collected at the
      affected sites. Failure to comply with applicable governmental regulations may also impact the ultimate quality and compliance of our finished biologic products, which may have a material adverse effect on our business.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we or our vendors cannot maintain appropriate FDA
      status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">There are no assurances we will be able to maintain compliance with all FDA or other regulations. Moreover, to the extent that we use third-party vendors to fulfill our regulatory or contractual requirements, these
      third-party vendors may perform activities for themselves or other clients and we may not be privy to all regulatory findings or issues discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely
      affect our ability to continue to work with these vendors, or our ability to release commercial drug product or perform necessary testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to
      commercialize our products. If we are not able to maintain manufacturing compliance at our facilities or our vendors&#8217; facilities for our products and product candidates, we may not be able to successfully develop and commercialize our products and
      product candidates and we may face potential contractual or regulatory actions, which would have an adverse impact on our business.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
      to limit commercialization of our products. Product liability claims may also result in recalls and/or regulatory enforcement actions. Even successful defense, however, could impair our results of operations. Our inability to obtain and maintain
      sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, either alone or with collaborators.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">52</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div><span style="font-style: italic; font-weight: bold;">Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to comply
      with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</span></div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div style="text-indent: 36pt;">The laws governing our conduct in the U.S. are enforceable on the federal, state and local levels by criminal, civil and administrative sanctions. Violations of laws such as the Federal Food, Drug, and Cosmetic Act, the
      Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of overpayments, other
      fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from federal and state programs, pursuant to
      enforcement actions by DOJ, Medicare, Medicaid, OIG and other regulatory authorities. Similarly, the violation of applicable laws, rules and regulations of states, including the State of Florida, with respect to the manufacture and marketing of our
      products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from applicable state programs. There can be no assurance that our activities will not come under the scrutiny of
      federal and/or state regulators and other government authorities or that our practices will not be found to violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value to induce or reward patient referrals, or in return for purchasing, leasing, ordering or
      arranging for or recommending the purchase, lease, or ordering of any item or service reimbursable in whole or in part by a federal healthcare program is prohibited.&#160; This places constraints on the marketing and promotion of products and on common
      business arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal penalties,
      including, among others, exclusion from participation in the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations, healthcare organizations, physicians and pharmacists must be
      structured with care to comply with applicable requirements. Legislators and regulators may seek to further restrict the scope of financial relationships that are considered appropriate. For example, HHS recently promulgated a regulation that is
      effective in two phases.&#160; First, the regulation excludes from the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan
      reflected in point-of sale reductions in price and (b) PBM service fees.&#160; Second, effective January 1, 2023, the regulation expressly provides that rebates to plan sponsors under Medicare Part D either directly to the plan sponsor under Medicare Part
      D, or indirectly through a pharmacy benefit manager, will not be protected under the Anti-Kickback Statute discounts safe harbor. Recent legislation delayed implementation of this portion of the rule until January 1, 2026, and previously proposed
      legislation would permanently prohibit implementation of the rule beginning in 2026.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Also, certain business practices, such as payments of consulting fees to healthcare professionals, sponsorship of educational or research grants, charitable donations, interactions with healthcare professionals who
      prescribe products for uses not approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of wrongfully influencing healthcare
      professionals to prescribe or purchase particular products or as a reward for past prescribing. Under the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) and the companion Health Care and Education Reconciliation Act, which together are referred
      to as the &#8220;Healthcare Reform Law,&#8221; payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program
      (with certain exceptions) to or at the request of covered recipients, such as, but limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S.
      teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report certain ownership interests held by physicians and their immediate family members. A number of states
      have similar laws in place. Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices have been found to be improper incentives to use such products, government investigations and sanctions
      against manufacturers have resulted in substantial fines, penalties and damages. Many manufacturers have been required to enter into consent decrees or orders that prescribe allowable corporate conduct and/or Corporate Integrity Agreements that
      impose ongoing compliance requirements on a manufacturer.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">53</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">Failure to satisfy requirements under the Federal Food, Drug, and Cosmetic Act can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct. In
      addition, while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the potential
      safety and efficacy of unapproved products in development. Companies in the U.S., Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the competent regulatory authorities such as
      the FDA in the U.S., nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of approved products or results of studies involving investigational products.
      If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or enforcement action by, these authorities. Furthermore, if such activities are prohibited, it
      may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of the Federal Food, Drug, and Cosmetic Act and subjects us to civil and criminal sanctions. Furthermore,
      sanctions under the federal False Claims Act have been brought against companies accused of promoting off-label uses of drugs, because such promotion induces unapproved the use and subsequent claims for reimbursement under Medicare and other federal
      programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law significantly strengthened provisions of the federal False Claims Act, the federal Anti-Kickback Statute that
      applies to government healthcare programs, and other healthcare fraud provisions, leading to the possibility of greatly increased lawsuits by whistleblowers for perceived violations. Violations or allegations of violations of the foregoing
      restrictions could materially and adversely affect our business.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to CMS for the purpose of calculating national reimbursement levels, certain federal prices and certain
      federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in criminal and/or civil liability under the federal False Claims Act, the federal Anti-Kickback Statute and various other laws, rules and
      regulations.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We have established systems for collecting and reporting this data accurately to CMS and have instituted a compliance program to assure that the information collected is complete in all respects. If we report pricing
      information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization in the European Union or
      otherwise market and sell our products outside of the U.S., we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity and timing. We may
      not obtain approvals from regulatory authorities outside the U.S. on a timely basis, if at all, which would preclude us from commercializing products in those markets.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities can take
      considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to
      other available therapies. Such trials may be time-consuming and expensive and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
      unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Also, under the U.S. Foreign Corrupt Practices Act, the U.S. has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the U.S., generally prohibiting remuneration to foreign officials
      for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such as the HHS Office of Inspector General (the &#8220;OIG&#8221;)
      have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the U.S. Sentencing Commission
      Guidelines Manual. Increasing numbers of U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the OIG&#8217;s recommendations and voluntary industry guidelines and
      train our employees. Such a program may be expensive and may not provide assurance that we will avoid compliance issues.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">54</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states and localities in which our business operates, including the State of Florida where our
      manufacturing facility is located.&#160; These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business.&#160; Although compliant with applicable federal requirements, we may be
      required to comply with additional state and local laws, rules, regulations and permits.&#160; Failure to appropriately comply with such state and local requirements could result in temporary or long-term cessation of our manufacturing operations, as well
      as fines and other sanctions.&#160; Any such penalties may have a material adverse effect on our business and results of operations.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory<span style="color: #0000FF;">&#160;</span>approvals
      before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain necessary capital in order
      to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Both before and after the approval of our products, our products, operations, facilities, suppliers and CROs are subject to extensive regulation by federal, state and local governmental authorities in the U.S. and other
      countries, with regulations differing from country to country. In the U.S., the FDA regulates, among other things, the pre-clinical and nonclinical testing, clinical trials, manufacturing, safety, efficacy, potency, labeling, storage, record keeping,
      quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions: notices of violation, untitled letters,
      warning letters, CRLs, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or product candidate, product recall or seizure, interruption of manufacturing or clinical trials, operating
      restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the U.S. without FDA and other federal, state and local business regulatory approvals. Any failure to receive the marketing
      approvals necessary to commercialize our products or product candidates could harm our business.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors, including government
      budget and funding levels, ability to hire and retain key personnel and to accept the payment of user fees, as well as statutory, regulatory, and policy changes. Average review times at the FDA and other federal, state and local business regulatory
      agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the
      political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate submissions to be reviewed and/or approved by necessary government agencies,
      which would adversely affect our business. For example, over the last several years, including in December 2018 and January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had
      to furlough critical employees and stop critical activities. If a prolonged government shutdown reoccurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and other reporting requirements
      which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</div>

    <div><br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">55</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For instance, improper
      storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing process, it may be necessary to
      discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma products is an extremely complex process of
      fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217; specifications through a failure in one or more of these process steps.
      We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process was not collected or stored in a compliant manner consistent with our cGMP or other
      regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe replaced or withdrawn from the market and therefore should be destroyed. Once manufactured, our
      plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, test, ship or distribute our products or product components to properly care for our products, may
      require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled. While we expect to write off small
      amounts of work-in-process inventory in the ordinary course of business due to the complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our expectations and the
      reserves we have established for these purposes. Such write-offs or losses and other costs could cause material fluctuations in our results of operations. Product or component quality issues may also result in regulatory enforcement actions,
      liability, corrective actions and recalls, among other actions, as described elsewhere in this annual report.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures, which could
      adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability damages and claims from companies
      for whom we do contract manufacturing.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and manufacturing
      processes against transmittable diseases.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease-causing agents, the risk of transmissible disease through blood plasma
      products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West Nile virus, H1N1 virus or &#8220;swine
      flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs worldwide were infected with HIV through the use of
      contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population from time to time. If a new infectious disease has a
      period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early in an outbreak of a new disease, tests for
      the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less sensitive and specific
      than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing process&#8217; capacity to
      inactivate or remove the infectious agent. To the extent our manufacturing processes are inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute our products would be impaired. If a new infectious disease
      were to emerge in the human population or if there were a reemergence of an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission of the disease that would impair our ability to procure
      plasma, manufacture our products or both. Such precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived products. In recent years, new testing and viral
      inactivation methods have been developed that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation methods will adequately screen for, and
      inactivate, infectious agents in the plasma used in the production of our products.</div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">56</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw
      materials.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must generally be licensed by the FDA and approved by the regulatory authorities of any country
      in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. Therefore, even if we are able
      to construct new plasma collection centers to complement our current plasma collection facilities, an unsatisfactory inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing license, among other
      enforcement actions. We do not and will not have adequate plasma to manufacture our products. Therefore, we are reliant on the purchase of plasma from third parties and the collection of plasma from our FDA-approved plasma collection centers to
      manufacture our products. We can give no assurances that appropriate plasma will be available to us on commercially reasonable terms, or at all, to manufacture our products. Further, the COVID-19 pandemic resulted in&#160; significant constraints in raw
      material supply across various different industries, including the supply of plasma. It is possible that in the future, pandemics and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and
      quality sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in
      compliance with cGMP and other applicable regulatory requirements, we may be unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if non-compliance
      in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could
      experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of
      plasma from third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facilities. This strategy is dependent upon our ability to maintain a cGMP compliant environment at our plasma collection facilities and to
      expand production and attract donors to our facilities. There is no assurance that the FDA will inspect and license any of our current or future unlicensed plasma collection facilities in a timely manner consistent with our production plans. If we
      misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper our operations and our ability to
      increase plasma collections. Our ability to expand production and increase our plasma collection facilities to more efficient production levels may be affected by changes in the economic environment and population in selected regions where ADMA
      BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the demographic potential of individual regions where ADMA BioCenters
      expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities held by us from time to time.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Additionally, our supply contract with Grifols for the purchase of normal source plasma (&#8220;NSP&#8221;) expired&#160; on December 31, 2022. There can be no assurances that we will be able to obtain an adequate supply of NSP from
      other third-party suppliers or be able to collect NSP in the same quantities, or at all, through our ADMA BioCenters plasma collection facilities at a cost that is not higher than the price we paid to Grifols for NSP. If our costs to obtain NSP
      through collections at our ADMA BioCenters plasma collection facilities or from other third-party suppliers are higher than what we paid to Grifols under our supply contract, our liquidity and results of operations could be adversely impacted.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from governmental agencies, health administration
      authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other governmental authorities for our product candidates.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of insurance coverage. Significant uncertainty exists as to the
      reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare, are challenging the prices charged
      for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates is approved by the
      FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our products, once
      approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to price controls in
      several of the world&#8217;s principal markets, including many countries within the European Union. In the U.S., where pricing levels for our products are substantially established by third-party payers, including Medicare, if payers reduce the amount of
      reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer lower doses, to substitute lower cost products or to seek additional price-related concessions. These
      actions could have a negative effect on our financial results, particularly in cases where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of treatment. The existence of direct and
      indirect price controls and pressures over our products could materially adversely affect our financial prospects and performance.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">57</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">The biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The Healthcare Reform Law introduced an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to an FDA-licensed biological product.&#160; A biological product may be demonstrated to be
      &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the
      reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the
      reference product was first licensed.&#160; Since the enactment of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition in
      the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further
      Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on
      commercially reasonable market-based terms. The FDA approved the first biosimilar product in 2015 and has since approved a number of biosimilars.&#160; As a result of the biosimilar pathway in the U.S., we expect in the future to face greater competition
      from biosimilar products, including a possible increase in patent challenges.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">The implementation of the Healthcare Reform Law in the U.S. may adversely affect our business.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Through the March 2010 adoption of the Healthcare Reform Law in the U.S., substantial changes are being made to the current system for paying for healthcare in the U.S., including programs to extend medical benefits to
      millions of individuals who currently lack insurance coverage. This reform establishes significant cost-saving measures with respect to several government healthcare programs, including Medicaid and Medicare Parts B and D, that may cover the cost of
      our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a manufacturer&#8217;s products to be reimbursed by federal funding under Medicaid, the manufacturer
      must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data provided by each state to the manufacturer and to CMS and pricing data provided by the manufacturer to the federal
      government. The states share these savings with the federal government, and sometimes implement their own additional supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug products was previously
      equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price, whichever is greater, plus the inflation penalty if applicable. Effective January 1, 2010, the Healthcare Reform Law generally increased the size of the
      Medicaid rebates paid by manufacturers for single source and innovator multiple source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions, plus the inflation penalty if applicable. For
      non-innovator multiple source (generic) products, the rebate percentage was increased from a minimum of 11.0% to a minimum of 13.0% of AMP, and the Bipartisan Budget Act of 2015 established a new inflation penalty for these drugs.&#160; In 2010, the
      Healthcare Reform Law also newly extended the Medicaid drug rebate obligation to prescription drugs covered by Medicaid managed care organizations. These increases in required rebates may adversely affect our future financial prospects and
      performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to
      participate in the 340B drug pricing program.&#160; The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.&#160; As the 340B drug pricing is determined based on AMP and Medicaid
      rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase, and recent regulations have established a civil monetary penalty for failure to refund these overcharges.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">58</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-indent: 36pt;">Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities
      according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">The Healthcare Reform Law also created new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65 years
      old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products to be reimbursed under Medicare
      Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer&#8217;s brand name drugs and
      biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). The Part D plan sponsor is
      responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate
      requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a manner that overstates our
      rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (&#8220;CER&#8221;). While
      the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any
      of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial
      prospects and results.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">There have been repeated legal challenges and attempts by Congress to repeal or change the Healthcare Reform Law and the possibility of future challenges or legislative changes contribute to the uncertainty of the
      ongoing implementation and impact of the law and also underscores the potential for additional reform going forward. We cannot assure that the law, as currently enacted or as amended in the future, will not adversely affect our business and financial
      results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.&#160; Certain provisions of enacted or proposed legislative changes may negatively impact coverage and
      reimbursement of, or rebates paid by manufacturers for, healthcare items and services. We will continue to evaluate the effect that the Healthcare Reform Law and any potential changes may have on our business.</div>

    <div>&#160;</div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">Corporate responsibility, specifically related to Environmental, Social and Governance (&#8220;ESG&#8221;) matters, may impose additional costs and expose us to new risks.</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;"><span style="color: #000000;">Public ESG and sustainability reporting is becoming more broadly expected by investors, stockholders and other third parties. Certain organizations that provide corporate governance and
        other corporate risk information to investors and stockholders have developed, and others may in the future develop, scores and ratings to evaluate companies and investment funds based upon ESG or &#8220;sustainability&#8221; metrics. Many investment funds
        focus on positive ESG business practices and sustainability scores when making investments and may consider a company&#8217;s ESG or sustainability scores as a reputational or other factor in making an investment decision. In addition, investors,
        particularly institutional investors, use these scores to benchmark companies against their peers and if a company is perceived as lagging, these investors may engage with such company to improve ESG disclosure or performance and may also make
        voting decisions, or take other actions, to hold these companies and their boards of directors accountable. Board diversity is an ESG topic that is, in particular, receiving heightened attention by investors, stockholders, lawmakers and listing
        exchanges. Certain states have passed laws requiring companies to meet certain gender and ethnic diversity requirements on their boards of directors. We may face reputational damage in the event our corporate responsibility initiatives or
        objectives, including with respect to board diversity, do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating
        from third-party rating</span><span style="color: #FF0000;">&#160;</span><span style="color: #000000;">services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from consideration
        by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks.</span></div>

    <div>&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">59</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-weight: bold;">Risks Relating to our Finances, Capital Requirements and Other Financial Matters</div>

    <div>&#160;</div>

    <div style="font-style: italic; font-weight: bold;">We may require additional funding and may be unable to raise capital when needed, which would adversely affect our operations and could force us to delay, curtail or eliminate some of our
      commercialization efforts or one or more of our research and development programs.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our operations have consumed substantial amounts of cash since inception. For the three months ended March 31, 2023 and 2022, we had negative cash flows from operations of $14.7 million and $26.0 million, respectively,
      and for the years ended December 31, 2022 and 2021, we had negative cash flows from operations of approximately $59.5 million and $112.4 million, respectively. We expect to continue to spend substantial amounts for collecting plasma at our plasma
      collection centers, plasma center expansion, maintaining our plasma centers, procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations, commercial product launches and capacity expansion at the Boca
      Facility. In addition, our end-to-end production cycle from collecting and procuring raw material source plasma to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial investments in
      raw material plasma and other manufacturing materials. We expect that we will not be able to generate a sufficient amount of product revenue to achieve profitability until the beginning of 2024 and if we do not achieve positive cash flow by the
      beginning of 2024 we may need to continue to finance our operations through additional equity or debt financings or corporate collaboration and licensing agreements. We currently anticipate, based upon our projected revenue and expenditures, that our
      current cash, cash equivalents and accounts receivable will be sufficient to fund our operations, as currently conducted, through the end of the second quarter of 2024, by which time we believe we will begin to generate positive cash flow from
      operations. This time frame may change based upon how quickly we are able to execute on our commercialization efforts and operational initiatives and whether or not the assumptions underlying our projected revenues and expenses are correct. If we are
      unable to generate sufficient revenue to achieve positive cash flow by the beginning of 2024, we may need to raise additional capital and if such capital is not available due to widespread liquidity constraints or significant market instability that
      could result from the COVID-19 pandemic, we will have to delay, curtail or eliminate our commercialization efforts or our product development activities.</div>

    <div><br />
    </div>

    <div style="color: #000000; font-style: italic; font-weight: bold;">We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">The Hayfin Credit Facility provides for a senior secured term loan facility in an aggregate principal amount of up to $175.0 million, of which $150.0 million has been drawn down and is currently outstanding. Borrowings
      under the Hayfin Credit Facility currently bear interest at a rate per annum equal to 8.5% plus the greater of (i) one or three-month SOFR as we elect and (ii) 1.25%, as more fully described in &#8220;Liquidity and Capital Resources&#8221;; provided, however,
      that upon, and during the continuance of, an Event of Default, the interest rate will automatically increase by an additional 300 basis points. We are currently required to make monthly payments of interest during the term of the Hayfin Credit
      Facility of approximately $1.5 million, with all principal and unpaid interest due at maturity. In addition, our monthly interest rate obligation is subject to rising interest rates. The Hayfin Credit Facility has a maturity date of March 23, 2027,
      subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default. All of our obligations under the Hayfin Credit Facility are secured by a first-priority lien and security interest in substantially all of our and
      our subsidiaries&#8217; tangible and intangible assets, including intellectual property, and all of the equity interests in our subsidiaries.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Our current cash, cash equivalents and accounts receivable may not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to achieve sufficient positive cash flow to repay
      our outstanding debt obligations as they mature, we will need to obtain additional financing in the amounts necessary to repay our outstanding debt obligations when due. If we are unable to achieve positive cash flow sufficient to repay our
      outstanding debt obligations when they mature, our creditors would be able to accelerate all of the amounts due and, in the case of the Hayfin Credit Facility, seek to enforce their security interests, which could lead to our creditors taking
      immediate possession of and selling substantially all of our assets with no return provided to our stockholders.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">60</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish
      proprietary rights.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among other restrictions,
      limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In addition, if we raise additional funds
      through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating accounts on a daily
      basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit cash fails or is subject to other adverse
      conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash equivalents will not be
      impacted by adverse conditions in the financial and credit markets.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm
      our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) and related rules, our management is required to report on the effectiveness of our internal control over financial reporting. The
      rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a
      reporting company under the Exchange Act, we have been required to upgrade, and may need to implement further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems and
      procedures and hire additional accounting and finance staff.</div>

    <div><br />
    </div>

    <div style="text-indent: 36pt;">Consequently, we have incurred increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act and will continue to do so. Our Audit Committee has retained the services of BDO, a Sarbanes-Oxley
      advisor, to assist with our internal control over financial reporting and information technology relating to Section 404. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our
      independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our common stock could decline and we could be subject to sanctions
      or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources.</div>

    <div> <br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We have incurred substantial losses during our history. As of December 31, 2022, we had federal and state NOLs of $334.5 million and $211.7 million, respectively. Federal and State NOLs of approximately $55.2 million and
      $91.8 million, respectively, will begin to expire at various dates beginning in 2027, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our
      ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code imposes limitations on a company&#8217;s ability to use NOLs upon
      certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs. The acquisition transaction that we completed
      on June 6, 2017 resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs. On October 25, 2021, we completed a public offering of our common stock whereby we issued
      57,500,000 shares of our common stock resulting in another change of ownership for ADMA under section 382 of the Code, resulting in an additional write-off of $3.0 million of federal NOLs, $28.1 million of state NOLs and $1.0 million of research and
      development credits. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership that we cannot predict or control that could result in further limitations being placed on our ability to utilize our
      federal NOLs.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">61</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-weight: bold;">Risks Associated with our Common Stock</div>

    <div>&#160;</div>

    <div style="font-style: italic; font-weight: bold;">The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our stock price may experience substantial volatility as a result of a number of factors, including:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>sales or potential sales of substantial amounts of our common stock;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>uncertainties in the equity markets related to the effects of the COVID-19 pandemic;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>delay in a decision by federal, state or local business regulatory authority;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>developments concerning our licensors or third-party vendors;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>conditions in the pharmaceutical or biotechnology industries;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>governmental regulation and legislation;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>overall market volatility;</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>variations in our anticipated or actual operating results; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div>Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations often
      have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">62</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">As of May 5, 2023, most of our 222,272,962 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public market,
      subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our common
      stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;), our Amended
      and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">As of March 31, 2023, BlackRock Inc., Perceptive Advisors, LLC, State Street Corp., Vanguard Group Inc., NWQ Investment Management Co. LLC, Caligan LP and our directors and executive officers and their affiliates owned
      approximately 36% of the outstanding shares of our common stock. Provisions of our Certificate of Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our
      Company or changes in our management, including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve
      transactions that they may deem to be in their best interests. These provisions include:</div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the inability of stockholders to call special meetings;</div>
            </td>

  </tr>


</table>
      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our Company; and</div>
            </td>

  </tr>


</table>
      <div style="text-indent: -18pt; margin-left: 36pt;"> <br />
      </div>

      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt;"><br />
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders.</div>
            </td>

  </tr>


</table>
    </div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together
      with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is
      approved in a prescribed manner.&#160; The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential
      acquirers of our company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders may, from
      time to time, observe instances where there may be less liquidity in the public markets for our securities.</div>

    <div><br />
    </div>

    <div style="font-style: italic; font-weight: bold;">We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">We have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and future
      debt agreements may preclude us from paying dividends. For example, the Hayfin Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable
      future.</div>

    <div> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">63</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="font-style: italic; font-weight: bold;">If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be
      delisted.&#160; If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</div>

    <div> <br />
    </div>

    <div style="text-indent: 36pt;">Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, market capitalization and
      stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but
      also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would view an
      investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common stock.
      Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</div>

    <div> <br />
    </div>

    <div style="text-align: justify; font-style: italic; font-weight: bold;">Penny stock regulations may affect your ability to sell our common stock.</div>

    <div style="text-align: justify;"> <br />
    </div>

    <div style="text-indent: 36pt;">Because the price of our common stock currently trades below $5.00 per share, our common stock is subject to Rule 15g-9 under the Exchange Act, which imposes additional sales practice requirements on broker-dealers which
      sell these securities to persons other than established customers and accredited investors. Under these rules, broker-dealers who recommend penny stocks to persons other than established customers and &#8220;accredited investors&#8221; must make a special
      written suitability determination for the purchaser and receive the purchaser&#8217;s written agreement to a transaction prior to sale, which includes an acknowledgement that the purchaser&#8217;s financial situation, investment experience and investment
      objectives forming the basis for the broker-dealer&#8217;s suitability determination are accurately stated in such written agreement. Unless an exception is available, the regulations require the delivery, prior to any transaction involving a penny stock,
      of a disclosure schedule explaining the penny stock market and the associated risks. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our common stock and may make
      it more difficult for holders of our common stock to sell shares to third parties or to otherwise dispose of them.</div>

    <div> <br />
    </div>

    <div style="text-align: justify; font-style: italic; font-weight: bold;">Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of
      holders of our common stock.</div>

    <div style="text-align: justify;"> <br />
    </div>

    <div style="text-indent: 36pt;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board.
      Currently, our Certificate of Incorporation authorizes the issuance of up to 300,000,000 shares of common stock. As of March 31, 2023, there were 29,380,820 shares remaining available for issuance, after giving effect to 28,346,315 shares of our
      common stock that were subject to outstanding stock options, RSUs and warrants as of March 31, 2023 that may be issued by us without stockholder approval, as well as an additional 20,010,277 shares reserved for the future issuance of awards under our
      equity compensation plans.</div>

    <div><br />
    </div>

    <a id="UnregisteredSalesofEquity"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Unregistered Sales of Equity Securities and Use of Proceeds.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="margin-left: 36pt;">None.</div>

    <div><br />
    </div>

    <a id="DefaultsUponSeniorSecurit"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Defaults Upon Senior Securities.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-indent: 36pt;">None.</div>

    <div><br />
    </div>

    <a id="MineSafetyDisclosures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Mine Safety Disclosures.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-indent: 36pt;">Not applicable.</div>

    <div><br />
    </div>

    <a id="OtherInformation."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold;">Other Information.</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-indent: 36pt;">None.</div>

    <div>
<div>&#160;
      </div>
<a id="Exhibits"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 63pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Exhibits</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

    </div>

    <div style="text-indent: 36pt;">See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.</div>

    <div style="text-indent: 36pt;"> <br />
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">64</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-align: center; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

    <div>&#160;</div>

    <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="vertical-align: top;" colspan="3">
            <div style="text-align: justify; font-weight: bold;">ADMA Biologics, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="vertical-align: top;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Date:<br />
            </div>
          </td>

    <td style="width: 45%; vertical-align: top;">May 10, 2023</td>

    <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;">By:</div>
          </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>
              <div style="text-align: justify;">/s/ Adam S. Grossman</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>

    <td style="width: 42%; vertical-align: top;">
            <div style="text-align: justify;">Adam S. Grossman</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>

    <td style="width: 42%; vertical-align: top;">
            <div style="text-align: justify;">President and Chief Executive Officer</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 42%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Date:<br />
            </div>
          </td>

    <td style="width: 45%; vertical-align: top;">May 10, 2023</td>

    <td style="width: 3%; vertical-align: top;">
            <div style="text-align: justify;">By:</div>
          </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div>
              <div style="text-align: justify;">/s/ Brian Lenz</div>
            </div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Name:</div>
          </td>

    <td style="width: 42%; vertical-align: top;">
            <div style="text-align: justify;">Brian Lenz</div>
          </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="2">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
            <div style="text-align: justify;">Title:</div>
          </td>

    <td style="width: 42%; vertical-align: top;">
            <div style="text-align: justify;">Executive Vice President and Chief Financial Officer</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="width: 100%;" class="BRPFPageFooter"></div>

      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">65</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div style="font-size: 8pt; font-style: italic;"><a href="#INDEX">Index</a></div>

      </div>

    </div>

    <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>

    <div>&#160;</div>

    <div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div><span style="text-decoration: underline;">Exhibit Number</span></div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div><span style="text-decoration: underline;">Description</span></div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 15%; vertical-align: top;">&#160;</td>

    <td rowspan="1" style="width: 85%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/brhc20052223_ex4-1.htm">4.1</a></div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 2, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123013467/brhc10049985_ex10-251.htm">10.1</a></div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="color: #000000;">Amendment No. 1 to Credit Agreement and Guaranty, dated March 22, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.25.1 of the Company&#8217;s
                Annual Report on Form 10-K filed with the SEC on March 23, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/brhc20052223_ex10-1.htm">10.2</a></div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Amendment No. 2 to the Credit and Guaranty Agreement, dated as of May 1, 2023, by and among the Company, Hayfin Services LLP and the lenders party thereto (incorporated by reference to Exhibit 10.1 of the
                Company&#8217;s Current Report on Form 8-K filed with the SEC on May 2, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div><a href="brhc20052583_ex31-1.htm">31.1*</a></div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="color: #000000;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc20052583_ex31-2.htm">31.2*</a></div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div><a href="brhc20052583_ex32-1.htm">32.1**</a></div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="color: #000000;">Certification of Principal Executive Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="brhc20052583_ex32-2.htm">32.2**</a></div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
              <div>101*</div>
            </td>

    <td style="width: 85%; vertical-align: top;">
              <div style="color: #000000;">The following materials from ADMA Biologics, Inc.&#8217;s Form 10-Q for the quarter ended March 31 2023, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets as of March
                31, 2023 (Unaudited) and December 31, 2022, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three months ended March 31, 2023 and 2022, (iii) Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity
                (Unaudited) for the three months ended March 31, 2023 and 2022, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the three months ended March 31, 2023 and 2022, and (v) Notes to (Unaudited) Condensed Consolidated
                Financial Statements.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>104</div>
            </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="color: #000000;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</div>
            </td>

  </tr>


</table>
    </div>

    <div><br />
    </div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto 0px 0px; height: 2px; width: 25%; color: #000000; margin-left: 0px; margin-right: auto;" /></div>

    <div>* Filed herewith.</div>

    <div><br />
    </div>

    <div>** In accordance with SEC Release 33-8238, Exhibit 32.1 and 32.2 are being furnished and not filed.</div>

    <div><br />
    </div>

    <div><br /></div>

    <div style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">66</span></div>

    <div>
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;" /></div>

  </div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>brhc20052583_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-align: justify;">I, Adam S. Grossman, certify that:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z397afac25d7c42c88b10ea193ffffc83" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zc6cc93c7e1894b4095601a08e3bc47c1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9f9ffd4abee04f82ae60ac4bc01a806c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z125dc2c67a394442b7a801881e9c31a2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdfd9572bc5d344dc901ac57ed00e2c74" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z505b7c033eb34267a37f072267b9017c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9ea03585b9e845c49a92e9f9618589b6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb136b39a73b4486bb0c5a0004de6adef" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z995e505d0b284264889263db347f39ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za9edba9dc8674cad855c343c382453ea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za1648d3fcf4a4bb1b5fd5fec90ef8285" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z90829374b5e140d7ad384e95d7134e05" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: May 10, 2023</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>brhc20052583_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-align: justify;">I, Brian Lenz, certify that:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z90207c04e0794a0c9c06e3e23e92423f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="ze52a8fdfeb7f4d4e8b744245b43ed23c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5235349cf2a643428e7db67507e4e3c2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z00cf7269972a41468d50f6b9c5ebaf93" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8201a1ebcd6e462c921f22b7374164e8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z6665e40dfbe74ff293e3d3c135387435" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zde1d84cb2cea404c817d8af1148c1a4b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3759688cd1a1412b86f3ffb089285965" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zb13ace669c3241b99d5ad5dd0e118aa0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zfa4f07124c41475ebc3ab1f229e221a2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z778b68ceb73e4f6daec4891192e9fc03" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z51c38245bc804ce69dcccdf21e3c1f7d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: May 10, 2023</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Brian Lenz</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Brian Lenz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>brhc20052583_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),
        I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0bdb4f96228740a5944208569dcf712b">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z69bbe6f5da054537b56e73eeafcb58b3">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zdf87f766eac745f8b8ff3505796c12c1">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: May 10, 2023</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>brhc20052583_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 23.3.2.5148
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),
        I, Brian Lenz, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3d9a21c58ba94e78ac339b558af87a1e">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z201a4afdbcae4dcc99feb7b5e0c5b7a0">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0d1d5e11346f42c1ba996ac274b739b2">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: May 10, 2023</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Brian Lenz</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Brian Lenz</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">&#160;</td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div><br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>adma-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<xs:schema targetNamespace="http://admabiologics.com/20230331" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:adma="http://admabiologics.com/20230331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>060100 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Inventories" id="Inventories">
        <link:definition>060300 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060400 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060500 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Debt" id="Debt">
        <link:definition>060700 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060800 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060900 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Segments" id="Segments">
        <link:definition>061100 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligations" id="LeaseObligations">
        <link:definition>061200 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" id="SupplementalDisclosureOfCashFlowInformation">
        <link:definition>061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEvent" id="SubsequentEvent">
        <link:definition>061400 - Disclosure - SUBSEQUENT EVENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesTables" id="InventoriesTables">
        <!--Parent Role: INVENTORIES-->
        <link:definition>080300 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtTables" id="DebtTables">
        <!--Parent Role: DEBT-->
        <link:definition>080700 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsTables" id="SegmentsTables">
        <!--Parent Role: SEGMENTS-->
        <link:definition>081100 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsTables" id="LeaseObligationsTables">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" id="SupplementalDisclosureOfCashFlowInformationTables">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" id="OrganizationAndBusinessDetails">
        <!--Parent Role: ORGANIZATION AND BUSINESS-->
        <link:definition>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" id="SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" id="SummaryOfSignificantAccountingPoliciesGoodwillDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" id="SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
        <link:definition>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)Default</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" id="SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" id="SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesDetails" id="InventoriesDetails">
        <!--Parent Role: INVENTORIES-->
        <link:definition>090300 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" id="IntangibleAssetsSummaryDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" id="IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetails" id="DebtDetails">
        <!--Parent Role: DEBT-->
        <link:definition>090700 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" id="StockholdersEquityPreferredStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" id="StockholdersEquityCommonStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" id="StockholdersEquityWarrantsDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" id="StockholdersEquityEquityIncentivePlansDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsDetails" id="SegmentsDetails">
        <!--Parent Role: SEGMENTS-->
        <link:definition>091100 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetails" id="LeaseObligationsDetails">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>091200 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" id="LeaseObligationsDetailsCalc2">
        <!--Parent Role: LEASE OBLIGATIONS (Details)-->
        <link:definition>091202 - Disclosure - LEASE OBLIGATIONS (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" id="SupplementalDisclosureOfCashFlowInformationDetails">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SubsequentEventDetails" id="SubsequentEventDetails">
        <!--Parent Role: SUBSEQUENT EVENT-->
        <link:definition>091400 - Disclosure - SUBSEQUENT EVENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xs:element name="WorkingCapital" id="adma_WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilities" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDAApprovedProduct" id="adma_NumberOfFDAApprovedProduct" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingAndFinancingLeaseLiability" id="adma_OperatingAndFinancingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PaymentOfDebtRefinancingFees" id="adma_PaymentOfDebtRefinancingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfLicenseRevenue" id="adma_AmortizationOfLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TaxesPaidOnVestedRestrictedStockUnits" id="adma_TaxesPaidOnVestedRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInDepositsAndOtherAssets" id="adma_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PostMarketingCommitmentsAbstract" id="adma_PostMarketingCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VendorAndLicensorCommitmentsAbstract" id="adma_VendorAndLicensorCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementTerm" id="adma_PlasmaPurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDAInspections" id="adma_NumberOfFDAInspections" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfPlasmaPurchasePriceEqualToCost" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilities" id="adma_NumberOfPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaSupplyAgreementTerm" id="adma_PlasmaSupplyAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfRenewalTerms" id="adma_NumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfInventoryPurchases" id="adma_PercentageOfInventoryPurchases" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchased" id="adma_PlasmaPurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementRenewalPeriod" id="adma_PlasmaPurchaseAgreementRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" id="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="InternationalCustomersMember" id="adma_InternationalCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BIVIGAMMember" id="adma_BIVIGAMMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementOneMember" id="adma_PlasmaPurchaseAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementTwoMember" id="adma_PlasmaPurchaseAgreementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ASCENIVMember" id="adma_ASCENIVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionsAbstract" id="adma_StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionsWeightedAverageExercisePriceAbstract" id="adma_StockOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionSharesAbstract" id="adma_StockOptionSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeesMember" id="adma_EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockUnitsAbstract" id="adma_RestrictedStockUnitsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="Two022CompensationPlanMember" id="adma_Two022CompensationPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="adma_EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermLiabilityEndOfTermFeePayable" id="adma_LongTermLiabilityEndOfTermFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DepositsAndOtherNoncurrentAssets" id="adma_DepositsAndOtherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="WarrantsIssuedInConnectionWithNotesPayable" id="adma_WarrantsIssuedInConnectionWithNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DeferredRevenueRemainingAmortizationPeriod" id="adma_DeferredRevenueRemainingAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BiotestLicenseAgreementMember" id="adma_BiotestLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfCustomers" id="adma_NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="FiveCustomersMember" id="adma_FiveCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TwoCustomersMember" id="adma_TwoCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ThreeCustomersMember" id="adma_ThreeCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" id="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ADMABioManufacturingSegmentMember" id="adma_ADMABioManufacturingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="InterestAndOtherNonoperatingIncomeExpense" id="adma_InterestAndOtherNonoperatingIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PlasmaCollectionCentersSegmentMember" id="adma_PlasmaCollectionCentersSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinCreditAgreementMember" id="adma_HayfinCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsAbstract" id="adma_WarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ChiefScientificOfficerAndChiefMedicalOfficerMember" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ArethLLCMember" id="adma_ArethLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PerceptiveCreditHoldingsIILPMember" id="adma_PerceptiveCreditHoldingsIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GenesisBPSMember" id="adma_GenesisBPSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MinimumPercentageOfCommonStockHeldByLender" id="adma_MinimumPercentageOfCommonStockHeldByLender" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedRebatesCurrent" id="adma_AccruedRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedTestingCurrent" id="adma_AccruedTestingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="HayfinCreditFacilityMember" id="adma_HayfinCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinClosingDateLoanMember" id="adma_HayfinClosingDateLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentInterestAmountToBePayInKind" id="adma_DebtInstrumentInterestAmountToBePayInKind" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentUpfrontFeePaidInKind" id="adma_DebtInstrumentUpfrontFeePaidInKind" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TrailingPeriodForVolumeWeightedAveragePrice" id="adma_TrailingPeriodForVolumeWeightedAveragePrice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentTermOfVariableRate" id="adma_DebtInstrumentTermOfVariableRate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentApplicableMargin" id="adma_DebtInstrumentApplicableMargin" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SeniorNotesPayableBeforeDebtDiscount" id="adma_SeniorNotesPayableBeforeDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="SharesIssuedUponExerciseOfWarrants" id="adma_SharesIssuedUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="HayfinDelayedDrawLoanMember" id="adma_HayfinDelayedDrawLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidAfterTheFirstAnniversaryMember" id="adma_PrepaidAfterTheFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidAfterTheSecondAnniversaryMember" id="adma_PrepaidAfterTheSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentFloorInterestRate" id="adma_DebtInstrumentFloorInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidOnOrPriorToFirstAnniversaryMember" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SubsequentEventAdditionalInformationAbstract" id="adma_SubsequentEventAdditionalInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfReductionPrepaymentFees" id="adma_PercentageOfReductionPrepaymentFees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="HayfinSecondAmendmentMember" id="adma_HayfinSecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RightToIntermediatesMember" id="adma_RightToIntermediatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>adma-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="calculation: Assets to DepositsAndOtherNoncurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesAndOtherLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SeniorLongTermNotes" xlink:title="calculation: Liabilities to SeniorLongTermNotes" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="calculation: Liabilities to LongTermLiabilityEndOfTermFeePayable" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpense" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpense" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NonoperatingIncomeExpense to GainsLossesOnExtinguishmentOfDebt" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: NetIncomeLoss to NonoperatingIncomeExpense" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: OperatingExpenses to AmortizationOfIntangibleAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OtherCostAndExpenseOperating" xlink:title="calculation: OperatingExpenses to OtherCostAndExpenseOperating" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: GrossProfit to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfRevenue" xlink:title="calculation: GrossProfit to CostOfRevenue" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="OperatingIncomeLoss" xlink:title="calculation: NetIncomeLoss to OperatingIncomeLoss" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to TaxesPaidOnVestedRestrictedStockUnits" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfNotesPayable" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromNotesPayable" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentOfDebtRefinancingFees" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentOfDebtRefinancingFees" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfFinancingCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfFinancingCosts" order="8.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfLicenseRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfLicenseRevenue" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDepositsAndOtherAssets" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationAndAmortization" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainsLossesOnExtinguishmentOfDebt" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryWorkInProcess" xlink:title="calculation: InventoryNet to InventoryWorkInProcess" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryRawMaterials" xlink:title="calculation: InventoryNet to InventoryRawMaterials" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryFinishedGoods" xlink:title="calculation: InventoryNet to InventoryFinishedGoods" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedRebatesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedRebatesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedTestingCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedTestingCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedSalariesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedSalariesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to OtherAccruedLiabilitiesCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedProfessionalFeesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedBonusesCurrent" order="5.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="calculation: SeniorLongTermNotes to DebtInstrumentUnamortizedDiscount" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="calculation: SeniorLongTermNotes to SeniorNotesPayableBeforeDebtDiscount" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>adma-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SubsequentEventDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20230331.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvent" xlink:type="simple" xlink:href="adma-20230331.xsd#SubsequentEvent" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20230331.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20230331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20230331.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20230331.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20230331.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20230331.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20230331.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvent" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: ConcentrationRiskLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskTable" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="definition: ConcentrationRiskTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to ThreeCustomersMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to TwoCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to TwoCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LandMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NotesPayableAbstract" xlink:title="definition: DebtInstrumentLineItems to NotesPayableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfNotesPayable" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfNotesPayable" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedPremium" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedPremium" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: DebtInstrumentLineItems to PaymentsOfDebtIssuanceCosts" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUpfrontFeePaidInKind" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUpfrontFeePaidInKind" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: DebtInstrumentLineItems to GainsLossesOnExtinguishmentOfDebt" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentBasisSpreadOnVariableRate1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTermOfVariableRate" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentApplicableMargin" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentApplicableMargin" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFloorInterestRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFloorInterestRate" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestAmountToBePayInKind" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestAmountToBePayInKind" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaidInKindInterest" xlink:title="definition: DebtInstrumentLineItems to PaidInKindInterest" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="definition: DebtInstrumentLineItems to PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPaymentPrincipal" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="definition: DebtInstrumentLineItems to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="Cash" xlink:title="definition: DebtInstrumentLineItems to Cash" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: DebtInstrumentLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SharesIssuedUponExerciseOfWarrants" xlink:title="definition: DebtInstrumentLineItems to SharesIssuedUponExerciseOfWarrants" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="definition: DebtInstrumentLineItems to TrailingPeriodForVolumeWeightedAveragePrice" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: DebtInstrumentLineItems to FairValueAdjustmentOfWarrants" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="definition: DebtInstrumentLineItems to SeniorNotesPayableBeforeDebtDiscount" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorLongTermNotes" xlink:title="definition: DebtInstrumentLineItems to SeniorLongTermNotes" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="30.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinClosingDateLoanMember" xlink:title="definition: HayfinCreditFacilityMember to HayfinClosingDateLoanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinDelayedDrawLoanMember" xlink:title="definition: HayfinCreditFacilityMember to HayfinDelayedDrawLoanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: DebtInstrumentTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="FederalFundsEffectiveSwapRateMember" xlink:title="FederalFundsEffectiveSwapRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="FederalFundsEffectiveSwapRateMember" xlink:title="definition: VariableRateDomain to FederalFundsEffectiveSwapRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="definition: VariableRateDomain to SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="BaseRateMember" xlink:title="definition: VariableRateDomain to BaseRateMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheSecondAnniversaryMember" xlink:label="PrepaidAfterTheSecondAnniversaryMember" xlink:title="PrepaidAfterTheSecondAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheSecondAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheSecondAnniversaryMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="definition: DebtInstrumentTable to StatementScenarioAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain_2" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain_2" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="definition: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAndRightsOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ClassOfWarrantOrRightLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ClassOfWarrantOrRightTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensation" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionSharesAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionSharesAbstract" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsWeightedAverageExercisePriceAbstract" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="46.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="47.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="48.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="definition: PlanNameDomain to Two022CompensationPlanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to OperatingExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionPurchasesFromRelatedParty" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="definition: RelatedPartyTransactionLineItems to MinimumPercentageOfCommonStockHeldByLender" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="ArethLLCMember" xlink:title="definition: RelatedPartyDomain to ArethLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="GenesisBPSMember" xlink:title="definition: RelatedPartyDomain to GenesisBPSMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ChiefScientificOfficerAndChiefMedicalOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: LossContingenciesLineItems to ResearchAndDevelopmentExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:title="definition: LossContingenciesLineItems to NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDAInspections" xlink:label="NumberOfFDAInspections" xlink:title="NumberOfFDAInspections" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfFDAInspections" xlink:title="definition: LossContingenciesLineItems to NumberOfFDAInspections" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: LossContingenciesLineItems to ConcentrationRiskPercentage1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionFacilities" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementTerm" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfRenewalTerms" xlink:title="definition: LossContingenciesLineItems to NumberOfRenewalTerms" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementRenewalPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="definition: LossContingenciesLineItems to PercentageOfPlasmaPurchasePriceEqualToCost" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaSupplyAgreementTerm" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchased" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchased" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PercentageOfInventoryPurchases" xlink:title="definition: LossContingenciesLineItems to PercentageOfInventoryPurchases" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementTwoMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementTwoMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: LossContingenciesTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="SalesRevenueNetMember" xlink:title="SalesRevenueNetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="SalesRevenueNetMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to SalesRevenueNetMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: LossContingenciesTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="MajorCustomersAxis" xlink:title="definition: LossContingenciesTable to MajorCustomersAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InternationalCustomersMember" xlink:label="InternationalCustomersMember" xlink:title="InternationalCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="InternationalCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to InternationalCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: LossContingenciesTable to ProductOrServiceAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="BIVIGAMMember" xlink:title="definition: ProductsAndServicesDomain to BIVIGAMMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="definition: ProductsAndServicesDomain to ASCENIVMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfFDALicensedPlasmaCollectionFacilities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:label="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:title="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: SegmentReportingInformationLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CostOfRevenue" xlink:title="definition: SegmentReportingInformationLineItems to CostOfRevenue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to OperatingIncomeLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InterestAndOtherNonoperatingIncomeExpense" xlink:label="InterestAndOtherNonoperatingIncomeExpense" xlink:title="InterestAndOtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InterestAndOtherNonoperatingIncomeExpense" xlink:title="definition: SegmentReportingInformationLineItems to InterestAndOtherNonoperatingIncomeExpense" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: SegmentReportingInformationLineItems to GainsLossesOnExtinguishmentOfDebt" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to NetIncomeLoss" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: SegmentReportingInformationLineItems to PaymentsToAcquirePropertyPlantAndEquipment" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: SegmentReportingInformationLineItems to DepreciationAndAmortization" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="Assets" xlink:title="definition: SegmentReportingInformationLineItems to Assets" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="definition: SegmentDomain to ADMABioManufacturingSegmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="definition: SegmentDomain to CorporateMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain_2" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain_2" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="definition: SegmentGeographicalDomain to US" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="definition: SegmentGeographicalDomain to NonUsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SubsequentEventAdditionalInformationAbstract" xlink:label="SubsequentEventAdditionalInformationAbstract" xlink:title="SubsequentEventAdditionalInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventAdditionalInformationAbstract" xlink:title="definition: SubsequentEventLineItems to SubsequentEventAdditionalInformationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentApplicableMargin" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentApplicableMargin" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="definition: SubsequentEventLineItems to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfReductionPrepaymentFees" xlink:label="PercentageOfReductionPrepaymentFees" xlink:title="PercentageOfReductionPrepaymentFees" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="PercentageOfReductionPrepaymentFees" xlink:title="definition: SubsequentEventLineItems to PercentageOfReductionPrepaymentFees" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: SubsequentEventLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: SubsequentEventLineItems to WarrantsAndRightsOutstanding" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventTable" xlink:title="definition: SubsequentEventLineItems to SubsequentEventTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: SubsequentEventTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: SubsequentEventTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="VariableRateAxis" xlink:title="definition: SubsequentEventTable to VariableRateAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="definition: VariableRateDomain to SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="definition: SubsequentEventTable to DebtInstrumentRedemptionPeriodAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheSecondAnniversaryMember" xlink:label="PrepaidAfterTheSecondAnniversaryMember" xlink:title="PrepaidAfterTheSecondAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheSecondAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheSecondAnniversaryMember" order="3.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>adma-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract_lbl">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableMember_lbl">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent_lbl">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableNetAbstract_lbl">Accounts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" xlink:title="label: AccountsReceivableNetAbstract to us-gaap_AccountsReceivableNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent_lbl">Accrued distribution fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1">Total accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent_lbl">Accrued incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedSalariesCurrent_lbl">Accrued payroll and other compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:title="label: AccruedSalariesCurrent to us-gaap_AccruedSalariesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl">Accrued Expenses and Other Current Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl">Warrants issued in connection with note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl">Potentially dilutive securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract_lbl">Impairment of Long-lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetUnderConstructionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetUnderConstructionMember_lbl" xml:lang="en-US" id="us-gaap_AssetUnderConstructionMember_lbl">Construction in Process [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember_lbl" xlink:title="label: AssetUnderConstructionMember to us-gaap_AssetUnderConstructionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BaseRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BaseRateMember_lbl" xml:lang="en-US" id="us-gaap_BaseRateMember_lbl">Base Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRateMember" xlink:to="us-gaap_BaseRateMember_lbl" xlink:title="label: BaseRateMember to us-gaap_BaseRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember_lbl">Buildings and Building Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingMember_lbl" xml:lang="en-US" id="us-gaap_BuildingMember_lbl">Building [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" xlink:title="label: BuildingMember to us-gaap_BuildingMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents - beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents - end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl">Net (decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash_lbl" xml:lang="en-US" id="us-gaap_Cash_lbl">Cash balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash_lbl" xlink:title="label: Cash to us-gaap_Cash_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashEquivalentsAtCarryingValue_lbl1">Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashEquivalentsAtCarryingValue to us-gaap_CashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" xlink:title="label: CashFlowSupplementalDisclosuresTextBlock to us-gaap_CashFlowSupplementalDisclosuresTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl">Warrant to purchase shares of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems_lbl">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable_lbl">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl">Warrant exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">COMMITMENTS AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common stock, available for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl1">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 222,262,588 and 221,816,930 shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByTypeAxis_lbl">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:title="label: ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskLineItems_lbl">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:title="label: ConcentrationRiskLineItems to us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskTypeDomain_lbl">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:title="label: ConcentrationRiskTypeDomain to us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskBenchmarkDomain_lbl">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:title="label: ConcentrationRiskBenchmarkDomain to us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl1">Percentage of consolidated revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl1" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl2" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl2">Percentage of account receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl2" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskTable_lbl">Schedule of Product Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:title="label: ConcentrationRiskTable to us-gaap_ConcentrationRiskTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:title="label: ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent_lbl">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CorporateMember_lbl" xml:lang="en-US" id="us-gaap_CorporateMember_lbl">Corporate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember_lbl" xlink:title="label: CorporateMember to us-gaap_CorporateMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateMember_lbl1" xml:lang="en-US" id="us-gaap_CorporateMember_lbl1">Corporate Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember_lbl1" xlink:title="label: CorporateMember to us-gaap_CorporateMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl">Cost of Product Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfRevenue_lbl" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CostOfRevenue_lbl1" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl1">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl1" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfRevenue_lbl2" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl2">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl2" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesMember_lbl">Cost of Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract_lbl">OPERATING EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember_lbl">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:title="label: DebtInstrumentRedemptionPeriodAxis to us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl">Increase applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl">Percentage of prepaid principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xlink:title="label: DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed to us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:title="label: DebtInstrumentRedemptionPeriodDomain to us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl">Credit agreement, interest rate provided</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:title="label: DebtInstrumentBasisSpreadOnVariableRate1 to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">DEBT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl1">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl1" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract_lbl">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl">Scheduled principal payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xlink:title="label: DebtInstrumentPeriodicPaymentPrincipal to us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Less: Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedPremium_lbl">Redemption premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xlink:title="label: DebtInstrumentUnamortizedPremium to us-gaap_DebtInstrumentUnamortizedPremium_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedPremium_lbl1">Debt Instrument, Unamortized Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xlink:title="label: DebtInstrumentUnamortizedPremium to us-gaap_DebtInstrumentUnamortizedPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent_lbl">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepreciationAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization_lbl1">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl1" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl">Loss Per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">BASIC LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">DILUTED LOSS PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl">Unrecognized compensation expense, non option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Unrecognized compensation expense recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Unrecognized compensation expense, stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="us-gaap_EquityAbstract_lbl">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants_lbl">Fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="FederalFundsEffectiveSwapRateMember" xlink:title="FederalFundsEffectiveSwapRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FederalFundsEffectiveSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FederalFundsEffectiveSwapRateMember_lbl" xml:lang="en-US" id="us-gaap_FederalFundsEffectiveSwapRateMember_lbl">Federal Funds Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalFundsEffectiveSwapRateMember" xlink:to="us-gaap_FederalFundsEffectiveSwapRateMember_lbl" xlink:title="label: FederalFundsEffectiveSwapRateMember to us-gaap_FederalFundsEffectiveSwapRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl">Payments on finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl">Remainder of 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl">Estimated Aggregate Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl3" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl3">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl3" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl">Impairment charges related to goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl1">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill_lbl" xml:lang="en-US" id="us-gaap_Goodwill_lbl">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Goodwill_lbl1" xml:lang="en-US" id="us-gaap_Goodwill_lbl1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill_lbl1" xlink:title="label: Goodwill to us-gaap_Goodwill_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl">INTANGIBLE ASSETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit_lbl" xml:lang="en-US" id="us-gaap_GrossProfit_lbl">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl">Other current and non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract_lbl">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods_lbl">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock_lbl">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InventoryNet_lbl1" xml:lang="en-US" id="us-gaap_InventoryNet_lbl1">Total inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl2" xml:lang="en-US" id="us-gaap_InventoryNet_lbl2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl2" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" id="us-gaap_InventoryRawMaterials_lbl">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess_lbl">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest_lbl">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock_lbl">LEASE OBLIGATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl">Remainder of 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">Year ended December 31, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Payments Under Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandMember_lbl" xml:lang="en-US" id="us-gaap_LandMember_lbl">Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandMember" xlink:to="us-gaap_LandMember_lbl" xlink:title="label: LandMember to us-gaap_LandMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" id="us-gaap_LeasesAbstract_lbl">LEASE OBLIGATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAxis_lbl">Lender Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:title="label: LineOfCreditFacilityAxis to us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLenderDomain_lbl">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:title="label: LineOfCreditFacilityLenderDomain to us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock_lbl">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems_lbl">Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="us-gaap_LossContingenciesTable_lbl">Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US" id="us-gaap_ManufacturingFacilityMember_lbl">Manufacturing and Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:title="label: ManufacturingFacilityMember to us-gaap_ManufacturingFacilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">NET LOSS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl3">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonUsMember_lbl" xml:lang="en-US" id="us-gaap_NonUsMember_lbl">International [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonUsMember" xlink:to="us-gaap_NonUsMember_lbl" xlink:title="label: NonUsMember to us-gaap_NonUsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl">Noncash Financing and Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense_lbl1">Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">OTHER INCOME (EXPENSE):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesPayableAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US" id="us-gaap_NotesPayableAbstract_lbl">Senior Notes Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" xlink:title="label: NotesPayableAbstract to us-gaap_NotesPayableAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember_lbl">Office Equipment and Computer Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl">Weighted average remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl">Lease obligations, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1">Balance at March 31, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Current portion of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Payments Under Lease Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right-to-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl">Cash payments for lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl">Aggregate lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl1">Operating Lease, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl1" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">LOSS FROM OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenseMember_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenseMember_lbl">Plasma Center Operating Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl" xlink:title="label: OperatingExpenseMember to us-gaap_OperatingExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember_lbl">Operating Segments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl">ORGANIZATION AND BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">ORGANIZATION AND BUSINESS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US" id="us-gaap_OtherCostAndExpenseOperating_lbl">Plasma center operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:title="label: OtherCostAndExpenseOperating to us-gaap_OtherCostAndExpenseOperating_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent_lbl">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US" id="us-gaap_PaidInKindInterest_lbl">Interest paid in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaidInKindInterest_lbl1" xml:lang="en-US" id="us-gaap_PaidInKindInterest_lbl1">Interest paid-in-kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl1" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract_lbl">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfFinancingCosts_lbl">Payment of deferred financing fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:title="label: PaymentsOfFinancingCosts to us-gaap_PaymentsOfFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfFinancingCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfFinancingCosts_lbl1">Payments of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl1" xlink:title="label: PaymentsOfFinancingCosts to us-gaap_PaymentsOfFinancingCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl">Payment for certain fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1">Preferred Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="us-gaap_PreferredStockValue_lbl">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl">Organization and Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromNotesPayable_lbl">Proceeds from issuance of note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:title="label: ProceedsFromNotesPayable to us-gaap_ProceedsFromNotesPayable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property Plant And Equipment By Type Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Total property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl1">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract_lbl">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems_lbl">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl">Purchased materials amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" xlink:title="label: RelatedPartyTransactionDueFromToRelatedPartyAbstract to us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" xlink:title="label: RelatedPartyTransactionDueFromToRelatedPartyAbstract to us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:title="label: RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty to us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyDomain_lbl">Related Party [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl">Related Party [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl">Principal payments on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl1">Payment for outstanding obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl2" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl2">Repayments of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl">Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerMember_lbl">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:title="label: RevenueFromContractWithCustomerMember to us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl">Net Revenues According to Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" xlink:title="label: RevenueFromExternalCustomersByGeographicAreasTableTextBlock to us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract_lbl">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual life of stock options, expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Weighted average remaining contractual life of stock options, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Weighted average remaining contractual life of stock options, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl">Intangible Asset Future Aggregate Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="SalesRevenueNetMember" xlink:title="SalesRevenueNetMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" id="us-gaap_SalesRevenueNetMember_lbl">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:title="label: SalesRevenueNetMember to us-gaap_SalesRevenueNetMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl">Schedule of Unvested RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:title="label: ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Schedule of Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Schedule of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:title="label: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock to us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl">Components of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDebtTableTextBlock_lbl">Summary of Outstanding Senior Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:title="label: ScheduleOfDebtTableTextBlock to us-gaap_ScheduleOfDebtTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl">Calculation of Diluted Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl">Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:title="label: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock to us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl">Summarized Financial Information Concerning Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xml:lang="en-US" id="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl">Secured Overnight Financing Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" xlink:title="label: SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember to us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl">SEGMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems_lbl">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain_lbl" xml:lang="en-US" id="us-gaap_SegmentDomain_lbl">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl">Segment Reporting Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">SEGMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeniorLongTermNotes_lbl" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes_lbl">Senior notes payable, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SeniorLongTermNotes_lbl1" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes_lbl1">Senior notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes_lbl1" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl">Forfeited, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Equity incentive plans, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Restricted stock units vested over a period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl">Unvested RSU, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl">Equity incentive plans, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Number of stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl">Number of restricted stock units granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Unvested RSU, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl">Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1">Unvested, Weighted average grant date fair value, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Total stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl2">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl2" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Granted, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl">Vested, Weighted average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl">Options outstanding, vested and expected to vest, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1">Options outstanding, vested and expected to vest, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl">Stock Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl">Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1">Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl">Total stock-based compensation expense, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" xlink:title="label: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock_lbl">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis_lbl">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Common stock shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl2">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl2" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsTextBlock_lbl">SUBSEQUENT EVENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:title="label: SubsequentEventsTextBlock to us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTable_lbl">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:title="label: SubsequentEventTable to us-gaap_SubsequentEventTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventLineItems_lbl">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:title="label: SubsequentEventLineItems to us-gaap_SubsequentEventLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventsAbstract_lbl">SUBSEQUENT EVENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:title="label: SubsequentEventsAbstract to us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowElementsAbstract_lbl">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xlink:title="label: SupplementalCashFlowElementsAbstract to us-gaap_SupplementalCashFlowElementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:title="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" xlink:title="label: UnrecognizedTaxBenefitsPeriodIncreaseDecrease to us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="us-gaap_VariableRateDomain_lbl">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" xlink:title="label: VariableRateDomain to us-gaap_VariableRateDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="us-gaap_VariableRateAxis_lbl">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:title="label: VariableRateAxis to us-gaap_VariableRateAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="us-gaap_WarrantMember_lbl">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:title="label: WarrantMember to us-gaap_WarrantMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl">Fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl1">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" id="srt_CounterpartyNameAxis_lbl">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" id="srt_ConsolidationItemsAxis_lbl">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" id="srt_ConsolidationItemsDomain_lbl">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_DirectorMember_lbl" xml:lang="en-US" id="srt_DirectorMember_lbl">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl" xlink:title="label: DirectorMember to srt_DirectorMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl1" xml:lang="en-US" id="srt_DirectorMember_lbl1">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl1" xlink:title="label: DirectorMember to srt_DirectorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MajorCustomersAxis_lbl" xml:lang="en-US" id="srt_MajorCustomersAxis_lbl">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MajorCustomersAxis_lbl1" xml:lang="en-US" id="srt_MajorCustomersAxis_lbl1">Major Customers [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl1" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="srt_NameOfMajorCustomerDomain_lbl">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xlink:title="label: NameOfMajorCustomerDomain to srt_NameOfMajorCustomerDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="srt_ProductsAndServicesDomain_lbl">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="srt_ProductOrServiceAxis_lbl">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl1" xml:lang="en-US" id="srt_RangeAxis_lbl1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl1" xlink:title="label: RangeAxis to srt_RangeAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain_lbl">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioForecastMember_lbl" xml:lang="en-US" id="srt_ScenarioForecastMember_lbl">Forecast [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:title="label: ScenarioForecastMember to srt_ScenarioForecastMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="srt_ScenarioUnspecifiedDomain_lbl">Scenario [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xlink:title="label: ScenarioUnspecifiedDomain to srt_ScenarioUnspecifiedDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="srt_SegmentGeographicalDomain_lbl">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xlink:title="label: SegmentGeographicalDomain to srt_SegmentGeographicalDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" id="srt_StatementGeographicalAxis_lbl">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:title="label: StatementGeographicalAxis to srt_StatementGeographicalAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementScenarioAxis_lbl" xml:lang="en-US" id="srt_StatementScenarioAxis_lbl">Scenario [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:title="label: StatementScenarioAxis to srt_StatementScenarioAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="srt_TitleOfIndividualAxis_lbl">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:label xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="country_US_lbl" xml:lang="en-US" id="country_US_lbl">United States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US_lbl" xlink:title="label: US to country_US_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" id="dei_DocumentQuarterlyReport_lbl">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WorkingCapital_lbl" xml:lang="en-US" id="adma_WorkingCapital_lbl">The amount of difference between current assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WorkingCapital_lbl1" xml:lang="en-US" id="adma_WorkingCapital_lbl1">Working Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl1" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WorkingCapital_lbl2" xml:lang="en-US" id="adma_WorkingCapital_lbl2">Working capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl2" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl">Number of plasma collection facilities having FDA license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1">Number of FDA-Licensed Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2">Number of FDA-licensed plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDAApprovedProduct_lbl" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl">Number of products approved by FDA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDAApprovedProduct_lbl1" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl1">Number of FDA Approved Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl1" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDAApprovedProduct_lbl2" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl2">Number of FDA approved product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl2" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl">Number of plasma collection facilities under various stages of development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1">Number of Plasma Collection Facilities Under Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2">Number of plasma collection facilities under approval and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl1" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl1">Operating and Financing Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl2" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl2">Operating and financing lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl2" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PaymentOfDebtRefinancingFees_lbl" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees_lbl">The cash outflow for payment of debt refinancing fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PaymentOfDebtRefinancingFees_lbl1" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees_lbl1">Payment of debt refinancing fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl1" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_PaymentOfDebtRefinancingFees_lbl2" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees_lbl2">Payment of debt refinancing fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl2" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AmortizationOfLicenseRevenue_lbl" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl">Amount of noncash revenue related to amortization of license revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AmortizationOfLicenseRevenue_lbl1" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl1">Amortization of License Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl1" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AmortizationOfLicenseRevenue_lbl2" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl2">Amortization of license revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl2" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl">Amount of cash outflow related to taxes on vested Restricted Stock Units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1">Taxes Paid on Vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2">Taxes paid on vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl">Amount of increase (decrease) in deposits and operating assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PostMarketingCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_PostMarketingCommitmentsAbstract_lbl1">Post-Marketing Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:title="label: PostMarketingCommitmentsAbstract to adma_PostMarketingCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract_lbl1">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VendorAndLicensorCommitmentsAbstract_lbl2" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract_lbl2">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract_lbl2" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl">Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl1">Plasma Purchase Agreement Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl1" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementTerm_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTerm_lbl2">Plasma purchase agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTerm" xlink:to="adma_PlasmaPurchaseAgreementTerm_lbl2" xlink:title="label: PlasmaPurchaseAgreementTerm to adma_PlasmaPurchaseAgreementTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDAInspections" xlink:label="NumberOfFDAInspections" xlink:title="NumberOfFDAInspections" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAInspections_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDAInspections_lbl" xml:lang="en-US" id="adma_NumberOfFDAInspections_lbl">Number of FDA inspections completed during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAInspections" xlink:to="adma_NumberOfFDAInspections_lbl" xlink:title="label: NumberOfFDAInspections to adma_NumberOfFDAInspections_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAInspections_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDAInspections_lbl1" xml:lang="en-US" id="adma_NumberOfFDAInspections_lbl1">Number of FDA Inspections</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAInspections" xlink:to="adma_NumberOfFDAInspections_lbl1" xlink:title="label: NumberOfFDAInspections to adma_NumberOfFDAInspections_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl">Percentage of plasma purchase price equal to cost purchased from collection centers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1">Percentage of Plasma Purchase Price Equal to Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xml:lang="en-US" id="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2">Percentage of plasma purchase price equal to cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:to="adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" xlink:title="label: PercentageOfPlasmaPurchasePriceEqualToCost to adma_PercentageOfPlasmaPurchasePriceEqualToCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl">Number of wholly-owned plasma collection facilities of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl1">Number of Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl2">Number of plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl2" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl">Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl1">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl2" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl2">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl2" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfRenewalTerms_lbl" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl">Number of renewal terms to extend purchase agreement, if agreed to by the parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfRenewalTerms_lbl1" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl1">Number of Renewal Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl1" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfRenewalTerms_lbl2" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl2">Number of renewal terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl2" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfInventoryPurchases_lbl" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl">Percentage of inventory purchases related to raw material plasma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfInventoryPurchases_lbl1" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl1">Percentage of Inventory Purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl1" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfInventoryPurchases_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfInventoryPurchases_lbl2" xml:lang="en-US" id="adma_PercentageOfInventoryPurchases_lbl2">Percentage of inventory purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfInventoryPurchases" xlink:to="adma_PercentageOfInventoryPurchases_lbl2" xlink:title="label: PercentageOfInventoryPurchases to adma_PercentageOfInventoryPurchases_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchased_lbl" xml:lang="en-US" id="adma_PlasmaPurchased_lbl">Amount of plasma purchased during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchased_lbl1" xml:lang="en-US" id="adma_PlasmaPurchased_lbl1">Plasma Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl1" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchased_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchased_lbl2" xml:lang="en-US" id="adma_PlasmaPurchased_lbl2">Plasma purchased from Grifols</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchased" xlink:to="adma_PlasmaPurchased_lbl2" xlink:title="label: PlasmaPurchased to adma_PlasmaPurchased_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl">Number of plasma collection centers that company may purchase RSV plasma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1">Number of Plasma Collection Centers Transferred to Acquired Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2">Number of plasma collection centers that collects RSV Plasma which were transferred to BPC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:to="adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" xlink:title="label: NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity to adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl">Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1">Plasma Purchase Agreement Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2">Plasma purchase agreement renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl">Number of plasma collection facilities having FDA licenses approved.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilitiesApproved to adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl1" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl1">Number of FDA-Licensed Plasma Collection Facilities Approved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl1" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilitiesApproved to adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl2" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl2">Number of FDA-licensed plasma collection facilities approved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl2" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilitiesApproved to adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InternationalCustomersMember" xlink:label="InternationalCustomersMember" xlink:title="InternationalCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_InternationalCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_InternationalCustomersMember_lbl" xml:lang="en-US" id="adma_InternationalCustomersMember_lbl">Information about international customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternationalCustomersMember" xlink:to="adma_InternationalCustomersMember_lbl" xlink:title="label: InternationalCustomersMember to adma_InternationalCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_InternationalCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_InternationalCustomersMember_lbl1" xml:lang="en-US" id="adma_InternationalCustomersMember_lbl1">International Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternationalCustomersMember" xlink:to="adma_InternationalCustomersMember_lbl1" xlink:title="label: InternationalCustomersMember to adma_InternationalCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BIVIGAMMember_lbl" xml:lang="en-US" id="adma_BIVIGAMMember_lbl">BIVIGAM an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember_lbl" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BIVIGAMMember_lbl1" xml:lang="en-US" id="adma_BIVIGAMMember_lbl1">BIVIGAM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember_lbl1" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_BIVIGAMMember_lbl2" xml:lang="en-US" id="adma_BIVIGAMMember_lbl2">BIVIGAM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember_lbl2" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl">Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl1">Plasma Purchase Agreement One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl2">2011 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl2" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl">Plasma purchase agreement to purchase normal source plasma ("NSP").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl1">Plasma Purchase Agreement Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementTwoMember_lbl2">2017 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementTwoMember" xlink:to="adma_PlasmaPurchaseAgreementTwoMember_lbl2" xlink:title="label: PlasmaPurchaseAgreementTwoMember to adma_PlasmaPurchaseAgreementTwoMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ASCENIVMember_lbl" xml:lang="en-US" id="adma_ASCENIVMember_lbl">ASCENIV an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ASCENIVMember_lbl1" xml:lang="en-US" id="adma_ASCENIVMember_lbl1">ASCENIV [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl1" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl">Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl">Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsAbstract_lbl1">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="adma_StockOptionsAbstract_lbl1" xlink:title="label: StockOptionsAbstract to adma_StockOptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1">Stock Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: StockOptionsWeightedAverageExercisePriceAbstract to adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2">Expired, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionSharesAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionSharesAbstract_lbl1">Stock Option, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionSharesAbstract" xlink:to="adma_StockOptionSharesAbstract_lbl1" xlink:title="label: StockOptionSharesAbstract to adma_StockOptionSharesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl">Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl">Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl">Number of shares under fully vested and expected to vest options that were exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2">Forfeited, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EmployeesMember_lbl" xml:lang="en-US" id="adma_EmployeesMember_lbl">A group of person working with the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EmployeesMember_lbl1" xml:lang="en-US" id="adma_EmployeesMember_lbl1">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl1" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EmployeesMember_lbl2" xml:lang="en-US" id="adma_EmployeesMember_lbl2">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl2" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl">Number of shares under fully vested and expected to vest options that were granted during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RestrictedStockUnitsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RestrictedStockUnitsAbstract_lbl1" xml:lang="en-US" id="adma_RestrictedStockUnitsAbstract_lbl1">Restricted Stock Units [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsAbstract" xlink:to="adma_RestrictedStockUnitsAbstract_lbl1" xlink:title="label: RestrictedStockUnitsAbstract to adma_RestrictedStockUnitsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl">The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2">Amount of shares withheld for tax withholding obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl">The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2">Shares withheld for tax withholding obligation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_Two022CompensationPlanMember_lbl" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl">Represents 2022 compensation plan of equity based compensation arrangement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_Two022CompensationPlanMember_lbl1" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl1">Two022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl1" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_Two022CompensationPlanMember_lbl2" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl2">2022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl2" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl">Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl1">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquityIncentivePlanMember_lbl2" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl2">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl2" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl">Principal balance of the loans and any other obligations advanced or otherwise owed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl1">Long Term Liability, End of Term Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl2" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl2">End of term fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl2" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl1">Deposits and Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl2" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl2">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl2" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl">Amount of warrants issued in connection with the issuance of notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1">Warrants Issued in Connection with Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl2" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl2">Warrants issued in connection with notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl2" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl">Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1">Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2">Equipment acquired reflected in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl">Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BiotestLicenseAgreementMember_lbl" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl">Name of license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BiotestLicenseAgreementMember_lbl1" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl1">Biotest License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl1" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfCustomers_lbl" xml:lang="en-US" id="adma_NumberOfCustomers_lbl">Number of major customers of the organization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfCustomers_lbl1" xml:lang="en-US" id="adma_NumberOfCustomers_lbl1">Number of Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl1" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_NumberOfCustomers_lbl2" xml:lang="en-US" id="adma_NumberOfCustomers_lbl2">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl2" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl2" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfCustomers_lbl3" xml:lang="en-US" id="adma_NumberOfCustomers_lbl3">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl3" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl3" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_FiveCustomersMember_lbl" xml:lang="en-US" id="adma_FiveCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_FiveCustomersMember_lbl1" xml:lang="en-US" id="adma_FiveCustomersMember_lbl1">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl1" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TwoCustomersMember_lbl" xml:lang="en-US" id="adma_TwoCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TwoCustomersMember_lbl1" xml:lang="en-US" id="adma_TwoCustomersMember_lbl1">Two Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl1" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl">Amount of allowance for contractual credits and doubtful accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1">Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2">Accounts receivable, allowances for contractual credits and doubtful accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ThreeCustomersMember_lbl" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ThreeCustomersMember_lbl1" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl1">Three Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl1" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:label="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:title="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl" xml:lang="en-US" id="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl">Number of remaining plasma collection facilities under construction during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:to="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl" xlink:title="label: NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction to adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl1" xml:lang="en-US" id="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl1">Number of Remaining Plasma Collection Facilities Under Construction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:to="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl1" xlink:title="label: NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction to adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl2" xml:lang="en-US" id="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl2">Number of remaining plasma collection facilities under construction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:to="adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl2" xlink:title="label: NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction to adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl">Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl1" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl1">ADMA BioManufacturing Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl2" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl2">ADMA BioManufacturing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl2" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InterestAndOtherNonoperatingIncomeExpense" xlink:label="InterestAndOtherNonoperatingIncomeExpense" xlink:title="InterestAndOtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="adma_InterestAndOtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_InterestAndOtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="adma_InterestAndOtherNonoperatingIncomeExpense_lbl">The amount of interest and other nonoperating income (expense).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAndOtherNonoperatingIncomeExpense" xlink:to="adma_InterestAndOtherNonoperatingIncomeExpense_lbl" xlink:title="label: InterestAndOtherNonoperatingIncomeExpense to adma_InterestAndOtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_InterestAndOtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_InterestAndOtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="adma_InterestAndOtherNonoperatingIncomeExpense_lbl1">Interest and Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAndOtherNonoperatingIncomeExpense" xlink:to="adma_InterestAndOtherNonoperatingIncomeExpense_lbl1" xlink:title="label: InterestAndOtherNonoperatingIncomeExpense to adma_InterestAndOtherNonoperatingIncomeExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_InterestAndOtherNonoperatingIncomeExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_InterestAndOtherNonoperatingIncomeExpense_lbl2" xml:lang="en-US" id="adma_InterestAndOtherNonoperatingIncomeExpense_lbl2">Interest and other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestAndOtherNonoperatingIncomeExpense" xlink:to="adma_InterestAndOtherNonoperatingIncomeExpense_lbl2" xlink:title="label: InterestAndOtherNonoperatingIncomeExpense to adma_InterestAndOtherNonoperatingIncomeExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl">Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl1" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl1">Plasma Collection Centers Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl2" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl2">Plasma Collection Centers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl2" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinCreditAgreementMember_lbl" xml:lang="en-US" id="adma_HayfinCreditAgreementMember_lbl">A Hayfin credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember_lbl" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinCreditAgreementMember_lbl1" xml:lang="en-US" id="adma_HayfinCreditAgreementMember_lbl1">Hayfin Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember_lbl1" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinCreditAgreementMember_lbl2" xml:lang="en-US" id="adma_HayfinCreditAgreementMember_lbl2">Hayfin Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember_lbl2" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsAbstract_lbl1" xml:lang="en-US" id="adma_WarrantsAbstract_lbl1">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl1" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsAbstract_lbl2" xml:lang="en-US" id="adma_WarrantsAbstract_lbl2">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl2" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl">Person with designation of chief scientific officer and chief medical officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1">Chief Scientific Officer and Chief Medical Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xml:lang="en-US" id="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2">Dr. James Mond [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:to="adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" xlink:title="label: ChiefScientificOfficerAndChiefMedicalOfficerMember to adma_ChiefScientificOfficerAndChiefMedicalOfficerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ArethLLCMember_lbl" xml:lang="en-US" id="adma_ArethLLCMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ArethLLCMember_lbl1" xml:lang="en-US" id="adma_ArethLLCMember_lbl1">Areth, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl1" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl">Name of the Lender in credit facility agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl1">Perceptive Credit Holdings II, LP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl2">Perceptive [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl2" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_GenesisBPSMember_lbl" xml:lang="en-US" id="adma_GenesisBPSMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_GenesisBPSMember_lbl1" xml:lang="en-US" id="adma_GenesisBPSMember_lbl1">GenesisBPS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl1" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_GenesisBPSMember_lbl2" xml:lang="en-US" id="adma_GenesisBPSMember_lbl2">Genesis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl2" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl">Minimum percentage of common stock held by lender and administrative agent of credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1">Minimum Percentage of Common Stock held by Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2">Minimum percentage of common stock held by lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedRebatesCurrent_lbl" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl">Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedRebatesCurrent_lbl1" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl1">Accrued Rebates, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl1" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedRebatesCurrent_lbl2" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl2">Accrued rebates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl2" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedTestingCurrent_lbl" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedTestingCurrent_lbl1" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl1">Accrued Testing, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl1" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedTestingCurrent_lbl2" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl2">Accrued testing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl2" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinCreditFacilityMember_lbl" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl1">Hayfin Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl1" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinClosingDateLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinClosingDateLoanMember_lbl" xml:lang="en-US" id="adma_HayfinClosingDateLoanMember_lbl">Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinClosingDateLoanMember" xlink:to="adma_HayfinClosingDateLoanMember_lbl" xlink:title="label: HayfinClosingDateLoanMember to adma_HayfinClosingDateLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinClosingDateLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinClosingDateLoanMember_lbl1" xml:lang="en-US" id="adma_HayfinClosingDateLoanMember_lbl1">Hayfin Closing Date Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinClosingDateLoanMember" xlink:to="adma_HayfinClosingDateLoanMember_lbl1" xlink:title="label: HayfinClosingDateLoanMember to adma_HayfinClosingDateLoanMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind_lbl">The interest amount to be pay in kind during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1">Debt Instrument, Interest Amount to be Pay in Kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind_lbl2" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind_lbl2">Percentage of interest amount to pay in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind_lbl2" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind_lbl">The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1">Debt Instrument, Upfront Fee, Paid in Kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind_lbl2" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind_lbl2">Upfront fee paid in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind_lbl2" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl">Number of business days for prior written notice to pay outstanding principal loans subject to payment conditions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1">Number of Business Days For Prior Written Notice to Prepay Outstanding Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl2" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl2">Number of business days prior written notice for prepay outstanding principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl2" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl">The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1">Trailing Period for Volume Weighted Average Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl2" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl2">Trailing period for VWAP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl2" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl">Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl1">Debt Instrument, Term of Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl2" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl2">Term of variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl2" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentApplicableMargin_lbl" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl">Percentage points added to the reference rate to compute the margin rate on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentApplicableMargin_lbl1" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl1">Debt Instrument Applicable Margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl1" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentApplicableMargin_lbl2" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl2">Applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl2" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl">Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1">Senior Notes Payable Before Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2">Notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants_lbl">Number of shares issued upon exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants_lbl" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants_lbl1">Shares Issued Upon Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SharesIssuedUponExerciseOfWarrants_lbl2" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants_lbl2">Shares issued upon exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants_lbl2" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinDelayedDrawLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinDelayedDrawLoanMember_lbl" xml:lang="en-US" id="adma_HayfinDelayedDrawLoanMember_lbl">Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinDelayedDrawLoanMember" xlink:to="adma_HayfinDelayedDrawLoanMember_lbl" xlink:title="label: HayfinDelayedDrawLoanMember to adma_HayfinDelayedDrawLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinDelayedDrawLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinDelayedDrawLoanMember_lbl1" xml:lang="en-US" id="adma_HayfinDelayedDrawLoanMember_lbl1">Hayfin Delayed Draw Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinDelayedDrawLoanMember" xlink:to="adma_HayfinDelayedDrawLoanMember_lbl1" xlink:title="label: HayfinDelayedDrawLoanMember to adma_HayfinDelayedDrawLoanMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl">The percentage of exit fee on outstanding principal amount being paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1">Percentage of Exit Fee of Outstanding Principal Amount being Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl2" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl2">Percentage of exit fee on outstanding principal amount being paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl2" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl">The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1">Prepaid after the First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl2" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl2">Prepaid after the First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl2" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheSecondAnniversaryMember" xlink:label="PrepaidAfterTheSecondAnniversaryMember" xlink:title="PrepaidAfterTheSecondAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheSecondAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidAfterTheSecondAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidAfterTheSecondAnniversaryMember_lbl">The second anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheSecondAnniversaryMember" xlink:to="adma_PrepaidAfterTheSecondAnniversaryMember_lbl" xlink:title="label: PrepaidAfterTheSecondAnniversaryMember to adma_PrepaidAfterTheSecondAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheSecondAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidAfterTheSecondAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidAfterTheSecondAnniversaryMember_lbl1">Prepaid after the Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheSecondAnniversaryMember" xlink:to="adma_PrepaidAfterTheSecondAnniversaryMember_lbl1" xlink:title="label: PrepaidAfterTheSecondAnniversaryMember to adma_PrepaidAfterTheSecondAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheSecondAnniversaryMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidAfterTheSecondAnniversaryMember_lbl2" xml:lang="en-US" id="adma_PrepaidAfterTheSecondAnniversaryMember_lbl2">Prepaid after the Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheSecondAnniversaryMember" xlink:to="adma_PrepaidAfterTheSecondAnniversaryMember_lbl2" xlink:title="label: PrepaidAfterTheSecondAnniversaryMember to adma_PrepaidAfterTheSecondAnniversaryMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentFloorInterestRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate_lbl">The percentage floor rate on debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate_lbl" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentFloorInterestRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate_lbl1">Debt Instrument, Floor Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate_lbl1" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentFloorInterestRate_lbl2" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate_lbl2">Percentage of floor interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate_lbl2" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl">The first anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1">Prepaid on or Prior to First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl2" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl2">Prepaid on or Prior to First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl2" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SubsequentEventAdditionalInformationAbstract" xlink:label="SubsequentEventAdditionalInformationAbstract" xlink:title="SubsequentEventAdditionalInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_SubsequentEventAdditionalInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SubsequentEventAdditionalInformationAbstract_lbl1" xml:lang="en-US" id="adma_SubsequentEventAdditionalInformationAbstract_lbl1">Subsequent Event Additional Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="adma_SubsequentEventAdditionalInformationAbstract_lbl1" xlink:title="label: SubsequentEventAdditionalInformationAbstract to adma_SubsequentEventAdditionalInformationAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SubsequentEventAdditionalInformationAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_SubsequentEventAdditionalInformationAbstract_lbl2" xml:lang="en-US" id="adma_SubsequentEventAdditionalInformationAbstract_lbl2">Subsequent Event [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="adma_SubsequentEventAdditionalInformationAbstract_lbl2" xlink:title="label: SubsequentEventAdditionalInformationAbstract to adma_SubsequentEventAdditionalInformationAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfReductionPrepaymentFees" xlink:label="PercentageOfReductionPrepaymentFees" xlink:title="PercentageOfReductionPrepaymentFees" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfReductionPrepaymentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfReductionPrepaymentFees_lbl" xml:lang="en-US" id="adma_PercentageOfReductionPrepaymentFees_lbl">The percentage of reduction to forego early prepayment fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReductionPrepaymentFees" xlink:to="adma_PercentageOfReductionPrepaymentFees_lbl" xlink:title="label: PercentageOfReductionPrepaymentFees to adma_PercentageOfReductionPrepaymentFees_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfReductionPrepaymentFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfReductionPrepaymentFees_lbl1" xml:lang="en-US" id="adma_PercentageOfReductionPrepaymentFees_lbl1">Percentage of Reduction Prepayment Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReductionPrepaymentFees" xlink:to="adma_PercentageOfReductionPrepaymentFees_lbl1" xlink:title="label: PercentageOfReductionPrepaymentFees to adma_PercentageOfReductionPrepaymentFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfReductionPrepaymentFees_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfReductionPrepaymentFees_lbl2" xml:lang="en-US" id="adma_PercentageOfReductionPrepaymentFees_lbl2">Percentage of reduction to forego early prepayment fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfReductionPrepaymentFees" xlink:to="adma_PercentageOfReductionPrepaymentFees_lbl2" xlink:title="label: PercentageOfReductionPrepaymentFees to adma_PercentageOfReductionPrepaymentFees_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinSecondAmendmentMember_lbl" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember_lbl">Entity entered into second amendment "Hayfin Second Amendment" in a debt arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember_lbl" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinSecondAmendmentMember_lbl1" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember_lbl1">Hayfin Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember_lbl1" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinSecondAmendmentMember_lbl2" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember_lbl2">Hayfin Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember_lbl2" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RightToIntermediatesMember_lbl" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RightToIntermediatesMember_lbl1" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl1">Right to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl1" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RightToIntermediatesMember_lbl2" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl2">Rights to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl2" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>adma-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 23.3.2.5148 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SubsequentEventDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20230331.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20230331.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/SubsequentEvent" xlink:type="simple" xlink:href="adma-20230331.xsd#SubsequentEvent" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20230331.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20230331.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20230331.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20230331.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20230331.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20230331.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20230331.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20230331.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20230331.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20230331.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20230331.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20230331.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20230331.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20230331.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20230331.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="presentation: AssetsAbstract to DepositsAndOtherNoncurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to SeniorLongTermNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermLiabilityEndOfTermFeePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: IncomeStatementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: IncomeStatementAbstract to CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: CostsAndExpensesAbstract to OtherCostAndExpenseOperating" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: CostsAndExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to CostsAndExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainsLossesOnExtinguishmentOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLicenseRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfLicenseRevenue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDepositsAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfDebtRefinancingFees" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentOfDebtRefinancingFees" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to TaxesPaidOnVestedRestrictedStockUnits" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfFinancingCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfFinancingCosts" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="CashFlowSupplementalDisclosuresTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to CashFlowSupplementalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEvent">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventsTextBlock" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsGoodwillPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="presentation: SegmentReportingAbstract to RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDAApprovedProduct" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDAApprovedProduct" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="WorkingCapital" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to WorkingCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="CashEquivalentsAtCarryingValue" xlink:title="CashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="CashEquivalentsAtCarryingValue" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to CashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to ThreeCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: ConcentrationRiskTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="presentation: AccountsReceivableNetAbstract to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: AccountsReceivableNetAbstract to NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: AccountsReceivableNetAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="presentation: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskLineItems" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskTable" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="GoodwillImpairmentLoss" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to GoodwillImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillImpairedAccumulatedImpairmentLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AssetImpairmentChargesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AssetImpairmentChargesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to TwoCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to FiveCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="presentation: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to DeferredRevenueRemainingAmortizationPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:title="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefitsPeriodIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryRawMaterials" xlink:title="presentation: InventoryDisclosureAbstract to InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryWorkInProcess" xlink:title="presentation: InventoryDisclosureAbstract to InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoods" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryNet" xlink:title="presentation: InventoryDisclosureAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRebatesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedRebatesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedTestingCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedTestingCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedSalariesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedSalariesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to OtherAccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesAndOtherLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinClosingDateLoanMember" xlink:title="presentation: HayfinCreditFacilityMember to HayfinClosingDateLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinDelayedDrawLoanMember" xlink:title="presentation: HayfinCreditFacilityMember to HayfinDelayedDrawLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: DebtInstrumentTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember" xlink:label="FederalFundsEffectiveSwapRateMember" xlink:title="FederalFundsEffectiveSwapRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="FederalFundsEffectiveSwapRateMember" xlink:title="presentation: VariableRateDomain to FederalFundsEffectiveSwapRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="presentation: VariableRateDomain to SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="BaseRateMember" xlink:title="presentation: VariableRateDomain to BaseRateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheSecondAnniversaryMember" xlink:label="PrepaidAfterTheSecondAnniversaryMember" xlink:title="PrepaidAfterTheSecondAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheSecondAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheSecondAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="presentation: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="ScenarioForecastMember" xlink:title="ScenarioForecastMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScenarioUnspecifiedDomain" xlink:to="ScenarioForecastMember" xlink:title="presentation: ScenarioUnspecifiedDomain to ScenarioForecastMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="presentation: StatementScenarioAxis to ScenarioUnspecifiedDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="StatementScenarioAxis" xlink:title="presentation: DebtInstrumentTable to StatementScenarioAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="presentation: NotesPayableAbstract to SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: NotesPayableAbstract to DebtInstrumentUnamortizedDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: NotesPayableAbstract to SeniorLongTermNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NotesPayableAbstract" xlink:title="presentation: DebtInstrumentsAbstract to NotesPayableAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: DebtInstrumentsAbstract to RepaymentsOfNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnamortizedPremium" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnamortizedPremium" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: DebtInstrumentsAbstract to PaymentsOfDebtIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUpfrontFeePaidInKind" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUpfrontFeePaidInKind" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: DebtInstrumentsAbstract to GainsLossesOnExtinguishmentOfDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentBasisSpreadOnVariableRate1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTermOfVariableRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentApplicableMargin" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentApplicableMargin" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFloorInterestRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFloorInterestRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateEffectivePercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestAmountToBePayInKind" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestAmountToBePayInKind" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: DebtInstrumentsAbstract to PaidInKindInterest" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="presentation: DebtInstrumentsAbstract to PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodicPaymentPrincipal" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="Cash" xlink:title="presentation: DebtInstrumentsAbstract to Cash" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: DebtInstrumentsAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="SharesIssuedUponExerciseOfWarrants" xlink:title="presentation: DebtInstrumentsAbstract to SharesIssuedUponExerciseOfWarrants" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="presentation: DebtInstrumentsAbstract to TrailingPeriodForVolumeWeightedAveragePrice" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: DebtInstrumentsAbstract to FairValueAdjustmentOfWarrants" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClassOfWarrantOrRightOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: WarrantsAbstract to WarrantsAndRightsOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: WarrantsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: EquityAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="presentation: PlanNameDomain to Two022CompensationPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to OperatingExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: StockOptionsAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: StockOptionsAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionSharesAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionsWeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: RestrictedStockUnitsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="ArethLLCMember" xlink:title="presentation: RelatedPartyDomain to ArethLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="GenesisBPSMember" xlink:title="presentation: RelatedPartyDomain to GenesisBPSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:label="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="ChiefScientificOfficerAndChiefMedicalOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ChiefScientificOfficerAndChiefMedicalOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ChiefScientificOfficerAndChiefMedicalOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="presentation: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="RelatedPartyTransactionDueFromToRelatedPartyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to RelatedPartyTransactionPurchasesFromRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="presentation: RelatedPartyTransactionDueFromToRelatedPartyAbstract to MinimumPercentageOfCommonStockHeldByLender" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to RelatedPartyTransactionDueFromToRelatedPartyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTwoMember" xlink:label="PlasmaPurchaseAgreementTwoMember" xlink:title="PlasmaPurchaseAgreementTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementTwoMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementTwoMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember" xlink:label="SalesRevenueNetMember" xlink:title="SalesRevenueNetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="SalesRevenueNetMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to SalesRevenueNetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: LossContingenciesTable to ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: LossContingenciesTable to ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InternationalCustomersMember" xlink:label="InternationalCustomersMember" xlink:title="InternationalCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="InternationalCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to InternationalCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: LossContingenciesTable to MajorCustomersAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="BIVIGAMMember" xlink:title="presentation: ProductsAndServicesDomain to BIVIGAMMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="presentation: ProductsAndServicesDomain to ASCENIVMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: LossContingenciesTable to ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfFDALicensedPlasmaCollectionFacilitiesApproved" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDAInspections" xlink:label="NumberOfFDAInspections" xlink:title="NumberOfFDAInspections" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfFDAInspections" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfFDAInspections" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfPlasmaCollectionFacilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementTerm" xlink:label="PlasmaPurchaseAgreementTerm" xlink:title="PlasmaPurchaseAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementTerm" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaPurchaseAgreementTerm" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfRenewalTerms" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfRenewalTerms" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaPurchaseAgreementRenewalPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:label="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfPlasmaPurchasePriceEqualToCost" xlink:label="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="PercentageOfPlasmaPurchasePriceEqualToCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PercentageOfPlasmaPurchasePriceEqualToCost" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PercentageOfPlasmaPurchasePriceEqualToCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaSupplyAgreementTerm" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaPurchased" xlink:label="PlasmaPurchased" xlink:title="PlasmaPurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaPurchased" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaPurchased" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfInventoryPurchases" xlink:label="PercentageOfInventoryPurchases" xlink:title="PercentageOfInventoryPurchases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PercentageOfInventoryPurchases" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PercentageOfInventoryPurchases" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: PostMarketingCommitmentsAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="presentation: SegmentDomain to ADMABioManufacturingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="presentation: SegmentDomain to CorporateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="presentation: SegmentGeographicalDomain to US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="presentation: SegmentGeographicalDomain to NonUsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="presentation: StatementGeographicalAxis to SegmentGeographicalDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:label="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:title="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to CostOfRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_InterestAndOtherNonoperatingIncomeExpense" xlink:label="InterestAndOtherNonoperatingIncomeExpense" xlink:title="InterestAndOtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="InterestAndOtherNonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to InterestAndOtherNonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to GainsLossesOnExtinguishmentOfDebt" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to DepreciationAndAmortization" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="Assets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to Assets" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseExpense" xlink:title="presentation: LeasesAbstract to OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LeasesAbstract to OperatingLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingAndFinancingLeaseLiability" xlink:title="presentation: LeasesAbstract to OperatingAndFinancingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to WarrantsIssuedInConnectionWithNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to NoncashInvestingAndFinancingItemsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: SupplementalCashFlowElementsAbstract to SupplementalCashFlowInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: SubsequentEventTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: SubsequentEventTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:label="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:title="presentation: VariableRateDomain to SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="VariableRateAxis" xlink:title="presentation: SubsequentEventTable to VariableRateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PrepaidAfterTheSecondAnniversaryMember" xlink:label="PrepaidAfterTheSecondAnniversaryMember" xlink:title="PrepaidAfterTheSecondAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheSecondAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheSecondAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="presentation: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="presentation: SubsequentEventTable to DebtInstrumentRedemptionPeriodAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_SubsequentEventAdditionalInformationAbstract" xlink:label="SubsequentEventAdditionalInformationAbstract" xlink:title="SubsequentEventAdditionalInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="DebtInstrumentApplicableMargin" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to DebtInstrumentApplicableMargin" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20230331.xsd#adma_PercentageOfReductionPrepaymentFees" xlink:label="PercentageOfReductionPrepaymentFees" xlink:title="PercentageOfReductionPrepaymentFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="PercentageOfReductionPrepaymentFees" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to PercentageOfReductionPrepaymentFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventAdditionalInformationAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: SubsequentEventAdditionalInformationAbstract to WarrantsAndRightsOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventLineItems" xlink:to="SubsequentEventAdditionalInformationAbstract" xlink:title="presentation: SubsequentEventLineItems to SubsequentEventAdditionalInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTable" xlink:to="SubsequentEventLineItems" xlink:title="presentation: SubsequentEventTable to SubsequentEventLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsAbstract" xlink:to="SubsequentEventTable" xlink:title="presentation: SubsequentEventsAbstract to SubsequentEventTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642288608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,272,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643690048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 69,204,163<span></span>
</td>
<td class="nump">$ 86,521,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">26,518,495<span></span>
</td>
<td class="nump">15,505,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">163,984,873<span></span>
</td>
<td class="nump">163,280,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,378,681<span></span>
</td>
<td class="nump">5,095,146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">264,086,212<span></span>
</td>
<td class="nump">270,401,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">57,370,783<span></span>
</td>
<td class="nump">58,261,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">834,577<span></span>
</td>
<td class="nump">1,013,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,529,509<span></span>
</td>
<td class="nump">3,529,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-to-use assets</a></td>
<td class="nump">10,247,700<span></span>
</td>
<td class="nump">10,485,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DepositsAndOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="nump">4,718,761<span></span>
</td>
<td class="nump">4,770,246<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">340,787,542<span></span>
</td>
<td class="nump">348,461,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,956,486<span></span>
</td>
<td class="nump">13,229,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">22,672,464<span></span>
</td>
<td class="nump">24,989,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">142,834<span></span>
</td>
<td class="nump">142,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">956,045<span></span>
</td>
<td class="nump">905,369<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">36,727,829<span></span>
</td>
<td class="nump">39,266,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable, net of discount</a></td>
<td class="nump">144,300,930<span></span>
</td>
<td class="nump">142,833,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,797,323<span></span>
</td>
<td class="nump">1,833,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermLiabilityEndOfTermFeePayable', window );">End of term fee</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">10,468,109<span></span>
</td>
<td class="nump">10,704,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">338,731<span></span>
</td>
<td class="nump">350,454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">195,132,922<span></span>
</td>
<td class="nump">196,487,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 222,262,588 and 221,816,930 shares issued and outstanding</a></td>
<td class="nump">22,226<span></span>
</td>
<td class="nump">22,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">630,437,880<span></span>
</td>
<td class="nump">629,968,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(484,805,486)<span></span>
</td>
<td class="num">(478,016,671)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">145,654,620<span></span>
</td>
<td class="nump">151,974,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 340,787,542<span></span>
</td>
<td class="nump">$ 348,461,881<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DepositsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DepositsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LongTermLiabilityEndOfTermFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal balance of the loans and any other obligations advanced or otherwise owed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LongTermLiabilityEndOfTermFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643597488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="nump">221,816,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="nump">221,816,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940738724656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 56,913,534<span></span>
</td>
<td class="nump">$ 29,103,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">40,400,544<span></span>
</td>
<td class="nump">25,441,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">16,512,990<span></span>
</td>
<td class="nump">3,662,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">855,351<span></span>
</td>
<td class="nump">624,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">1,780,463<span></span>
</td>
<td class="nump">3,974,589<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">178,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">14,511,656<span></span>
</td>
<td class="nump">13,699,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,326,308<span></span>
</td>
<td class="nump">18,477,113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(813,318)<span></span>
</td>
<td class="num">(14,815,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">166,971<span></span>
</td>
<td class="nump">33,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(6,115,484)<span></span>
</td>
<td class="num">(3,389,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,669,941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(26,984)<span></span>
</td>
<td class="num">(166,880)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(5,975,497)<span></span>
</td>
<td class="num">(10,192,791)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (6,788,815)<span></span>
</td>
<td class="num">$ (25,007,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC LOSS PER COMMON SHARE (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED LOSS PER COMMON SHARE (in dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">221,921,750<span></span>
</td>
<td class="nump">195,871,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">221,921,750<span></span>
</td>
<td class="nump">195,871,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642803392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 19,581<span></span>
</td>
<td class="nump">$ 553,265,706<span></span>
</td>
<td class="num">$ (412,112,721)<span></span>
</td>
<td class="nump">$ 141,172,566<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">195,813,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with note payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,569,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,569,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,641,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,641,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</a></td>
<td class="nump">$ 54<span></span>
</td>
<td class="num">(442,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(442,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)</a></td>
<td class="nump">533,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,007,857)<span></span>
</td>
<td class="num">(25,007,857)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 19,635<span></span>
</td>
<td class="nump">564,034,008<span></span>
</td>
<td class="num">(437,120,578)<span></span>
</td>
<td class="nump">126,933,065<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">196,347,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22,182<span></span>
</td>
<td class="nump">629,968,704<span></span>
</td>
<td class="num">(478,016,671)<span></span>
</td>
<td class="nump">151,974,215<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">221,816,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,110,166<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,110,166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="num">(640,990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(640,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)</a></td>
<td class="nump">443,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,788,815)<span></span>
</td>
<td class="num">(6,788,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 22,226<span></span>
</td>
<td class="nump">$ 630,437,880<span></span>
</td>
<td class="num">$ (484,805,486)<span></span>
</td>
<td class="nump">$ 145,654,620<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940644199360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,788,815)<span></span>
</td>
<td class="num">$ (25,007,857)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,032,965<span></span>
</td>
<td class="nump">1,590,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">18,096<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">979,978<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,110,166<span></span>
</td>
<td class="nump">1,641,388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">487,889<span></span>
</td>
<td class="nump">584,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,669,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(35,708)<span></span>
</td>
<td class="num">(35,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(11,013,446)<span></span>
</td>
<td class="nump">2,947,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(704,826)<span></span>
</td>
<td class="num">(14,422,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">716,465<span></span>
</td>
<td class="num">(1,180,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">289,232<span></span>
</td>
<td class="nump">1,397,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(272,904)<span></span>
</td>
<td class="nump">1,685,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,353,815)<span></span>
</td>
<td class="num">(1,775,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(187,551)<span></span>
</td>
<td class="num">(111,064)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,722,274)<span></span>
</td>
<td class="num">(26,013,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,944,596)<span></span>
</td>
<td class="num">(2,842,085)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,944,596)<span></span>
</td>
<td class="num">(2,842,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(100,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PaymentOfDebtRefinancingFees', window );">Payment of debt refinancing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">151,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TaxesPaidOnVestedRestrictedStockUnits', window );">Taxes paid on vested Restricted Stock Units</a></td>
<td class="num">(640,946)<span></span>
</td>
<td class="num">(91,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="num">(9,563)<span></span>
</td>
<td class="num">(8,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,378,366)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(650,509)<span></span>
</td>
<td class="nump">47,271,326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents</a></td>
<td class="num">(17,317,379)<span></span>
</td>
<td class="nump">18,415,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of year</a></td>
<td class="nump">86,521,542<span></span>
</td>
<td class="nump">51,089,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of year</a></td>
<td class="nump">$ 69,204,163<span></span>
</td>
<td class="nump">$ 69,504,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash revenue related to amortization of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PaymentOfDebtRefinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of debt refinancing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PaymentOfDebtRefinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TaxesPaidOnVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow related to taxes on vested Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TaxesPaidOnVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649393200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text">
<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                  </td>

  </tr>


</table>
          </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical
            company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted
            patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters
              Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#8220;BTBU&#8221;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#8220;BPC&#8221; and,
              together with Biotest AG, &#8220;Biotest&#8221;) on June 6, 2017. The acquisition included certain assets of BTBU, including the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma
              fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;) (the &#8220;Biotest Transaction&#8221;). BTBU had previously been the Company&#8217;s third-party contract manufacturer. ADMA BioCenters is the Company&#8217;s source plasma
              collection business with</span><span style="font-size: 10pt; font-family: 'Times New Roman';"> ten plasma collection facilities
              located throughout the U.S., eight <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of which hold an approved license with the FDA.</span></span> </div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> <span style="font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the
              treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in
              August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October
              2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its
              commercially available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin
              production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at
              risk for certain infectious diseases.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
              </span> </div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of March 31, 2023, the Company had working capital of $227.4 million, including $69.2 </span>million of cash and cash
              equivalents. Based upon the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s management currently
              believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#8217;s operations, as currently conducted, through the end of the second quarter of 2024, by which time the Company believes it
              will have begun generating positive cash flow from operations. These estimates may change based upon several factors, including the success of the Company&#8217;s commercial efforts with respect to the sale of its products, whether or not the
              assumptions underlying the Company&#8217;s projected revenues and expenses are correct and the acceptability of ADMA&#8217;s immune globulin products by physicians, patients or payers. There can be no assurance that the Company&#8217;s approved products will
              be commercially viable, or that plant capacity expansion or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the
              biologics, biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
              personnel, inflationary pressures, supply chain constraints, protection of proprietary technology and compliance with FDA and other governmental regulations and approval requirements.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
              </span></div>

<div><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;">T<span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">he
                Company continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The exploration of value-creating opportunities remains a top corporate priority for ADMA.</span><br/>
            </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649258032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> </span><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2022 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 23, 2023.&#160; The accompanying consolidated balance sheet as of December 31,
              2022 was derived from the audited financial statements as of and for the year ended December 31, 2022. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8
              of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have
              been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and
              assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2023 and its results of operations, changes in stockholders&#8217; equity and cash flows for the three months
              ended March 31, 2023 and 2022.</span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts
              presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
              granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts in
            the amount of $0.1 million at March<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> 31</span>, 2023 and December 31, 2022, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The



              Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an
              ongoing basis.</span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023, five customers accounted for an aggregate of 98% of the Company&#8217;s total accounts receivable, and at December 31, 2022, two customers accounted for approximately 92% of the Company&#8217;s total
            accounts receivable.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><br/></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct
              and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable
              supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square
              footage of the facility.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of
              conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160; Goodwill
              at <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and December 31, 2022 was $3.5 million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to the Biotest
              Transaction.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
              goodwill impairment test as of October 1, 2022 did not result in a goodwill impairment charge, and the Company did not <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three months
                ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022, the Company
              determined that there was no impairment of its long-lived assets.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023</span>
                and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the
                Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the
                out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance
                with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a
                period of approximately 22 years.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based
              on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin
              products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other
              wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates,
              control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the three months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> three customers represented an aggregate of 76% of the Company&#8217;s consolidated revenues. For the three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2022, three customers represented an aggregate
              of 83% of the Company&#8217;s consolidated revenues.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products,
              intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the
              activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss Per Common Share</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the
                weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if
                any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock
                options and warrants, using the treasury stock method, as well as Restricted Stock Units (&#8220;RSUs&#8221;). Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be
                anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported
                a net loss for all periods presented. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">For the three months ended </span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">March 31</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;">, 2023</span></span></span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"> and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For the Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,945,703</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,686,068</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,875,464</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,729,758</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,525,148</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,631,207</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">28,346,315</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,047,033</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is
              generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
              related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2018 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by
                the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is
                greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company
                has determined that it has not incurred any liability for unrecognized tax benefits as of March 31, 2023 and December 31,
                2022, and during the three months ended March 31, 2023 and 2022, the Company recognized</span><span style="font-size: 10pt;"> no
                adjustments for uncertain tax positions.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940646197760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">55,747,754</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,644,527</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,087,760</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,170,853</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">46,149,359</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">58,464,667</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">163,984,873</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">163,280,047</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit. All other activities and materials associated with the production of
            inventories used in research and development activities are expensed as incurred.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s
            immunoglobulin products. </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643554528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,416,706</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">683,340</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,270,276</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">829,770</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">756,184</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">151,237</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">723,776</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">183,645</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,007,467</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,172,890</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">834,577</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,007,467</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,994,052</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,013,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization expense
              related to these intangible assets was $0.2 million for the three months ended March 31, 2023 and 2022. Estimated future
              aggregate amortization expense is expected to be as follows:</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span><br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">536,514</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">298,063</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649172224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,828,570</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">18,767,807</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,939,060</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,318,669</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,662,407</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,109,898</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,515,267</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,726,995</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,514,697</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">17,930,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,856,505</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,544,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">78,655,947</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">77,738,022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(21,285,164</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(19,476,541</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property, plant and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">57,370,783</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">58,261,481</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_4342de1675c9405cb8dc40be8462b988">three</span> to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company recorded depreciation expense on property and equipment for the three
              months ended March 31, 2023 and 2022 of $1.9 million and $</span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.4<span style="color: rgb(0, 0, 0);"> million, respectively.<br/>
              </span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642125104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,129,902</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11,436,484</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,406,033</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,166,896</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,179,600</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,193,919</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">169,825</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">309,867</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br/>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,745,245</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,086,379</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,041,859</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,795,804</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">22,672,464</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">24,989,349</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643464016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">155,727,724</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">154,747,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,426,794</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,914,683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">144,300,930</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">142,833,063</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On March 23,&#160;2022 (the &#8220;Hayfin Closing Date&#8221;), the Company and all of its subsidiaries entered into a Credit and Guaranty Agreement (the &#8220;Hayfin Credit Agreement&#8221;) with Hayfin
                Services LLP (&#8220;Hayfin&#8221;). The Hayfin Credit Agreement provides for a senior secured term loan facility in a principal amount of up to $175.0
                million (the &#8220;Hayfin Credit Facility&#8221;), composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0
                million (the &#8220;Hayfin Closing Date Loan&#8221;), and (ii) a delayed draw term loan in the principal amount of $25.0 million (the &#8220;Hayfin
                Delayed Draw Loan&#8221; and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans&#8221;). The obligation of the lenders to make the Hayfin Delayed Draw Loan was to have expired on March 22, 2023 and is subject to the satisfaction of certain conditions, including, but not limited to, the Company&#8217;s meeting certain 12-month revenue targets as set
                forth in the Hayfin Credit Agreement. The Hayfin Credit Facility has a maturity date of March 23, 2027 (the &#8220;Hayfin Maturity
                Date&#8221;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement). </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On March 22, 2023, the Company and Hayfin entered into an amendment to the Hayfin Credit Agreement whereby the lenders&#8217; obligation to
                make the Hayfin Delayed Draw Loan was extended to June 30, 2023.</span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On the Hayfin Closing Date, the Company used $100.0 million of
                the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previously existing credit facility (the &#8220;Perceptive Credit Facility&#8221;) with Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;).
                The Company also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used
                approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with
                this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding
                principal balance in accordance with the terms of the Hayfin Credit Agreement. In connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt
                in the amount of $6.7 million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the
                redemption premium paid to Perceptive.</span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the Hayfin Credit Agreement bear interest, at the Company&#8217;s election, at either (a) a base rate (equal to the highest of (i) the rate of interest per annum
                last quoted by The Wall Street Journal as the &#8220;Prime Rate&#8221; in the United States, (ii) the federal funds rate in effect on such day plus 0.50%
                and (iii) adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221;) for a one-month tenor in effect on such day plus 1.00%), plus an applicable margin of 8.5%,
                or (b) adjusted Term SOFR for either a one-month or three-month tenor, as elected by the Company, and subject to a floor of 1.25%,
                plus an applicable margin of 9.5% (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an
                Event of Default, the Applicable Margin increases by an additional 3% per annum. On the last day of each calendar month or
                quarter during the term of the Hayfin Credit Facility, the Company will pay accrued interest to Hayfin. The rate of interest in effect as of March 31,2023 and December 31, 2022&#160; was 14.4% and 13.9%, respectively. The Company is also
                permitted to pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly or quarterly interest period in an amount equal to 2.5%
                per annum, which is added to the principal amount of the outstanding debt under the Hayfin Credit Facility. <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For</span> the three months ending March 31,2023, approximately $1.0 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.</span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">On the Hayfin Maturity Date, the Company will pay Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as
                well as an exit fee of 1.0% of the outstanding principal amount being paid. This exit fee is recorded separately as a
                non-current liability on the accompanying consolidated balance sheets as of March 31,2023 and December 31,2022. Prior to the Hayfin Maturity Date, there are no scheduled principal payments on the Hayfin Loans. The Company may prepay outstanding principal on the Hayfin Loans at any time and from time to time upon <span style="-sec-ix-hidden:Fact_5ecb5c13cda94b628b0011be8e172a1f">five</span> business days&#8217; prior written notice, subject to the payment to Hayfin of, (A) any accrued but unpaid interest on the prepaid principal amount plus (B) an early
                prepayment fee in the amount equal to (i) 7.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary
                of the Hayfin Closing Date, (ii) 3.0% of the prepaid principal amount, if prepaid after the first anniversary of the Hayfin
                Closing Date and on or prior to the second anniversary of the Hayfin Closing Date, or (iii) 1.0% of the prepaid principal
                amount, if prepaid after the second anniversary of the Hayfin Closing Date and on or prior to the third anniversary of the Hayfin Closing Date. In addition, for any prepayments of principal or payment of principal on the Hayfin Maturity
                Date, the Company is also required to pay the exit fee.</span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">All of the Company&#8217;s obligations under the Hayfin Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible
                and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Hayfin Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and
                conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin
                Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain
                Investments or Restricted Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">other </span>indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that
                have the impact of restricting the Company&#8217;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company is required (i) at all times prior to the Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that
                exceed the amounts set forth in the Hayfin Credit Agreement, which range from $75.0 million for the fiscal quarter ended June
                30,&#160;2022 to $250.0 million for the fiscal quarter ended December 31,&#160;2026. As of March 31,&#160;2023, the Company was in compliance
                with all of the covenants contained in the Hayfin Credit Agreement.</span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As consideration for the Hayfin Credit Agreement, the Company issued to various entities affiliated with Hayfin, on the Hayfin Closing Date, warrants to purchase an aggregate
                of 9,103,047 shares of the Company&#8217;s common stock (the &#8220;Hayfin Warrants&#8221;). The Hayfin Warrants have an exercise price equal to $1.6478 per share, which is equal to the trailing 30-day
                Volume Weighted-average Price of the Company&#8217;s common stock on the business day immediately prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $9.6 million as of the Hayfin Closing Date and have an expiration date of March 23, 2029.</span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and the value of the Hayfin
                Warrants, the Company recognized an aggregate discount on the Hayfin Loans in the amount of $13.9 million. The Company records
                debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Hayfin Warrants and the aggregate amount
                of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the Hayfin Loans as of March 31,2023 and December 31,&#160;2022 was approximately 16.6% and 16.1%, respectively.</span> </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; margin-left: 27pt; text-indent: 9pt;">See Note 14 for discussion of an additional amendment to the Hayfin Credit Facility.</div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642714640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                  </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share.
              There were no shares of preferred stock outstanding at March 31, 2023 and December 31, 2022.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of March 31, 2023 and December 31, 2022, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001
              par value per share, and 222,262,588 and 221,816,930 shares of common stock were outstanding as of March 31, 2023 and December 31, 2022, respectively. After giving effect to the 48,356,592 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of March 31, 2023
              there were 29,380,820 shares of common stock available for issuance.<br/>
              <br/>
            </div>

<div><span style="font-style: italic;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</span></span></span></div>

<div> &#160; <br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">In connection with the Hayfin Credit Agreement that the Company entered into on March 23, 2022 (see Note 7), the
              Company issued the Hayfin Warrants to purchase 9,103,047 shares of the Company&#8217;s common stock. The Hayfin Warrants were valued at
              $9.6 million using the Black-Scholes option-pricing model assuming an expected term of seven years, a volatility of 68.1%, a dividend yield of 0% and a risk-free rate of interest of 2.36%.
              At March 31, 2023 and December 31,2022, the Company had outstanding warrants to purchase an aggregate of 13,525,148 shares of
              common stock, with a weighted-average exercise price of $1.99 per share with expiration dates ranging between May 2023 and
              December 2030 (see Note 14).</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             &#160; <br/></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under the Company&#8217;s equity incentive plans was determined on the
                date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition,
                option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of
                traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2023 and 2022:</span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
            &#160; <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">68</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">68</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.20-4.24</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.72-1.73</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>


</table>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>&#160; <br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">On June 21, 2022, the
                Company&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#8220;2022 Equity Plan&#8221;), which replaced the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan.&#160; Approval of the 2022 Equity Plan resulted in
                approximately 18 million additional shares of the Company&#8217;s common stock being reserved for future awards. </span>During the
              three months ended March 31, 2023 and 2022, the Company granted options to purchase an aggregate of 1,727,510 and 1,194,032 shares of common stock, respectively, to its directors and employees.&#160; The weighted average remaining contractual life of stock options
              outstanding and expected to vest at March 31, 2023 is 6.6 years. The weighted average remaining contractual life of stock
              options exercisable at March 31, 2023 is 5.3 years. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">During
                the three months ended March 31, 2023, options to purchase 5,416 shares of common stock were exercised in a cashless transaction
                resulting in the issuance of 2,443 shares of common stock.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
              follows:</div>

<div>
            &#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Weighted </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Average </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,256,211</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.37</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(15,555</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.29</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,047</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.06</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,727,510</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.35</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">(5,416</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">2.08</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,945,703</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.36</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,660,313</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.67</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of March 31, 2023, the Company had $5.6 million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average
              period of 3.0 years.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> &#160; <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">During the three months ended March 31, 2023 and 2022, the Company granted RSUs representing an aggregate
                of 2,666,260 and 1,059,266
                shares, respectively, to certain employees of the Company and to members of its Board of Directors</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">. These RSUs generally vest annually over a period<span style="font-variant: normal; text-transform: none;"> of four years for employees and semi-annually over a period of one year for directors</span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> During the <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">three months ended March 31, 2023</span>, an aggregate of 628,283
                shares of common stock vested in connection with grants of RSUs. With respect to these vested RSUs, 185,068 shares valued at
                approximately $0.6 million were withheld by the Company to cover employees&#8217; tax liabilities. These shares were no longer
                outstanding as of <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March
                    31, 2023</span></span>. <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">A
                summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Weighted </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Average Grant</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,866,987</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.59</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,666,260</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.35</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(628,283</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.76</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(29,500</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.25</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,875,464</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.53</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></span>, the Company had $12.0 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a
              weighted-average period of 3.4 years.</div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span> <span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
              months ended March 31, 2023 and 2022 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,385</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,671</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">23,055</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,052</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">978,124</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,517,602</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">103,602</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">98,063</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,110,166</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,641,388</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940648491120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;)
        pursuan<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">t to an agreement for services
          effective as of January 1, 2016, as amended from time to time<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and pays monthly rent on this facility in the amount of $10,000 through December 31, 2026</span>. Rent expense for the three months ended March 31, 2023 and 2022 amounted to $30,000 (see</span> Note 12). Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the three months
        ended March 31, 2023 and 2022. </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">During the <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">three months ended March 31, 2023 and 2022, the Company purchased certain specialized medical equipment and
          services primarily related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#8220;Genesis&#8221;), aggregating to $0.1 million and $43,000, respectively. Genesis is owned by Dr.
          Grossman and Adam Grossman.<br/>
        </span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">See Note 7 for a discussion of the Company&#8217;s former credit facility and related
        transactions with Perceptive, a holder of more than 5% of the Company&#8217;s common stock during<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> the three months ended March 31, 2022. There were no transactions with Perceptive
          during the three months ended March 31, 2023.</span><br class="Apple-interchange-newline"/>
      </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643531680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection
            with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COVID-19 Pandemic</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the emergence of
            the Delta, Omicron and BA.2 variants and other resistant strains of the coronavirus, and its impacts to the Company&#8217;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement
            of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale. A substantial portion of such testing has
            historically been performed by contract laboratories outside the United States.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Due to a combination of previously mandated state and local &#8220;shelter-in-place&#8221; orders, as well as government stimulus
            packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company at times experienced lower than normal donor collections at its FDA approved plasma collection centers <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">during 2021 and part of 2022. From time to time during 2021 and 2022, t</span>he Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as
            delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. In addition, the Company has been subject to supply chain delays as a
            result of certain of its suppliers diverting significant resources towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company has elected to carry more raw materials inventory than it has in the past. The
            COVID-19 pandemic previously impacted, to a certain degree, the Company&#8217;s customer engagement initiatives, whereby ADMA&#8217;s sales and medical affairs field personnel faced difficulties communicating directly with physicians and other healthcare
            professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#8217;s ability to communicate with potential customers.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The pandemic could also impact the Company&#8217;s ability to interact with the FDA or other regulatory authorities and could result in delays in the conduct of inspections
              or review of pending applications or submissions. Although the Company has received <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">FDA approvals for five of its plasma collection centers since January 1, 2022 and</span> </span>received several other FDA approvals while two FDA inspections of the Boca Facility were completed during the year ended December 31, 2021, no assurances can be provided as to the timing for completion of any
              future regulatory submissions or applications that may be impacted by restrictions related to COVID-19.</span></div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, revenue attributable to international customers was
              approximately 7% and 6%,
              respectively, of the Company&#8217;s total revenues. As the Company seeks to grow this aspect of its business, it may also be subject to the impacts of the COVID-19 pandemic in locations outside the United States.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#8217;s financial
            condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#8217;s contract fill/finishers or its plasma collection facilities have been significantly impacted by the COVID-19
            pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#8217;s property and equipment, goodwill or intangible assets.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#8217;s capital and financial
            resources, because the Company is unable to determine the ultimate severity or duration of the COVID-19 pandemic or other pandemics or their long-term effects on, among other things, the global, national or local economies, the capital and
            credit markets or the Company&#8217;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 or other pandemics will have a material adverse impact on the Company&#8217;s business, financial condition,
            liquidity or results of operations.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="font-style: italic;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br/>
            </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span><span style="font-family: 'Times New Roman';"> </span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase
            Agreement&#8221;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
            volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During
            2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its
            reach for raw material supply as it executes its commercialization plans for ASCENIV. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June
            2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations
            Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing
            antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company could purchase RSV plasma from Grifols from the two
            plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus five percent (5%) (without any additional increase due to inflation). Effective January 1, 2022, RSV plasma purchased from these two plasma collection centers are subject to the pricing terms in effect for RSV plasma purchased from other plasma collection centers owned by
            Grifols.<br/>
          </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an
            exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#8220;2017 Plasma Purchase Agreement&#8221;),
            pursuant to which ADMA BioManufacturing purchases normal source plasma (&#8220;NSP&#8221;) from BPC at agreed upon annual quantities and prices. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among
            other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC.
            Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years 2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts,
            provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA
            BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#8217;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#8217;s election not to
            supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement whereby, among other things, the term of the agreement was
              extended through December 31, 2022, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">however Grifols&#8217; commitment
                to supply the Company with NSP under this agreement was not satisfied until March of 2023</span>. In order to maintain a reliable supply of raw material plasma thereafter, the Company has executed additional agreements with multiple
              third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement. The Company has also increased its number of planned plasma collection center buildouts such that the Company expects to have ten FDA-approved plasma collection centers in operation by the end of 2023, while also continuing to increase its plasma collection capabilities
              at its ADMA BioCenters plasma collection centers business segment.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Through December 31, 2022, the</span>
            Company purchased substantially all of its raw material plasma from Grifols. For the three months ended March 31, 2023, plasma purchases from Grifols totaled $11.6 million, or approximately 40% of the Company&#8217;s total inventory
            purchases. For the three months ended March 31, 2022, plasma purchases from Grifols totaled approximately $15.5 million, representing
            approximately 75% of the Company&#8217;s total inventory purchases.</div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-Marketing Commitments</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the approval of the BLA for BIVIGAM, on December 19, 2012, Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a
            post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The pediatric study for BIVIGAM has been completed, and the safety study has been completed pending a clinical study report to
              the FDA</span>. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. For the three months ended March 31, 2023 and 2022, the Company incurred expenses
            related to these studies of $0.4 million. The Company currently expects to incur expenses of&#160; approximately $1.5 million to $2.0 million to
            complete the safety study, which is required to be completed by June of 2023.</div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2023 and 2022, the Company
            incurred expenses related to these studies in the amount of $0.2 million and $0.1 million, respectively. The Company expects to incur expenses of approximately $1.5 million to complete this study, which is currently required to be completed by June of 2023. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company has submitted an extension request to the FDA.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment Contracts</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company has entered into employment agreements with Mr. Grossman and with Brian Lenz, its Executive Vice President,
            Chief Financial Officer and General Manager, ADMA BioCenters.<br/>
          </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span>
           <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-style: italic;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: italic;"><span style="text-decoration: underline;">Other Commitments</span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="text-decoration: underline;"> <br/>
              </span></span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is
            unknown as of March 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643495136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
            </td>

  </tr>


</table>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The
          Company&#8217;s ADMA BioManufacturing segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers segment consists of ten<span style="color: rgb(0, 0, 0);"> operational plasma collection facilities located throughout the U.S., eight of which currently hold FDA</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0);">licenses</span></span>.
          The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze
          performance and allocate resources. The Company&#8217;s CODM is its President and Chief Executive Officer. <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is shown in the following tables:</span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2023</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Plasma Collection</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">49,576,935</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,300,891</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">35,708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,913,534</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">33,933,782</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,466,762</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">40,400,544</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,476,441</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(946,334</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,343,425</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(813,318</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(23,779</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(227</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,951,491</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,975,497</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net income (loss)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,452,662</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(946,561</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,294,916</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,788,815</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">452,032</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,492,564</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,944,596</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,292,608</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">740,357</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,032,965</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">234,894,891</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">38,853,662</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,038,989</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">340,787,542</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Plasma Collection </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,728,625</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,338,760</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">35,708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">29,103,093</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">22,213,781</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,227,265</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,441,046</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,442,684</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,863,094</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,509,288</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(14,815,066</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(49,267</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(729</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,472,854</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,522,850</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Loss on extinguishment of debt<br/>
            </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(6,669,941</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(6,669,941</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,491,951</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,863,823</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(16,652,083</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(25,007,857</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,310,379</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,531,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,842,085</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,111,951<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">477,503<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">763<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,590,217<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">214,150,322</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">32,568,911</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">61,313,259</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,032,492</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
      </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><br/></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                </span> </div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                </span> </div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,694,723</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,316,151</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,218,811</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,786,942</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,913,534</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">29,103,093</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643531680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or
            less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease
            payments arising from the lease.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For all of its leases, the Company has elected and applies the practical expedient available to lessees to combine non-lease components with their related
                lease components and account for them as a single combined lease component.</span></span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include
            options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a
            straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense for the Company&#8217;s leases for the three months ended March 31, 2023 and 2022
            was approximately $0.6 million and $0.4
            million, respectively. Cash paid for the Company&#8217;s leases for the three months ended March 31, 2023 and 2022 was approximately $0.6
            million and $0.4 million, respectively. <br/>
          </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Including a finance lease the Company entered into in June 2018, the Company has aggregate lease
              liabilities of $11.4 million and $11.6
              million as of March 31, 2023 and December 31, 2022, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin
              manufacturing operations.&#160; The Company&#8217;s operating leases have a weighted average remaining term of 8.3 years. <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">Scheduled payments under the
              Company&#8217;s lease obligations are as follows:</span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,805,644</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,343,314</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,366,432</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,116,036</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2027</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,040,690</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2028</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,087,825</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,150,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">18,910,687</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(7,486,533</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(956,045</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 4px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,468,109</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642193280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the three months ended March 31, 2023 and 2022 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,639,283</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,525,987</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">530,434</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,940,425</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt;">Warrants issued in connection with notes payable<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">9,569,604</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649093936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
            <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUBSEQUENT EVENT<br/>
              </span></div>
          </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;&#160;</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">On May 1, 2023, the Company entered into a second amendment (the &#8220;Hayfin Second Amendment&#8221;) to the
      Hayfin Credit Agreement (see Note 7) whereby the Applicable Margin for adjusted Term SOFR Loans was reduced from 9.5% to 8.5%. The Hayfin Second Amendment also extended the obligation of the lenders to make the Hayfin Delayed Draw Loan from June 30, 2023 to December 31,
      2023. </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Under the terms of the Hayfin Second Amendment, in the event the Company elects to prepay all or any
      portion of the outstanding principal on the Hayfin Loans, the Company will be subject to an early prepayment fee in the amount equal to (i) 7.0%
      of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Hayfin Second Amendment, (ii) 3.0% of the prepaid
      principal amount, if prepaid after the first anniversary of the Hayfin Second Amendment and on or prior to the second anniversary of the Hayfin Second Amendment, or (iii) 1.0% of the prepaid principal amount, if prepaid after the second anniversary of the Hayfin Second Amendment and on or prior to the third anniversary of the Hayfin Second Amendment. In
      addition, the Hayfin Second Amendment provides for a 50% reduction to the foregoing early prepayment fees if the Hayfin Loans are prepaid
      in connection with a change in control of the Company or other strategic transactions as further described in the Hayfin Second Amendment.<br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
    </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> In connection with the Hayfin Second Amendment, the Company issued&#160; additional warrants to the lenders
      to purchase 2,391,244 shares of the Company&#8217;s common stock at an exercise price of $3.2619 per share (&#8220;the Hayfin Second Amendment Warrants&#8221;). The Hayfin Second Amendment Warrants were valued at approximately $5.6 million and have an expiration date of May 1, 2030.  </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643600736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"> </span><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2022 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on March 23, 2023.&#160; The accompanying consolidated balance sheet as of December 31,
              2022 was derived from the audited financial statements as of and for the year ended December 31, 2022. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8
              of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have
              been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and
              assumptions that impact the financial statements) considered necessary to present fairly the Company&#8217;s financial position as of March 31, 2023 and its results of operations, changes in stockholders&#8217; equity and cash flows for the three months
              ended March 31, 2023 and 2022.</span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three months ended March 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts
              presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
              granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#8217;s deferred tax assets.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts in
            the amount of $0.1 million at March<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> 31</span>, 2023 and December 31, 2022, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The



              Company extends credit to its customers based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an
              ongoing basis.</span> Based on these evaluations, the Company has concluded that its credit risk is minimal. At <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023, five customers accounted for an aggregate of 98% of the Company&#8217;s total accounts receivable, and at December 31, 2022, two customers accounted for approximately 92% of the Company&#8217;s total
            accounts receivable.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Inventories</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct
              and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable
              supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s products relative to the total square
              footage of the facility.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of
              conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160; Goodwill
              at <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and December 31, 2022 was $3.5 million.&#160; All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to the Biotest
              Transaction.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#8217;s annual
              goodwill impairment test as of October 1, 2022 did not result in a goodwill impairment charge, and the Company did not <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three months
                ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023 and 2022, the Company
              determined that there was no impairment of its long-lived assets.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023</span>
                and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the
                Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the
                out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance
                with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a
                period of approximately 22 years.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based
              on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin
              products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other
              wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates,
              control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the three months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2023<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> three customers represented an aggregate of 76% of the Company&#8217;s consolidated revenues. For the three months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">March 31</span>, 2022, three customers represented an aggregate
              of 83% of the Company&#8217;s consolidated revenues.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA approved products,
              intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the
              activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Loss Per Common Share</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Basic loss per common share is computed by dividing net loss attributable to common stockholders by the
                weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if
                any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock
                options and warrants, using the treasury stock method, as well as Restricted Stock Units (&#8220;RSUs&#8221;). Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be
                anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported
                a net loss for all periods presented. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">For the three months ended </span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">March 31</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;">, 2023</span></span></span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"> and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For the Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,945,703</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,686,068</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,875,464</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,729,758</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,525,148</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,631,207</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">28,346,315</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,047,033</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is
              generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
              related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2018 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by
                the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is
                greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company
                has determined that it has not incurred any liability for unrecognized tax benefits as of March 31, 2023 and December 31,
                2022, and during the three months ended March 31, 2023 and 2022, the Company recognized</span><span style="font-size: 10pt;"> no
                adjustments for uncertain tax positions.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI https://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643025248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Calculation of Diluted Loss Per Common Share</a></td>
<td class="text"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">For the three months ended </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">March 31</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;">, 2023</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"> and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span>
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For the Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock options</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,945,703</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,686,068</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,875,464</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,729,758</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,525,148</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,631,207</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">28,346,315</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,047,033</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649129216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">55,747,754</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,644,527</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,087,760</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,170,853</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">46,149,359</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">58,464,667</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">163,984,873</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">163,280,047</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643447120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,416,706</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">683,340</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100,046</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,270,276</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">829,770</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">756,184</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">151,237</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">723,776</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">183,645</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,007,467</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,172,890</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">834,577</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,007,467</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,994,052</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,013,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Intangible Asset Future Aggregate Amortization Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">All of the Company&#8217;s intangible assets were acquired in the Biotest Transaction. Amortization expense
              related to these intangible assets was $0.2 million for the three months ended March 31, 2023 and 2022. Estimated future
              aggregate amortization expense is expected to be as follows:</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span><br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">536,514</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2024</span><br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">298,063</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643550048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,828,570</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">18,767,807</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,939,060</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,318,669</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,662,407</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,109,898</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,515,267</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,726,995</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,514,697</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">17,930,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,856,505</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">19,544,307</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">78,655,947</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">77,738,022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(21,285,164</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(19,476,541</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property, plant and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">57,370,783</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">58,261,481</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643554528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 are as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,129,902</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11,436,484</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,406,033</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,166,896</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,179,600</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,193,919</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">169,825</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">309,867</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br/>
                  </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,745,245</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,086,379</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,041,859</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,795,804</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">22,672,464</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">24,989,349</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643550048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Outstanding Senior Notes Payable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2022</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">155,727,724</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">154,747,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,426,794</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,914,683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">144,300,930</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">142,833,063</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940645237216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2023 and 2022:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
            &#160; <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">68</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">68</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">%</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                      </span></div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.20-4.24</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.72-1.73</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">%</div>
                  </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
              follows:</div>

<div>
            &#160;</div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Weighted </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Average </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,256,211</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.37</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(15,555</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.29</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,047</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.06</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,727,510</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.35</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">(5,416</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
                  </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">2.08</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,945,703</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.36</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,660,313</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.67</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested RSU Activity</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">A
                summary of the Company&#8217;s unvested RSU activity and related information is as follows:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
              </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Weighted </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Average Grant</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2022</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,866,987</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.59</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,666,260</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.35</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(628,283</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.76</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(29,500</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.25</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,875,464</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.53</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> </span>
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
              months ended March 31, 2023 and 2022 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                      </span> </div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,385</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,671</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">23,055</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,052</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">978,124</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,517,602</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">103,602</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">98,063</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 67.86%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,110,166</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,641,388</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649150656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Concerning Reportable Segments</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is shown in the following tables:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2023</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Plasma Collection</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">49,576,935</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,300,891</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">35,708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,913,534</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">33,933,782</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,466,762</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">40,400,544</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,476,441</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(946,334</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,343,425</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(813,318</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(23,779</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(227</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,951,491</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,975,497</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net income (loss)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,452,662</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(946,561</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,294,916</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,788,815</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures <br/>
            </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">452,032</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,492,564</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,944,596</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,292,608</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">740,357</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,032,965</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">234,894,891</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">38,853,662</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,038,989</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">340,787,542</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31, 2022</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"> Plasma Collection </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
              <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,728,625</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,338,760</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">35,708</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">29,103,093</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">22,213,781</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,227,265</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25,441,046</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Loss from operations</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,442,684</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,863,094</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,509,288</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(14,815,066</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(49,267</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(729</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,472,854</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,522,850</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Loss on extinguishment of debt<br/>
            </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(6,669,941</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(6,669,941</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net loss</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,491,951</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,863,823</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(16,652,083</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(25,007,857</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,310,379</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,531,706</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,842,085</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,111,951<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">477,503<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">763<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,590,217<br/>
              </div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
            </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">214,150,322</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">32,568,911</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">61,313,259</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,032,492</div>
            </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Net Revenues According to Geographic Area</a></td>
<td class="text">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><br/></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended March 31,</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                </span> </div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                </span> </div>
            </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,694,723</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,316,151</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,218,811</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,786,942</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">56,913,534</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
              <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">29,103,093</div>
            </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643427872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments Under Lease Obligations</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;">Scheduled payments under the
              Company&#8217;s lease obligations are as follows:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Remainder of <span style="text-indent: 0pt;">2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,805,644</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Year ended December 31, <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,343,314</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,366,432</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,116,036</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2027</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,040,690</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-indent: 0pt;">2028</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,087,825</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Thereafter</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,150,746</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total payments</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">18,910,687</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: imputed interest</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(7,486,533</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Current portion</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(956,045</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 14%; padding-bottom: 4px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">March 31, 2023</span></div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,468,109</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649102320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Supplemental cash flow information for the three months ended March 31, 2023 and 2022 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2022<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,639,283</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,525,987</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">530,434</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,940,425</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt;">Warrants issued in connection with notes payable<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">9,569,604</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643647280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Product </div>
<div>Facility</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of plasma collection facilities under approval and development | Facility</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDAApprovedProduct', window );">Number of FDA approved product | Product</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WorkingCapital', window );">Working capital | $</a></td>
<td class="nump">$ 227.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="nump">$ 69.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAApprovedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAApprovedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between current assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940639389728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts', window );">Accounts receivable, allowances for contractual credits and doubtful accounts | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers | Customer</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of account receivables</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for contractual credits and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642291552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,529,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,529,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642291104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long-lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940643603216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details) - Customer<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adma_TwoCustomersMember', window );">Two Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adma_FiveCustomersMember', window );">Five Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember', window );">Biotest License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredRevenueRemainingAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredRevenueRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredRevenueRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642840176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">28,346,315<span></span>
</td>
<td class="nump">27,047,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">9,945,703<span></span>
</td>
<td class="nump">8,686,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">4,875,464<span></span>
</td>
<td class="nump">4,729,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">13,525,148<span></span>
</td>
<td class="nump">13,631,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642755920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Equity incentive plans, term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642195520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940648336576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 55,747,754<span></span>
</td>
<td class="nump">$ 48,644,527<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">62,087,760<span></span>
</td>
<td class="nump">56,170,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">46,149,359<span></span>
</td>
<td class="nump">58,464,667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 163,984,873<span></span>
</td>
<td class="nump">$ 163,280,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940639471648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Summary (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5,007,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,007,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">4,172,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,994,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">834,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,013,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">178,838<span></span>
</td>
<td class="nump">$ 178,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember', window );">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">4,100,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">3,416,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,270,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">683,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">829,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember', window );">Rights to Intermediates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">907,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">756,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 151,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940648369504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated Aggregate Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 536,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2024</a></td>
<td class="nump">$ 298,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940638872384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 78,655,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,738,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(21,285,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,476,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">57,370,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,261,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 19,828,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,767,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,939,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,662,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,109,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,515,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,726,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">20,514,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,930,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,339,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,339,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 19,856,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,544,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940738715872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">$ 13,129,902<span></span>
</td>
<td class="nump">$ 11,436,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">4,406,033<span></span>
</td>
<td class="nump">3,166,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentives</a></td>
<td class="nump">1,179,600<span></span>
</td>
<td class="nump">4,193,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedTestingCurrent', window );">Accrued testing</a></td>
<td class="nump">169,825<span></span>
</td>
<td class="nump">309,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other compensation</a></td>
<td class="nump">1,745,245<span></span>
</td>
<td class="nump">4,086,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,041,859<span></span>
</td>
<td class="nump">1,795,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 22,672,464<span></span>
</td>
<td class="nump">$ 24,989,349<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940636873744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 23, 2022 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2026 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,727,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,747,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="num">$ (13,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,426,794)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,914,683)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,300,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,833,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for outstanding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,669,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,913,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,103,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 23,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentUpfrontFeePaidInKind', window );">Upfront fee paid in kind</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (6,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentInterestAmountToBePayInKind', window );">Percentage of interest amount to pay in kind</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid', window );">Percentage of exit fee on outstanding principal amount being paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Scheduled principal payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase applicable margin</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal', window );">Number of business days prior written notice for prepay outstanding principal | d</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SharesIssuedUponExerciseOfWarrants', window );">Shares issued upon exercise of warrants (in shares) | shares</a></td>
<td class="nump">9,103,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.6478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TrailingPeriodForVolumeWeightedAveragePrice', window );">Trailing period for VWAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash balance</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Maximum [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Prepaid on or Prior to First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Prepaid after the First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Prepaid after the Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Federal Funds Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit agreement, interest rate provided</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Secured Overnight Financing Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit agreement, interest rate provided</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Secured Overnight Financing Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Secured Overnight Financing Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentFloorInterestRate', window );">Percentage of floor interest rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 23,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member] | Hayfin Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Notes payable</a></td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember', window );">Hayfin Closing Date Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for outstanding obligations</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember', window );">Hayfin Closing Date Loan [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Notes payable</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Redemption premium</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment for certain fees and expenses</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember', window );">Hayfin Delayed Draw Loan [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Notes payable</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 22,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentApplicableMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the margin rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentApplicableMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage floor rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentInterestAmountToBePayInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest amount to be pay in kind during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentInterestAmountToBePayInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentTermOfVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentTermOfVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentUpfrontFeePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentUpfrontFeePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days for prior written notice to pay outstanding principal loans subject to payment conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exit fee on outstanding principal amount being paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TrailingPeriodForVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TrailingPeriodForVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642132448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642244624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="nump">221,816,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">48,356,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="nump">29,380,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940639463088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,356,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="nump">9,103,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">68.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 1.6478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,525,148<span></span>
</td>
<td class="nump">13,525,148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940636147344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="nump">29,380,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,110,166<span></span>
</td>
<td class="nump">$ 1,641,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,385<span></span>
</td>
<td class="nump">4,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Plasma Center Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">23,055<span></span>
</td>
<td class="nump">21,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">978,124<span></span>
</td>
<td class="nump">1,517,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Total stock-based compensation expense, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 103,602<span></span>
</td>
<td class="nump">$ 98,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember', window );">2022 Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="nump">1,727,510<span></span>
</td>
<td class="nump">1,194,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, expected to vest</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock shares issued (in shares)</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionSharesAbstract', window );"><strong>Stock Option, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, beginning balance (in shares)</a></td>
<td class="nump">8,256,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber', window );">Forfeited (in shares)</a></td>
<td class="num">(15,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber', window );">Expired (in shares)</a></td>
<td class="num">(17,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber', window );">Granted (in shares)</a></td>
<td class="nump">1,727,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber', window );">Exercised (in shares)</a></td>
<td class="num">(5,416)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">9,945,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">6,660,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice', window );">Forfeited, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">2.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice', window );">Expired, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">7.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, stock options</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted (in shares)</a></td>
<td class="nump">2,666,260<span></span>
</td>
<td class="nump">1,059,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities', window );">Shares withheld for tax withholding obligation (in shares)</a></td>
<td class="nump">185,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities', window );">Amount of shares withheld for tax withholding obligation</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Unvested RSU, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,866,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,666,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(628,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(29,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">4,875,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">1.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted average grant date fair value, ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, non option</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RestrictedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RestrictedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were granted during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940639021808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember', window );">Perceptive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_MinimumPercentageOfCommonStockHeldByLender', window );">Minimum percentage of common stock held by lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember', window );">Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Rent expense</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember', window );">Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchased materials amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 43,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumPercentageOfCommonStockHeldByLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock held by lender and administrative agent of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumPercentageOfCommonStockHeldByLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adma_GenesisBPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940638738128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>Center </div>
<div>Term</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>Facility</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved', window );">Number of FDA-licensed plasma collection facilities approved | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDAInspections', window );">Number of FDA Inspections | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchased', window );">Plasma purchased from Grifols</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">$ 15,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfInventoryPurchases', window );">Percentage of inventory purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855,351<span></span>
</td>
<td class="nump">$ 624,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_BIVIGAMMember', window );">BIVIGAM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_ASCENIVMember', window );">ASCENIV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Customer Concentration Risk [Member] | International Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementTerm', window );">Plasma purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity', window );">Number of plasma collection centers that collects RSV Plasma which were transferred to BPC | Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfPlasmaPurchasePriceEqualToCost', window );">Percentage of plasma purchase price equal to cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember', window );">2017 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAInspections">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of FDA inspections completed during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAInspections</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA licenses approved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection centers that company may purchase RSV plasma.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned plasma collection facilities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of renewal terms to extend purchase agreement, if agreed to by the parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of inventory purchases related to raw material plasma.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfPlasmaPurchasePriceEqualToCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of plasma purchase price equal to cost purchased from collection centers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfPlasmaPurchasePriceEqualToCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plasma purchased during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PostMarketingCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PostMarketingCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VendorAndLicensorCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VendorAndLicensorCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_BIVIGAMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_BIVIGAMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_ASCENIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_ASCENIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_InternationalCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_InternationalCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940638400480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction', window );">Number of remaining plasma collection facilities under construction | Facility</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 56,913,534<span></span>
</td>
<td class="nump">$ 29,103,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">40,400,544<span></span>
</td>
<td class="nump">25,441,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(813,318)<span></span>
</td>
<td class="num">(14,815,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_InterestAndOtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(5,975,497)<span></span>
</td>
<td class="num">(3,522,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,669,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(6,788,815)<span></span>
</td>
<td class="num">(25,007,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">1,944,596<span></span>
</td>
<td class="nump">2,842,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">2,032,965<span></span>
</td>
<td class="nump">1,590,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">340,787,542<span></span>
</td>
<td class="nump">308,032,492<span></span>
</td>
<td class="nump">$ 348,461,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">52,694,723<span></span>
</td>
<td class="nump">27,316,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,218,811<span></span>
</td>
<td class="nump">1,786,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">35,708<span></span>
</td>
<td class="nump">35,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(5,343,425)<span></span>
</td>
<td class="num">(6,509,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_InterestAndOtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(5,951,491)<span></span>
</td>
<td class="num">(3,472,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,669,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(11,294,916)<span></span>
</td>
<td class="num">(16,652,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,038,989<span></span>
</td>
<td class="nump">61,313,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49,576,935<span></span>
</td>
<td class="nump">25,728,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">33,933,782<span></span>
</td>
<td class="nump">22,213,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">5,476,441<span></span>
</td>
<td class="num">(4,442,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_InterestAndOtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(23,779)<span></span>
</td>
<td class="num">(49,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">5,452,662<span></span>
</td>
<td class="num">(4,491,951)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">452,032<span></span>
</td>
<td class="nump">1,310,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,292,608<span></span>
</td>
<td class="nump">1,111,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">234,894,891<span></span>
</td>
<td class="nump">214,150,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,300,891<span></span>
</td>
<td class="nump">3,338,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">6,466,762<span></span>
</td>
<td class="nump">3,227,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(946,334)<span></span>
</td>
<td class="num">(3,863,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_InterestAndOtherNonoperatingIncomeExpense', window );">Interest and other expense, net</a></td>
<td class="num">(227)<span></span>
</td>
<td class="num">(729)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(946,561)<span></span>
</td>
<td class="num">(3,863,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="nump">1,492,564<span></span>
</td>
<td class="nump">1,531,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">740,357<span></span>
</td>
<td class="nump">477,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 38,853,662<span></span>
</td>
<td class="nump">$ 32,568,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_InterestAndOtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other nonoperating income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_InterestAndOtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of remaining plasma collection facilities under construction during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940642228320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for lease</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingAndFinancingLeaseLiability', window );">Operating and financing lease liabilities</a></td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Payments Under Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 1,805,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2024</a></td>
<td class="nump">2,343,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">2,366,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">2,116,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">2,040,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">2,087,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">6,150,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">18,910,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(7,486,533)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(956,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(905,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Balance at March 31, 2023</a></td>
<td class="nump">$ 10,468,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,704,176<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingAndFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingAndFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940649549760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 4,639,283<span></span>
</td>
<td class="nump">$ 2,525,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing and Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">530,434<span></span>
</td>
<td class="nump">1,940,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsIssuedInConnectionWithNotesPayable', window );">Warrants issued in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,569,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsIssuedInConnectionWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued in connection with the issuance of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsIssuedInConnectionWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139940638907680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENT (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hayfin Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfReductionPrepaymentFees', window );">Percentage of reduction to forego early prepayment fees</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="nump">2,391,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 3.2619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hayfin Second Amendment [Member] | Prepaid on or Prior to First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hayfin Second Amendment [Member] | Prepaid after the First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hayfin Second Amendment [Member] | Prepaid after the Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Hayfin Second Amendment [Member] | Secured Overnight Financing Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SubsequentEventAdditionalInformationAbstract', window );"><strong>Subsequent Event [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentApplicableMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the margin rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentApplicableMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfReductionPrepaymentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of reduction to forego early prepayment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfReductionPrepaymentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SubsequentEventAdditionalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SubsequentEventAdditionalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>brhc20052583_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20230331"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adma-20230331.xsd" xlink:type="simple"/>
    <context id="c20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-05-05</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_TypeOfArrangementAxis_BiotestLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20261001to20261231_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_StatementScenarioAxis_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220621_PlanNameAxis_Two022CompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:Two022CompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20160101to20160131_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:ArethLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:InternationalCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:InternationalCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ProductOrServiceAxis_BIVIGAMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20121219to20121219_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-19</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="c20190401to20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c20121219to20121219_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-19</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ProductOrServiceAxis_BIVIGAMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20220331_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>adma:Facility</measure>
    </unit>
    <unit id="U005">
        <measure>adma:Product</measure>
    </unit>
    <unit id="U006">
        <measure>adma:Customer</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>utr:D</measure>
    </unit>
    <unit id="U009">
        <measure>adma:Term</measure>
    </unit>
    <unit id="U010">
        <measure>adma:Center</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20230101to20230331"
      id="Fact_2e64117d18464d49aecdd898b33655bd">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20230101to20230331"
      id="Fact_3048083e6df1471d98b6ea583393e433">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20230101to20230331"
      id="Fact_201f815237e24e2bb0cbb6492bd63806">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20230101to20230331"
      id="Fact_cb89b750ba74428abca9019a30e62ec9">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20230101to20230331"
      id="Fact_d7c5e0f25d8342ca84c2245f7a32857c">0001368514</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20230101to20230331_RangeAxis_MinimumMember"
      id="Fact_4342de1675c9405cb8dc40be8462b988">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="INF"
      id="Fact_5ecb5c13cda94b628b0011be8e172a1f"
      unitRef="U008">5</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20230331"
      id="Fact_9109aae765d343688bd225ff5a0745fd"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20221231"
      id="Fact_cd2a31ec8a274e85bda554fc0b8b2bc8"
      unitRef="U002"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="c20230101to20230331"
      id="Fact_a0d9e94c759448c09df2bc1351396d8c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20230101to20230331"
      id="Fact_b53cb21a99644ac4b9204b3b460c13ad">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20230101to20230331"
      id="Fact_ce58c97ebbcb4fcea326afe3780ddae3">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20230101to20230331"
      id="Fact_d85353686fbe48bf8e7878419b56f8ae">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20230101to20230331"
      id="Fact_859779f71d204f3798e344b5e49be48b">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20230101to20230331"
      id="Fact_82b3a17aa92149bb84de1feff5b8c57c">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20230101to20230331"
      id="Fact_b28ddabe7c884ea6b9a2f113c7e08a6b">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20230101to20230331"
      id="Fact_4a217cad01224ff2aa08e144ce21933b">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20230101to20230331"
      id="Fact_45757d4814314793b088f54205f44d05">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20230101to20230331"
      id="Fact_7e236f72d44a4e27853e1438eaa465bd">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20230101to20230331"
      id="Fact_d9cb8bb1b42f4e20a9b3dbab349bed9f">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20230101to20230331"
      id="Fact_e7ab623e44b84a8088674e45263ccdd8">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20230101to20230331"
      id="Fact_8a402689f3a74b43935688aff4a2ae50">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20230101to20230331"
      id="Fact_e1300f532a5446569ff2d35af10bf003">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20230101to20230331"
      id="Fact_e4972f0dbab549bb8e505344fb693cb8">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20230101to20230331"
      id="Fact_ac6430b6bc59416e9fda32973cc3d616">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20230101to20230331"
      id="Fact_931b5bd883384f379da9cc5695705e29">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20230101to20230331"
      id="Fact_809cb7bbffaa41d7b65263f51cbc291f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20230101to20230331"
      id="Fact_e8acb1809c6c46b1bacf6022a51d02bb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20230101to20230331"
      id="Fact_6a96681819934be289daf11217252615">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20230101to20230331"
      id="Fact_6f5313fab06c4d629f1a90897bbc09ae">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20230101to20230331"
      id="Fact_1895b40d8e2546a1af8881b6b76362f2">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20230101to20230331"
      id="Fact_3b5c972b64d64c658153a4a1362a7945">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20230505"
      decimals="INF"
      id="Fact_4002b2b468c14c6d9d0e621bba575953"
      unitRef="U001">222272962</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="0"
      id="Fact_2433aaa0f77c4c2088cd8707941d7e68"
      unitRef="U002">69204163</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20221231"
      decimals="0"
      id="Fact_9cbd99f142bc49918de54d35b82c9d7f"
      unitRef="U002">86521542</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_a65a3741507a430fb1245c9c1f8d85e2"
      unitRef="U002">26518495</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_86347a9c044b48f19dc559a37403ea87"
      unitRef="U002">15505048</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20230331"
      decimals="0"
      id="Fact_9142fbb79b634d9da8f751e35db17e72"
      unitRef="U002">163984873</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_c733c840f9854e208bc854b08f2bbeeb"
      unitRef="U002">163280047</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6"
      unitRef="U002">4378681</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_9177520ab36c49ea97cd19a1c968df92"
      unitRef="U002">5095146</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd"
      unitRef="U002">264086212</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_f45b3271b441455cb2105680565b129e"
      unitRef="U002">270401783</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20230331"
      decimals="0"
      id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab"
      unitRef="U002">57370783</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_c7aaf9819ea84e03bf8722ce95af85af"
      unitRef="U002">58261481</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20230331"
      decimals="0"
      id="Fact_f17de370315f4091b0f89c2e84d973d1"
      unitRef="U002">834577</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20221231"
      decimals="0"
      id="Fact_0514a0e23bdc4d0ea5e717bdf3754926"
      unitRef="U002">1013415</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="c20230331"
      decimals="0"
      id="Fact_769d5f0c97eb4064bdb43ac410530a21"
      unitRef="U002">3529509</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20221231"
      decimals="0"
      id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2"
      unitRef="U002">3529509</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20230331"
      decimals="0"
      id="Fact_bbc32b4cc98043e9a94ba4f7220fb722"
      unitRef="U002">10247700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20221231"
      decimals="0"
      id="Fact_6dd902973f4846a4bb1c1594e27f8f57"
      unitRef="U002">10485447</us-gaap:OperatingLeaseRightOfUseAsset>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20230331"
      decimals="0"
      id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e"
      unitRef="U002">4718761</adma:DepositsAndOtherNoncurrentAssets>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20221231"
      decimals="0"
      id="Fact_a50743018b6247889bc69ddeeb66ade6"
      unitRef="U002">4770246</adma:DepositsAndOtherNoncurrentAssets>
    <us-gaap:Assets
      contextRef="c20230331"
      decimals="0"
      id="Fact_c2f9187a8f1347b180e4de1c4e0650a0"
      unitRef="U002">340787542</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231"
      decimals="0"
      id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1"
      unitRef="U002">348461881</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_7dde0dfcef624d98a7c818296df97379"
      unitRef="U002">12956486</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_79f8959f51c440058a2b2ae73dcbf97b"
      unitRef="U002">13229390</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20230331"
      decimals="0"
      id="Fact_dd0f579f43084bb2aa500ce0cc36df30"
      unitRef="U002">22672464</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20221231"
      decimals="0"
      id="Fact_0e9ccf6016784da8a8b04f3a1af923c3"
      unitRef="U002">24989349</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_717f5016a22d44e788a7623ed89d02dc"
      unitRef="U002">142834</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_f9a0da175433427abcd2517ac58e7ac3"
      unitRef="U002">142834</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_e15d10dae4084e71835cb788dda3105c"
      unitRef="U002">956045</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff"
      unitRef="U002">905369</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_e040cd8f2ecf4ad193d82978ff855ac5"
      unitRef="U002">36727829</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_df082a6c52ae4c43b80203fb015af4c8"
      unitRef="U002">39266942</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20230331"
      decimals="0"
      id="Fact_5dbbafa983e447648edea5d160779986"
      unitRef="U002">144300930</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20221231"
      decimals="0"
      id="Fact_a253f9727f7042bdb255854fc1f4cc07"
      unitRef="U002">142833063</us-gaap:SeniorLongTermNotes>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_c6a34d215f70489cb00ad0517bb21b35"
      unitRef="U002">1797323</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_c686e6297dea4e4d93efce7816cca250"
      unitRef="U002">1833031</us-gaap:DeferredRevenueNoncurrent>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20230331"
      decimals="0"
      id="Fact_4d410e2a246640308a098f9cd7fdd048"
      unitRef="U002">1500000</adma:LongTermLiabilityEndOfTermFeePayable>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20221231"
      decimals="0"
      id="Fact_a0a3d9326c654effa015cbfada21a58e"
      unitRef="U002">1500000</adma:LongTermLiabilityEndOfTermFeePayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_67604891dc8248dba7f483ed9d867778"
      unitRef="U002">10468109</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7"
      unitRef="U002">10704176</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_1425725201a64a6b81c6061265b988a6"
      unitRef="U002">338731</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_019efd73590a4e5fb4700d5a202f9ba9"
      unitRef="U002">350454</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20230331"
      decimals="0"
      id="Fact_4b09c740ef954edab33c4b39d9ffc56e"
      unitRef="U002">195132922</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20221231"
      decimals="0"
      id="Fact_95d12ad8d1e64b189d1268bbd917203d"
      unitRef="U002">196487666</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_4b322bc4ff9047ada11d276fba00f032"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="4"
      id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_c51731a3209d45bc9c438cd58e2594ec"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_6460774f302542369b031f1439c51371"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20221231"
      decimals="INF"
      id="Fact_7357d7c8b24b4172b404e8fb73377a70"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20230331"
      decimals="INF"
      id="Fact_6a23abbcd48d427490a73e11ae49d3bd"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20221231"
      decimals="INF"
      id="Fact_985ef26e70de4d438886de20409f6e62"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20230331"
      decimals="INF"
      id="Fact_65817be99e324befbc84fa32051df194"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20230331"
      decimals="0"
      id="Fact_32421b2e655449bc95407ba53997b2dd"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20221231"
      decimals="0"
      id="Fact_1b0624f0760d4befb7bf3f49d8cdc325"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_772895fcdb8948edaa197e1a3cbda00b"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="4"
      id="Fact_0b9116e5ffd647cd91be96bc28d8ec95"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_a6da05b44012449790cf1f8fefcf0523"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_e17fd8ff3db44d0db345255c9de5d29c"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_be2280b446274185893dcebcbf2be1f3"
      unitRef="U001">222262588</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230331"
      decimals="0"
      id="Fact_a47a04445e0a40c0ac5864df134f7b0a"
      unitRef="U001">222262588</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_6acdb1cf62784deea606e18a567d8916"
      unitRef="U001">221816930</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20221231"
      decimals="0"
      id="Fact_4889dba395554041a519d29516e511d1"
      unitRef="U001">221816930</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20230331"
      decimals="0"
      id="Fact_58134c88742643e59d1016963f21fc5a"
      unitRef="U002">22226</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20221231"
      decimals="0"
      id="Fact_a9deedc4c75a4eca9914e129648a18c2"
      unitRef="U002">22182</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20230331"
      decimals="0"
      id="Fact_c293fe47874d4c80ae1b7165eead05cc"
      unitRef="U002">630437880</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20221231"
      decimals="0"
      id="Fact_393b6c347b684f7c93234fece20c7a2e"
      unitRef="U002">629968704</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20230331"
      decimals="0"
      id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46"
      unitRef="U002">-484805486</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20221231"
      decimals="0"
      id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a"
      unitRef="U002">-478016671</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="0"
      id="Fact_1a6712ef74b145788070fef039c2ef2d"
      unitRef="U002">145654620</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_3acf9855c6604de4b9fef2d7902b6e9c"
      unitRef="U002">151974215</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20230331"
      decimals="0"
      id="Fact_b55ab3549e7148a98c2fb93694e5d4ad"
      unitRef="U002">340787542</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_cceb9a747e2849a3a60625fde7c5ccf2"
      unitRef="U002">348461881</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_e1a7bf1ebf4940a9ac52031b4c09a220"
      unitRef="U002">56913534</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_6b5d3f97463c401a87c32670456c3435"
      unitRef="U002">29103093</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_54ecfb1fca31461f8721b04faf5e7414"
      unitRef="U002">40400544</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_af6c05a9f3024b4391ad85666edd8a66"
      unitRef="U002">25441046</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_dbecef88bfea4621a31c61eaf0c420bb"
      unitRef="U002">16512990</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_08e2ddd1f7c44aa7a6dd24b4768fdbd1"
      unitRef="U002">3662047</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_615dea589ffb4335b67030347f30a99e"
      unitRef="U002">855351</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_77fdf3e87b344c129c955fd6ab5a8f35"
      unitRef="U002">624111</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_bab9b38c1d2f492b8af3f48d7277931b"
      unitRef="U002">1780463</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_ce7e63f3d9944cad8002dcc0a7838249"
      unitRef="U002">3974589</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_f38461586708484abff1ba3bcbf27632"
      unitRef="U002">178838</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_59646d8e9d9f4993a493e59764cb973a"
      unitRef="U002">178838</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_8309a23ecae0401582dad9aa52200854"
      unitRef="U002">14511656</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_6d1aebc0edf747a8a862967456b523bd"
      unitRef="U002">13699575</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_825cd8cce1eb49ef98f0fc3183a63e80"
      unitRef="U002">17326308</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_40366600d6b1473f888d814c6b9af5b3"
      unitRef="U002">18477113</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_a9d19c3dc40a448d962464e0e9595d92"
      unitRef="U002">-813318</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_f9a09c65f0fa4802b39a57cea8cc63bb"
      unitRef="U002">-14815066</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_974134faa6a64a578613db71d029091a"
      unitRef="U002">166971</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_bd144782dbb743568eaefb57b6253e69"
      unitRef="U002">33068</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_69a47bd0a77143c1b4d83d79922787a9"
      unitRef="U002">6115484</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_8cfce7d67ef447bda059c26df59959d2"
      unitRef="U002">3389038</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_16d2a88ce7ef411382fc61ae9a260ab4"
      unitRef="U002">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_5ef7ff9cfb3643079fd29eedf459a70a"
      unitRef="U002">-6669941</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_03381f8457df47f783cd742e63a14267"
      unitRef="U002">-26984</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_e6163902b75c42e6b186529957d79cb3"
      unitRef="U002">-166880</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_18e76cd651af46308b002f0fda03523e"
      unitRef="U002">-5975497</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_fcb8c0059fd642f78f92174435ea2ef2"
      unitRef="U002">-10192791</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_b61a3cd5083041568d8f9f2b65d6a19b"
      unitRef="U002">-6788815</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_032522af1eea4b4bb8be8ed607d36873"
      unitRef="U002">-25007857</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_6f12964ec58f4ee4b944dbcaf88ca639"
      unitRef="U003">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_2490adcca0ce4b4b9fb500d82d60a0d6"
      unitRef="U003">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_8346916284f042e79bb7fb835ced2ee9"
      unitRef="U003">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_7fe7614164aa439a80e6048fb7a3df80"
      unitRef="U003">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_72538301662d490499d94942ed29f5de"
      unitRef="U001">221921750</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_189471ab7a1343b7879585c1a633996f"
      unitRef="U001">221921750</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_8abba748112d400f858988b59d813858"
      unitRef="U001">195871932</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_059b576bade5410dbe0737e32c1c183e"
      unitRef="U001">195871932</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a62f749fd1664bca8c6adbbfa5588954"
      unitRef="U001">221816930</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ee83ffd3663847a59cd370d5bda40ef6"
      unitRef="U002">22182</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_0a6b44af90004426a8f294edf299950d"
      unitRef="U002">629968704</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_9a6c2292e6684b2490ad5c92b8e1aef4"
      unitRef="U002">-478016671</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="0"
      id="Fact_c0a1b6000dfb4ca5bbee90933e9c0425"
      unitRef="U002">151974215</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6587a89ac47f4696832b56606c3095c1"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_c332687a9e504b96984768e306bb356d"
      unitRef="U002">1110166</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_c4c2621be76b4dbd863076582d033d7b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_10a99c1fa49446c79d5365a2444fabab"
      unitRef="U002">1110166</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bec0e3ba2b49431f8e6f5fd0e709d6ad"
      unitRef="U001">443215</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b5f7f04cc7074cccae7a1e3e924e6c06"
      unitRef="U002">44</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_d8aea68e63a345edb705675a05049cac"
      unitRef="U002">-640990</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_af6e11e186e24992a4141639daeb9f99"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_31287449ee1e43079a950abf3fca2614"
      unitRef="U002">-640946</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6677a165ddff41bb8a3a3cb9fc262fa3"
      unitRef="U001">2443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_91b1dfa7002d4ebebbd03a312fe6889b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_3920e3f9effa48f4b6e9389e4dfc4d1a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_35b9411fde6b46868f022f98e42d349f"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_262e390c1a644219800014c0ad1a957d"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d72d92fa55c2487db85fd407ede3e976"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_6b0b40f5e72a454d89879ad7eac300b7"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_3569a30027e84def80f3e99b71692ba5"
      unitRef="U002">-6788815</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_b5175c9db7354a63b37c9eedf7cb6414"
      unitRef="U002">-6788815</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a0aed09d0df84d75a1f0df353f6c7ffb"
      unitRef="U001">222262588</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_525af4fdcf7c44b6b537ca5ffcd9f2e0"
      unitRef="U002">22226</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_aadcb5bf1094428686dee5e620a2ed17"
      unitRef="U002">630437880</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_d4893889d68f4a5281c440b9104bf27e"
      unitRef="U002">-484805486</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="0"
      id="Fact_e954c6a864264c98ac4a960c9ca3abe0"
      unitRef="U002">145654620</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ec44f0d1ba5a43078f4539332440aca1"
      unitRef="U001">195813817</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_eea7468bf242442b9080e37d9ea4e64c"
      unitRef="U002">19581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_5d6ff8b442ac477d9237640c161cbedb"
      unitRef="U002">553265706</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_00d3de036ac74e2ba85b466425d52038"
      unitRef="U002">-412112721</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="0"
      id="Fact_4149bd8a07914db3b171faaa195732af"
      unitRef="U002">141172566</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_397fa125fadf4dc795659a5ace38a204"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_9c93139521444a7eabaaea4036fe96a4"
      unitRef="U002">9569604</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_11a92a4ebdb64053ba221055cd91d4cf"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_c741d2e617cf45a88160b06d80fb55df"
      unitRef="U002">9569604</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2ad8790f46e7423394ff4abbcd958a97"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_1ba6f3ce039e458894c0d5ec7ae6dad0"
      unitRef="U002">1641388</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_882704c07b6849348d45a123adc9dab7"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_ef3d75afc3a343ef9291cc6b52d85bae"
      unitRef="U002">1641388</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_08b9170314564933aa0a2e4acbddfb91"
      unitRef="U001">533712</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_479f03bcf3914d87bf32fd4c1c121d71"
      unitRef="U002">54</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_64b69570bf5744a7a2b3db3977639922"
      unitRef="U002">-442690</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_eb32e8d428c24cba8f95e2525e0b593f"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_7a44f5d4a8ed400da35805f4e985c69f"
      unitRef="U002">-442636</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_7025cf294da1491698a1ea040c60f93e"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_05a1ad779e704642a286f47d38dc2e28"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_00eae54f7e1f46919a6253785e3f4455"
      unitRef="U002">-25007857</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_b106ffb9d0b04e8bb7813315001ccb6d"
      unitRef="U002">-25007857</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_fad7ceda95614b4da079d0981f4dadc6"
      unitRef="U001">196347529</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_42f5e4ede4e54c8dbbd4b4ed6a333051"
      unitRef="U002">19635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact_2a052e1527054a168c68425e82de9544"
      unitRef="U002">564034008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="0"
      id="Fact_36e7d75bd73a4ed0a0dba9310659d7e6"
      unitRef="U002">-437120578</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20220331"
      decimals="0"
      id="Fact_4e615f2a583f409a8e87fd68ae41a730"
      unitRef="U002">126933065</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_606e384999c44b89a2f45b44d9be2517"
      unitRef="U002">-6788815</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_554cda1cba654604bbccaaebde7db98c"
      unitRef="U002">-25007857</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_83080cccdd6c41ebbae85287f51e38d5"
      unitRef="U002">2032965</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_ca7370b0b19e46f99b974659c5ad04e6"
      unitRef="U002">1590217</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_515262ae94b843ba8af2bd8952c28fa5"
      unitRef="U002">-18096</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_68fa0d6ea69d4931b29a903cca06f2d5"
      unitRef="U002">-2000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_a7a703ba8e0641b5a8eb820d496f2cb7"
      unitRef="U002">979978</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_d8e180512f2644cf831d6f64ad829e56"
      unitRef="U002">0</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_8d5c2bb295224d419c3420694af40e45"
      unitRef="U002">1110166</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_670daf81ec0e4ae59184cfe715be7bcc"
      unitRef="U002">1641388</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_fd92d9f44d34479786a5d68a3983d2af"
      unitRef="U002">487889</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_f13bdc7f5a914f4084b4953436f3654d"
      unitRef="U002">584842</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_8b1568f9e4594e87bbace8ab3717b33c"
      unitRef="U002">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_92904d881f344c8f93453ce44c45aef8"
      unitRef="U002">-6669941</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_3e57e53903a545c1ac13b4b75ab07fce"
      unitRef="U002">-35708</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_89a9d124aac042ee93e9b2e64f0875e0"
      unitRef="U002">-35708</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_1dd109c39b304e7c91c47847eb964c36"
      unitRef="U002">11013446</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_9b8f4c75f5734cdc85490f66d98fe227"
      unitRef="U002">-2947233</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_264d1acc9c834f019a733c35d2177df8"
      unitRef="U002">704826</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_a9b6140c5d234afdb8706bbbf1d75f35"
      unitRef="U002">14422219</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_f5acef387bce4b40a96171dd2a65c78a"
      unitRef="U002">-716465</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_c77b61709a1d49c7b5267b2f15dde1bc"
      unitRef="U002">1180056</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_b1d73d329b954767897f8f303d9ffebf"
      unitRef="U002">-289232</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8"
      unitRef="U002">-1397672</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_3f886d78219940d3ae9eb541eb90c632"
      unitRef="U002">-272904</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_5bbf598ffc494351b32f0efe70ce5fee"
      unitRef="U002">1685724</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_40dbe8521d1446c6936e91f772fa3bf3"
      unitRef="U002">-1353815</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9"
      unitRef="U002">-1775526</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_f25bbf8593734543b01b1dfd3ea1038e"
      unitRef="U002">-187551</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f"
      unitRef="U002">-111064</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_6cfe9408e8844ab9b40d95553100bcca"
      unitRef="U002">-14722274</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_a0dea6324de24915a75e5abd788855e6"
      unitRef="U002">-26013413</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_b1f5fe8caf7047798637405d4650fbb9"
      unitRef="U002">1944596</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_4e1c44f0ac144022bf9d800076d23a3a"
      unitRef="U002">2842085</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_8b1af39671aa45ceb09f7ef327d9e32a"
      unitRef="U002">-1944596</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_d8843976a13c448cafd94324f9287089"
      unitRef="U002">-2842085</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_3e5c9553ac2b423384ae3a9c73edfe26"
      unitRef="U002">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_a2ae51b9989a401c98d739f9f793d1be"
      unitRef="U002">100000000</us-gaap:RepaymentsOfNotesPayable>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_e1a434839c5c4e438182727f622e3fb7"
      unitRef="U002">0</adma:PaymentOfDebtRefinancingFees>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_946f591d558d46f9bea90b6cd5f7f278"
      unitRef="U002">2000000</adma:PaymentOfDebtRefinancingFees>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_927b588459b84c0d9a76a6fbdf5630cf"
      unitRef="U002">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_4ab5374da80148589efe2ba7ac99535c"
      unitRef="U002">151750000</us-gaap:ProceedsFromNotesPayable>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4"
      unitRef="U002">640946</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_f2f6799b325341b3a9d32f52e87bc068"
      unitRef="U002">91367</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_32e891ca8de644d3b4189b5bb7913221"
      unitRef="U002">9563</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1"
      unitRef="U002">8941</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_748f6b7e930442dc979dc2c05008d02f"
      unitRef="U002">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_b63adce01c9d440bb05114c85e487919"
      unitRef="U002">2378366</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_69272294317744fcbfbcc384392b85ee"
      unitRef="U002">-650509</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb"
      unitRef="U002">47271326</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_45c3b87b315a4c698252bde2791e3307"
      unitRef="U002">-17317379</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_79454785ed50456da17cfe72739aa946"
      unitRef="U002">18415828</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="0"
      id="Fact_b2be9221ca3942a0b45e4f329506aeb1"
      unitRef="U002">86521542</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="0"
      id="Fact_2bd75314b7494603aa085ca7d4edf16b"
      unitRef="U002">51089118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230331"
      decimals="0"
      id="Fact_ab8dcca17d114290a2011513bb272e45"
      unitRef="U002">69204163</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20220331"
      decimals="0"
      id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e"
      unitRef="U002">69504946</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_014177761dc640798f373cc359e0df61">
&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is an end-to-end commercial biopharmaceutical
            company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#x2019;s targeted
            patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA BioManufacturing&#x201d;) and ADMA BioCenters
              Georgia Inc. (&#x201c;ADMA BioCenters&#x201d;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of the Biotest Therapy Business Unit (&#x201c;BTBU&#x201d;) from BPC Plasma, Inc. (formerly Biotest Pharmaceuticals Corporation) (&#x201c;BPC&#x201d; and,
              together with Biotest AG, &#x201c;Biotest&#x201d;) on June 6, 2017. The acquisition included certain assets of BTBU, including the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma
              fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;) (the &#x201c;Biotest Transaction&#x201d;). BTBU had previously been the Company&#x2019;s third-party contract manufacturer. ADMA BioCenters is the Company&#x2019;s source plasma
              collection business with&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; ten plasma collection facilities
              located throughout the U.S., eight &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;of which hold an approved license with the FDA.&lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;span style="font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company has three FDA-approved products, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin (&#x201c;IVIG&#x201d;) product indicated for the
              treatment of Primary Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary Immunodeficiency Disease (&#x201c;PIDD&#x201d;) or Inborn Errors of Immunity, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in
              August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October
              2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its
              commercially available immunoglobulin products, the Company provides contract manufacturing and laboratory services for certain clients and generates revenues from the sale of intermediate by-products that result from the immunoglobulin
              production process. The Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at
              risk for certain infectious diseases.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of March 31, 2023, the Company had working capital of $227.4 million, including $69.2 &lt;/span&gt;million of cash and cash
              equivalents. Based upon the Company&#x2019;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#x2019;s commercialization and expansion activities, the Company&#x2019;s management currently
              believes that its cash, cash equivalents, projected revenue and accounts receivable will be sufficient to fund ADMA&#x2019;s operations, as currently conducted, through the end of the second quarter of 2024, by which time the Company believes it
              will have begun generating positive cash flow from operations. These estimates may change based upon several factors, including the success of the Company&#x2019;s commercial efforts with respect to the sale of its products, whether or not the
              assumptions underlying the Company&#x2019;s projected revenues and expenses are correct and the acceptability of ADMA&#x2019;s immune globulin products by physicians, patients or payers. There can be no assurance that the Company&#x2019;s approved products will
              be commercially viable, or that plant capacity expansion or other capital improvements will be successfully completed or that any product developed in the future will be approved. The Company is subject to risks common to companies in the
              biologics, biotechnology and pharmaceutical manufacturing industries including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key
              personnel, inflationary pressures, supply chain constraints, protection of proprietary technology and compliance with FDA and other governmental regulations and approval requirements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"&gt;T&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;he
                Company continues to evaluate a variety of strategic alternatives through its ongoing engagement with Morgan Stanley. The exploration of value-creating opportunities remains a top corporate priority for ADMA.&lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_031fdfc61f444092b07221fedfa54d04"
      unitRef="U004">10</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_5b60fa18617a487692f8cc703f2d5d9a"
      unitRef="U004">8</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <adma:NumberOfFDAApprovedProduct
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_53446129f2e5474f80608ef59aff3c5e"
      unitRef="U005">3</adma:NumberOfFDAApprovedProduct>
    <adma:WorkingCapital
      contextRef="c20230331"
      decimals="-5"
      id="Fact_4c06658812404b328b80d471b74113fc"
      unitRef="U002">227400000</adma:WorkingCapital>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="c20230331"
      decimals="-5"
      id="Fact_e65765eb0cfc4a08a4f5865223f909f6"
      unitRef="U002">69200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20230101to20230331"
      id="Text_de030162bc8b448998134934872398f9">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;)
              of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2022 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 23, 2023.&#160; The accompanying consolidated balance sheet as of December 31,
              2022 was derived from the audited financial statements as of and for the year ended December 31, 2022. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8
              of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have
              been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and
              assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March 31, 2023 and its results of operations, changes in stockholders&#x2019; equity and cash flows for the three months
              ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the three months ended March 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts
              presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
              granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts Receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts in
            the amount of $0.1 million at March&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; 31&lt;/span&gt;, 2023 and December 31, 2022, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The



              Company extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an
              ongoing basis.&lt;/span&gt; Based on these evaluations, the Company has concluded that its credit risk is minimal. At &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023, five customers accounted for an aggregate of 98% of the Company&#x2019;s total accounts receivable, and at December 31, 2022, two customers accounted for approximately 92% of the Company&#x2019;s total
            accounts receivable.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct
              and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable
              supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s products relative to the total square
              footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of
              conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160; Goodwill
              at &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and December 31, 2022 was $3.5 million.&#160; All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to the Biotest
              Transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#x2019;s annual
              goodwill impairment test as of October 1, 2022 did not result in a goodwill impairment charge, and the Company did not &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;record any impairment charges related to goodwill for the three months
                ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and 2022, the Company
              determined that there was no impairment of its long-lived assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Revenues for the three months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023&lt;/span&gt;
                and 2022 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;(ii) product revenues from the sale of human plasma collected through the
                Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the
                out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance
                with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a
                period of approximately 22 years.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based
              on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin
              products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other
              wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates,
              control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;,&lt;/span&gt; three customers represented an aggregate of 76% of the Company&#x2019;s consolidated revenues. For the three months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2022, three customers represented an aggregate
              of 83% of the Company&#x2019;s consolidated revenues.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved products,
              intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the
              activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Loss Per Common Share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Basic loss per common share is computed by dividing net loss attributable to common stockholders by the
                weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if
                any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock
                options and warrants, using the treasury stock method, as well as Restricted Stock Units (&#x201c;RSUs&#x201d;). Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be
                anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported
                a net loss for all periods presented. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;For the three months ended &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;March 31&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;"&gt;, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt; and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,945,703&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,686,068&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,875,464&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,729,758&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,525,148&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,631,207&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;28,346,315&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,047,033&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is
              generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
              related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/div&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2018 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by
                the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is
                greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company
                has determined that it has not incurred any liability for unrecognized tax benefits as of March 31, 2023 and December 31,
                2022, and during the three months ended March 31, 2023 and 2022, the Company recognized&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; no
                adjustments for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_1b842d491338428ea527247b3dcb683e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;)
              of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2022 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 23, 2023.&#160; The accompanying consolidated balance sheet as of December 31,
              2022 was derived from the audited financial statements as of and for the year ended December 31, 2022. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q and Article 8
              of Regulation S-X, and therefore omit or condense certain footnotes and other information normally included in complete consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have
              been eliminated in consolidation.&#160; In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and
              assumptions that impact the financial statements) considered necessary to present fairly the Company&#x2019;s financial position as of March 31, 2023 and its results of operations, changes in stockholders&#x2019; equity and cash flows for the three months
              ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the three months ended March 31, 2023 and 2022, comprehensive loss was equal to the net loss amounts
              presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full fiscal year.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20230101to20230331"
      id="Text_8dc991838e454edf8db537076279b401">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, the realizable value of accounts receivable, valuation of inventory, assumptions used in projecting future liquidity and capital requirements, assumptions used in the fair value of awards
              granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/span&gt;&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20230101to20230331"
      id="Text_960edfd623ae41ecbb40cabb46d04a99">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior secured term loan (see Note 7) approximates fair value due to the variable interest rate on this debt.&lt;/span&gt;&lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_1d7ad30ef88342e895d372c263a22966">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts Receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and doubtful accounts in
            the amount of $0.1 million at March&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; 31&lt;/span&gt;, 2023 and December 31, 2022, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The



              Company extends credit to its customers based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an
              ongoing basis.&lt;/span&gt; Based on these evaluations, the Company has concluded that its credit risk is minimal. At &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023, five customers accounted for an aggregate of 98% of the Company&#x2019;s total accounts receivable, and at December 31, 2022, two customers accounted for approximately 92% of the Company&#x2019;s total
            accounts receivable.&lt;/div&gt;
</us-gaap:ReceivablesPolicyTextBlock>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20221231"
      decimals="-5"
      id="Fact_cfab2d27358740db9a85eae8e0318f0a"
      unitRef="U002">100000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20230331"
      decimals="-5"
      id="Fact_9fbbea8fa36e46c5a460641570a41692"
      unitRef="U002">100000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:NumberOfCustomers
      contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="INF"
      id="Fact_78bf5fdf2a604699a853f57695ffc0dc"
      unitRef="U006">5</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="2"
      id="Fact_0af5136c7efb412ebc55f2f32a88e933"
      unitRef="U007">0.98</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="INF"
      id="Fact_fa9f45706d4b4a6590bcd0cf4e417a27"
      unitRef="U006">2</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="2"
      id="Fact_c5bb4b08114e4ff7a9e41821281f6bee"
      unitRef="U007">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_a6c7a7396fa04bec80b800afedb33d14">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs for direct
              and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance, consumable
              supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s products relative to the total square
              footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs associated with the production of
              conformance or engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="c20230101to20230331"
      id="Text_0213f3d0f66b495f8215943a938312e6">
&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company.&#160; Goodwill
              at &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and December 31, 2022 was $3.5 million.&#160; All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment and is related to the Biotest
              Transaction.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year.&#160; The Company&#x2019;s annual
              goodwill impairment test as of October 1, 2022 did not result in a goodwill impairment charge, and the Company did not &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;record any impairment charges related to goodwill for the three months
                ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="c20221231"
      decimals="-5"
      id="Fact_f79119270e7845dd876b490ea8c3034b"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20230331"
      decimals="-5"
      id="Fact_8fb2c4dc9bee48798bb21997549153e0"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_3c189550ae83447e817a2fe8093be0f5"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_bc7b74c485e04e909989644e60dd9b1f"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_545ada14f0fa4349907835c9c9451111">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023 and 2022, the Company
              determined that there was no impairment of its long-lived assets.&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_f65f3194e4f3411c821464e58b6f7048"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_cc9222cb585d436b901d2321f2d48ec2"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_3fb205bcaf1f40118c3c5793f85cc5d1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Revenues for the three months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023&lt;/span&gt;
                and 2022 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, BIVIGAM, ASCENIV and Nabi-HB, &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;(ii) product revenues from the sale of human plasma collected through the
                Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the
                out-licensing of ASCENIV to Biotest in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance
                with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a
                period of approximately 22 years.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenue is recognized when the customer is deemed to have control over the product. Control is determined based
              on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin
              products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, price protection arrangements and customer incentives, including prompt pay discounts, wholesaler chargebacks and other
              wholesaler fees. These estimates are based on historical experience and certain other assumptions, and the Company believes that such estimates are reasonable. For revenues associated with contract manufacturing and the sale of intermediates,
              control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the three months ended &lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2023&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;,&lt;/span&gt; three customers represented an aggregate of 76% of the Company&#x2019;s consolidated revenues. For the three months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 31&lt;/span&gt;, 2022, three customers represented an aggregate
              of 83% of the Company&#x2019;s consolidated revenues.&lt;/div&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <adma:DeferredRevenueRemainingAmortizationPeriod
      contextRef="c20230101to20230331_TypeOfArrangementAxis_BiotestLicenseAgreementMember"
      id="Fact_a821e18e7c8d4e27add102e33df431e0">P22Y</adma:DeferredRevenueRemainingAmortizationPeriod>
    <adma:NumberOfCustomers
      contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="INF"
      id="Fact_4b251da8bcd647d0b7f165f5bb4402d1"
      unitRef="U006">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="2"
      id="Fact_a811fd670ab54d42b8312414824f25ea"
      unitRef="U007">0.76</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="INF"
      id="Fact_b178290194c84c27b8790aad16d6bb57"
      unitRef="U006">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="2"
      id="Fact_95a4e52f604b4c3885bcc11c83e1be0d"
      unitRef="U007">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_6ca79cd1448e48568dbd38122f71c2fe">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA approved products,
              intermediates and the sale of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products. When the
              activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/div&gt;
</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_daa896e121f44c169299ec74eac4e54f">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Loss Per Common Share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Basic loss per common share is computed by dividing net loss attributable to common stockholders by the
                weighted average number of shares of common stock outstanding during the period.&#160; Diluted loss per common share is calculated by dividing net loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if
                any, by the weighted average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock
                options and warrants, using the treasury stock method, as well as Restricted Stock Units (&#x201c;RSUs&#x201d;). Potentially dilutive common stock is excluded from the diluted loss per common share computation to the extent that it would be
                anti-dilutive. As a result, no potentially dilutive securities are included in the computation of any of the accompanying diluted loss per share amounts in the accompanying condensed consolidated financial statements as the Company reported
                a net loss for all periods presented. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;For the three months ended &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;March 31&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;"&gt;, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt; and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,945,703&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,686,068&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,875,464&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,729,758&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,525,148&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,631,207&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;28,346,315&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,047,033&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20230101to20230331"
      id="Text_ab7f841969c94f449bf078e68e34cc98">&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;For the three months ended &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;March 31&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt;"&gt;, 2023&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt; and 2022, the
                following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For the Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022 &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,945,703&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,686,068&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,875,464&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,729,758&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,525,148&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,631,207&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;28,346,315&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,047,033&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_bf5a3c7624b0421294b6356dfb118016"
      unitRef="U001">9945703</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f056fa61cab34068b74393112340514a"
      unitRef="U001">8686068</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_b4756af683ed4195aed24751abbfb8d9"
      unitRef="U001">4875464</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_2ecb69dec99547d39716a1aec878c546"
      unitRef="U001">4729758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_45736de5d542415aa1154fa3c6b401fa"
      unitRef="U001">13525148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_e615d86f57ae41aa9826f425d451538d"
      unitRef="U001">13631207</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_0dcbd75585ae49d3bb1506f1132bb62f"
      unitRef="U001">28346315</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_c42349cd4ca2490caba90853bcf504ed"
      unitRef="U001">27047033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20230101to20230331"
      id="Text_a536cdb4a1e2457ebf1b43140fa12824">
&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions is
              generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense
              related to forfeitures of unvested stock options is fully reversed at the time of forfeiture.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20230101to20230331"
      id="Fact_475316ece6474ec7a06853b791a13749">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20230101to20230331"
      id="Fact_1ac80000485044f4aa252591c1129398">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20230101to20230331"
      id="Text_4e76a2f0cb524e40a7bd3220a1b1553c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2018 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by
                the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is
                greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company
                has determined that it has not incurred any liability for unrecognized tax benefits as of March 31, 2023 and December 31,
                2022, and during the three months ended March 31, 2023 and 2022, the Company recognized&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; no
                adjustments for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20221231"
      decimals="0"
      id="Fact_3c6f65c7c92e49fbabc14928d484db1f"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20230331"
      decimals="0"
      id="Fact_7f358321ebd84922853fd1abcc000f10"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_e942c2c5233d44339db919ed6f249e6e"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_5ab2eab5db4640c0a4c1ce853db1b06a"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_b0ac280d826c42309d29f504917785df">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INVENTORIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;55,747,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,644,527&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,087,760&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,170,853&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;46,149,359&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;58,464,667&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;163,984,873&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;163,280,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials includes plasma and other materials expected to be used in the production of BIVIGAM, ASCENIV and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit. All other activities and materials associated with the production of
            inventories used in research and development activities are expensed as incurred.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#x2019;s
            immunoglobulin products. &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection centers that is expected to be sold to third-party customers.&lt;/div&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_bf83d86f9e0a4222991cdbebd88801ef">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;55,747,754&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,644,527&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,087,760&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,170,853&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;46,149,359&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;58,464,667&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;163,984,873&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;163,280,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="c20230331"
      decimals="0"
      id="Fact_2d34d457b6124f25b65b906e1d6a3b96"
      unitRef="U002">55747754</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20221231"
      decimals="0"
      id="Fact_521767692cd54c1791539f8b12b3b5d3"
      unitRef="U002">48644527</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20230331"
      decimals="0"
      id="Fact_49f2133999b84ab093232b2701426613"
      unitRef="U002">62087760</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20221231"
      decimals="0"
      id="Fact_93477d87adf649a19d47496f71eb41fe"
      unitRef="U002">56170853</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20230331"
      decimals="0"
      id="Fact_042a02e65df74d36aaf611d3b9a896b0"
      unitRef="U002">46149359</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20221231"
      decimals="0"
      id="Fact_d6497a5b9f85488c9d8e9f886b1f02e7"
      unitRef="U002">58464667</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="c20230331"
      decimals="0"
      id="Fact_980f682de67e4587a8c03ea0526072ef"
      unitRef="U002">163984873</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_b72d8c93d4cb4f2c92132f52742a7a50"
      unitRef="U002">163280047</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_f46b388b3a2a480ca88f823b8eb2cec7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,416,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;683,340&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,270,276&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;829,770&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;756,184&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;151,237&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;723,776&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;183,645&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,007,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,172,890&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;834,577&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,007,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,994,052&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,013,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;All of the Company&#x2019;s intangible assets were acquired in the Biotest Transaction. Amortization expense
              related to these intangible assets was $0.2 million for the three months ended March 31, 2023 and 2022. Estimated future
              aggregate amortization expense is expected to be as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;536,514&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;298,063&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_198a34bb24c64972a597f9e24fef66c1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at March 31, 2023 and December 31, 2022 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,416,706&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;683,340&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100,046&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,270,276&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;829,770&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;756,184&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;151,237&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;723,776&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;183,645&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,007,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,172,890&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;834,577&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,007,467&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,994,052&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,013,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_b142be7350dc46018989319caa2d1951"
      unitRef="U002">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_6c470f7e0b5b4990a4686a3e6a68ca9f"
      unitRef="U002">3416706</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_598b71b281fc4100834e3b762665f564"
      unitRef="U002">683340</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_af30414e56764200b4a622796ed1b64e"
      unitRef="U002">4100046</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_2e08ae71786b411ab93439db67e89543"
      unitRef="U002">3270276</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="0"
      id="Fact_5c065f733c7c47d79071b687d9de2e7a"
      unitRef="U002">829770</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_de6ece799bdf4966bf8cf65088951c65"
      unitRef="U002">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_f7ba28f86ba44f6ab88bb969791826aa"
      unitRef="U002">756184</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20230331_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_0578913d955a4388aaa8d526f1a8450b"
      unitRef="U002">151237</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_3870bc08ca464369b992f87f26e9f4ef"
      unitRef="U002">907421</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_7d88f316f6824144a34cf1d77dc7f80f"
      unitRef="U002">723776</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20221231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="0"
      id="Fact_eed44b0536ce45a69e167c819f42fdb5"
      unitRef="U002">183645</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20230331"
      decimals="0"
      id="Fact_234a57eeb3d048cd86051b403d6e5621"
      unitRef="U002">5007467</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20230331"
      decimals="0"
      id="Fact_758873bdcb3f4cf687d50a95e0b99abb"
      unitRef="U002">4172890</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20230331"
      decimals="0"
      id="Fact_44efd124cf7d477cb9c5d8821f93c955"
      unitRef="U002">834577</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20221231"
      decimals="0"
      id="Fact_1a797a3450c147479fa8fa7872060bec"
      unitRef="U002">5007467</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20221231"
      decimals="0"
      id="Fact_6f19060c80e1410290899b776b18fd53"
      unitRef="U002">3994052</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_5be46883f3d645729f059bbfe124e986"
      unitRef="U002">1013415</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_4116e731c5374a47a052e2a92e8e2c69">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;All of the Company&#x2019;s intangible assets were acquired in the Biotest Transaction. Amortization expense
              related to these intangible assets was $0.2 million for the three months ended March 31, 2023 and 2022. Estimated future
              aggregate amortization expense is expected to be as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;536,514&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;298,063&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20220101to20220331"
      decimals="-5"
      id="Fact_65a7bc614d9040c6b6a3c9fcdc3baebf"
      unitRef="U002">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20230331"
      decimals="-5"
      id="Fact_4b3e6aff8c2b4408b8f4bf75481aa17c"
      unitRef="U002">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="c20230331"
      decimals="0"
      id="Fact_f940e9f5d5894e4e9e3c5f65b0b4dff7"
      unitRef="U002">536514</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="c20230331"
      decimals="0"
      id="Fact_02501b664c4649f285d8ea7164f950b3"
      unitRef="U002">298063</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_c58c1d3b3a2e40808b659d66e69f3c99">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;Property and equipment and related accumulated depreciation are summarized as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,828,570&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,767,807&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,939,060&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,318,669&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,662,407&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,109,898&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,515,267&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,726,995&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,514,697&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,930,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,856,505&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,544,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;78,655,947&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;77,738,022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(21,285,164&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(19,476,541&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property, plant and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;57,370,783&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;58,261,481&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#x2019;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from &lt;span style="-sec-ix-hidden:Fact_4342de1675c9405cb8dc40be8462b988"&gt;three&lt;/span&gt; to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company recorded depreciation expense on property and equipment for the three
              months ended March 31, 2023 and 2022 of $1.9 million and $&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.4&lt;span style="color: rgb(0, 0, 0);"&gt; million, respectively.&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20230101to20230331"
      id="Text_593a680e06f44efe9f78af2c2597bdb7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;Property and equipment and related accumulated depreciation are summarized as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,828,570&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,767,807&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,939,060&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,318,669&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,662,407&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,109,898&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,515,267&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,726,995&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,514,697&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;17,930,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,856,505&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;19,544,307&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;78,655,947&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;77,738,022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(21,285,164&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(19,476,541&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property, plant and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;57,370,783&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;58,261,481&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="0"
      id="Fact_4381ec9eb69146a7b6ded74b8862a92a"
      unitRef="U002">19828570</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="0"
      id="Fact_c01caccf89d34729a8ff2c9a8cb90cfd"
      unitRef="U002">18767807</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="0"
      id="Fact_aedd1b1a3adf4ea7a03017bcf30bf182"
      unitRef="U002">5939060</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="0"
      id="Fact_3f513f6217484aafa0bd921692b4c4ae"
      unitRef="U002">5318669</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact_283eea153dc043e08551cdbf652e961f"
      unitRef="U002">5662407</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact_6e75c54251264674af56251ab8ead733"
      unitRef="U002">5109898</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="0"
      id="Fact_e500159dd50d4f799deb69fa59591632"
      unitRef="U002">2515267</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="0"
      id="Fact_95f5a0118f9a4fb68139ee4b1ca494c7"
      unitRef="U002">6726995</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_a347a7edc2604a1abb3cd9f39655549d"
      unitRef="U002">20514697</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact_9c6faa54c0364f2b8eb9a2050d265e4a"
      unitRef="U002">17930905</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="0"
      id="Fact_b68d9c63283247e8b19af5c866fe181a"
      unitRef="U002">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="0"
      id="Fact_a22589e4dad1465a8c12ca444d4b3d26"
      unitRef="U002">4339441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="0"
      id="Fact_6644f2a91a1843199a929973020c21e9"
      unitRef="U002">19856505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="0"
      id="Fact_83da68f762f74c529fcfee12c54ec639"
      unitRef="U002">19544307</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20230331"
      decimals="0"
      id="Fact_8c1b574ebceb466c91533ca010853c96"
      unitRef="U002">78655947</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20221231"
      decimals="0"
      id="Fact_c62855bfb4a940d19484f97925c3ec33"
      unitRef="U002">77738022</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20230331"
      decimals="0"
      id="Fact_c7a4df061f7e4e128948669f3300c241"
      unitRef="U002">21285164</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20221231"
      decimals="0"
      id="Fact_0ce41a39c07c461b9de62a208a07c978"
      unitRef="U002">19476541</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20230331"
      decimals="0"
      id="Fact_7aa94e8510a44158a2b209a0661a95ff"
      unitRef="U002">57370783</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20221231"
      decimals="0"
      id="Fact_20f890a061d446d0bbd7c407105293c0"
      unitRef="U002">58261481</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20230101to20230331_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"
      id="Fact_7a90c5724662448dac546b240cdf9e1b">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20230101to20230331_RangeAxis_MaximumMember"
      id="Fact_5dab68a3af58417694a9f3e8a202739b">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20230101to20230331"
      decimals="-5"
      id="Fact_44dce707cb694a1f995df3dcde8a7d31"
      unitRef="U002">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20220101to20220331"
      decimals="-5"
      id="Fact_1e9e1cd910984b8b9d475e03f82e97dd"
      unitRef="U002">1400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_ba86dceeeabc4c1dba19c743f8d13860">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,129,902&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11,436,484&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,406,033&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,166,896&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,179,600&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,193,919&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;169,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;309,867&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll and other compensation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,745,245&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,086,379&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,041,859&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,795,804&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;22,672,464&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24,989,349&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_6310a76925dc44908412817c735f99a4">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at March 31, 2023 and December 31, 2022 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,129,902&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11,436,484&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,406,033&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,166,896&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,179,600&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,193,919&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;169,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;309,867&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll and other compensation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,745,245&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,086,379&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,041,859&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,795,804&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;22,672,464&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24,989,349&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <adma:AccruedRebatesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_2d8d6ef258404312be938ac34bf0addd"
      unitRef="U002">13129902</adma:AccruedRebatesCurrent>
    <adma:AccruedRebatesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_da6545af9b834d399a86744f1a09ea77"
      unitRef="U002">11436484</adma:AccruedRebatesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_1f7c338b74294c4182143601e4448804"
      unitRef="U002">4406033</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_3aaadfb6cc5a4618b73884d645def646"
      unitRef="U002">3166896</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_0f62571a884541d3b182a3379d5ffeff"
      unitRef="U002">1179600</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_c460a945127c40ef8d3eab26304a9250"
      unitRef="U002">4193919</us-gaap:AccruedBonusesCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_236e06b899cd4a4e97e28bec8a12fdaa"
      unitRef="U002">169825</adma:AccruedTestingCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_3b19311eed7043d182b46a1632ebc3e0"
      unitRef="U002">309867</adma:AccruedTestingCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_56bab8a0ca744761a118592cea38fb92"
      unitRef="U002">1745245</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_d44067eb37304808af273609f6319689"
      unitRef="U002">4086379</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_8ed8710b20cf4e688dbdad8c2d713072"
      unitRef="U002">2041859</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20221231"
      decimals="0"
      id="Fact_c20ccd0344c8496a89b4a1a148bddcae"
      unitRef="U002">1795804</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20230331"
      decimals="0"
      id="Fact_d9ee88aba9574787b61abd43b04a9e8b"
      unitRef="U002">22672464</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20221231"
      decimals="0"
      id="Fact_d646dc143942428a8cc7c4d07f0a6b39"
      unitRef="U002">24989349</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="c20230101to20230331"
      id="Text_c8c0406143ff4d4fa3adaf8468c4a17c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: bold;"&gt;7.&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;DEBT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;155,727,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;154,747,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,426,794&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,914,683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;144,300,930&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;142,833,063&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On March 23,&#160;2022 (the &#x201c;Hayfin Closing Date&#x201d;), the Company and all of its subsidiaries entered into a Credit and Guaranty Agreement (the &#x201c;Hayfin Credit Agreement&#x201d;) with Hayfin
                Services LLP (&#x201c;Hayfin&#x201d;). The Hayfin Credit Agreement provides for a senior secured term loan facility in a principal amount of up to $175.0
                million (the &#x201c;Hayfin Credit Facility&#x201d;), composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0
                million (the &#x201c;Hayfin Closing Date Loan&#x201d;), and (ii) a delayed draw term loan in the principal amount of $25.0 million (the &#x201c;Hayfin
                Delayed Draw Loan&#x201d; and, together with the Hayfin Closing Date Loan, the &#x201c;Hayfin Loans&#x201d;). The obligation of the lenders to make the Hayfin Delayed Draw Loan was to have expired on March 22, 2023 and is subject to the satisfaction of certain conditions, including, but not limited to, the Company&#x2019;s meeting certain 12-month revenue targets as set
                forth in the Hayfin Credit Agreement. The Hayfin Credit Facility has a maturity date of March 23, 2027 (the &#x201c;Hayfin Maturity
                Date&#x201d;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement). &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On March 22, 2023, the Company and Hayfin entered into an amendment to the Hayfin Credit Agreement whereby the lenders&#x2019; obligation to
                make the Hayfin Delayed Draw Loan was extended to June 30, 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On the Hayfin Closing Date, the Company used $100.0 million of
                the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under the Company&#x2019;s previously existing credit facility (the &#x201c;Perceptive Credit Facility&#x201d;) with Perceptive Credit Holdings II, LP (&#x201c;Perceptive&#x201d;).
                The Company also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used
                approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with
                this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#x201c;in kind&#x201d; and was added to the outstanding
                principal balance in accordance with the terms of the Hayfin Credit Agreement. In connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt
                in the amount of $6.7 million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the
                redemption premium paid to Perceptive.&lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;Borrowings under the Hayfin Credit Agreement bear interest, at the Company&#x2019;s election, at either (a) a base rate (equal to the highest of (i) the rate of interest per annum
                last quoted by The Wall Street Journal as the &#x201c;Prime Rate&#x201d; in the United States, (ii) the federal funds rate in effect on such day plus 0.50%
                and (iii) adjusted Term Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) for a one-month tenor in effect on such day plus 1.00%), plus an applicable margin of 8.5%,
                or (b) adjusted Term SOFR for either a one-month or three-month tenor, as elected by the Company, and subject to a floor of 1.25%,
                plus an applicable margin of 9.5% (the &#x201c;Applicable Margin&#x201d;); provided, however, that upon, and during the continuance of, an
                Event of Default, the Applicable Margin increases by an additional 3% per annum. On the last day of each calendar month or
                quarter during the term of the Hayfin Credit Facility, the Company will pay accrued interest to Hayfin. The rate of interest in effect as of March 31,2023 and December 31, 2022&#160; was 14.4% and 13.9%, respectively. The Company is also
                permitted to pay &#x201c;in kind&#x201d; a portion of the interest on the Hayfin Loans for each monthly or quarterly interest period in an amount equal to 2.5%
                per annum, which is added to the principal amount of the outstanding debt under the Hayfin Credit Facility. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For&lt;/span&gt; the three months ending March 31,2023, approximately $1.0 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.&lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;On the Hayfin Maturity Date, the Company will pay Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as
                well as an exit fee of 1.0% of the outstanding principal amount being paid. This exit fee is recorded separately as a
                non-current liability on the accompanying consolidated balance sheets as of March 31,2023 and December 31,2022. Prior to the Hayfin Maturity Date, there are no scheduled principal payments on the Hayfin Loans. The Company may prepay outstanding principal on the Hayfin Loans at any time and from time to time upon &lt;span style="-sec-ix-hidden:Fact_5ecb5c13cda94b628b0011be8e172a1f"&gt;five&lt;/span&gt; business days&#x2019; prior written notice, subject to the payment to Hayfin of, (A) any accrued but unpaid interest on the prepaid principal amount plus (B) an early
                prepayment fee in the amount equal to (i) 7.0% of the prepaid principal amount, if prepaid on or prior to the first anniversary
                of the Hayfin Closing Date, (ii) 3.0% of the prepaid principal amount, if prepaid after the first anniversary of the Hayfin
                Closing Date and on or prior to the second anniversary of the Hayfin Closing Date, or (iii) 1.0% of the prepaid principal
                amount, if prepaid after the second anniversary of the Hayfin Closing Date and on or prior to the third anniversary of the Hayfin Closing Date. In addition, for any prepayments of principal or payment of principal on the Hayfin Maturity
                Date, the Company is also required to pay the exit fee.&lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;All of the Company&#x2019;s obligations under the Hayfin Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#x2019;s tangible
                and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s subsidiaries. The Hayfin Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and
                conditions that are customarily required for similar financings. The negative covenants restrict or limit the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin
                Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or its subsidiaries&#x2019; business activities; make certain
                Investments or Restricted Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;other &lt;/span&gt;indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that
                have the impact of restricting the Company&#x2019;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company is required (i) at all times prior to the Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that
                exceed the amounts set forth in the Hayfin Credit Agreement, which range from $75.0 million for the fiscal quarter ended June
                30,&#160;2022 to $250.0 million for the fiscal quarter ended December 31,&#160;2026. As of March 31,&#160;2023, the Company was in compliance
                with all of the covenants contained in the Hayfin Credit Agreement.&lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;As consideration for the Hayfin Credit Agreement, the Company issued to various entities affiliated with Hayfin, on the Hayfin Closing Date, warrants to purchase an aggregate
                of 9,103,047 shares of the Company&#x2019;s common stock (the &#x201c;Hayfin Warrants&#x201d;). The Hayfin Warrants have an exercise price equal to $1.6478 per share, which is equal to the trailing 30-day
                Volume Weighted-average Price of the Company&#x2019;s common stock on the business day immediately prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $9.6 million as of the Hayfin Closing Date and have an expiration date of March 23, 2029.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and the value of the Hayfin
                Warrants, the Company recognized an aggregate discount on the Hayfin Loans in the amount of $13.9 million. The Company records
                debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. Based on the fair value of the Hayfin Warrants and the aggregate amount
                of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the Hayfin Loans as of March 31,2023 and December 31,&#160;2022 was approximately 16.6% and 16.1%, respectively.&lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; margin-left: 27pt; text-indent: 9pt;"&gt;See Note 14 for discussion of an additional amendment to the Hayfin Credit Facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_113038a69c3c4b0e9deb47d766fca208">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2022&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;155,727,724&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;154,747,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,426,794&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,914,683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;144,300,930&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;142,833,063&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20230331"
      decimals="0"
      id="Fact_fcb36d3c9d95436cb714320f28004118"
      unitRef="U002">155727724</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20221231"
      decimals="0"
      id="Fact_c47c7a5145544370ba72ba371849f1aa"
      unitRef="U002">154747746</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20230331"
      decimals="0"
      id="Fact_e49189797899423686b8b3938c7fb42f"
      unitRef="U002">11426794</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20221231"
      decimals="0"
      id="Fact_a95400604367415ea7e3ffd314aceb1e"
      unitRef="U002">11914683</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20230331"
      decimals="0"
      id="Fact_c16a548d11dd4edd99ed6a6ec9e004e8"
      unitRef="U002">144300930</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20221231"
      decimals="0"
      id="Fact_49d61dd3ca5c4a358b7b5d13a9a0de31"
      unitRef="U002">142833063</us-gaap:SeniorLongTermNotes>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember"
      decimals="-5"
      id="Fact_a9641ae020244e5da4847a57ffc293f4"
      unitRef="U002">175000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_1cde708ded3641e88f10932f96e87c0a"
      unitRef="U002">150000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"
      decimals="-5"
      id="Fact_ebf3fb1b78c8491e87ae171a65fcb083"
      unitRef="U002">25000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"
      id="Fact_78b0dcc7209b4c0d913d4ab786f2ae15">2023-03-22</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember"
      id="Fact_b8dd537d34f349c18c39d3244efe7c61">2027-03-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_d1e68345a7db439193b393c68a29b784"
      unitRef="U002">100000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_16383f29eb5d481891afd14a04e94164"
      unitRef="U002">2000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_ac50e8813f4c4fef9dfe5f3f939e9470"
      unitRef="U002">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <adma:DebtInstrumentUpfrontFeePaidInKind
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_ac99ee091f704bea9013683e53b1f172"
      unitRef="U002">1800000</adma:DebtInstrumentUpfrontFeePaidInKind>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_150377055ead4b22a544db11793d89fd"
      unitRef="U002">-6700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_FederalFundsEffectiveSwapRateMember"
      decimals="4"
      id="Fact_45f895148fb84101817f7c6ad3d951dd"
      unitRef="U007">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      id="Fact_8f8b66f0cb5e49899ba112a3b5a6280d">P1M</adma:DebtInstrumentTermOfVariableRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      decimals="4"
      id="Fact_f1dfcc79263941a3bb20782bd24c26cb"
      unitRef="U007">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      decimals="3"
      id="Fact_a4500fc57c9347a4a167d14455c5f402"
      unitRef="U007">0.085</adma:DebtInstrumentApplicableMargin>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      id="Fact_d87e9e34443d430b9e2f596596745b98">P1M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      id="Fact_fda2f9efe7194d2f97edde559195e333">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentFloorInterestRate
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember"
      decimals="4"
      id="Fact_d0bef17cd8294ce3a8e10f2fa2677aea"
      unitRef="U007">0.0125</adma:DebtInstrumentFloorInterestRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_76064f1e6e1f4f69956fb70e1e3efb4b"
      unitRef="U007">0.095</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="2"
      id="Fact_58655071fdfb4015b3851747c518593d"
      unitRef="U007">0.03</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="3"
      id="Fact_d43820058cb14f37b3d613c89f129df4"
      unitRef="U007">0.144</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="3"
      id="Fact_83e68a911c3f4e189b1bcb271d50f1b8"
      unitRef="U007">0.139</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adma:DebtInstrumentInterestAmountToBePayInKind
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_f3fba596db074f2c99098c82999923d2"
      unitRef="U007">0.025</adma:DebtInstrumentInterestAmountToBePayInKind>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_81a2b8669d0141bb8b2f4a322c0bfd5c"
      unitRef="U002">1000000</us-gaap:PaidInKindInterest>
    <adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_b7d7483c6757441bb6107f3f4e1d8176"
      unitRef="U007">0.01</adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-6"
      id="Fact_3e17b499c53446489c2059d44f848ae3"
      unitRef="U002">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"
      decimals="3"
      id="Fact_1eb80172398b447d960459a2852ce6dd"
      unitRef="U007">0.07</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"
      decimals="3"
      id="Fact_759fcbb0fe47407cb4dc631898bbb604"
      unitRef="U007">0.03</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember"
      decimals="3"
      id="Fact_f3974a5b12564abfa57b2bc5ac1d8f88"
      unitRef="U007">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:Cash
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_7a9dc232ae404931b5b587e15f8ca3c5"
      unitRef="U002">6000000</us-gaap:Cash>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_64b18c68f468478eb1977f96000cefef"
      unitRef="U002">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20261001to20261231_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember_StatementScenarioAxis_ScenarioForecastMember"
      decimals="-5"
      id="Fact_74ff21d9ac2c47eab9c170e93fcad207"
      unitRef="U002">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:SharesIssuedUponExerciseOfWarrants
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="0"
      id="Fact_f9c543c53ef84ecaa7e33e494d71fdc5"
      unitRef="U001">9103047</adma:SharesIssuedUponExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="4"
      id="Fact_72404f5ccbd047ff8182de4ead9e4b7d"
      unitRef="U003">1.6478</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adma:TrailingPeriodForVolumeWeightedAveragePrice
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      id="Fact_f344dbea5a2c4dd3aec9029fda8ac4b2">P30D</adma:TrailingPeriodForVolumeWeightedAveragePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_524515b3c29c4b1ea760e7de8280b193"
      unitRef="U002">9600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      id="Fact_c074ac2f22004c1e883b0fcce021ea04">2029-03-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20220323"
      decimals="-5"
      id="Fact_2a4ed928ded0448a874422150b3a24f4"
      unitRef="U002">13900000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_9971d5f1e8304944a23a89a764162457"
      unitRef="U007">0.166</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_90beff2c86b24c29b9c843b52535255c"
      unitRef="U007">0.161</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_5ecaf0c606624acda2de24059b4958ef">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par value per share.
              There were no shares of preferred stock outstanding at March 31, 2023 and December 31, 2022.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of March 31, 2023 and December 31, 2022, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001
              par value per share, and 222,262,588 and 221,816,930 shares of common stock were outstanding as of March 31, 2023 and December 31, 2022, respectively. After giving effect to the 48,356,592 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#x2019;s equity incentive plans, as of March 31, 2023
              there were 29,380,820 shares of common stock available for issuance.&lt;br/&gt;
              &lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &#160; &lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In connection with the Hayfin Credit Agreement that the Company entered into on March 23, 2022 (see Note 7), the
              Company issued the Hayfin Warrants to purchase 9,103,047 shares of the Company&#x2019;s common stock. The Hayfin Warrants were valued at
              $9.6 million using the Black-Scholes option-pricing model assuming an expected term of seven years, a volatility of 68.1%, a dividend yield of 0% and a risk-free rate of interest of 2.36%.
              At March 31, 2023 and December 31,2022, the Company had outstanding warrants to purchase an aggregate of 13,525,148 shares of
              common stock, with a weighted-average exercise price of $1.99 per share with expiration dates ranging between May 2023 and
              December 2030 (see Note 14).&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
             &#160; &lt;br/&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The fair value of stock options granted under the Company&#x2019;s equity incentive plans was determined on the
                date of grant using the Black-Scholes option valuation model. The Black-Scholes model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition,
                option valuation models require the input of certain subjective assumptions including the expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of
                traded options, and changes in the subjective input assumptions can materially affect the fair value estimate. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2023 and 2022:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
            &#160; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.20-4.24&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.72-1.73&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&#160; &lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;On June 21, 2022, the
                Company&#x2019;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#x201c;2022 Equity Plan&#x201d;), which replaced the ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan.&#160; Approval of the 2022 Equity Plan resulted in
                approximately 18 million additional shares of the Company&#x2019;s common stock being reserved for future awards. &lt;/span&gt;During the
              three months ended March 31, 2023 and 2022, the Company granted options to purchase an aggregate of 1,727,510 and 1,194,032 shares of common stock, respectively, to its directors and employees.&#160; The weighted average remaining contractual life of stock options
              outstanding and expected to vest at March 31, 2023 is 6.6 years. The weighted average remaining contractual life of stock
              options exercisable at March 31, 2023 is 5.3 years. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;During
                the three months ended March 31, 2023, options to purchase 5,416 shares of common stock were exercised in a cashless transaction
                resulting in the issuance of 2,443 shares of common stock.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as
              follows:&lt;/div&gt;

&lt;div&gt;
            &#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Weighted &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Average &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,256,211&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.37&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,555&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.29&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,047&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.06&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,727,510&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.35&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;(5,416&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;2.08&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,945,703&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.36&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,660,313&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.67&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of March 31, 2023, the Company had $5.6 million of unrecognized compensation expense related to options granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average
              period of 3.0 years.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &#160; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;During the three months ended March 31, 2023 and 2022, the Company granted RSUs representing an aggregate
                of 2,666,260 and 1,059,266
                shares, respectively, to certain employees of the Company and to members of its Board of Directors&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;. These RSUs generally vest annually over a period&lt;span style="font-variant: normal; text-transform: none;"&gt; of four years for employees and semi-annually over a period of one year for directors&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; During the &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;three months ended March 31, 2023&lt;/span&gt;, an aggregate of 628,283
                shares of common stock vested in connection with grants of RSUs. With respect to these vested RSUs, 185,068 shares valued at
                approximately $0.6 million were withheld by the Company to cover employees&#x2019; tax liabilities. These shares were no longer
                outstanding as of &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March
                    31, 2023&lt;/span&gt;&lt;/span&gt;. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;A
                summary of the Company&#x2019;s unvested RSU activity and related information is as follows:&lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Weighted &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Average Grant&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,866,987&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.59&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,666,260&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.35&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(628,283&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.76&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(29,500&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.25&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,875,464&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.53&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;March 31, 2023&lt;/span&gt;&lt;/span&gt;, the Company had $12.0 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a
              weighted-average period of 3.4 years.&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&lt;/span&gt; &lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three
              months ended March 31, 2023 and 2022 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,385&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,671&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;23,055&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,052&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;978,124&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,517,602&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;103,602&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;98,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,110,166&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,641,388&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20221231"
      decimals="-6"
      id="Fact_6148f1619d4d4af8866241695b9e89fd"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20230331"
      decimals="-6"
      id="Fact_2cc258f189594bd1bfdfbefcee2aa432"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="4"
      id="Fact_e266a99f1b614d429d1c4a39756f751b"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_3f0785c459d84156a90607d414818e93"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20230331"
      decimals="INF"
      id="Fact_407b812d081740ee83ec7aa2358211c6"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20221231"
      decimals="INF"
      id="Fact_3f0f3064d1b14c959dcb73ca5523d2ad"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20221231"
      decimals="0"
      id="Fact_a046785ef18a437198ed297a9d5b7db8"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20230331"
      decimals="0"
      id="Fact_3b9e44eb949042d2ae26365247588421"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20230331"
      decimals="4"
      id="Fact_66f73f0e4eb3476393c5d4095002c914"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20221231"
      decimals="4"
      id="Fact_50fec3bead3a4ca7a88ed6e40c49194e"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_441f449bd9ac48e4ad39a873bda7f2b6"
      unitRef="U001">222262588</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20221231"
      decimals="0"
      id="Fact_2c6accfe3e0d4da3b6d9344e407213a9"
      unitRef="U001">221816930</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20230331"
      decimals="0"
      id="Fact_727f47289d314df8921bbd058ddffb77"
      unitRef="U001">48356592</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20230331"
      decimals="0"
      id="Fact_82baa76c618a428fad8740745caf2e7f"
      unitRef="U001">29380820</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="0"
      id="Fact_f428b0ea7b534a4196d7b030cd4dab8d"
      unitRef="U001">9103047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_8335c214c487470ab23e3680a7e50d5c"
      unitRef="U002">9600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_CounterpartyNameAxis_HayfinCreditAgreementMember"
      id="Fact_42f0e33974714447b220b4e846accef7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_8fdf8ce1691a498482cca65b0a7b0862"
      unitRef="U007">0.681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="2"
      id="Fact_a0c5c5cf2cd8452696c515e71704f320"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="4"
      id="Fact_e69854533be24024b1ac02d3e1437b52"
      unitRef="U007">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c9f00ccef15e493d800f48de7609fdc4"
      unitRef="U001">13525148</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_8604e95ee0184bd09bf477fc3d5b72e7"
      unitRef="U001">13525148</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20230331"
      decimals="2"
      id="Fact_cfc2b564eb4344d18277a08a980b6321"
      unitRef="U003">1.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20221231"
      decimals="2"
      id="Fact_63b91e2af63a4861ab46d42a6fcf46fb"
      unitRef="U003">1.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_91b9573094e44c8f81d6558493652ebe">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;The following assumptions were used to determine the fair value of options granted during the three months ended March 31, 2023 and 2022:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
            &#160; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                      &lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.20-4.24&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.72-1.73&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;%&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_473ac0f0030843c29a48fe34c056128f">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_4b4b926eb239435c92ad52d7be99b429">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_a7d8abb2dd2d4764b0c3a81e823cc8bd">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_a4734cfb5d014ec48b8be311a9601004">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_6821d8848d6c4f039848cf5721df3d0e"
      unitRef="U007">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_8823310d38ba4e259e1451f2d5cc7e9f"
      unitRef="U007">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_38140635326c4da9ac4a72fdc1432b7e"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_f4953db0b85a4a90ac70dae5ff6f2294"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_43174049f52a4cc59d32b04cd55da070"
      unitRef="U007">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_172b5386ff5a41babb48025d4999dc22"
      unitRef="U007">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_3e9df7be035d41f788a4d5a3749f1e45"
      unitRef="U007">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_1ce561a689e34c36b160d4e7653fa3be"
      unitRef="U007">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20220621_PlanNameAxis_Two022CompensationPlanMember"
      decimals="-6"
      id="Fact_b3c7212a503a4445bf12af8c988b5ec5"
      unitRef="U001">18000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_06f01f65f4e44445ac037a4ef76d98f1"
      unitRef="U001">1727510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20220331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_04afc859757d4c06baf6ecf37c9aeef8"
      unitRef="U001">1194032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_ec77ed4127b04edb99b57f1faf82a8cb">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_b2bd3c79df8b4333a5ec2522d5fb5ba8">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_f401657979dc4ee8b4bf72fd035a1f4c">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_14a2ed725dc84076889a7954444b8e99"
      unitRef="U001">5416</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_4488de17cbd247ee98cde51e112076c2"
      unitRef="U001">2443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_619c0196e81947b1af4e026299b00e41">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as
              follows:&lt;/div&gt;

&lt;div&gt;
            &#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Weighted &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Average &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,256,211&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.37&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,555&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.29&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,047&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.06&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,727,510&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.35&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;(5,416&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;2.08&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,945,703&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.36&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,660,313&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.67&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_25e7337318414c89a428e1b19b42b681"
      unitRef="U001">8256211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_3319708b964d406e9b1e5a4535a95319"
      unitRef="U003">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f6489c7676fb4ddf9cc09c13a2792787"
      unitRef="U001">15555</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_2f1f43aeb041426791db13b4878ecf14"
      unitRef="U003">2.29</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_a7fa45effef1422cb5dfc931ba325f49"
      unitRef="U001">17047</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_56c8a4f324e34217a6f797e9316b5e83"
      unitRef="U003">7.06</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c5b88ccb8eec493aa8b33637d1911eb2"
      unitRef="U001">1727510</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_f1e9f901cef4414bbda6b9ac0e5be636"
      unitRef="U003">3.35</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_5016699cc900467ba5d927a12cf12385"
      unitRef="U001">5416</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_eea81ecb589649abbafc1fe30bb274c6"
      unitRef="U003">2.08</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_eb2597933319447fba5ff42635e0fd81"
      unitRef="U001">9945703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_bd6e25cb95a14cfa89698d85c74f5e9d"
      unitRef="U003">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_5bc64833a0c1493ba7c44101723a051a"
      unitRef="U001">6660313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_1a9db572936b44f1aa32b2461a170cf8"
      unitRef="U003">3.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_7ed2a0340a9a48e58b9be44815ff08c4"
      unitRef="U002">5600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20230101to20230331_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_2e9d97e87a744b6f85fa18fc2cdef9ab">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_42c7c49a3ea44c8b8de8390f2e73c9ec"
      unitRef="U001">2666260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20220101to20220331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_46fadf1fefe14e3fa72bf32a2fefbca9"
      unitRef="U001">1059266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"
      id="Fact_a8e2c17260254c9c924f8af68977cc43">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_7804c9f805744bfabcdbe7505cf5fe7b">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ec480c04c85d46c38b3fc005607426a2"
      unitRef="U001">628283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_9922205a4b424dcca98bb0084b7e48b7"
      unitRef="U001">185068</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_59e019bcd33e42e2b345f5fdb0cce604"
      unitRef="U002">600000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_71b5a908ff2b4457976debb0a68ec1ca">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;A
                summary of the Company&#x2019;s unvested RSU activity and related information is as follows:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Weighted &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Average Grant&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2022&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,866,987&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.59&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,666,260&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.35&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(628,283&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.76&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(29,500&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.25&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,875,464&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.53&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_65f67c03386f4d369b00a49851dd37be"
      unitRef="U001">2866987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_85905970f8dd4decaa82cc07ff786ce2"
      unitRef="U003">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ca69bc415d7b47738a66578202a0f985"
      unitRef="U001">2666260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_76431cc418784863896d14f84f14bf9a"
      unitRef="U003">3.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_0a727f5d64504bc68cbeec7bfb27a05c"
      unitRef="U001">628283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_1ef195ac4c084888b9f567078be07388"
      unitRef="U003">1.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_5fc0ea8813994a9a885df1baa3152643"
      unitRef="U001">29500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_8b30b82d06a142c4857578632d1b29fa"
      unitRef="U003">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_760bd1a1f22749cb925f25da6a242cbe"
      unitRef="U001">4875464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_84f337121311474d885f9cc13dbfcab1"
      unitRef="U003">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_821c5235207a4d4282868b95e36e92da"
      unitRef="U002">12000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20230101to20230331_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_d7c6246721de4dd392193caba756695b">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_0cfebe5db0554c4a8d6b82f250a91866">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three
              months ended March 31, 2023 and 2022 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                      &lt;/span&gt; &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,385&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,671&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;23,055&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,052&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;978,124&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,517,602&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;103,602&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;98,063&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 67.86%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,110,166&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.61%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.81%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,641,388&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1.32%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_aedf9500aff549b7ad9ca08d0a685181"
      unitRef="U002">5385</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Fact_93da4be6d8f44c7abb248d80d07698cd"
      unitRef="U002">4671</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_0b74025b985044469546e6ede8f892ec"
      unitRef="U002">23055</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="0"
      id="Fact_ce16641e4b77464bbb8a55a8ce2b73ef"
      unitRef="U002">21052</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_7a44d39cde314d6fbca2b4fbb90d3cf0"
      unitRef="U002">978124</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="0"
      id="Fact_366cfc8f370f4946a34ede7141df09c8"
      unitRef="U002">1517602</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_b57b7ad2a48e49869d45a09685b8dd40"
      unitRef="U002">103602</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="0"
      id="Fact_2d397230a3f542bf980e4871a9f1dead"
      unitRef="U002">98063</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_3d15b40761384452b3f03c941ce9d3c1"
      unitRef="U002">1110166</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_08d3dd33248e4e6195db11a4ff5f2b12"
      unitRef="U002">1641388</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_c780bfd708e44e8fa86486118498f0cb">
&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;  &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;&lt;span style="text-decoration: underline;"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company leases an office building and equipment from Areth, LLC (&#x201c;Areth&#x201d;)
        pursuan&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;t to an agreement for services
          effective as of January 1, 2016, as amended from time to time&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, and pays monthly rent on this facility in the amount of $10,000 through December 31, 2026&lt;/span&gt;. Rent expense for the three months ended March 31, 2023 and 2022 amounted to $30,000 (see&lt;/span&gt; Note 12). Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#x2019;s Board of Directors, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive
        Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the three months
        ended March 31, 2023 and 2022. &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;During the &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;three months ended March 31, 2023 and 2022, the Company purchased certain specialized medical equipment and
          services primarily related to the Company&#x2019;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#x201c;Genesis&#x201d;), aggregating to $0.1 million and $43,000, respectively. Genesis is owned by Dr.
          Grossman and Adam Grossman.&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;See Note 7 for a discussion of the Company&#x2019;s former credit facility and related
        transactions with Perceptive, a holder of more than 5% of the Company&#x2019;s common stock during&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; the three months ended March 31, 2022. There were no transactions with Perceptive
          during the three months ended March 31, 2023.&lt;/span&gt;&lt;br class="Apple-interchange-newline"/&gt;
      &lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20160101to20160131_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"
      decimals="0"
      id="Fact_89da785ebbf342e7931b4ec9afeef58f"
      unitRef="U002">10000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"
      decimals="0"
      id="Fact_281c722cca424cf3915d23ec0c4269b5"
      unitRef="U002">30000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_ArethLLCMember"
      decimals="0"
      id="Fact_104d285391014103b76b2b0386a39ccc"
      unitRef="U002">30000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20230101to20230331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"
      decimals="-5"
      id="Fact_723420fd7a9449be9c9b9b432233e5d5"
      unitRef="U002">100000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20220101to20220331_RelatedPartyTransactionsByRelatedPartyAxis_GenesisBPSMember"
      decimals="0"
      id="Fact_02a9473ca8c94c9281e72d6d39b5ab6c"
      unitRef="U002">43000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <adma:MinimumPercentageOfCommonStockHeldByLender
      contextRef="c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember"
      decimals="2"
      id="Fact_38bf9630d6e44419af753fcf4a8b8099"
      unitRef="U007">0.05</adma:MinimumPercentageOfCommonStockHeldByLender>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_4473a060a68a403d939a6af745d8e9bf">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;General Legal Matters&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;From time to time, the Company is or may become subject to certain legal proceedings and claims arising in connection
            with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s liquidity, results of operations or financial condition.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company continues to monitor the ongoing developments related to the COVID-19 pandemic, including the emergence of
            the Delta, Omicron and BA.2 variants and other resistant strains of the coronavirus, and its impacts to the Company&#x2019;s commercial and manufacturing operations and plasma collection facilities, including collections of source plasma, procurement
            of raw materials and packaging materials, a portion of which are sourced internationally, and the testing of finished drug product that is required prior to its availability for commercial sale. A substantial portion of such testing has
            historically been performed by contract laboratories outside the United States.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Due to a combination of previously mandated state and local &#x201c;shelter-in-place&#x201d; orders, as well as government stimulus
            packages, persisting social distancing measures and varying roll-outs of vaccinations by state, the Company at times experienced lower than normal donor collections at its FDA approved plasma collection centers &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;during 2021 and part of 2022. From time to time during 2021 and 2022, t&lt;/span&gt;he Company was also subject to delays in shipments of source plasma from its contracted third-party suppliers, as well as
            delays in deliveries for personal protective equipment, reagents and other non-plasma raw materials and supplies used in the manufacture and distribution of its products. In addition, the Company has been subject to supply chain delays as a
            result of certain of its suppliers diverting significant resources towards the rapid development and distribution of COVID-19 vaccines and, as a result, the Company has elected to carry more raw materials inventory than it has in the past. The
            COVID-19 pandemic previously impacted, to a certain degree, the Company&#x2019;s customer engagement initiatives, whereby ADMA&#x2019;s sales and medical affairs field personnel faced difficulties communicating directly with physicians and other healthcare
            professionals, as well as the cancellation or postponement of a number of key scientific and medical meetings, further limiting the Company&#x2019;s ability to communicate with potential customers.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The pandemic could also impact the Company&#x2019;s ability to interact with the FDA or other regulatory authorities and could result in delays in the conduct of inspections
              or review of pending applications or submissions. Although the Company has received &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;FDA approvals for five of its plasma collection centers since January 1, 2022 and&lt;/span&gt; &lt;/span&gt;received several other FDA approvals while two FDA inspections of the Boca Facility were completed during the year ended December 31, 2021, no assurances can be provided as to the timing for completion of any
              future regulatory submissions or applications that may be impacted by restrictions related to COVID-19.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the three months ended March 31, 2023 and 2022, revenue attributable to international customers was
              approximately 7% and 6%,
              respectively, of the Company&#x2019;s total revenues. As the Company seeks to grow this aspect of its business, it may also be subject to the impacts of the COVID-19 pandemic in locations outside the United States.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Notwithstanding the foregoing, the COVID-19 pandemic to date has not had a material impact on the Company&#x2019;s financial
            condition or results of operations, and the Company does not believe that its production operations at the Boca Facility, the Company&#x2019;s contract fill/finishers or its plasma collection facilities have been significantly impacted by the COVID-19
            pandemic. As a result, the Company does not anticipate and has not experienced any material impairments with respect to any of its long-lived assets, including the Company&#x2019;s property and equipment, goodwill or intangible assets.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Although the COVID-19 pandemic has not, to date, materially adversely impacted the Company&#x2019;s capital and financial
            resources, because the Company is unable to determine the ultimate severity or duration of the COVID-19 pandemic or other pandemics or their long-term effects on, among other things, the global, national or local economies, the capital and
            credit markets or the Company&#x2019;s workforce, customers or our suppliers, at this time the Company is unable to predict whether COVID-19 or other pandemics will have a material adverse impact on the Company&#x2019;s business, financial condition,
            liquidity or results of operations.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Vendor Commitments&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Pursuant to the terms of a plasma purchase agreement with BPC dated as of November 17, 2011 (the &#x201c;2011 Plasma Purchase
            Agreement&#x201d;), the Company agreed to purchase from BPC an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
            volume from BPC, but may also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection facilities. During
            2015, the Company and BPC amended the 2011 Plasma Purchase Agreement to allow the Company the ability to collect its raw material RSV high-titer plasma from other third-party collection organizations, thus allowing the Company to expand its
            reach for raw material supply as it executes its commercialization plans for ASCENIV. As part of the closing of the Biotest Transaction, the parties amended the 2011 Plasma Purchase Agreement to extend the initial term through the ten-year anniversary of the closing date of the Biotest Transaction. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June
            2027, after which it may be renewed for two additional five-year periods if agreed to by the parties. On December 10, 2018, BPC assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations
            Limited (&#x201c;Grifols&#x201d;) as its successor-in-interest, effective January 1, 2019. On January 1, 2019, Grifols and the Company entered into an additional amendment to the 2011 Plasma Purchase Agreement for the purchase of source plasma containing
            antibodies to RSV from Grifols. Pursuant to this amendment, until January 1, 2022, the Company could purchase RSV plasma from Grifols from the two
            plasma collection centers that were transferred to BPC on January 1, 2019 at a price equal to cost plus five percent (5%) (without any additional increase due to inflation). Effective January 1, 2022, RSV plasma purchased from these two plasma collection centers are subject to the pricing terms in effect for RSV plasma purchased from other plasma collection centers owned by
            Grifols.&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Supply Agreement pursuant to which BPC supplies, on an
            exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July 19, 2018, the Company and BPC entered into an amendment to the Plasma Supply Agreement to provide, among other things, that in
            the event BPC elects not to supply in excess of ADMA BioManufacturing&#x2019;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit
            percentage of the price that ADMA BioManufacturing pays to BPC, then BPC shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, BPC assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 2019.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company and BPC entered into a Plasma Purchase Agreement (the &#x201c;2017 Plasma Purchase Agreement&#x201d;),
            pursuant to which ADMA BioManufacturing purchases normal source plasma (&#x201c;NSP&#x201d;) from BPC at agreed upon annual quantities and prices. On July 19, 2018, the Company and BPC entered into an amendment to the 2017 Plasma Purchase Agreement to, among
            other things, provide agreed upon amounts of normal source plasma to be supplied by BPC to ADMA BioManufacturing in calendar year 2019 at a specified price per liter, provided that ADMA BioManufacturing delivers a valid purchase order to BPC.
            Additionally, pursuant to the amendment to the 2017 Plasma Purchase Agreement, BPC agreed that, for calendar years 2020 and 2021, it shall supply no less than a high double-digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts,
            provided that such requested NSP amounts are within an agreed range, at a price per liter to be mutually determined. Furthermore, pursuant to the amendment to the 2017 Plasma Purchase Agreement, in the event BPC fails to supply ADMA
            BioManufacturing with at least a high double-digit percentage of ADMA BioManufacturing&#x2019;s requested NSP amounts, BPC shall promptly reimburse ADMA BioManufacturing the difference in price ADMA BioManufacturing incurs due to BPC&#x2019;s election not to
            supply NSP to ADMA BioManufacturing in such amounts as requested. On December 10, 2018, BPC assigned its rights and obligations under the Plasma Purchase Agreement to Grifols, effective January 1, 2019. &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Effective as of May 12, 2021, the Company and Grifols amended the foregoing 2017 Plasma Purchase Agreement whereby, among other things, the term of the agreement was
              extended through December 31, 2022, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;however Grifols&#x2019; commitment
                to supply the Company with NSP under this agreement was not satisfied until March of 2023&lt;/span&gt;. In order to maintain a reliable supply of raw material plasma thereafter, the Company has executed additional agreements with multiple
              third-party suppliers of NSP to supplement the 2017 Plasma Purchase Agreement. The Company has also increased its number of planned plasma collection center buildouts such that the Company expects to have ten FDA-approved plasma collection centers in operation by the end of 2023, while also continuing to increase its plasma collection capabilities
              at its ADMA BioCenters plasma collection centers business segment.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Through December 31, 2022, the&lt;/span&gt;
            Company purchased substantially all of its raw material plasma from Grifols. For the three months ended March 31, 2023, plasma purchases from Grifols totaled $11.6 million, or approximately 40% of the Company&#x2019;s total inventory
            purchases. For the three months ended March 31, 2022, plasma purchases from Grifols totaled approximately $15.5 million, representing
            approximately 75% of the Company&#x2019;s total inventory purchases.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Post-Marketing Commitments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with
            the approval of the BLA for BIVIGAM, on December 19, 2012, Biotest committed to perform two additional post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a
            post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in BIVIGAM-treated patients with primary humoral immunodeficiency. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The pediatric study for BIVIGAM has been completed, and the safety study has been completed pending a clinical study report to
              the FDA&lt;/span&gt;. ADMA has assumed the remaining obligations, and the costs of the studies will be expensed as incurred as research and development expenses. For the three months ended March 31, 2023 and 2022, the Company incurred expenses
            related to these studies of $0.4 million. The Company currently expects to incur expenses of&#160; approximately $1.5 million to $2.0 million to
            complete the safety study, which is required to be completed by June of 2023.&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with
            the FDA&#x2019;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the three months ended March 31, 2023 and 2022, the Company
            incurred expenses related to these studies in the amount of $0.2 million and $0.1 million, respectively. The Company expects to incur expenses of approximately $1.5 million to complete this study, which is currently required to be completed by June of 2023. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company has submitted an extension request to the FDA.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Employment Contracts&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company has entered into employment agreements with Mr. Grossman and with Brian Lenz, its Executive Vice President,
            Chief Financial Officer and General Manager, ADMA BioCenters.&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
           &lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt; &lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-style: italic;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Other Commitments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is
            unknown as of March 31, 2023. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilitiesApproved
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_198cd67edccb4c8ca1bab6db0498e936"
      unitRef="U004">5</adma:NumberOfFDALicensedPlasmaCollectionFacilitiesApproved>
    <adma:NumberOfFDAInspections
      contextRef="c20210101to20211231"
      decimals="INF"
      id="Fact_eae5538634cf4fde9e72aa4704ccdfd2"
      unitRef="U004">2</adma:NumberOfFDAInspections>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20230331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember"
      decimals="2"
      id="Fact_ab52f13454084277b4a14d6c31060815"
      unitRef="U007">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20220101to20220331_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_InternationalCustomersMember"
      decimals="2"
      id="Fact_3d6a4261879443e794c3a35b548ff4b9"
      unitRef="U007">0.06</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c20230101to20230331_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_ce732eded190416dbdfc77722e4e6dff"
      unitRef="U004">5</adma:NumberOfPlasmaCollectionFacilities>
    <adma:PlasmaPurchaseAgreementTerm
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      id="Fact_501ecfdcddaa474991fa1c349d30a1f7">P10Y</adma:PlasmaPurchaseAgreementTerm>
    <adma:NumberOfRenewalTerms
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_8347d0a47967428f861c361edf8658b4"
      unitRef="U009">2</adma:NumberOfRenewalTerms>
    <adma:PlasmaPurchaseAgreementRenewalPeriod
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      id="Fact_c01546d85f4d47ccbbf445b78ba26355">P5Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_5acd5a659e6842959f033a3e4234348a"
      unitRef="U010">2</adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity>
    <adma:PercentageOfPlasmaPurchasePriceEqualToCost
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="2"
      id="Fact_4d8d467429f5490bbdd4a5da986890af"
      unitRef="U007">0.05</adma:PercentageOfPlasmaPurchasePriceEqualToCost>
    <adma:PercentageOfPlasmaPurchasePriceEqualToCost
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="2"
      id="Fact_4050a02fd1c94bb28345e9bedf0b9fd5"
      unitRef="U007">0.05</adma:PercentageOfPlasmaPurchasePriceEqualToCost>
    <adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_c15d536757ea42e0b82c3479e024b7e0"
      unitRef="U010">2</adma:NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity>
    <adma:PlasmaSupplyAgreementTerm
      contextRef="c20230101to20230331"
      id="Fact_9a329f5292134d8b8f01ce4bd8f701fd">P10Y</adma:PlasmaSupplyAgreementTerm>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c20230101to20230331_TypeOfArrangementAxis_PlasmaPurchaseAgreementTwoMember"
      decimals="INF"
      id="Fact_78dfde90b4e74057bcec1e23690d6c06"
      unitRef="U004">10</adma:NumberOfPlasmaCollectionFacilities>
    <adma:PlasmaPurchased
      contextRef="c20230101to20230331"
      decimals="-5"
      id="Fact_e4c3bfd3b6734ef09677e8ee45ed7c9b"
      unitRef="U002">11600000</adma:PlasmaPurchased>
    <adma:PercentageOfInventoryPurchases
      contextRef="c20230101to20230331"
      decimals="2"
      id="Fact_7553125fb9c34038a49a31fc63f98be9"
      unitRef="U007">0.40</adma:PercentageOfInventoryPurchases>
    <adma:PlasmaPurchased
      contextRef="c20220101to20220331"
      decimals="-5"
      id="Fact_7defc904079541e8aaa61f9587d5d124"
      unitRef="U002">15500000</adma:PlasmaPurchased>
    <adma:PercentageOfInventoryPurchases
      contextRef="c20220101to20220331"
      decimals="2"
      id="Fact_e3350024fc7a4d0c89a3ddd6a47de8df"
      unitRef="U007">0.75</adma:PercentageOfInventoryPurchases>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230331_ProductOrServiceAxis_BIVIGAMMember"
      decimals="-5"
      id="Fact_d5166901d9d94b9e9c36a0bce66d8f35"
      unitRef="U002">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20220331_ProductOrServiceAxis_BIVIGAMMember"
      decimals="-5"
      id="Fact_b2e9ce47e2644275aa4ba8acdbc030d8"
      unitRef="U002">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20121219to20121219_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_58515ccbc51142c087e9b17417b66ebf"
      unitRef="U002">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20121219to20121219_RangeAxis_MaximumMember"
      decimals="-5"
      id="Fact_cb29b92ea0bb4432b14f538cd1990e2c"
      unitRef="U002">2000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230331_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_b7f5ecd39e5a46b7a7ae9ea86a6c3816"
      unitRef="U002">200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20220331_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_adbe550f099146c4b9039cfc9b44130f"
      unitRef="U002">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20190401to20190401"
      decimals="-5"
      id="Fact_bdabb02754b941b588085acdb0f068a2"
      unitRef="U002">1500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20230101to20230331"
      id="Text_8d577c5a49fb4883907c94d4289126da">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SEGMENTS&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The
          Company&#x2019;s ADMA BioManufacturing segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers segment consists of ten&lt;span style="color: rgb(0, 0, 0);"&gt; operational plasma collection facilities located throughout the U.S., eight of which currently hold FDA&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;licenses&lt;/span&gt;&lt;/span&gt;.
          The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) to analyze
          performance and allocate resources. The Company&#x2019;s CODM is its President and Chief Executive Officer. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);"&gt;Summarized financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31, 2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Plasma Collection&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,576,935&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,300,891&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,913,534&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,933,782&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,466,762&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;40,400,544&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,476,441&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(946,334&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,343,425&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(813,318&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(23,779&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(227&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,951,491&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,975,497&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net income (loss)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,452,662&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(946,561&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,294,916&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,788,815&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;452,032&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,492,564&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,944,596&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,292,608&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;740,357&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,032,965&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;234,894,891&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;38,853,662&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,038,989&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;340,787,542&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Plasma Collection &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25,728,625&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,338,760&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,103,093&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;22,213,781&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,227,265&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25,441,046&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,442,684&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,863,094&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,509,288&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(14,815,066&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(49,267&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(729&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,472,854&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,522,850&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Loss on extinguishment of debt&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(6,669,941&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(6,669,941&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,491,951&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,863,823&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(16,652,083&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,007,857&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,310,379&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,531,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,842,085&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,111,951&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;477,503&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;763&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,590,217&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;214,150,322&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,568,911&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;61,313,259&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,032,492&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,694,723&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,316,151&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,218,811&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,786,942&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,913,534&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,103,093&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <adma:NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_35b721651aab431fab846eb589a872c5"
      unitRef="U004">10</adma:NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20230101to20230331"
      decimals="INF"
      id="Fact_02754c26802d4dd1ac4f66ceea59dfa6"
      unitRef="U004">8</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20230101to20230331"
      id="Text_60d8002bb1ba4c9dae45985bc0826d46">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);"&gt;Summarized financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31, 2023&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Plasma Collection&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,576,935&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,300,891&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,913,534&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;33,933,782&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,466,762&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;40,400,544&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,476,441&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(946,334&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,343,425&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(813,318&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(23,779&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(227&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,951,491&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,975,497&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net income (loss)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,452,662&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(946,561&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,294,916&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,788,815&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures &lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;452,032&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,492,564&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,944,596&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,292,608&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;740,357&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,032,965&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;234,894,891&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;38,853,662&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,038,989&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;340,787,542&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31, 2022&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt; Plasma Collection &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
              &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25,728,625&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,338,760&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;35,708&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,103,093&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;22,213,781&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,227,265&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25,441,046&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Loss from operations&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,442,684&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,863,094&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,509,288&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(14,815,066&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(49,267&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(729&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,472,854&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,522,850&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Loss on extinguishment of debt&lt;br/&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(6,669,941&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(6,669,941&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net loss&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,491,951&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,863,823&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(16,652,083&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(25,007,857&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,310,379&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,531,706&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,842,085&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,111,951&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;477,503&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;763&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,590,217&lt;br/&gt;
              &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;214,150,322&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,568,911&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;61,313,259&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,032,492&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_c55eb74805d64ff2819a4629aba290c9"
      unitRef="U002">49576935</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b906122c1c0844f4851925fd57677283"
      unitRef="U002">7300891</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_2048d782268d4bb9b931f485df12636d"
      unitRef="U002">35708</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_a310760096a9468882d3d78fb2536bc5"
      unitRef="U002">56913534</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_f0bc7941a21049069f1e5a7c311548d5"
      unitRef="U002">33933782</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_5ef41d8ca94c40e3ba73e665aa2a6e0d"
      unitRef="U002">6466762</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_5c111919d5634633ad1ca856ee9fcf53"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_6966b051cd7a484ba18a179e9fe090f2"
      unitRef="U002">40400544</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_2c49490e810743e2ae586fc8f71e76b2"
      unitRef="U002">5476441</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b3ba2a7cc6904cc2b5316047a3000cf6"
      unitRef="U002">-946334</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_0331bbc26bbb41f3bbdde436414311a8"
      unitRef="U002">-5343425</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_6af9e88a051c44468a9821e6a63f3e67"
      unitRef="U002">-813318</us-gaap:OperatingIncomeLoss>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_fd7d366b5a9047dfbf476f31da57b583"
      unitRef="U002">-23779</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_8bd0923a77ae45f4b1067e0a93645422"
      unitRef="U002">-227</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_22afae65e94749039ecf4929f3166042"
      unitRef="U002">-5951491</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_2e7eeb0e259f49b48c22fe2156db8e96"
      unitRef="U002">-5975497</adma:InterestAndOtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_c654536d25014ac988e7f4fd1577f6db"
      unitRef="U002">5452662</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_d48c5f4c909040458cdc0a6fca8b93a1"
      unitRef="U002">-946561</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_abe5e1bb770f4ceca49ce35c7a7b3216"
      unitRef="U002">-11294916</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_c2f7b73ef6394474b8e57c81d5bbf4a0"
      unitRef="U002">-6788815</us-gaap:NetIncomeLoss>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_30be93c9d53b4854ac3118a6ba829ca9"
      unitRef="U002">452032</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_ae98b8b7c13349abb69c76e4f498e9b7"
      unitRef="U002">1492564</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_aa4e0ffdadec4355895a3206107b0988"
      unitRef="U002">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_03d939784ac345c59badcf90f01776f3"
      unitRef="U002">1944596</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_5fa324bc0d01497ca5e41d8b784d24b9"
      unitRef="U002">1292608</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_f1d2cd6d3fd14b6691b2481a4583f3a1"
      unitRef="U002">740357</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_1fc144cc8544479dbf9b45f5da98d12a"
      unitRef="U002">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_e25af2dd80ab4ea0adf42532f65abdae"
      unitRef="U002">2032965</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_901bd8aaeb374d4d8a2a46c7e6d7ae12"
      unitRef="U002">234894891</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_9840e5d2c5e847d899afe4ff6e314b6b"
      unitRef="U002">38853662</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_94dfb8f45b2040d5968d8330f4ad4f96"
      unitRef="U002">67038989</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230331"
      decimals="0"
      id="Fact_46eab75f11d647af9abffb270f09b45f"
      unitRef="U002">340787542</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_7ce8d71b19e8430381e40b6c12e8d672"
      unitRef="U002">25728625</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_0d360a26d94e4e518e385e886facab58"
      unitRef="U002">3338760</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_ae58fe9a63f64ddb943d2ecc2f670100"
      unitRef="U002">35708</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_c4e64f6189274be397430f9455cb16ab"
      unitRef="U002">29103093</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_63258479b7684b58a82a8faa57923fa1"
      unitRef="U002">22213781</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_1c2bcec538cf42489f6c90fbb106a86d"
      unitRef="U002">3227265</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_9030a94d1b4942a2a767136e984f07c9"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_0cf291f1a46747a58126aa45c55b31a1"
      unitRef="U002">25441046</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_36ed2499f82f47798c893e1af8296ab8"
      unitRef="U002">-4442684</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_d7db869e4bd5408bb37b6b1c30e95a6e"
      unitRef="U002">-3863094</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_2f2aaed9af6a4675b577ec785a219739"
      unitRef="U002">-6509288</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_0e654d59f74a4834b6f9a95397193466"
      unitRef="U002">-14815066</us-gaap:OperatingIncomeLoss>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_2cafeea62a354e85a19f99cda86edc6e"
      unitRef="U002">-49267</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_271834e4129b4275986e72beb1f24e99"
      unitRef="U002">-729</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_c3688ad888ba470384ff2fc2016602c4"
      unitRef="U002">-3472854</adma:InterestAndOtherNonoperatingIncomeExpense>
    <adma:InterestAndOtherNonoperatingIncomeExpense
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_c88533a3708741549ef4b6db59d3a987"
      unitRef="U002">-3522850</adma:InterestAndOtherNonoperatingIncomeExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_cbff0de3d37b4e0aa89c37227e14fd84"
      unitRef="U002">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_07c704f81b7543f2bca19b2ab7c50ae4"
      unitRef="U002">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_3a582a35a44c46b9859f894a7d05f860"
      unitRef="U002">-6669941</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_9efcfa0c8f4e44d38cae34d2132d4a4f"
      unitRef="U002">-6669941</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_466d99a5ae574142aa74b35f176c46ae"
      unitRef="U002">-4491951</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_c1411fd3e7b94e0da85f0460de263a5b"
      unitRef="U002">-3863823</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_d9f5143c2c9a479a8e242ec9806ae670"
      unitRef="U002">-16652083</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_a096e19498994fbe849ab7fd46bfd34d"
      unitRef="U002">-25007857</us-gaap:NetIncomeLoss>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_6d9da38483f54e70bbf2741e0117b4ff"
      unitRef="U002">1310379</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_b094387e2cf44e83bea143a6bce17efb"
      unitRef="U002">1531706</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_1caf2627137c4bc79326aff1b429022a"
      unitRef="U002">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_8128f2942f2f4f1c81174156d85257d7"
      unitRef="U002">2842085</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_6d2f46cffa244bb8bcb92c875822d286"
      unitRef="U002">1111951</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_896d8abdea724e3d9ad17eca72264567"
      unitRef="U002">477503</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_24af592968314ea1925475f659430fc3"
      unitRef="U002">763</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_2a2bfbd2c3b74a2f84dfa354ff4cbb40"
      unitRef="U002">1590217</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="0"
      id="Fact_b2186393b1974c289384d2cefeb46e09"
      unitRef="U002">214150322</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20220331_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="0"
      id="Fact_7d797816588e4dc3860427afefd8427d"
      unitRef="U002">32568911</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20220331_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="0"
      id="Fact_051f815197b44be68b086586e8a4c221"
      unitRef="U002">61313259</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20220331"
      decimals="0"
      id="Fact_113c873d836b41bcaf40535fd87aad69"
      unitRef="U002">308032492</us-gaap:Assets>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_cb3457db51a845d5ad4ccf3d19e66190">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended March 31,&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 70%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,694,723&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,316,151&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,218,811&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,786,942&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 70%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;56,913,534&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11.72%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
              &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;29,103,093&lt;/div&gt;
            &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_0b12dcd8893447519dafb472c230c362"
      unitRef="U002">52694723</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331_StatementGeographicalAxis_US"
      decimals="0"
      id="Fact_70a098b5bec04ce0b38e504fbc0ded7c"
      unitRef="U002">27316151</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_0cf14b2741724840ae7ed7de970ad42d"
      unitRef="U002">4218811</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331_StatementGeographicalAxis_NonUsMember"
      decimals="0"
      id="Fact_21fd3fb597d841a2839d2abb4c6f3003"
      unitRef="U002">1786942</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_2323efd47254438f832ea8aeb803ebe9"
      unitRef="U002">56913534</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_0e4a8f3a6f3a43a698e8f8c50c73851e"
      unitRef="U002">29103093</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20230101to20230331"
      id="Text_07c47f886b1349e5b405490a00370332">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;LEASE OBLIGATIONS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#x2019;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company determines if an arrangement is an operating lease at inception. Leases with an initial term of 12 months or
            less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities representing the obligation to make lease
            payments arising from the lease.&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For all of its leases, the Company has elected and applies the practical expedient available to lessees to combine non-lease components with their related
                lease components and account for them as a single combined lease component.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include
            options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s incremental borrowing rate. The Company&#x2019;s lease expense is recognized on a
            straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. Aggregate lease expense for the Company&#x2019;s leases for the three months ended March 31, 2023 and 2022
            was approximately $0.6 million and $0.4
            million, respectively. Cash paid for the Company&#x2019;s leases for the three months ended March 31, 2023 and 2022 was approximately $0.6
            million and $0.4 million, respectively. &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Including a finance lease the Company entered into in June 2018, the Company has aggregate lease
              liabilities of $11.4 million and $11.6
              million as of March 31, 2023 and December 31, 2022, respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers and a warehouse lease for raw material storage related to the Company&#x2019;s immunoglobulin
              manufacturing operations.&#160; The Company&#x2019;s operating leases have a weighted average remaining term of 8.3 years. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;Scheduled payments under the
              Company&#x2019;s lease obligations are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,805,644&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,343,314&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,366,432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,116,036&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2027&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,040,690&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2028&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,087,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,150,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,910,687&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,486,533&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(956,045&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 4px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,468,109&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20230101to20230331"
      decimals="-5"
      id="Fact_9dcf8695c71f4f7db5e674e2fbf5b0f3"
      unitRef="U002">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20220101to20220331"
      decimals="-5"
      id="Fact_8819e5ce7b984c79b27968018eeb2de4"
      unitRef="U002">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230101to20230331"
      decimals="-5"
      id="Fact_b5b62b48619645a58510c7ee5149cd3c"
      unitRef="U002">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20220101to20220331"
      decimals="-5"
      id="Fact_fe43622c7d86462ab118ba33645d09a1"
      unitRef="U002">400000</us-gaap:OperatingLeasePayments>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20230331"
      decimals="-5"
      id="Fact_de9c25558eda4c78b95fcd16a28ae7a6"
      unitRef="U002">11400000</adma:OperatingAndFinancingLeaseLiability>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20221231"
      decimals="-5"
      id="Fact_48357cad25f64c6bb156da1348dcf02b"
      unitRef="U002">11600000</adma:OperatingAndFinancingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20230331"
      id="Fact_4e486c3580ef42199c9a5adacb166b66">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_405210bb330f4623aeab49dce8f76c74">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: #000000;"&gt;Scheduled payments under the
              Company&#x2019;s lease obligations are as follows:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,805,644&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,343,314&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,366,432&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,116,036&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2027&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,040,690&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-indent: 0pt;"&gt;2028&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,087,825&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,150,746&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;18,910,687&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(7,486,533&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 2px; text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(956,045&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 14%; padding-bottom: 4px; background-color: rgb(204, 238, 255); text-align: right; white-space: nowrap;"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;March 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 74%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,468,109&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20230331"
      decimals="0"
      id="Fact_612cda4c4f3b41a3aecc33a67d0bd827"
      unitRef="U002">1805644</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20230331"
      decimals="0"
      id="Fact_f8402c9f05754531a2f762918b0d6ef2"
      unitRef="U002">2343314</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20230331"
      decimals="0"
      id="Fact_00e2fd2caebf49349134462ca42d4025"
      unitRef="U002">2366432</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20230331"
      decimals="0"
      id="Fact_600cdb5d9f704e53ba49347b8fc4fbcb"
      unitRef="U002">2116036</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20230331"
      decimals="0"
      id="Fact_794fbef32f9d4855aef767d7bfa10e02"
      unitRef="U002">2040690</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20230331"
      decimals="0"
      id="Fact_3dc6ff11ba774dfda1276d6642a8ef44"
      unitRef="U002">2087825</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20230331"
      decimals="0"
      id="Fact_c5186f0c06994c8ea14527ce55ee369a"
      unitRef="U002">6150746</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20230331"
      decimals="0"
      id="Fact_c6efbcfee0774faeaa9c6a48a365cbcf"
      unitRef="U002">18910687</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20230331"
      decimals="0"
      id="Fact_970cb57242b8418480dfa6c6afb4aadb"
      unitRef="U002">7486533</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_53818766e4e84ac6983c20cedad7e4d7"
      unitRef="U002">956045</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20230331"
      decimals="0"
      id="Fact_6ac3fbf1c1a84c2fa55731dff151422e"
      unitRef="U002">10468109</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="c20230101to20230331"
      id="Text_673ec408ded04a738b2e6188e9f26692">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Supplemental cash flow information for the three months ended March 31, 2023 and 2022 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,639,283&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,525,987&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Noncash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;530,434&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,940,425&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Warrants issued in connection with notes payable&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;9,569,604&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="c20230101to20230331"
      id="Text_35fb1c620ab44388bdc46b9d5e9dccc2">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Supplemental cash flow information for the three months ended March 31, 2023 and 2022 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2022&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,639,283&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,525,987&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Noncash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;530,434&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,940,425&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt;"&gt;Warrants issued in connection with notes payable&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;9,569,604&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_7002684da4844380b5c50aa5f72764df"
      unitRef="U002">4639283</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_2819a460546e47c7a3241f931dc14230"
      unitRef="U002">2525987</us-gaap:InterestPaidNet>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_7cc46def58e442bebe794c59f7b2f17c"
      unitRef="U002">530434</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_de6d1c57e82a452f915f8ca1ed6e778c"
      unitRef="U002">1940425</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20230101to20230331"
      decimals="0"
      id="Fact_6fc90e03e0654ad190e44990fcfd6621"
      unitRef="U002">0</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20220101to20220331"
      decimals="0"
      id="Fact_18e26e2fd0cc4c9f87be7a9d78d68656"
      unitRef="U002">9569604</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="c20230101to20230331"
      id="Text_96ad9ee9489b4607a5eadc16385dbcf3">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
            &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUBSEQUENT EVENT&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;
          &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;On May 1, 2023, the Company entered into a second amendment (the &#x201c;Hayfin Second Amendment&#x201d;) to the
      Hayfin Credit Agreement (see Note 7) whereby the Applicable Margin for adjusted Term SOFR Loans was reduced from 9.5% to 8.5%. The Hayfin Second Amendment also extended the obligation of the lenders to make the Hayfin Delayed Draw Loan from June 30, 2023 to December 31,
      2023. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Under the terms of the Hayfin Second Amendment, in the event the Company elects to prepay all or any
      portion of the outstanding principal on the Hayfin Loans, the Company will be subject to an early prepayment fee in the amount equal to (i) 7.0%
      of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Hayfin Second Amendment, (ii) 3.0% of the prepaid
      principal amount, if prepaid after the first anniversary of the Hayfin Second Amendment and on or prior to the second anniversary of the Hayfin Second Amendment, or (iii) 1.0% of the prepaid principal amount, if prepaid after the second anniversary of the Hayfin Second Amendment and on or prior to the third anniversary of the Hayfin Second Amendment. In
      addition, the Hayfin Second Amendment provides for a 50% reduction to the foregoing early prepayment fees if the Hayfin Loans are prepaid
      in connection with a change in control of the Company or other strategic transactions as further described in the Hayfin Second Amendment.&lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
    &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; In connection with the Hayfin Second Amendment, the Company issued&#160; additional warrants to the lenders
      to purchase 2,391,244 shares of the Company&#x2019;s common stock at an exercise price of $3.2619 per share (&#x201c;the Hayfin Second Amendment Warrants&#x201d;). The Hayfin Second Amendment Warrants were valued at approximately $5.6 million and have an expiration date of May 1, 2030.  &lt;/div&gt;
</us-gaap:SubsequentEventsTextBlock>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      decimals="3"
      id="Fact_dba2d970d6a24fd1926d60d126b52c1c"
      unitRef="U007">0.095</adma:DebtInstrumentApplicableMargin>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember_VariableRateAxis_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"
      decimals="3"
      id="Fact_9f7e3de86e1a43f1a9daeee801a8fcaf"
      unitRef="U007">0.085</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="3"
      id="Fact_c317fce6c4f24a5fbb8a6c50ea7e2e9f"
      unitRef="U007">0.07</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="3"
      id="Fact_71309a42a94f41148e761d8b09551a8c"
      unitRef="U007">0.03</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheSecondAnniversaryMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="3"
      id="Fact_95009fba074444afb57a70e5ca0a0ddf"
      unitRef="U007">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <adma:PercentageOfReductionPrepaymentFees
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="2"
      id="Fact_a93dce55a3cf42baae06a275e9558dab"
      unitRef="U007">0.50</adma:PercentageOfReductionPrepaymentFees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="0"
      id="Fact_34940b2621ff4c139d449aab3407eb84"
      unitRef="U001">2391244</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="4"
      id="Fact_34919303ef094e48a9552305878c0b18"
      unitRef="U003">3.2619</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_fb2c3b32e02e403490c5cf22c87b9568"
      unitRef="U002">5600000</us-gaap:WarrantsAndRightsOutstanding>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MQ@#^OE @E/<WYA-*^<FL_R]02P,$%     @ %(BJ5GJTQ\?] @  4PH  !@
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6RM5FMOVC 4_2M6-FVMU)$7!.@@
M$@6F5NL*:^BF?723"[&:Q)EMH-NOGYVD&6G#JUL^$#_N.3['N<:WMZ;L@8<
M CW&4<+[6BA$>J[KW \AQKQ!4TCDS)RR& O990N=IPQPD('B2+<,P]%C3!+-
M[65C4^;VZ%)$)($I0WP9QYC]NH"(KON:J3T-W))%*-2 [O92O  /Q%TZ9;*G
MERP!B2'AA":(P;RO#<SSH6DH0!;QC<":;[21LG)/Z8/J7 5]S5"*( )?* HL
M7RL80A0I)JGC9T&JE6LJX&;[B?U39EZ:N<<<AC3Z3@(1]K6.A@*8XV4D;NGZ
M$@I#+<7GTXAGOVB=QSIM#?E++FA<@*6"F"3Y&S\6&[$!,)M; %8!L X%V 7
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MGJV6:/X9S1_&B\%J @;H CTN1^C#KQ][70G-JR#===[4S:$ITM 415.>R*U
MXR1@P:E_%[ +=O+.?D-: T[]]!)1_ D1@U -S_#GW4D+#BU22;-X]$RI_'/P
M)&0*\_@O72X/;9GZMM3BOA([?\VN.[!Z!4M?6*?_VR_8-G[7)>),P4[28A9I
M,=NB]Q?LA25[)G2=/'C:F:<J."]]R_8PM:C9Z[X<=Z!N2#QL4,.CA>$)G%7
M6:UP0RXDXL]HE_)@OY90F#)8'>LAD'6$8!JF85AFE;5N2, (&Z:M9[4+5KN5
M]3;E0BC2YU#J .U:N]BV,/$\HP)8-Z2V30S3T?,Y!9_3.O_SJ3V[1>,_'M1"
M6%[I,)US3NPS!3OIKUOTU_W!Q!;,3]=;Y"<!*,<+2.(.!$X[-FXMY:YE40M7
M1J9N9A,38ZP?&*\ ]5I!'R)?Q#Y: QM+$>P 4E^&R0:Q-]@,"/W*].J3R7%A
M"M,*<=V.>HYIN9X>&1NE+AFMT(.8IS+\Q\_$'E9HF$@_V81/$4.^$$QJJ?.8
M%6R7NA7J']N=4A^I*6ZE7L)^!%+["6U8 FF.LKGA!R#<H:KU:LNBY<9U'M/"
ML'[M*KG&DMJ>9SE6 SLIV4DK^XI+ /ZYZ9&'.DT@)38U:JG66+JFXV#<4+IQ
MJ;>X5;?Z]_/E$GU>S*='JJJ%I36$"Q=3BFNL&D-LNM@R[(;:C4L5Q&9[=5S=
MC1=H,AO.IV/T(:^0'[45$K<*ZG\MD>>*=MKO4F!QN\).5-%AH+)ALN:Q?O;7
M%1/;MN=4JZ/&CE+#;EJTI:[B=F$M$/,9KV6LB^:%C;%ENE7YUUE2ZGI&8W4I
M!1:WZEG_7FT H!RR-[5 ]Z'8*KU1U3%@3UK=R0,>PU1W QJ3"QO2[YD-LH-+
M@<3M"CF76Q"<MJS6!>^"V%X]IQH[F"*N:S0@EM*(V[7Q!/$32I@^C769N[ \
MQS(]ITJJL<0&]HCC-:23E))(VB5Q-EXA5?-TA+FK?3**(&E0O"J$.DMB&8;C
M6@T;0%+*'VF7OYO!<C+,&!%49#@'3:?S&5K>#190\\($!3R*_!0VL9!SL?53
MICU&YHVXQX3&I5'=>NC-FF2%E#I(VG5P-+E_5 >W_]T-\G/=T)HU=J-41])^
M'/TZGMS>J7X,OH XWHY/N@%GT<<5G$QG(]BO:T6(G/4 >JYHI[DHQ9>TGT%O
M?!&NLZ'+ADOHQ\NL']P(K%SL6-6:J3'%GN4ZV*.D8=Q*P23M@CD*H[UDP0]I
M-<?,)EJ-OC;0=H]NDF*6;K(+-H'6?)_(P\5,\;6XQ!MD5U>5[S?X:GBXBBO#
M'&X&IWZZ"1.!(O8,(8U+![C2PV7;X47R779?]<2EY''VN&5^P%)E /]_YER^
MOZ@&BBO/_K]02P,$%     @ %(BJ5AU2,G#Q!0  MQX  !@   !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6R]66USFS@0_BL:W\U=,U/72 @!O<0SB4VOF6N3
M7)RT<].Y#PK(,5- +LAQ^N]/8(J-!-CN,?D2\[+[2/NLM-HGG*YY^C5;,";
M<QPEV=E@(<3R[6B4^0L6T^P-7[)$OIGS-*9"WJ:/HVR9,AH43G$T0H9!1C$-
MD\'XM'AVDXY/^4I$8<)N4I"MXIBFWR]8Q-=G SCX\> V?%R(_,%H?+JDCVS&
MQ/WR)I5WHPHE"&.69"%/0,KF9X-S^-9#*'<H+#Z%;)WM7(,\E ?.O^8WE\'9
MP,AGQ"+FBQR"RI\G-F%1E"/)>7PK00?5F+GC[O4/]'=%\#*8!YJQ"8\^AX%8
MG V< 0C8G*XB<<O7[UD9D)7C^3S*BK]@7=H: ^"O,L'CTEG.( Z3S2]]+HG8
M<9"!-CN@T@$I#B9I<3!+!U,=P6UQP*4#5AP@;G&P2H<B]-$F]H*X*15T?)KR
M-4AS:XF67Q3L%]Z2KS#)%\I,I/)M*/W$>')]-?6N9MX4R*O9]8?+Z?F=O)G=
MR9^/WM7=#%R_ Y/WYU=_>C-P>25?7$_^>G_]8>K=SGX'WM_WEW?_@"&XGTW!
MJU]/3D="SBE''OGE^!>;\5';^#R.Y7J9">Y_!5\^LOB!I?\VP$RZ8<Z#(,P7
M'HW #0V#89B "5V&0MYW@$[W@/K^*EY%5+  3-D\]$/1A>9UH]UQ.9NZVT@F
MJ\H8JC*&"AS<@G-!(YKX#% A)^6_ 29\#9"!8!/W&R12(.4EXVD,7<N1ID^[
MU.I6EF4B8MD&J5M.=<LAA@A"9",%U&L8&D-H(XML06OQFU7\YD'QOY(YSA8T
M9=G)05QL4"V5"].!ML)'Y_AYY7Z;+:G/S@:R-&<L?6*#\6^_0&+\T;3$^@3S
M>@*K\8XKWG&!;K;P?IGX\B3*)/&2ZN+J!(3ESEWP*&!I)@O"MU4HOH,OMSR*
M@*SD:YH&37OE O=(RZ1/L&F?8%Y/8+6$657"K,Z-\IFF*4U$!L(L6\D2)I/E
M\R0I3^AU*!8@X8*!)?U.'R+6E"5+V\2&LE<L;5>Y%G&)@97*H=LI2-Y^I!H+
MI&*!=+)0K,]AWDL$,OQ8-E@9S0EH"I?LF^1$MX $RQKB*.'N1?+V(]7"M:MP
M[<YP/[%,A,DCX'-P*R_3T,]/K\WQ>I^$(GL-$ME^RM>;VEFL@P6+ B";3B#H
MLWQ$DT#V@"),6=#$DJT?%TJV)[86W!!C1%R%A*ENI]+4@F2V'").19/SDC3M
M'D9-E#E:%)9IVA IM'7.^=@ZUB>8UQ-8+5=NE2NW,U=7,A$1S[(F8MV]!<K=
MM\2FNL40689A.Y;2&'B'6-9"A,:V#3<.[>H^TK3J9%!C1VTTM'7$M)3(2[/:
MJB/8,+%AJ.6JP72(\P5J6+9BZS780KFU3=,@5@L+.V($_DQOMY\1V-#<$1/;
M%G)55CIG<.PFZQ7-ZPNMSOY66,"?4A;-C.O]/4+042M::;:;&()<ESBVUB$T
MF ZQ[1B0$%L5%PVVT(*NC1%L6X-;>0'_M[YH9D07&#DC4&X-M29US^#H-=BK
MQ.@+K<[^5F3 EU09L%>9T2O:M%<TKR^T>MJV4@-V:XUCNFRX7U5 70Q "/-2
MH!:-_;KB *QZT%ME ;NEQ0OTVN4,=KG":K,-=2DQE.>\JW7;#88:62U8N(VL
MK2Z!+RI,]G7<4!<.&)N[QT-)7N>LC][3?:)Y?:'5,[:52+!;(WG/+/5#68KS
MG!1YXLM\3S<VXB56YZ;659"V0O>:>)TF]4BW @-V*XS62/>N,ET1(+G,U, [
M1S]ZC?6)YO6%5O]7]E;VH&[9TZ7MD"YSU"6%="VB+JD&DR&Q'<=12X%WB&4]
MS*VN08?I&D7+F(UAPX;.&B&BAJZ;$=.0HLUQ- ITTR%VL&-8V"$J";HMQ!:Q
M,$$MVPSM?+@X3%]TJ+MF1O1NOV $6>K_W2;=,SAVJ_6*YO6%MF%_M//-+_^D
M*UE\#&7%BMA<PAMO;$E7NOE*NKD1?%E\!GS@0O"XN%PP*AOJW$"^GW,N?MSD
M7Q:K;]7C_P!02P,$%     @ %(BJ5L5V>[\=!P  (1T  !@   !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6RM66MOV[@2_2N$]^*B!=:U2.J9FQAPG6370.,8
M<=K]+$MTS*TL>4DZC_WU=R@YDBU13 JD""I*'H[./#B'(YX_%>*GW#"FT/,V
MR^7%8*/4[FPTDLF&;6/YI=BQ''Y9%V(;*[@5#R.Y$RQ.RTG;;$0<QQ]M8YX/
MQN?ELX48GQ=[E?&<+022^^TV%B]?658\70SPX/7!'7_8*/U@-#[?Q0]LR=3W
MW4+ W:C6DO(MRR4O<B38^F(PP6=3ZND)I<0/SI[DT1AI4U9%\5/?S-*+@:,1
ML8PE2JN(X?+(IBS+M"; \<]!Z:!^IYYX/'[5?ET:#\:L8LFF1?873]7F8A .
M4,K6\3Y3=\73G^Q@4 DP*3)9_H^>*MG 'Z!D+U6Q/4P&!%N>5]?X^>"(HPF@
MQSR!'":0]@2W9P(]3*"EH16RTJS+6,7C<U$\(:&E09L>E+XI9X,U/-=A7"H!
MOW*8I\;3V_GEU7QY=8E@M+S]-KN<W,/-\AXN-U?S^R6ZO4;3R?)/=/WM]J\E
M&J+ORTOTZ3^?ST<*7J^5C)+#J[Y6KR(]KZ+HILC51J*K/&7IZ?P1P*ZQDU?L
M7XE5X4TLOB"*?T?$(=2 9_K^Z<0"A]:NI*4^VN?*QDO7=[<WZ'9Q=3>YG\W_
M0)/I_>S'['YVM3PSN:U2ZYK5ZG5\)G=QPBX&L% E$X]L,/[O;]AW_F>R^8.4
MG7C K3W@VK2/YU!VLD)*DY'53+^<J6O+XWCH!V$88N]\]'AL@$&0>(X3A%Y0
M2YZ@\VITGC4^D_1O6$]0@I1$JH :E!1YPC.&\@-L_52/DUANT%ZR%/$<0<$4
ML>+Y0U5QN.),&J/H?604/TC9B9_\VD^^-8J7#)0F/*[*;)ZB>%L(Q?\M'Y@L
MK]1Y1Q$C#B61WXYL5PY[D4-P3UR#&F]@Q?M-APZ@IESN"AEGJ%BC-7^&\,52
M,F7,QJ +)70BOP6X*P7LZ)C1AC7:T(IVEBL&,5-H%_,RP7[R/#5!##LOCX(H
M"L(6QJY8#\"H!AA9 2Y5D?P<:FI,45)L8;\@>R,?==V(L8/]MB,-<KZ+:1B:
MH6*G82_'"G9RE)HZ[BE;*9T(2;'/E9&BG X4-X0Z%+40&^2\T U=TH/XB&_Q
MN[*5/>NBLN=RHRO2*W8C9&P)\0%M5\3W_2AR<0]<TL EO^3@C">0$ RJYR/+
M]\R(EW3 #*D7..W,?5ON%'/#P_@-(M[$^0.3K>I=UH*RGF4\7O&LOY+C#R7D
MC])VZHR&DK&=DR=)N1:DYCO&'^-59@Z:VPV&7LK4==N+V2!*(C<@E/8$KB%H
M;.4UJ(V05*H0$!@C1J^+,7#<D'00&@2QZQ)"<-2#L2%';&?'A6!EY6;/NC*R
M*J,*M6$"MNM"Z+7<3SNX2X$!5,(.4QKD(!JAXWA^#_Z&++&=+8'="\G5,6X+
M7@,#AA&AI(W7P*<T"OR@KUPV;(GM=%FG[RY^Z<W=+@<.24 BQVW#[ IB'_:5
MQ.V!V7 FMI,FP!1[UF2%$6:7!8>8>K2[!39*!H'GD9[PDX8PB9TP;T\S%7(@
M+_+AZ_U193190+JD.,0AX,(M XR"4$[\'D>3ACZ)G3[G[]F?&[%W*1)J0@ U
M(6BGB4F4^+H6XIX21QH^)>27FL39_,?5\CU-(K'R]*^2TD=I._5"P]#$2GKC
MQ5XD&]AAZAW%3N@0JI<R&=D_>[[3&R*C"Z@AA)'K>IV-NTF2P.;-";V> #9\
M2M[N<4\2D -IR?<DH(EAS>@-DG;T#<,2>P_<3K_KV7PRG[XG_3ZTO?TH;:=>
M:#B<O,7A'#K_';2*P"K5!P'8W>:%8E:>(5U6;F_$#2)#[!S^]02OH6YBI^Y%
M!;;N<P1;\SP&2R#WUJPGZ[K,W,'<%1D2*^*&O8F=O1>B2!A+)5J+8HNXE'N
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M ">J\[CJ1A6[\DAK52A5;,OAAL4I$UH ?E\70"^'&_V"^E1T_']02P,$%
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MWO(8'!LVWPT;0Z7-1316M]C<@@"\@3V;3;MV$6KCG5J^.TV4/@1X'0R&K8G
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M@#0*>%X*H?<+<\'X*;3X'U!+ P04    "  4B*I6I,SD20T#  #U!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RM55V/FS@4?>=76&S5)VL XQ"8
M32(EF52-U$Y'R<SN2JM]<. F6 6<VLYD^N][#0E-M=-(E?H"OO8YYW[!]>BH
M]&=3 ECR4E>-&?NEM?O;(#!Y";4P-VH/#9YLE:Z%15/O K/7((J65%<!"\,D
MJ(5L_,FHW7O0DY$ZV$HV\*").=2UT%]G4*GCV(_\\\9*[DKK-H+):"]VL ;[
MM'_0: 6]2B%K:(Q4#=&P'?O3Z';&';X%_"7A:"[6Q&6R4>JS,Y;%V ]=0%!!
M;IV"P-<SS*&JG!"&\>6DZ?<N'?%R?59_U^:.N6R$@;FJ_I:%+<=^ZI,"MN)0
MV94ZOH=3/@.GEZO*M$]R[+ #!.<'8U5](F,$M6RZMW@YU>&"D(8_(; 3@;5Q
M=X[:*.^$%9.15D>B'1K5W*)-M65C<+)Q35E;C:<2>78RG<]73XL[LOCG87&_
M7JS)]/Z.?'I\OUB1^=-JM;A_)!^6T]GRP_)QN5B/ HL^'3/(3_JS3I_]1#\F
M'U5C2T,630'%C_P 8^T#9N> 9^RJX$>A;T@<4<)"%E_1B_L"Q*U>_%L*0/Z=
M;HS5^"W]]UHM.E?\=5?N_[HU>Y'#V,<?R(!^!G_R]H\H"?^\D@CO$^'7U']#
M)Z_JOQY]<N/]8@&G>:X/4!!XP;EBP!#1%$39$C1^[EI#8TDEQ496TDIW:@EV
M/"_[EK?X.\BAWB#EM,N(T$"$(5M5X9@QM]Z/).]_!.\<AX:-L&"\-UX4TXAE
M- N9,R+*XX3RE/?(0F+GY>;03I,M((=3'B8TC&,/J4E"TRSIT;+),1><.,:+
M:#3,:!*&2(BRF&91UL/0M97-SHN2C*9LX,4AOI-A?[X77S7F=%DE5;O*"1<&
M2@_Y@#(^0.DP36@\S+Q/#N8Q&O*(IH/,8;(!34/N/2HK4.J7.H"U8(PF0T9Y
MPIW!:99F-.89>>VC#2Y&40UZUPY<@T$?&MM-I7ZWG^G3;I1]AW<7 K9P)QM#
M*M@B-;P9#GRBNR';&5;MV\&V41;'9+LL\5X"[0!XOE7*G@WGH+_I)M\ 4$L#
M!!0    ( !2(JE9T8H.42 P  )0A   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;*5:VW+;.!)]YU>@-/&44Z7(NEFVX\15=BZ;3"4;5YR9/&SM T2"
M$B8DP0"@%>W7[VF 5XE2LK4/B<4+&MV-[CZG6WJQ4?J;60MAV8\TR<S+P=K:
M_/G9F0G7(N5FI'*1X4FL=,HM+O7JS.1:\,@M2I.SZ7B\.$NYS 8W+]R]>WWS
M0A4VD9FXU\P4:<KU]DXD:O-R,!E4-S[+U=K2C;.;%SE?B0=A_\SO-:[.:BF1
M3$5FI,J8%O'+P>WD^=V<WG<O_"7%QK0^,[)DJ=0WNG@?O1R,22&1B-"2!(X_
MC^*52!(2!#6^ES(']9:TL/VYDO[6V0Y;EMR(5RKY*B.[?CFX'+!(Q+Q([&>U
M>2=*>\Y)7J@2X_YG&__N9#%@86&L2LO%T""5F?_+?Y1^:"VX'!]8,"T73)W>
M?B.GY6MN^<T+K39,T]N01A^<J6XUE),9'<J#U7@JL<[>O'YS]^7%F84DNCX+
MRU5W?M7TP*H9^Z@RNS;L31:)J+O^#!K4:DPK->ZF1P5^Y'K$9I,AFXZGLR/R
M9K59,R=O=L0L]J_;I;$:Y_[O/@N]@'F_ ,J%YR;GH7@Y0+ ;H1_%X.;WWR:+
M\?41]>:U>O-CT@]Z_>BJ?ITN1H$S]K;**Z9BANPSEF>1S%;,B$PJS3)EA6$Y
MW_)E(I@TC!L6JP1):9X'<'^XKOT?O!:A2)="5W>FP3_;JX,GP>3\?'@QO<"_
MN;N:#R_FN)HO@@_"0.!KL;0LDB9416:#T\ED.)\NAA=7\^"IN[J:S(>+RQFN
M'GK4(Y'S^7 V'@^O9F-W-1U>SF;#\6(6?,J85W<Z\\JQ4[L6[/??+J?3\?4[
MOHUEQEXERI#QR GAGDRNGPX9O?=*I3G/M@S>83Q)R%O2&CAO:60DN9900V16
M:!$QF5G%.'N%S]*Z%?\HN.:9W;+;E18"Q<GV[NX7U.]4&B"W[9KYEV"X?I0A
M=OOPX9Z==@14[X_8%\@^()3E6CW*2- Q:FA9GK,184&ZPX*4)8IG+.:A3"1T
MAA".53(+9<X3QE,Z'') D3,8^F1R<3X:!ZE,$JJ7A^UZ6PIL'!O"J<I@5P@[
ME4^Q3;-]RB/!(,^V3&F=#FE%C_KT>C(Y'_]$H[:D#]BNT8F.ZU0Z92*1\"VT
MBS3?M#0[MO,4KF"'-T: >Y&O261K8]H6@:96 FNT/_!#EM,R'Y1=H^B^Z<:
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M"TCPI1T%B5&ETZ8=EQVM4H0UH1"1JR+D+8XTC42:^XC7(I5%2L]:BI)C::.
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MG2HN_ZTSXV.)#679%I1-IE=&PP_B=I&5_"UPF6E^ME12HFS!82NA=T"#EY+
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MN\ L!JXNLW9Q'GT8X20,=08M8\6A4"J4X7(7E):HV'ME L_R4Y0-L[,V$=,
M<['5_7ZE*E/4I)H4S WB'4E?1$_Y^[29QXYXIADC/&%A946LMFF*+[DE:I"%
M@45L LMAM*1;'%228 ?>V%@/GKZA0;Z9V;F2ZX0&XZI&,I1',S7HPV%KG.0
M91UJGE5U/?!0O*X=^5=IG?H&FD[M>9=8IE(;W\LII)CLGE_PJ *<&Y1<X?^D
MWAYJ0]'E@H:>GX/O?P+=3<6(XUJ.VM=,8H+-DC*(O4-1R"[0&KTGV+=KI+ZD
MASJ8(+IB. Z8KM$RCL:#%$;;R-CV0KV6NIWA?PX25_!3-5GOGT5RGYW2>F\.
M)GT6FW(^,';AK?(>MK7[W*YHABIZS2",QQ.&.(?+.C?NR\7.2Z9LM$HM4_]T
MMKJ'ZCTC9^RAXDU0O+-[B")R+UML)70PQ]<\+24]]4>#5_UW(9@7+NV:2ZUV
M@O#VC%'O_.K#U9NS:R[".P>*F0R'-8.&*'1Z5R!= &^W_@MBJFR9\J$NN+P'
M_*A"RX!(X8=QQ@->:IIH,#Q,Z=HACR[AY50%GGXDWCC_S+4I$'1Q1E=88"^%
M?[IED1F?G6X5T]PGT6E/G$9@X^&^CW=;"P@7;\"=]A]3@T#/^"4ROK'@DC/G
MSSA^XXJ"^$HL'@<TAZ0=6MW=7@ <Z-TU,:\!I[P7G8<M%*2EVX]U;!:VM=,S
M"S<,?#D# RP,8+KH[I4V!+R_L+L2%;E!)T0C^+C6*;KP)]QI[FCW. U^ZNYY
M>PZ4!FGD,V>0T72SC:UQ>_MZ0L]K/N\.23"^JVD\HW?J 7= ^DH%]M?<M?:8
MSABSB6.ZHZJH>MQ\208 E!R[R6U=@_/]Z7",IM.8QGOP8-0\&(C^+>SF9#J^
M=>3C7 'G=X?32'_C5O?[T?!Q>P;/,J*Y(\RP/@?-O,X+EJ6*F:VSQ$3UO 3%
M'Q?T"7DV&2.OXAMT#GU9Q6%F>L62<T]3",!5@/T@:M<<&Q?I2M+?H[=1"*MN
M1PN1*7BNW1#0:SW /VHSWE_0BT7BK:K^'G!">\7#7THW'R@1W])K1@65'MG%
M7*NI>-W>NKPC5Z+XI[237E>+KX"A6&U2[D4<B""?QDNA36 -NUXJZVYX[@WS
M?!0R;W6Q.6S@UZ02UFFZ:XK7K\T[96'.(_"H(D5(:B! Y2U=<K7W71$SE5MR
MA1<K1A(@U7%;(=F<DJ;E!5PB#S91L5%#GFXGJ*8<T*44S=H&\0#"DMTO@33.
MT-0HN5S(/%U=O-^QOI2?>#(#/[?TDDU7@-#-C./2-6I=^ZRN/E9V5;7U1#^*
M-]UUU[TS!+2S2O\=1T/K_BVW,-:W$<[EG=W!PG#7^Y@GO7=H^:4X>E.8;A\
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MP87$9(!XQJ\?8J@Z:$5]'1^L0PG((XB@ CG2&*<Y\NE1>9FEP:TFIY6UTME
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M#%$QHN7+:KXG5A8*1C?K38LD;"U\NW=2(%C:UC(37VM2YXYMP4@WEA7<B0>
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MO478,45 SF\B5(M;T9&@[<RW0M?SLV'*]H(;(-]CS2L:14'J6\'W'?$-3D_
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M[;!0^L<--GAA2 #O5UJ[_D &#O\3S/\'4$L#!!0    ( !2(JE;Z*^Q$_ (
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M >R/->[$^L,;6([IP_\!4$L#!!0    ( !2(JE9!LJ$DEA8  %5%   9
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*U<6W/;QI)^QZ^8TMD]95=!E*B[
M$]M5DFQG59LX6LE*=FMK'X; D)P8Q/!@ %$ZOW[[,C>0(",[YR&Q1&)ZNGNZ
MO[Y,0V]7IOEJYTJUXFE1U?;=WKQMES\<'-ABKA;2CLQ2U?#-U#0+V<*OS>S
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MCY]O?L/OK[2A< "V>'0X/N)+KN:K8CRQV/V@Z.^5#\]][!" _/>L8G)@ZNG
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M*VQ;1BSQ/P&$5L#U/<>#Z@?:P?#GL?P/4$L#!!0    ( !2(JE:^(L<):@,
M !@'   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)55;6_;-A#^KE]!
M:,.0 $3T_F+/-F G+EJ@:;TTW3 ,^T!+)YNH)*HD%2?[]3M*LNH,CH%]D>[(
MN^>>._*.LX.0W]0>0)/GJJS5W-YKW4P=1V5[J)BZ$0W4N%,(63&-JMPYJI'
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M2=:V<]S:0.IA-* L&B"UG\0T'*9.>X,.HWX4T&20VIQT0!,_<M;2<*3Z3S>
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M[Q%$4($<:>1ICGP&5%IF:?2HO5-IK7(V8ER@9B+4C8-8RD, 68[M!2V+,N*
MR(L<E6#?%!G['T3&H"56T(QYD:&.H)5G\;[(6$F3F-.XY"^*C#'*$B\R1$E1
M6<J0B#./#>'06&31KRCA?[1U(K".3!9!4YP6F7<CAD*F<4E9480:"U]2&F?9
M]V@,;<.R(*Z<E0.PR!ERO_&2,C^),0FD0F$=DK9J[,(?!S[ 6CTY*..,@$B6
ME1!(0DZ_F@2!>F&&*,K$Z_@YB@('@B<. R^X(LR0CCC.X3M_29T)^@B*RDN,
M4A0]CS-P %WA0=+OUF>2#'Q$#F'%/,HSCJ]I&:-,^;\4BN0F*9Q"7=QW!&29
M)%'FJ:"6*10:%T'<:!ARY,9(=S=&>O3&\'G;ZH]<594V=3AH-7FG]-S(Y:*I
MR!7>:8?NAJ/0A^\&[\]L_<E]?_-G?Q+^:'@EU5X0_@YH=36D%7)80V4J?-TJ
M/]P8S7*I:NK'TF[NC&]<%5&X*D(K?^@;M"*9.G2D;T1_MN&DR+&.GL-Q#_$D
MJ&'0>Q^HR#82J* _X!+4,R]P_/MC(]33//?TWK6PW[X'JS?>>X)URLS#0]/B
MPESU;GB-[;[NWK)7PQ/N>?OP$$:4\Z:WI%4SF,:O<E3+#(_+8>+T,CSHGK3#
M\S ,%WB/*^,W8'VFM=M.O(/="W_R#U!+ P04    "  4B*I6,D6$1/H"   >
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6R-56UOVC 0_IY?8:53
MU4I1\TH(%)" =ELENJ)"-TW3/ICD(%&=.+.=TO[[G1-(F431OA"??<]SS]EW
MQV#+Q;-, 11YS5DAAV:J5-FW;1FGD%-YQ4LH\&3-14X5FF)CRU( 36I0SFS/
M<4([IUEAC@;UWER,!KQ2+"M@+HBL\IR*MPDPOAV:KKG?>,PVJ=(;]FA0T@TL
M0#V5<X&6W;(D60Z%S'A!!*R'YMCM3P+M7SM\SV K#]9$9[+B_%D;=\G0=+0@
M8! KS4#Q\P)38$P3H8P_.TZS#:F!A^L]^^<Z=\QE125,.?N1)2H=FI%)$EC3
MBJE'OOT*NWPZFB_F3-:_9-OX^KY)XDHJGN_ J"#/BN9+7W?W< "(G \ W@[@
MU;J;0+7*&ZKH:"#XE@CMC6QZ4:=:HU%<5NA'62B!IQGBU&AV.U[<DH?)[.[+
M>'GW\&U!+I9TQ4!>#FR%_-K+CG=<DX;+^X#+)_>\4*DDMT4"R;]X&W6UXKR]
MN(EWDO">BBOBNQ;Q',\_P>>WR?HUG__?R?X:KZ026!J_CZ7;L 7'V72[]&5)
M8QB:V \2Q N8H_,S-W2N3V@-6JW!*?;1G+YA[2M)GO R!9D!EAYY6+%L0W4Y
MRV-Z3S(>U[O +D\J!@DI]P&K.J!*P9CRO*3%V_E9Y+G=:TE8+8*_BR!4 *&2
MK#G#[I9]XQ'T(-!XOJY?S?ADN%;D=*PP"(R?0 4!71SD!F+(5^BW>][ \"P_
M\"W?Q97C=;09AE;@>]H,T73=T'+\4)M=-)W L<*>H\U(FU'7BA"V3 %GTUJ!
M,$++[3A6-PB-)5>4M0D:;F3U7$1'76,&4O9)EI>50E%9@3B0RKCH6D$46AW?
M-RZ-:24$XDC)A4[:N.AU4$G0P:,)9;2(\0H4P5J-T[98==J.%821Y3H]<JP<
M[(.>S4%LZLDD2<RK0C7MV^ZVPV_<]/R[>S,Y,?0F*_3SK!'J7'4[)A'--&H,
MQ<MZ JRXPGE2+U,<X""T YZO.5=[0P=H_Q)&?P%02P,$%     @ %(BJ5C*C
MWF\) P  AP8  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK55=;]I*
M$'WG5XS<ZNI6<F-C&QHH(!$**E(24$AN'J[ZL-@#7M7>=7?7H?WWG5T3)Y$H
M3WVP/?LQYYS9C^/10:KO.D<T\+,LA!Y[N3'5, ATFF/)](6L4-#(3JJ2&6JJ
M?: KA2QS26411&'8#TK&A3<9N;ZUFHQD;0HN<*U UV7)U*\K+.1A['6]YXX[
MOL^-[0@FHXKM<8/FH5HK:@4M2L9+%)I+ 0IW8V_:'5XE=KZ;\!_'@WX5@ZUD
M*^5WVUAF8R^T@K# U%@$1I\GG&%16""2\>.(Z;64-O%U_(R^<+53+5NF<2:+
M1YZ9?.Q=>I#ACM6%N9.'KWBLIV?Q4EEH]X9#,[<?>I#6VLCRF$P*2BZ:+_MY
M7(=7"9=_2HB."9'3W1 YE5^889.1D@=0=C:AV<"5ZK))'!=V4S9&T2BG/#/9
M/*S7U_.;^>W]]!J^+#>SZ]7FX6X.JP7,IINOL+A>/<+R=K&ZNYG>+U>W\.\]
MVQ:H/XP"0_06)$B/5%<-5?0'JAANI#"YAKG(,'N;'Y#L5GOTK/TJ.@MXP]0%
MQ%T?HC"*S^#%[5K$#B_^6VOQ_W2KC:*#]>W4:C1DR6DR>]F&NF(ICCVZ31K5
M$WJ3?]YU^^'G,Z4D;2G).?3)IJZJ NGR&%; C.D<%G3]8"F::TSWX93BLYBG
M%;\A2BW1SA+Q%R*@"$R.]"A$*)LS@/8, .U@FK=;"$QD-HB :V":$@O"TL..
M';2OJ/-FBTYNRK#CRJT8SQPS%P9)K>F\[R1^/Q[XT65,<>3WHIX_N/S4N97"
MZ5YPP43*Q=[)6(HG2K*MJ?4-;CB2D/F/FE>V6'(3"A650"9B'88B;CTFE;4P
MFNA_V6OBH*A3U31><+;EA4,B ;TX]),XH:CK#Q**HU[GD2G%;#K7NFX04RG$
MT< .W.0@I,$7^/?PD9Z!W^L/_'Z8P*F3$[PRAQ+5WEF@!B>T\8FVMW79:6,N
M+],;BZ;MVG.AH< =I887GWH>J,;VFH:1E;.:K31D7"[,Z4^!RDZ@\9TD^<>&
M)6C_/9/?4$L#!!0    ( !2(JE8=#L2;Y0(  "X'   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,R+GAM;(V5;6_:,!" _\HIJZ96VDA(>&L'D:"T&Q]*45E7
M:=,^F,00JTZ<V@ZT4W_\SDG(V!JB?0';N9?GSG?GX4[(1Q51JN$YYHD:69'6
MZ85MJR"B,5$MD=($OZR%C(G&K=S8*I64A+E2S&W7<7IV3%AB^</\;"']H<@T
M9PE=2%!9'!/Y,J%<[$96V]H?W+%-I,V![0]3LJ%+JN_3A<2=75D)64P3Q40"
MDJY'UKA],1D8^5S@&Z,[=; &$\E*B$>SF84CRS% E-- &PL$_[;TDG)N#"'&
M4VG3JEP:Q</UWOIU'CO&LB**7@K^P$(=C:R!!2%=DXSK.['[0LMXNL9>(+C*
M?V%7RCH6!)G2(BZ5D2!F2?%/GLL\'"AXYT<4W%+!S;D+1SGEE&CB#Z78@332
M:,TL\E!S;81CB;F4I9;XE:&>]F_O/H_GL^_CK[/;.8SG4YC<+V?SJ^423J=4
M$\;5&9P 2^"&<8YI5$-;HUNC; >EBTGAPCWBPH,;D>A(P542TO!O?1MQ*V9W
MSSQQ&PW>$-D"K_T!7,?UX'XYA=.3,UA($6:!AFL2,,[T2X,CKTJ.ESORCB5'
M;DC"?I&B?I(0)IE"$:7@QWBEM,22^EF7C\)JI]ZJ:;,+E9* CBSL(T7EEEK^
M^W?MGO.I@;E3,7>:K/OS+%Y1"6(-*2<J)H 5LF^!=9$:1A5D>!<22)I*L24\
M#RZD6^S1%#M.P^N1-!;Q%03=G,!T_=9O.T-[6T/=K:B[_TE]/1U_Y"S MJ=A
M<PC-C-TWC(-ZQ%Z%V/M_Q#)S!K$LN]=] =;!]-[ >/4P_0JFWPCS@*..)1L(
M2,HTWM\KG-3Y+8R<'_AUW7ZK4^][4/D>-/J^)"K*"R8P"_J4,:P@+!IUC&+P
MAJ)WWG+_@; /9EA,Y2:?U JO/DMT,<ZJT^HQ&!<S\(]X\9+@?-BP1 &G:U1U
M6GU,O"RF<['1(LTGXDIHG*_Y,L('C4HC@-_70NC]QCBHGDC_-U!+ P04
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MG(C_#)$ QCQ5:PGOTACC&O^PV;_E-P"X.BIE:/Q]:*[\1L0Q$6<0M$[!]_P
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MN/:<CGW5L:Y<<[UK1F.&UYKQ?-(]G9U:9Z=19Y@5.&6R"PL4)9@M@<M63+"
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M+PH3H/<7G*OMQ!S0=?3H#U!+ P04    "  4B*I6B=#\)FT#  "<#@  &0
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M0VK5$ 0O(0@:SM!"L"G\AM2J^"^G,M]^+!NF7"CV/:_+6Q",Q[7,=I4@(-^
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M)T&[!'N^5 IW@2O03-[D#U!+ P04    "  4B*I6-IKS#J0"  "F!P  &0
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M$#0M'C=86FV6?R#?KR@5+XT\0'WY&/P/4$L#!!0    ( !2(JE9_Q'<Y+P(
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M970T-"YX;6RMEFUOXC@0Q[^*E5NMNM)N\^0X21>0*+ J4J];07M[TNE>F#"
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M>?H=KMU]=N;Z>^L":@M#:01*HRB:J@MI"WOO.VE F[<>^#S/%A<G+G,3>G=
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M;("R ;@_E]+<36QG:C]$R5]02P,$%     @ %(BJ5G72+"C* @  8 @  !D
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M-,6!C)/\52H/L91QF']<<F_.199 _;Z(8[DYR JH7A T^ ]02P,$%     @
M%(BJ5J>WX^C2"   %#L  !D   !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
MM9MM;]O($<>_"J$610*<(^XCR=068(M)&Z"^!O&E?7'H"UI:6<1)I$JN[%QQ
M'[[+!VO%W?5()*@@2"1R=CC_X3[\.%I>O^3%;^5:".G]V&ZR\F:REG+W<3HM
M%VNQ3<H/^4YDZLPJ+[:)5%^+IVFY*T2RK!MM-U/L^WRZ3=)L,KNNCWTM9M?Y
M7F[23'PMO'*_W2;%[W=BD[_<3-#D]<"W]&DMJP/3V?4N>1(/0G[??2W4M^G!
MRS+=BJQ,\\PKQ.IF<HL^QHQ4#6J+?Z7BI3SZ[%52'O/\M^K+E^7-Q*\B$ANQ
MD)6+1/WW+.9BLZD\J3C^VSJ='*Y9-3S^_.K]<RU>B7E,2C'/-_].EW)],PDG
MWE*LDOU&?LM?_BY:0:SRM\@W9?VO]]+8!M'$6^Q+F6_;QBJ";9HU_R<_VD0<
M-2#HC0:X;8"-!AB_T8"T#<BY#6C;@-:9::34>8@3F<RNB_S%*RIKY:WZ4">S
M;JWDIUEUWQ]DH<ZFJIV</7SZV_VGGW]Y\-[%0B;IIGQ_/97*;W5VNFA]W#4^
M\!L^B'>?9W)=>I^RI5AVVT]5/(>@\&M0=QAT>)\4'SR"?O*PCXGW_2'VWOWY
MO?<Y6:2;5/[N"'!^OC_\ZL_A)H;=Q&)QRDU'+CG< U+[)6_= _&D1I+TOHE=
M7L@T>_*^9,V(KD;&K[>/I2S4^/B/Z\XTGJG;<S5I?"QWR4+<3-2L4(KB64QF
M?_D3XOY?75D<TUD\DK-.1NDAHQ3R/OMYOWT4A9>OO,_Q[=4F7:B)2BR]W28I
MMXFGQLSKM+-J^E0J2N\/J(/=-==C]?6JN?1Y%EY/GX^3!T;4-WDC.>LDCQV2
MQ\Y,7B&JE:/JD&#F]FK8%^I<IOKIOCD+)Y-9R42^D4TPQ+[9',E9)YO\D$T.
M9O.;>!;97I2N/#0M^5$>&(\0880:V; -<81\XD>D:QB#L0Q4&AR4!J#2>5[*
MJM?LBGRINH'J/;5RE_# Z@#4I[[/J"G<-L3*"/F4&\+!T 8*#P_"0U#XEVR1
M;X7W;I.7Y7MO5>1;3W%944_?SOL>6JJN0D0(,J<4AQVB(6(^-^6# 0Z4'QWD
M1R?D2Z&\2B_)EEXNUVHN$#]VU8S[DY<)Z4I 9 MC4<!H%!@9<!@2AG'(C/DB
M!D,<F #D:XCRP13\0]UY3TU[XD>U?._3<ETOZ&HP+,6C,P.MPV-EYA3H,+GB
MG$<1189X.+JAZH\0$L$+AGH\28_'@%,P<J@)PE!U9U.WPQ(SWP]"%IC"P<"&
M"L=:.(9GO&27RF33=/=E*O>%>YYOW706O(A2%G%3NFV(0XK]D)G"P<"&"M?
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M:ZALS;'LQ%: ,_F=.6A4/:<R;DX(+D-&4.";>[SAP(8*U]C*8&P=#/#,AM2
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MFOH1P/P.XAA#X&G$$<P!>,"0.+;OP9WW4;1Z3T7K__"-?@-02P,$%     @
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MM;<Y7'4C<948BMM,'A#>I@/'@W3#8$X#1N=$_F*A[\V=1.[,'-\)7$H42 .
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M%^CM-:UUV1SR6?>5PN034$L! A0#%     @ %(BJ5@=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  4
MB*I6.E$8[^T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  4B*I6F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !2(JE;>UK]0
MO@4  , >   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  4B*I6\4=Z%<8&   ^&P  &
M@($ #@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ %(BJ
M5GJTQ\?] @  4PH  !@              ("!_!0  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( !2(JE;3E=JWA04  /X4   8
M      " @2\8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  4B*I6'5(R</$%  "W'@  &               @('J'0  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ %(BJ5L5V>[\=!P  (1T  !@
M             ("!$20  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( !2(JE;G:BW\N0<  "L2   8              " @60K  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  4B*I6*M41<] 5  "-
M/P  &               @(%3,P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ %(BJ5F7&HGD7!   W0@  !@              ("!64D
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !2(JE9C7/"H
MB0,  ,4'   9              " @:9-  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ %(BJ5F_"=-X[!   %@D  !D
M ("!9E$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  4
MB*I6I,SD20T#  #U!@  &0              @('850  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !2(JE9T8H.42 P  )0A   9
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M970Q-RYX;6Q02P$"% ,4    "  4B*I6L^R/MGD%   ?#   &0
M    @('8B0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M !2(JE;Z*^Q$_ (  ,$&   9              " @8B/  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ %(BJ5DY;K3*C!   L@L  !D
M             ("!NY(  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  4B*I60;*A))86  !510  &0              @(&5EP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !2(JE9P]Y\3$ ,
M &(&   9              " @6*N  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ %(BJ5N#0("BL @  H@4  !D              ("!
MJ;$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  4B*I6
M]H<25KH#  "%"   &0              @(&,M   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( !2(JE:^(L<):@,  !@'   9
M      " @7VX  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ %(BJ5N%O^]\< P  S 8  !D              ("!'KP  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  4B*I6%*=*RXH"  "3!0
M&0              @(%QOP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( !2(JE8864Z>'P4  ,<,   9              " @3+"  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ %(BJ5A+&./Y-
M!0  [0L  !D              ("!B,<  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  4B*I6,D6$1/H"   >!@  &0
M@($,S0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !2(
MJE8RH]YO"0,  (<&   9              " @3W0  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ %(BJ5AT.Q)OE @  +@<  !D
M         ("!?=,  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M    "  4B*I6J&=CQRL#  #5"0  &0              @(&9U@  >&PO=V]R
M:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !2(JE;4^OC9I (  *@'
M   9              " @?O9  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
M4$L! A0#%     @ %(BJ5J^^*;-N @  W04  !D              ("!UMP
M 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  4B*I6B=#\
M)FT#  "<#@  &0              @(%[WP  >&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+ 0(4 Q0    ( !2(JE;I0]:Q:@,   ,.   9
M  " @1_C  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M%(BJ5IJGFL!< @  A04  !D              ("!P.8  'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  4B*I6-IKS#J0"  "F!P  &0
M            @(%3Z0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( !2(JE;0Q'?ZD (  - &   9              " @2[L  !X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ %(BJ5F$JEV,T!
MB!0  !D              ("!]>X  'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  4B*I6?\1W.2\"  "S!   &0              @(%@
M\P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !2(JE:]
MS%Z&0 8  /,N   9              " @<;U  !X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ %(BJ5CD6.8 ] P  - D  !D
M     ("!/?P  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !2(JE;)H4<;YPP  &YR   9              "
M@=88 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ %(BJ
M5N,V24YM P  1P\  !D              ("!]"4! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  4B*I6/4T!A]8'   L2   &0
M        @(&8*0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( !2(JE:GM^/HT@@  !0[   9              " @:4Q 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ %(BJ5H*@N&.R!   \Q8
M !D              ("!KCH! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  4B*I6D0[>31L#  !Q"   &0              @(&7/P$
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !2(JE;N@USE
M)04  %DD   9              " @>E" 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ %(BJ5NJ#1O\Y P  [A,   T
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;72YX;6Q02P4&     #\ /P P$0  ;54!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>153</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>63</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Segments</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligations</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - SUBSEQUENT EVENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEvent</Role>
      <ShortName>SUBSEQUENT EVENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080300 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Inventories</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080700 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Debt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/StockholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>081100 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Segments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligations</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusinessDetails</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090300 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/InventoriesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsSummaryDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090700 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>091100 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SegmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>091200 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="brhc20052583_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091400 - Disclosure - SUBSEQUENT EVENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SubsequentEventDetails</Role>
      <ShortName>SUBSEQUENT EVENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SubsequentEvent</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 3 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. brhc20052583_10q.htm 9318</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal, us-gaap:PropertyPlantAndEquipmentUsefulLife -  brhc20052583_10q.htm 11</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="brhc20052583_10q.htm">brhc20052583_10q.htm</File>
    <File>adma-20230331.xsd</File>
    <File>adma-20230331_cal.xml</File>
    <File>adma-20230331_def.xml</File>
    <File>adma-20230331_lab.xml</File>
    <File>adma-20230331_pre.xml</File>
    <File>brhc20052583_ex31-1.htm</File>
    <File>brhc20052583_ex31-2.htm</File>
    <File>brhc20052583_ex32-1.htm</File>
    <File>brhc20052583_ex32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="543">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "brhc20052583_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 25,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 543,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 153,
   "dts": {
    "calculationLink": {
     "local": [
      "adma-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "brhc20052583_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adma-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 492,
   "entityCount": 1,
   "hidden": {
    "http://admabiologics.com/20230331": 1,
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 9
   },
   "keyCustom": 55,
   "keyStandard": 231,
   "memberCustom": 27,
   "memberStandard": 34,
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://admabiologics.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - INTANGIBLE ASSETS",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://admabiologics.com/role/IntangibleAssets",
     "shortName": "INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - PROPERTY AND EQUIPMENT",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://admabiologics.com/role/PropertyAndEquipment",
     "shortName": "PROPERTY AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - DEBT",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://admabiologics.com/role/Debt",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://admabiologics.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - RELATED PARTY TRANSACTIONS",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://admabiologics.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://admabiologics.com/role/CommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061100 - Disclosure - SEGMENTS",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://admabiologics.com/role/Segments",
     "shortName": "SEGMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061200 - Disclosure - LEASE OBLIGATIONS",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://admabiologics.com/role/LeaseObligations",
     "shortName": "LEASE OBLIGATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061400 - Disclosure - SUBSEQUENT EVENT",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://admabiologics.com/role/SubsequentEvent",
     "shortName": "SUBSEQUENT EVENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080300 - Disclosure - INVENTORIES (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://admabiologics.com/role/InventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://admabiologics.com/role/IntangibleAssetsTables",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentTables",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - DEBT (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://admabiologics.com/role/DebtTables",
     "shortName": "DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://admabiologics.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081100 - Disclosure - SEGMENTS (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://admabiologics.com/role/SegmentsTables",
     "shortName": "SEGMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081200 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://admabiologics.com/role/LeaseObligationsTables",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://admabiologics.com/role/OrganizationAndBusinessDetails",
     "shortName": "ORGANIZATION AND BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U006",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - INVENTORIES (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://admabiologics.com/role/InventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
     "shortName": "INTANGIBLE ASSETS, Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetails",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:AccruedRebatesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:AccruedRebatesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - DEBT (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://admabiologics.com/role/DebtDetails",
     "shortName": "DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
     "shortName": "STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20211231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20211231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adma:MinimumPercentageOfCommonStockHeldByLender",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20220101to20220331_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adma:MinimumPercentageOfCommonStockHeldByLender",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilitiesApproved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilitiesApproved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "reportCount": 1,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091100 - Disclosure - SEGMENTS (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://admabiologics.com/role/SegmentsDetails",
     "shortName": "SEGMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "INF",
      "lang": null,
      "name": "adma:NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091200 - Disclosure - LEASE OBLIGATIONS (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://admabiologics.com/role/LeaseObligationsDetails",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091300 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230331",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091400 - Disclosure - SUBSEQUENT EVENT (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://admabiologics.com/role/SubsequentEventDetails",
     "shortName": "SUBSEQUENT EVENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_SubsequentEventTypeAxis_SubsequentEventMember",
      "decimals": "2",
      "lang": null,
      "name": "adma:PercentageOfReductionPrepaymentFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U007",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - ORGANIZATION AND BUSINESS",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://admabiologics.com/role/OrganizationAndBusiness",
     "shortName": "ORGANIZATION AND BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - INVENTORIES",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://admabiologics.com/role/Inventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "brhc20052583_10q.htm",
      "contextRef": "c20230101to20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 63,
   "tag": {
    "adma_ADMABioManufacturingSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "ADMA BioManufacturing Segment [Member]",
        "terseLabel": "ADMA BioManufacturing [Member]"
       }
      }
     },
     "localname": "ADMABioManufacturingSegmentMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ASCENIVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASCENIV an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "ASCENIV [Member]"
       }
      }
     },
     "localname": "ASCENIVMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for contractual credits and doubtful accounts.",
        "label": "Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts",
        "terseLabel": "Accounts receivable, allowances for contractual credits and doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AccruedRebatesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.",
        "label": "Accrued Rebates, Current",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebatesCurrent",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AccruedTestingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Testing, Current",
        "terseLabel": "Accrued testing"
       }
      }
     },
     "localname": "AccruedTestingCurrent",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_AmortizationOfLicenseRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash revenue related to amortization of license revenue.",
        "label": "Amortization of License Revenue",
        "terseLabel": "Amortization of license revenue"
       }
      }
     },
     "localname": "AmortizationOfLicenseRevenue",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ArethLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "Areth, LLC [Member]"
       }
      }
     },
     "localname": "ArethLLCMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_BIVIGAMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIVIGAM an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "BIVIGAM [Member]",
        "terseLabel": "BIVIGAM [Member]"
       }
      }
     },
     "localname": "BIVIGAMMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_BiotestLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of license agreement.",
        "label": "Biotest License Agreement [Member]"
       }
      }
     },
     "localname": "BiotestLicenseAgreementMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_ChiefScientificOfficerAndChiefMedicalOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief scientific officer and chief medical officer.",
        "label": "Chief Scientific Officer and Chief Medical Officer [Member]",
        "terseLabel": "Dr. James Mond [Member]"
       }
      }
     },
     "localname": "ChiefScientificOfficerAndChiefMedicalOfficerMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_DebtInstrumentApplicableMargin": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the margin rate on the debt instrument.",
        "label": "Debt Instrument Applicable Margin",
        "terseLabel": "Applicable margin"
       }
      }
     },
     "localname": "DebtInstrumentApplicableMargin",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_DebtInstrumentFloorInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage floor rate on debt instrument.",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Percentage of floor interest rate"
       }
      }
     },
     "localname": "DebtInstrumentFloorInterestRate",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_DebtInstrumentInterestAmountToBePayInKind": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest amount to be pay in kind during the reporting period.",
        "label": "Debt Instrument, Interest Amount to be Pay in Kind",
        "terseLabel": "Percentage of interest amount to pay in kind"
       }
      }
     },
     "localname": "DebtInstrumentInterestAmountToBePayInKind",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_DebtInstrumentTermOfVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term of Variable Rate",
        "terseLabel": "Term of variable rate"
       }
      }
     },
     "localname": "DebtInstrumentTermOfVariableRate",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_DebtInstrumentUpfrontFeePaidInKind": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.",
        "label": "Debt Instrument, Upfront Fee, Paid in Kind",
        "terseLabel": "Upfront fee paid in kind"
       }
      }
     },
     "localname": "DebtInstrumentUpfrontFeePaidInKind",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_DeferredRevenueRemainingAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization period"
       }
      }
     },
     "localname": "DeferredRevenueRemainingAmortizationPeriod",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_DepositsAndOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.",
        "label": "Deposits and Other Noncurrent Assets",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherNoncurrentAssets",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_EmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A group of person working with the entity.",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeesMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.",
        "label": "Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Equipment acquired reflected in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.",
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_FiveCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Five Customers [Member]"
       }
      }
     },
     "localname": "FiveCustomersMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_GenesisBPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "GenesisBPS [Member]",
        "terseLabel": "Genesis [Member]"
       }
      }
     },
     "localname": "GenesisBPSMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_HayfinClosingDateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Closing Date Loan [Member]"
       }
      }
     },
     "localname": "HayfinClosingDateLoanMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_HayfinCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Hayfin credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Hayfin Credit Agreement [Member]",
        "terseLabel": "Hayfin Credit Agreement [Member]"
       }
      }
     },
     "localname": "HayfinCreditAgreementMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_HayfinCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Credit Facility [Member]"
       }
      }
     },
     "localname": "HayfinCreditFacilityMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_HayfinDelayedDrawLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Delayed Draw Loan [Member]"
       }
      }
     },
     "localname": "HayfinDelayedDrawLoanMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_HayfinSecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity entered into second amendment \"Hayfin Second Amendment\" in a debt arrangement.",
        "label": "Hayfin Second Amendment [Member]",
        "terseLabel": "Hayfin Second Amendment [Member]"
       }
      }
     },
     "localname": "HayfinSecondAmendmentMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_IncreaseDecreaseInDepositsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits and operating assets classified as other.",
        "label": "Increase (Decrease) in Deposits and Other Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositsAndOtherAssets",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_InterestAndOtherNonoperatingIncomeExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest and other nonoperating income (expense).",
        "label": "Interest and Other Nonoperating Income (Expense)",
        "verboseLabel": "Interest and other expense, net"
       }
      }
     },
     "localname": "InterestAndOtherNonoperatingIncomeExpense",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_InternationalCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about international customers accounting for a percentage of consolidated revenues.",
        "label": "International Customers [Member]"
       }
      }
     },
     "localname": "InternationalCustomersMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_LongTermLiabilityEndOfTermFeePayable": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal balance of the loans and any other obligations advanced or otherwise owed.",
        "label": "Long Term Liability, End of Term Fee Payable",
        "terseLabel": "End of term fee"
       }
      }
     },
     "localname": "LongTermLiabilityEndOfTermFeePayable",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_MinimumPercentageOfCommonStockHeldByLender": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock held by lender and administrative agent of credit facility.",
        "label": "Minimum Percentage of Common Stock held by Lender",
        "terseLabel": "Minimum percentage of common stock held by lender"
       }
      }
     },
     "localname": "MinimumPercentageOfCommonStockHeldByLender",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days for prior written notice to pay outstanding principal loans subject to payment conditions.",
        "label": "Number of Business Days For Prior Written Notice to Prepay Outstanding Principal",
        "terseLabel": "Number of business days prior written notice for prepay outstanding principal"
       }
      }
     },
     "localname": "NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers of the organization.",
        "label": "Number of Customers",
        "terseLabel": "Number of customers",
        "verboseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDAApprovedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products approved by FDA.",
        "label": "Number of FDA Approved Product",
        "terseLabel": "Number of FDA approved product"
       }
      }
     },
     "localname": "NumberOfFDAApprovedProduct",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDAInspections": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of FDA inspections completed during the period.",
        "label": "Number of FDA Inspections"
       }
      }
     },
     "localname": "NumberOfFDAInspections",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities having FDA license.",
        "label": "Number of FDA-Licensed Plasma Collection Facilities",
        "terseLabel": "Number of FDA-licensed plasma collection facilities"
       }
      }
     },
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilities",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilitiesApproved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities having FDA licenses approved.",
        "label": "Number of FDA-Licensed Plasma Collection Facilities Approved",
        "terseLabel": "Number of FDA-licensed plasma collection facilities approved"
       }
      }
     },
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilitiesApproved",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection centers that company may purchase RSV plasma.",
        "label": "Number of Plasma Collection Centers Transferred to Acquired Entity",
        "terseLabel": "Number of plasma collection centers that collects RSV Plasma which were transferred to BPC"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionCentersTransferredToAcquiredEntity",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly-owned plasma collection facilities of the entity.",
        "label": "Number of Plasma Collection Facilities",
        "terseLabel": "Number of plasma collection facilities"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionFacilities",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities under various stages of development.",
        "label": "Number of Plasma Collection Facilities Under Development",
        "verboseLabel": "Number of plasma collection facilities under approval and development"
       }
      }
     },
     "localname": "NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of remaining plasma collection facilities under construction during the period.",
        "label": "Number of Remaining Plasma Collection Facilities Under Construction",
        "terseLabel": "Number of remaining plasma collection facilities under construction"
       }
      }
     },
     "localname": "NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_NumberOfRenewalTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal terms to extend purchase agreement, if agreed to by the parties.",
        "label": "Number of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "localname": "NumberOfRenewalTerms",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adma_OperatingAndFinancingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Operating and Financing Lease, Liability",
        "terseLabel": "Operating and financing lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinancingLeaseLiability",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PaymentOfDebtRefinancingFees": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of debt refinancing fees.",
        "label": "Payment of debt refinancing fees",
        "negatedLabel": "Payment of debt refinancing fees"
       }
      }
     },
     "localname": "PaymentOfDebtRefinancingFees",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of exit fee on outstanding principal amount being paid.",
        "label": "Percentage of Exit Fee of Outstanding Principal Amount being Paid",
        "terseLabel": "Percentage of exit fee on outstanding principal amount being paid"
       }
      }
     },
     "localname": "PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PercentageOfInventoryPurchases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of inventory purchases related to raw material plasma.",
        "label": "Percentage of Inventory Purchases",
        "terseLabel": "Percentage of inventory purchases"
       }
      }
     },
     "localname": "PercentageOfInventoryPurchases",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PercentageOfPlasmaPurchasePriceEqualToCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of plasma purchase price equal to cost purchased from collection centers.",
        "label": "Percentage of Plasma Purchase Price Equal to Cost",
        "terseLabel": "Percentage of plasma purchase price equal to cost"
       }
      }
     },
     "localname": "PercentageOfPlasmaPurchasePriceEqualToCost",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PercentageOfReductionPrepaymentFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of reduction to forego early prepayment fees.",
        "label": "Percentage of Reduction Prepayment Fees",
        "terseLabel": "Percentage of reduction to forego early prepayment fees"
       }
      }
     },
     "localname": "PercentageOfReductionPrepaymentFees",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adma_PerceptiveCreditHoldingsIILPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Lender in credit facility agreement.",
        "label": "Perceptive Credit Holdings II, LP [Member]",
        "terseLabel": "Perceptive [Member]"
       }
      }
     },
     "localname": "PerceptiveCreditHoldingsIILPMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaCollectionCentersSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "Plasma Collection Centers Segment [Member]",
        "terseLabel": "Plasma Collection Centers [Member]"
       }
      }
     },
     "localname": "PlasmaCollectionCentersSegmentMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchaseAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.",
        "label": "Plasma Purchase Agreement One [Member]",
        "terseLabel": "2011 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementOneMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchaseAgreementRenewalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Renewal Period",
        "terseLabel": "Plasma purchase agreement renewal period"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementRenewalPeriod",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PlasmaPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Term",
        "terseLabel": "Plasma purchase agreement term"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementTerm",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PlasmaPurchaseAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase normal source plasma (\"NSP\").",
        "label": "Plasma Purchase Agreement Two [Member]",
        "terseLabel": "2017 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PlasmaPurchaseAgreementTwoMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PlasmaPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plasma purchased during the period.",
        "label": "Plasma Purchased",
        "terseLabel": "Plasma purchased from Grifols"
       }
      }
     },
     "localname": "PlasmaPurchased",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma supply agreement term",
        "terseLabel": "Plasma supply agreement term"
       }
      }
     },
     "localname": "PlasmaSupplyAgreementTerm",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_PostMarketingCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Marketing Commitments [Abstract]"
       }
      }
     },
     "localname": "PostMarketingCommitmentsAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_PrepaidAfterTheFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid after the First Anniversary [Member]",
        "terseLabel": "Prepaid after the First Anniversary [Member]"
       }
      }
     },
     "localname": "PrepaidAfterTheFirstAnniversaryMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PrepaidAfterTheSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The second anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid after the Second Anniversary [Member]",
        "terseLabel": "Prepaid after the Second Anniversary [Member]"
       }
      }
     },
     "localname": "PrepaidAfterTheSecondAnniversaryMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_PrepaidOnOrPriorToFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to First Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to First Anniversary [Member]"
       }
      }
     },
     "localname": "PrepaidOnOrPriorToFirstAnniversaryMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_RestrictedStockUnitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Abstract]"
       }
      }
     },
     "localname": "RestrictedStockUnitsAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_RightToIntermediatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Right to Intermediates [Member]",
        "terseLabel": "Rights to Intermediates [Member]"
       }
      }
     },
     "localname": "RightToIntermediatesMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_SeniorNotesPayableBeforeDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/DebtDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.",
        "label": "Senior Notes Payable Before Debt Discount",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "SeniorNotesPayableBeforeDebtDiscount",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities",
        "terseLabel": "Amount of shares withheld for tax withholding obligation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities",
        "terseLabel": "Shares withheld for tax withholding obligation (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were granted during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adma_SharesIssuedUponExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued upon exercise of warrants.",
        "label": "Shares Issued Upon Exercise Of Warrants",
        "terseLabel": "Shares issued upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "SharesIssuedUponExerciseOfWarrants",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_StockOptionSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Shares [Abstract]"
       }
      }
     },
     "localname": "StockOptionSharesAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_StockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "localname": "StockOptionsAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_StockOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "StockOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_SubsequentEventAdditionalInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Additional Information [Abstract]",
        "verboseLabel": "Subsequent Event [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventAdditionalInformationAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_TaxesPaidOnVestedRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow related to taxes on vested Restricted Stock Units.",
        "label": "Taxes Paid on Vested Restricted Stock Units",
        "negatedLabel": "Taxes paid on vested Restricted Stock Units"
       }
      }
     },
     "localname": "TaxesPaidOnVestedRestrictedStockUnits",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_ThreeCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Three Customers [Member]"
       }
      }
     },
     "localname": "ThreeCustomersMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]",
        "terseLabel": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]"
       }
      }
     },
     "localname": "TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_TrailingPeriodForVolumeWeightedAveragePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Trailing Period for Volume Weighted Average Price",
        "terseLabel": "Trailing period for VWAP"
       }
      }
     },
     "localname": "TrailingPeriodForVolumeWeightedAveragePrice",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adma_Two022CompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2022 compensation plan of equity based compensation arrangement plan.",
        "label": "Two022 Compensation Plan [Member]",
        "terseLabel": "2022 Compensation Plan [Member]"
       }
      }
     },
     "localname": "Two022CompensationPlanMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_TwoCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Two Customers [Member]"
       }
      }
     },
     "localname": "TwoCustomersMember",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adma_VendorAndLicensorCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Licensor Commitments [Abstract]",
        "terseLabel": "Vendor and Licensor Commitments [Abstract]"
       }
      }
     },
     "localname": "VendorAndLicensorCommitmentsAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, amount",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired"
       }
      }
     },
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired, shares",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes and retired (in shares)"
       }
      }
     },
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredShares",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "adma_WarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "localname": "WarrantsAbstract",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adma_WarrantsIssuedInConnectionWithNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants issued in connection with the issuance of notes payable.",
        "label": "Warrants Issued in Connection with Notes Payable",
        "terseLabel": "Warrants issued in connection with notes payable"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithNotesPayable",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adma_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of difference between current assets and liabilities.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://admabiologics.com/20230331",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r174",
      "r208",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r230",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r283",
      "r285",
      "r286",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r174",
      "r208",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r230",
      "r275",
      "r276",
      "r277",
      "r278",
      "r280",
      "r281",
      "r283",
      "r285",
      "r286",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r291",
      "r308",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r236",
      "r483",
      "r535",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r329",
      "r415",
      "r436",
      "r460",
      "r461",
      "r480",
      "r484",
      "r490",
      "r533",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r329",
      "r415",
      "r436",
      "r460",
      "r461",
      "r480",
      "r484",
      "r490",
      "r533",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r236",
      "r483",
      "r535",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r232",
      "r417",
      "r481",
      "r488",
      "r528",
      "r529",
      "r535",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r232",
      "r417",
      "r481",
      "r488",
      "r528",
      "r529",
      "r535",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r327",
      "r329",
      "r358",
      "r359",
      "r360",
      "r414",
      "r415",
      "r436",
      "r460",
      "r461",
      "r480",
      "r484",
      "r490",
      "r525",
      "r533",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r271",
      "r272",
      "r273",
      "r274",
      "r327",
      "r329",
      "r358",
      "r359",
      "r360",
      "r414",
      "r415",
      "r436",
      "r460",
      "r461",
      "r480",
      "r484",
      "r490",
      "r525",
      "r533",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r291",
      "r308",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r330",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r188",
      "r330",
      "r497",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r482",
      "r489",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r445",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r482",
      "r489",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r188",
      "r330",
      "r497",
      "r498",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r515",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Abstract]"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r238",
      "r239"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued incentives"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities [Abstract]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued distribution fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r19",
      "r464"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll and other compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79",
      "r149"
     ],
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r508",
      "r509",
      "r510",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r86",
      "r91",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Warrants issued in connection with note payable"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r35",
      "r45",
      "r117",
      "r303"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r45",
      "r68",
      "r73"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Potentially dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets [Abstract]"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetUnderConstructionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset in process of being built.",
        "label": "Construction in Process [Member]"
       }
      }
     },
     "localname": "AssetUnderConstructionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r124",
      "r134",
      "r152",
      "r171",
      "r216",
      "r222",
      "r228",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r378",
      "r380",
      "r386",
      "r487",
      "r531",
      "r532",
      "r575"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r144",
      "r155",
      "r171",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r378",
      "r380",
      "r386",
      "r487",
      "r531",
      "r532",
      "r575"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Buildings and Building Improvements [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r443",
      "r444",
      "r487",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash balance"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r47",
      "r147",
      "r462"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r47",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of year",
        "periodStartLabel": "Cash and cash equivalents - beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r116"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Warrant exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Warrant to purchase shares of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Warrants outstanding (in shares)",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r97",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r128",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r268",
      "r269",
      "r447",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, available for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r508",
      "r509",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 222,262,588 and 221,816,930 shares issued and outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r113",
      "r114",
      "r236",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r55",
      "r56",
      "r113",
      "r114",
      "r236",
      "r442",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r55",
      "r56",
      "r113",
      "r114",
      "r236",
      "r446",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r55",
      "r56",
      "r113",
      "r114",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Percentage of account receivables",
        "terseLabel": "Percentage of consolidated revenues",
        "verboseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r57",
      "r113",
      "r115",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r113",
      "r114",
      "r236",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r322",
      "r323",
      "r326"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Current portion of deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateMember": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.",
        "label": "Corporate Segment [Member]",
        "terseLabel": "Corporate [Member]"
       }
      }
     },
     "localname": "CorporateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r30",
      "r171",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r386",
      "r531"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of product revenue",
        "verboseLabel": "Cost of product revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Product Revenue [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Product Revenue"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r54",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r125",
      "r126",
      "r133",
      "r174",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r395",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Credit agreement, interest rate provided"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r21",
      "r118",
      "r305",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.",
        "label": "Increase applicable margin"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r156",
      "r475",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r174",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r395",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "Scheduled principal payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Percentage of prepaid principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r22",
      "r92",
      "r93",
      "r94",
      "r95",
      "r117",
      "r118",
      "r120",
      "r132",
      "r174",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r395",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r117",
      "r120",
      "r534"
     ],
     "calculation": {
      "http://admabiologics.com/role/DebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: Debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "auth_ref": [
      "r117",
      "r120",
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt premium.",
        "label": "Debt Instrument, Unamortized Premium",
        "terseLabel": "Redemption premium"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r500"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r45",
      "r77"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r45",
      "r211"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r164",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r189",
      "r191",
      "r193",
      "r194",
      "r195",
      "r197",
      "r384",
      "r385",
      "r433",
      "r435",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "BASIC LOSS PER COMMON SHARE (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r164",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r191",
      "r193",
      "r194",
      "r195",
      "r197",
      "r384",
      "r385",
      "r433",
      "r435",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "DILUTED LOSS PER COMMON SHARE (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Common Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Unrecognized compensation expense, non option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r564"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Unrecognized compensation expense, stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r91",
      "r141",
      "r160",
      "r161",
      "r162",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r199",
      "r241",
      "r321",
      "r363",
      "r364",
      "r365",
      "r376",
      "r377",
      "r383",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r404",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r45",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value of warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Federal Funds Rate [Member]"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r151",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r258",
      "r259",
      "r260",
      "r261",
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class Axis"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Aggregate Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r72",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r69",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r72",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r505",
      "r523",
      "r524"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r45",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r150",
      "r245",
      "r432",
      "r474",
      "r487",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r256",
      "r257",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]",
        "terseLabel": "Goodwill [Abstract]"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r45",
      "r246",
      "r251",
      "r256",
      "r474"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment charges related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r29",
      "r171",
      "r216",
      "r221",
      "r227",
      "r230",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r386",
      "r473",
      "r531"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r45",
      "r76",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r263",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r159",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r67",
      "r70"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r119",
      "r130",
      "r163",
      "r210",
      "r394"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r165",
      "r167",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r154",
      "r463",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r146",
      "r153",
      "r198",
      "r242",
      "r243",
      "r244",
      "r416",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r33",
      "r209"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Payments Under Lease Obligations"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "Year ended December 31, 2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2028"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "LEASE OBLIGATIONS"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r18",
      "r171",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r379",
      "r380",
      "r381",
      "r386",
      "r472",
      "r531",
      "r575",
      "r576"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r127",
      "r136",
      "r487",
      "r507",
      "r520",
      "r570"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r20",
      "r145",
      "r171",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r379",
      "r380",
      "r381",
      "r386",
      "r487",
      "r531",
      "r575",
      "r576"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r17",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r17",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r84",
      "r85",
      "r270",
      "r271",
      "r272",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing and Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r43",
      "r46"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r28",
      "r46",
      "r129",
      "r139",
      "r143",
      "r157",
      "r158",
      "r162",
      "r171",
      "r178",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r187",
      "r192",
      "r216",
      "r221",
      "r227",
      "r230",
      "r240",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r282",
      "r284",
      "r286",
      "r287",
      "r385",
      "r386",
      "r473",
      "r531"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net income (loss)",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "International [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Financing and Investing Activities [Abstract]"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Payable [Abstract]"
       }
      }
     },
     "localname": "NotesPayableAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment and Computer Software [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Plasma Center Operating Expenses [Member]"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r216",
      "r221",
      "r227",
      "r230",
      "r473"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "verboseLabel": "Aggregate lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current portion of lease obligations",
        "negatedLabel": "Current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Lease obligations, net of current portion",
        "verboseLabel": "Balance at March 31, 2023"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash payments for lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-to-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r401",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "ORGANIZATION AND BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Plasma center operating expenses"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Interest paid in kind",
        "terseLabel": "Interest paid-in-kind"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payment for certain fees and expenses"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance.",
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r504"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]",
        "terseLabel": "Organization and Business [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type Axis"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r82",
      "r448",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r78",
      "r148"
     ],
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r80",
      "r137",
      "r434",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r328",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchased materials amount"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r328",
      "r407",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r405",
      "r406",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on notes payable",
        "terseLabel": "Payment for outstanding obligations"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r108",
      "r140",
      "r583"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r96",
      "r135",
      "r440",
      "r441",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r141",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r241",
      "r363",
      "r364",
      "r365",
      "r376",
      "r377",
      "r383",
      "r437",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r207",
      "r208",
      "r220",
      "r225",
      "r226",
      "r232",
      "r233",
      "r236",
      "r324",
      "r325",
      "r417"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r236",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "terseLabel": "Revenues [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Net Revenues According to Geographic Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r236",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Calculation of Diluted Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Summary of Outstanding Senior Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r69",
      "r71",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r74",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Components of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Summarized Financial Information Concerning Reportable Segments"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r100",
      "r102",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Intangible Asset Future Aggregate Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate [Member]"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r266",
      "r267",
      "r474",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r216",
      "r219",
      "r224",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "SEGMENTS"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLongTermNotes": {
     "auth_ref": [
      "r22",
      "r487"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://admabiologics.com/role/DebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.",
        "label": "Senior notes payable, net of discount",
        "totalLabel": "Senior notes payable"
       }
      }
     },
     "localname": "SeniorLongTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total stock-based compensation expense, Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Equity incentive plans, term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Restricted stock units vested over a period",
        "terseLabel": "Equity incentive plans, vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Forfeited, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Unvested RSU, Shares [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested, Weighted average grant date fair value, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested, Weighted average grant date fair value, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested RSU, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Vested, Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, vested and expected to vest, weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r336",
      "r355",
      "r356",
      "r357",
      "r358",
      "r361",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life of stock options, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Weighted average remaining contractual life of stock options, expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r50",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r142",
      "r204",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r230",
      "r236",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r264",
      "r266",
      "r267",
      "r474",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r91",
      "r141",
      "r160",
      "r161",
      "r162",
      "r175",
      "r176",
      "r177",
      "r179",
      "r185",
      "r187",
      "r199",
      "r241",
      "r321",
      "r363",
      "r364",
      "r365",
      "r376",
      "r377",
      "r383",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r404",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r199",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r91",
      "r96",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options (in shares)",
        "terseLabel": "Common stock shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r91",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r65",
      "r487",
      "r507",
      "r520",
      "r570"
     ],
     "calculation": {
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "verboseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r170",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r393",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r393",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r393",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r393",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENT [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENT"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r368",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.",
        "label": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r200",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "verboseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r190",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r189",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r492": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r493": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r494": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r495": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r496": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001140361-23-023920-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-23-023920-xbrl.zip
M4$L#!!0    ( !2(JE;;])ZY>1(  )C2   1    861M82TR,#(S,#,S,2YX
M<V3M7=USV[JQ?^_,_1]8O_1TIO[.2>/,\>E07S:GLJ@KR4G/?>G )"1C0@$*
M2-I6__HN0%+B)TA*LD/?\"61B06PB]\"V%TN@=_^\;)TM"?,7<+H]='YR=F1
MAJG%;$(7UT>^>XQ<BY"C?_S^/W_Z[<_'QS>88HX\;&L/:ZW#&;(YL1=8&T_,
M.7&P=G%Y<GER<?+K^8=/L>+C8U']Q?WL6H]XB30/\07V1FB)W16R\/71H^>M
M/I^>(GN)'@ASV()8[HG%EJ<79Q>79Y>7Y\"4@Y>8>@/&EST\1[[C71]]]Y%#
MY@3;1QI(0=W/+^ZFK>?GYY/GRQ/&%]#(V?GIO^Z&4]E[1"LZJ]1S0.X0^BW1
M^,L#=Z+F+T]%\0-R\8:3#'W(S/G5U=6I+-V00D-$T32AKH>HA>/TMK>I$"?^
M]30HC$@!/V^]PMM1F2/W01)')4+.BXC<Y5X1_:8H4<'&),F'BZV3!7LZA8(D
MH<=3+2?DA.)342SJG!V?G1]?G!^!RFB:4!I$*?.0!_HI'X4/5RM"YRQ\ L_$
MB'Z.4)C@N2;'^+-H]?K()<N5(P90/GOD>'Y])" _CE#^]XKC$V U(N',P0I(
M1/$I5'%!(R5GPVW'41.(6YE6,CH C; 5YAZ!@=VJT.G!Q+*04U<LJ&+Y3J.E
MLO&\KE10A5#29*$<]%!7**B"G=>51[0S PDT\>-^8BA63,E2CUF^6*=U:O>I
M1[RU ;.4+Z4Z'6G$OCY24FQZC_K?XO;[&2SC9V?:L1:U$/^)J*T%S6FQ]GX[
M33>2;M]WL6W2W^7O](0.:X<DJIJI.5.]8E(M\^N%3R,D]@2HRZB-*?0 /USF
M$%OLYAWDB!UF^HBQYP8P5:!3@@502;"F,)XX1*MKCGK]T;3?$[^FYM#HZ3/X
MHZ,/]5&WKTUO^_W9M,5L!\S&B,,H/&*/@%A5 4Q6BLL,EEY0J$V@_\_5@)-6
MGDHASG=3".V7!*-_;16DFH)L!MHUY^9*F.W D6IV%U10HGI1?9I/9_#?77\$
MB)H#S1SW)_K, ((6S_IX=A\176#7H%./6=\>F6.#!]?_[L/^5Q%@50M*Q"]W
M1;Q[JX]N^E/-&$&!V?WGK3GL]2?3OVC]_[TW9G^T:K"#&B#W<>"PYZJS>DNO
MA/C#SA#KTUMM,#2_MI,ZBZ;)%XB2_TA>P?CM^"ZAV VA*RI4XO0Q,HB):SG,
M]3F&/\S)C3XR_D^NK9H^@MWT?FJ,^M,6DBPD4W^Y1'QMSJ=D0<D<S OP2RR+
M^>!)T,48II %[E& 4$7:$L NLH!-[^_N],D?8OY,C9N1,3"Z^FBFZ=VN>3^:
M&:,;;0S3K6OT6P2S"!KT"61D? -3_$$)%I=9+(S1%UC+S$D[V/F#[8'10!X<
MK+ONQE/,/"T9]@]YPSX#V\#H#/N:/IVV3F#>X(^#<,U:Q$W 3%N)?3D (+>D
M!(1?LR",)\(FG_TA-PUADXW%OMXBD4$"5GWN8[O_LA+&E@O#;H)SRKL^%V[J
MD$ =AWB;%:DZ>0EF'[.8P28QN0<SK/^OL3#.IA([<W;;GVC=^\D$\-.&AMXQ
MAL:L7=)RXY7X(9Q%\E<) G_/(M#K=]HYDF-9%?BE=;W-CV>?<BRFUGVL@L$$
M.\(!'"/8&V8<41=9L1!086D)'E=9/";]H70&Q[K8/F83?335NVULI\BI7RZ)
M)QURV K 4Q?N Z9;1T-%H,;F_"R+3=>\NS-F@8<N-@?PWH5/T1^U#D7^PH47
M<NC#Y2KZJV3@<_SP:?]&CGH[QIDQ'F+D8O/!(8MX3#KSM&3,<USI85^?]C6S
M,S1NVMAR8<QCM0IR:9"S';QM;##SPK9.A1+(<CSNZ?UX/)011'VH]8QI=VA.
M[R?]1#01_,.!.;F3D+:(YB#ZX.+O/LC9?]HXA>F')<CD..73^\X4;"OA0_2_
MM)[@[O'#7>*(N?'$]&O9ZI'#DG>S?]\O+JG]$K';OIS=54EFZ,&IIR)AC3=1
MD$_[*DC ;*L>R@AV7 >RCU5 Q^+6I4BJP]XM5-7CWTF\<LO4H*6BWJ7050F=
MMP#6BZ''0524JX#,CYR7HEDY!M]">H!@?!SGNI54X-<+P9<JQ=Y!_E99U-'^
MN![$_E9!+&+\I< 5O!MHX:CSDB!A!1>5*BW>G%<#I=!5?,700ED>-DT F'RF
MA"T,EI9!I0JTMO!4C[C&82HH4\&5B;.6XE8E6-L">)"H;3*24+>:.IQ0+U9;
MJA4'B >W2E,[X[2'/40<=>)I1*-2A\),TQ+<KVJEK6J_A+RT".\:6PR?N!-L
M8?(DIDM"!?9MY$TBD%?[12#_ID7\:UL!6M7:6[5N&+.?B>/LH%#IJF^F1A?[
MJ%'$=:L[>^N.L5PAPH5Q8LZ'C"X<\H3M('JZ@SI5:.W--.S#/AJV%41C<TV(
M<BQET0)A6L7;6_$F^ E3'\-&P!8!?SOH6W$C;Z9F'_=1LY!_+29 JUJOIUKA
MH34'T;"HK1^H("$+K9[LJ"=#YKICS$6N)Z/31U@B=EB"BAMYLR7HTSX:)OC7
M5IAK@02:%*%=A/96+ADY%^>YV#"PXA47VG&/4S?T5DIVOI??)V4XED)H<2E:
M/=O?@*=0 <_0"][)8,_6?C.-VLL%#!C7).>M%E5+;4KH1\[SPR0W794F-[5H
M5<YN"F=Q"CDES2&SG:XJ93O!^AZPT$); ]J![\%XZHL%QPOD87W)N!>^ PAS
M8I2H5Z]^:(7(K-LY"A%PIVW8T^+\:2&#K;K43)-+*(2*0 7Y3HER5W42Y5I4
M]\^42T!=NY8*_X/FRET=(E>NU1=ELEQ"%>(/5"A72)>[*DZ7:Q&ID2\WYGB.
M82;:LBCIA%4D5OI<];/IKJIFT_U-V_ 3^.@M]+6@#Z-^%7#/H7P%T+,N=2[H
M4:BO1;PVXE\1YXBF7XZ6DKT"UMGWF[E81YRT.-?".?C7H!;(3I[PV$&T#'-5
ME5? /_M>*1?_@"MMPY8F^6JU88<S6Q+XEQ&I$"\^JZ44]UHGO[0H[W8&3 +H
M"G0JK)5GOY3!7?LPF1;Q"M]')-?QU$/E2EWM"XDK]1<2+4*5/Y%((%54J$*L
M[D<25Q4_DF@QK(MA%R2X4 (94-1"<PM$!5PSSI&B.4TPHUVT\.[S$4SJ?73M
M>NHWT0?]#.;J,)_!M,M"U0.24KJ16Z;&/WDP4BF^%0Y7^BGP^^TT=7-;\"!Y
MOYNXW8TL5XQ[&LW<$!B_OVZ!T"J\9"ZX5W#(+-E,0.U&=]+EUCG%CN=&3\0E
M7!<G+ZX=W7^EY*'@HCLE#VER\6./7F4J#5_7Z3E>)?IC'P[D^Q^K'@OQ.IN_
M]F "OUB/=1C8T,M?>W1,$:PO=7K>5@A^[M&W2ZPZ/4?DXD>]7M.7SET%BRF5
M+]7M_.[3U1S.$[6.13O'YQ?'YQ_WY\.KS8.W2__)X?16O-;P1_3RUWX Q*\"
MK2*XK"+^.H[J"?$OA?B7YSMS\>&4BYL&*S(@J46W'X[//AV?G]4;]<RUIA5[
MC2J(CG^MW&71Y:A[["ZRF7VG77B=(_!G><?X9>4@BCS&UP/XN_H4B+?2WS:R
MRXR(WPI;:XPB^F!\Q)VRM8:F\#;:77O?%YZ\>VL+F2FK*?]VTXR$]QY+3JZ/
MOC+^C=!%%ZV(%UWT)XS>?Z<+@EM'Y=7"GY<,5C[$UX:'E\(: Q;!Z/6(YPL&
M;SCS5Q$I 9(CC1+'$=_'7A]YW =R!-0<U.;Z:(X<><>Q)%YA3I@]DST%*XP7
M%3T$]PQ>'UD<V\0K%FCD+Q\P-^>#GCXDEKR\:NP@=XFZS'&P#&N#FB?N4Y#R
MUJP7'PY"/;S _#5'P_9Y>(!N!;GUU8JS)^"?,]NWO'PA,T2-E:@8AGMJ8][#
M3]AAL=M+$I+6J=RX$0CO3*0+G=H#0F$"P&\9<(K2I-8QD2M1OY=I/$;KX,M;
MD2,T$0YB(,\ )V:MFNRMA=TB6E/:>$*I.0_7G_!SN9BT:K+&2&OC!Y6P\C.'
M,2+@WG_!+MCP$_B7$\L+\XCN*?'B&%>D;XSX96 ;%"B02&D._C=H#Z^82[Q-
M+F3\,BPY!-6KO)M1&#/7NT/\&Q8K5ORU9-AG?)*7DL:E%KI!%P>0.?A[EW7[
M"Z8VXP!-,$495\M7C;QA,@8;Z]CGUB,HI+[@6);.,%_&H5-1Q26*.FR&R0'V
MD4'=%8Y?;Y,VH!($C3,=QIB+'!FTP)$-%($PAJ43][_[R)FQ+LRL.%HU*@42
M@]<1^#R"/5&W&?C5LOC?E9D?,"O?/ZW5DRZ7IKE3;H(I?@;U C;S0$H6-P^6
MV,R)/D9<1Y/'+9AB>82-G%;)M< N7-_M!MD?)49HT>3O @GFKDR""W+)9TRW
MOOL$?O6IE_2X]FFD>2J<OU6'$V\LVRK?V5/DS5UO*L5YHB#)KG&B;?W&P6T(
M%:62"#E=W_78$E3V#@OI$IZ'BBR]6MELB<@A -[=+NT87XP;_2XC2.IY SDO
MF%$FQ1EARDG?CWRS9U95OAAI ^73I]W^R/B2$2;UO(&<B[ *^)/"RLI&5D;8
M,^?R(!WW*_$>'[%C#QB701EP62?@E,.NIB]% D#"ISU4DXVQ*,HB&ON+')0?
M=!2C)A/1 _GLQVX_4@QS)=WGG)!(?G'#0B!Q)K]BLG@$>/0GS,&X[[^ W4Y"
MO[E$OFI5FR:[T*%.^B G77R>M9!TG?66)(S2Z\^(VZ'00217?.[_(J(HPD(6
MC^ OH;6J(8F/X@]D(L=1DWTU9EH%,U^M>VF:GT/)8)6<8^#:#FSYUU>H3(>-
M6XU?=2*]U3"GNOMI!CE8E]YPF%,=_B0#O9G%/W9WJLA&0_>GUQF3&_%5^(\&
MIA(3S82EOUPY;(UQ-OZ3*6F@^_JZ>+[5LIKJ[B=95#>;R8\V^2NQT<S9FQ<<
MR+'[U63_7TS_Z. *8,&7&10R/6;VB&BH 8'/\P4Y/HZ%33;KW R]Q,X@.X3F
M'9JC]Y+"]]H#UBCTZ@+W^DOZ!K;"/+QG=G9Q$1\.<9I*Q@)0DS70',@YNB9K
MUA33-% B<66+R'S8Y/'VJ6W.Q9,!QJ"LHK^8<-7(W\LRDLYT'#$:?.GG9=(D
MRTF;(G1)=D)TSI7ANCZV#=IEE ;OEL4Z,V*>2(A-PUZGTKMYJ;(Y#3;*GYC@
MN2,--X-&%["%4@'JX=FB^5O _DTU9M1*U*<7'H.XN>]%K&#BPX!8_G@FH:-.
MI>:E=72(T&\O3,G8O#'.I@&HZ1JX^$<))YODBYQDE%A9XQ)-!K"_%N>7Y)8V
M$ 6P@HJ%R"MLH S9"S=UQV'/8DD9B*1S*GOPD=.5B[+81GO,?_#FOA-5C:<U
M'**UINS'9=O0[!$6"H4"Y!8W4 6VZ;3AZE[R?1S *!P?*V@U)RMWEV8:MT3I
MO3L=-H8[1'WQ,;,OHA_A46K9;)YRV@;B+M/X8-^+6<8L^EPPN'TF/(\]G?I7
MK4YC#*/2KX[R,W6+P*Y&WD"\;]%Z3FBP\A8;0TJJ!DH5>3@YP<UL4<,"FMU'
M@N=3BXB PYQ8YAS^P>*C+UEP!Q!8R F?9H#:I7(#\=,Y]AZ'PVYV44T5-)!W
M^>'&2@2+@OERRQP;=,HUC.$XNVY4(&Z@C#>88I>XG?$T(U&VJ('\WX$MLO27
M\6]L8D?5WV+'[JR'6!@D,<GJ5,IY__/CO\X)(Q43_(# M0WO44D:ZGGE[\7T
M#MF?!:FPA>*ER]^+>/$].+2:U\J-.DW4P'D8LNLP%Q#I@=8-64X,7DG50*G$
M$1/;]T ;ZUBFJ<]81T36#?I/0I-!M<IU&KFV)/F_7\TY^/7R+0*Q2X3-)WXW
MGD+DXG9\4$_LNCVT=@>,CZ%I_I43S\-TQ#PPN&9LS/$*K4W?$RN V.>!B%ID
ME3A/Z4#M-<YWGG$$RQ'P*&N!1%^8 _BG\BC2:1RU:C4OVIS4=/%FS9Q_09R(
MCB:PDA5.BCS2IHNGKU8.^!?0R1WB"T(+A<L2-G)-FV(*<R[^/JR#YTQ<=?[@
MB2-U4U\R52-_+^9&D*T0O"*\7XGK-8,$)W,>>=#II(D2XK=-:JAJ>_2P@];8
M[G'TK+ ]"J@::'O$O9/^"Q&[JCG/VR$"TZ*#Q3/8=@M.'JC71"-GL=PDB:W/
M/9&-@P>$BT@E!9>;NS#WLBYY-?HF8I_D?(HM1NT:HA96:*"LR0UEX##&(Z-9
MN:_F4#99:TUJ!I;?C%55W I5&HAGZC!\W;;E.>_(B=V0D/>)6JUJ#8OTQA?:
M";:#MUZ!32]5%1<>"%-(W4A=#O;0<'6!Y[;B'4,!50,U=B(\D!F3:\D2;"D1
M,\L(I2)JH$S@;=EXB?BWZ%7>]OYU*8D;WO\V8R/T0&X[V??;.S;P@\="W@81
MG)[\^W\!4$L#!!0    ( !2(JE:XUBIO? \  *+3   5    861M82TR,#(S
M,#,S,5]C86PN>&UL[5U9<]LX$G[?JOT/6N^SK-B>V9VDXIER?*1<ZU@NV9G9
M?9JB2,A"A2*T).5C?_T"O$2 .!JD+(*9J9K*)&)WHX\/C1OX^,O+*AP]H3C!
M)#H].#I\=S!"D4\"'#V>'FR2L9?X&!_\\O-?__+Q;^/Q9Q2AV$M1,)J_CC[%
MQ MB'#RBT=ULNL A&AV?')X<'A_^>/3#3[7/XS%C#W'T[0/[8^XE:$2+C9(/
M+PD^/5BFZ?K#9/+\_'SX?')(XL?)\;MW1Y-_?[FY]Y=HY8UQE*1>Y*.#$:7_
MD&0_WA#?2S.=:^PO\S@L!9Q,JK*4%.Q?XY)LS'X:'QV/3XX.7Y+@H%"1?084
M4I*_-.@+FX[>OW\_R;Y6I%00UHBNS*;>&XUR_\4D1#.T&+'_?YU=5]Q>L/+F
MF(3D$?O)H4]6$T8QN4%4M>D\Q(^9LY(+E'HX3,Z]T#^F:F0BT]<U.CU(\&H=
MHO*W98P6IP=,*/7*\<F[D]PG?]?+F^Q<T1WJV$F]"S1/.ZC$L7=0X\SWXPT*
M+E_6*$I0<A8%TW2)XO--'*,HO<&4)\0I1EW<9U]&!X/N8K)&<?I*2[G\[P:O
M5[2(#KIKQ750\SIZHI)(W,VS,BD=E#HG4<!"%-"_)"3$ <O+]RG]DYF=3!?G
M7K*\"LES*V5MI+^E$=,U:W!8/7X3*^KB=VW&)R]DZ?M^B5"Z.^T%J76E?9J&
M-V%FS@W]-U<B>DD1E1:493*U=V!55GI9?DA\KLR0M=$DYLUD12:TS*RM6WC)
M/&OP:$_CT?/6M.$[/IZ@,$W*7YA'CC-O%#_\?I8D-7^&WAR%IP?\CRE.F77E
MCY/>M"RRIE19X1NG<_6M#]59S:89E/V/9=$G+V1UY2P]]^+XE?8+?_7"#1),
MLN(I3 7R\"ZH8?PLYKWAQ7Y9 OTK!_!FYZJ@F"2;U2J3-L8T*93\BYBL5'$B
M[:RM*?YAQ$D>I60$E$CB ,6G!S^P;OHSPH_+M.BS]P)QWR<;JN4,^8AJ/ _1
M+4H5B >0EA5 2^H@&"QLTV- +Z@(_8D3H;^+T=K#92>Q["/J<IX%1^$L$(>#
M>+"W5 \+D+P"'4=.H*/LZ+Y2_ HPD'TJO,!_<C"P&MWU$>09BU =&T*U?Y.Y
MI&8'URQ]21'YCUT@LMDU9K_\?H'6),%I-4:])9&?%R_M(T+)"S/-Y"X%S-(X
M10S-4IQ*-,7H+7K,YGQF3)OIXBM-DDQ9(?H@VL([!EJ7XFYCEB+H!A' ?+6O
MCD<^PW-'!Z%I?9JGV=1 2*NNAH[4I7!;&*6(MEY"$>P?G0CV9T*"9QR&0F#%
MGPM[MS^[%#"%LHK@;*F=ZNY?1ZD7/6(Z(LE5I5"Y?/'##5LE4@3)AJ7J $)8
M7 IN"R,5@8=)<FKX7UL*H&GD/B7^MR4)J8()2RGIJP (*'GA)S-Y'S8;K33:
MY8HE=%2Y0+1GE[M6-J6GH=B.T)L4_=5/C>\)Q!RN:C:%%6/QII"B5KYSHE:>
MD]6*1,J@JCZ74[*-SZZ&TV (()9-"4Z-;69LB3!"P:471[012,Y\?[-B)J'@
M BVPC\7^+IRA\!&$P=7P6QL+  1$IE/=LK,@P,P@+[SS<' =G7MKG'IB3\Q
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M].H%M3W>5GQ@?\RI[)__#U!+ P04    "  4B*I6B7)/MU$Y  #3W , %0
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MS>(<T%Q!'B<[<[X^>G68##[$]NG!=?@/;@C[_W"F'"7T,J:Q"69A'^U48_W
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M!9U.#9T">!)]7/=R3&%@2@1]JBJN^>GE38@$I@\V'VK*] 478 PG#)O]F3R
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M)1&]#PY-1+J.%CE:LY&H5+W62QPV^ZHB:I#4Y29&ISJW\0+5L,8L859=NNL
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M8N Z -"+H]<D_BA';TS7%/G!%4'T^MP0?VPN%;KB'.CS[#E$^BK<A4FD@+I
MJ(OUGI 9L#-F+:"=[P$ =YYB@_>G\"4OP*Y=;9!'6I44NU:\X( HK'T22(+
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MWQ!/TFRG-A"T91"YRSN\M10*"S''B0<6>3(D/@S+I7H=<@(\6 >95NT,Z0"
M/(Y#V^DW"3=1K6(0;U[D\'-\F]'#\^C!+=<)?HSVC](T+I'G9G*NO%&><3S8
MR^=B9W"2B6ST:+;-!>EI*86D3Q23@4#(,D6<9#SCJ(JI)O3CA&QQ%FVCW9YN
MP%[AS3XIQB'G7S>[_19O+_)O2YN!^ZPJ^SQ,XBB^3_,V7]E0?.$;X-UO8]]3
M37";GL:F!GME,YI4K!=3FHXL>P_:[]%!P(\KAR;@"9D<D$SVM.>TDW=M_S9_
M,O95^(C+*WE :;<O+LV=;7$K"?#@P/P*,9A#_7S$F! EE1-$!7VY, F*!F6&
MX$<,0O.#IIJKK)<)P&=N@!KH;"SR3K]MZ(DZPH:QYZHS/*X*RWL>^_ZV;),V
MS;2Y:YMN6]=E*3QJ1W<*9+'%W/(37).,GL<5[G8OJ,DIZ:&-_&/.G90JI3_Y
MF%"&PMA<D[B/(J.-W]*\P69NN[Q'F.(NHQ@O,OQH>+RA9]9,HFN9=9OKFH)X
ME.[8,EG,>%U7P@&!VAZB*0>U+-+AS]HFRHV6\_'H,[6+"L->-K=&P-]<@N1"
MSVB.;#P83)-,J9UD2CHULWA\"J.$3N*?Y<6Z%Z]_!PG764TA/#972<T;S4 0
M3]*\HC80'%[3-'!)XOLWNQQ46U3-LGES@!8, F1(H!B^2O4Z+ 1X<,:M3_$6
M)V<DS@NS+[;M\;=! T3;O!**FF"5P+AQ3LG]*!DE4P_:S^G>B.N$;'":^K+]
M&1)NED. L' 8)-#J\4=JW1E[I#61M.8Q7--8/+"49UX)?G;#T&HU7[N^R90?
M$Q;&T-0O3O6&S_#LF30W7,LUK1=;.A3K81- ,\ZB$56-0+L:+>4N\^0NYS2T
M;'/0\DSU]1;@M9BM-9?KY7IVB?Q)+F*PJ9))'UL&DX>%I %/%E62J&X2\6%I
M(B!4TGS CY53_@NN+."]ZV0#8Q<4M*U9R@T:=Q+TY"OXU;?5^ -#V7T#HF_*
MPR3O=H&^ONDH&TXJC&6M$#?MD)/Z$/MC"Z\TYT#BZT,&DO:'!#*\C&2X=\18
M-3Y4('  1G"WMW3625.NCTB0ADX$:&@GBA$7XMO]:!G=('839OQKX_DOJQ_,
MOAR)Z*XYDU#F6I9AF*,0T&>(/O1D+$L0&@+YH%W$=N7:4.59<(31*%W>59?^
M1O']-=E%FY?ROVO\-7N?^_VSCUT-I0.F04KCL0YP8Y@#<(\*;D -!84LG5BY
MSK]'GNT\.#I!$Q5D3,QZ- /H,_0#>W1"RWVTV])3;^)M_=?%XU-"GHM]ZRF_
M1M'1J4D)TQG+28@7HY34<"AE)-A.4+\O[PNJ_X7:XKY4;UHX(2/"R+ 4HMXA
M*=R?2XY*R2AEG6%ZV>.1-F%XS/ ,_FJ<0P$M1JYKB-(3U7+VT#_H'13/X8X2
M9Y:=A4GRDI?O]W"W9U&EI5-]$*#.2)R#O)B$OXY#&2O@=@(J4]0@Q3F(^"#M
MEC1ZH" C8M:E&$B]S3P-?ZX(R93M!J=9$FTRO*W*WGW0DN00=;2M%H%'V#)
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MB:QTI\4N5IUA5I*+G-!59I609Y3BQ5Q&)T%L%%1J:4EIU+-N&5JF!ZK4WL9
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M%(*$G<]Q$'+='>6-L_5?L3G3S C;P9AN;E1?0]$W#H)Y,ZSF7P84CI/P/Z,
MIKT!$E;;<%2ULICR:B2>=9VXYBEK37V@Z%C#JTI#BOCVT\W8 +\U7DVU#.O$
M]FVG.KIR/V>M%]BWXP+[UG$]<A-^^1CF:3D*=\*Q&IX,6[-T94QAM6W52@>5
MXP"$W9Y>D#]!C_4C3R#,#1P/RZ+O+,!T6YP+[KX]IR#_@R1_TG7/9(-3(<JY
M0BS,&2%3..^8M0)TG@<0TON* 7WT)HK?/)4//0$[/WX\M N_M@#N'7DNWCD6
M70$^S>@1N>6!H?4T&@?R,K$6Z/EB!F#/,VP:^!(?*N@+50]SN%'QTCWXI9$D
M>E^]3P">!DL!L547)+C,*8CQ83<I7=:>B@8=8<+59U$)CZ2%W+Q)<H \R2@"
M,!!<SF>K.5J^OUQ\*$\S=TL58*3)D'AT:2/7:Y,'XL$7"M6[LE^NPQ=*]_0&
MTYL*MCA9WEU$Z2;<_0V'"8!>>H8DU(,:LD!+F&O;E-4JA2Z=-8P'S2MZ\UR.
MIG?^45T3=8HTH!]_=8J V52E#YV2>9M:SO>8EO(B>F9).51=)XUTU*=('BV'
MDZ>,ON_1B8(U&>0@^)<CR @\V.CF 4$H!["_94F;\[U2^,STV5W>8QA)=ZX-
M3<XS-B8B?L>K"_;S"F B!?3M!NN'O&L8TN?'D0WXJ!J0$H1!'I87.N:&) =.
M>7S.$+2DZR]D1%.@I3V@)5!H3]@0R/U96'0TK 2F6@.U1=H8^)_'07\6. /;
M DPTAS<%<D-#6P)-&:9'L;'E4 -]&P;PZ0]!J=7>GE,HGJ!&]83&Z197VWR*
M;ENN_BVB7K#L85K8.UJKI=54SUDWIJO;4A_2U2W4I^SJYH:<=74/OHUU=6N3
MM';[?X^'YQW8#.WJ,J$<T=7-+0WNZC:E\)GI5_AKMOZ"=\_X(XFS!W8IPE@S
MFLSOFYDH [".'39V!44QD1BXIH.B,8#C+=ZB<[S!C[<X0>].3^BH^?\XCL0A
M1-^ !")#PK!$PEH<DE#XI7)(CLG;T*)"V.+%T%;U,G:\ ,,7THQL9]MBS1&T
MO->YSS&S3!W](8-+I?Z4'7/JT?4 4ZL,QGKHC4W:#/_GXT@,?0@-[7"S41W1
MXZ:F!O>Y#^5P@6DWPTUM[\;A/'C(B1KX5EE@8N#)" U\K (_Q=LH+2X.I<=_
MTS7+LT?Z+YUJ4&4#4A6*;=A,'2*OX"H1?ISAF'(,SB-2NT4J^15%CT_[_+4G
MYXZ- QHT54#BKI$M1.; &4->'E<,F*8"597 "OB!%6G;!"IMH-+(M\Z2(96J
M59KX6+E^#+-]DO^YIA=RZ^P[ %J 5*PB"S:3"M_G9+,\4O>#TXG$:E"W^&C"
MP$F92-#R=A?ES8*(Q([WQ8U!&#17J$.ND2CXQL!I0E86[W)$J[,P<.AIX(C3
M9)UR[9-!5$=(:#HVT0NO5BT6!T\\58\])C4/'0.ZT>/'D(;TF2<=,7(R4&1R
M?&C0L-"W =V1 S]#L>NJ)1K&VX_%+#);C_1>U#5%Z\58NC6FC+;R6*M2PG2%
M _IO]+E\XO@ ,TX$B.K;,9AM9#JH9#3=-&YR*M!+PA:/3PEYQ@43^#A42S9-
M&(GDZ(I!:-ML!T7E1I[\Y=I!(X#:$K[ '1!HHAT1-HD+E;IY6V';&652P=GQ
M_)=M8J3&3HCOFC,.?]:R$O%=A?ZQ =X< "\($@MJ[J?EX#CEG>S.L^ $K54S
M)\H+$V_[=T**<*RI5B,<K#86^T!'1EFAYU/*%QU3P>5B]GYQN5C32Q1F5^=H
MM5Z>_=MOR\OS^<WJG]#\WS\MUG]SS"A=N)!QH618"+30X:>65Q^9J\E83:9:
M9ZCY<268PS&TK,:1ENO9)3I^4@XAXW 2ZI#/S!@2P(FYL2.@L['HHV-%!S%$
M.\GER]<)-=$8D&&LN1KS.11-G,S%>=LD0VQF8[W$*\BQWN!; 650@A3@TW3:
MLY7A-)-9/V\=4S#5*4@23?>)Y6R?)+B_(% HT$\SC8 Y8%8F;2:=K@L@4MM*
MU73AIGR$=AZBEPT='\2<CRV$<B4K0'3'DA4TV,A6C'E]*'1SUPFJ7ATO#-0I
M#8P#;Q*<>AQ+("A,>#;&JAC3ED:G^%[T@-\=@3KK9\%??<,_<(Q)$@(5'13C
M2%S+;M@1X^7=68*W4781;HI9[MG7J-_)D(LUS!")C>8%W[!95DA]R#DA40TN
M<;%6\"I\Q.@S?>QZ3D,53*+WX5DN\#6Z3)!9]84'9=S."3U+%< 'GKB$%UUQ
M"_QH.[#-$XXO7;[T3 14BAXN7,JA6O $583Z7 I[R"8N%!2L$H5+S:ZVIHIE
M?2].V$;B^S5.'L_Q;29<+2^3J7G%EQE+)IY5HPR2.)#21J@7G,_?KQWS0!HO
MHO%Y&<3SQ#LP%]MS@^TT/2,Q73R(XTW>UJ,T7&3XL=>F4@HV*!<+CH:ZR+19
MO"N\R$$O50XZ[]#GHM(H7KNN%]3A);J!8)DATNG20V[9"XX4&SA4_.@(B;A1
M"9GF16'6*B?:'K3X<%!DN5"\\8T&W2C**-#[Y@KX%_)2Z+<LNH#]QS#>W^7=
M_7V2EZAND7%7T (DJX\AE1S) HEMDU10NY'Q0:4== 2*:?#+\)8D-+XOQ8SX
M$UTKZLF*6DC@B7:$NL21*+79H[3M@D)7.#L+TX?KA#Q'6[Q]__(IQ=M%?!'%
M8<[P^'ZVR:+G<@:?/\H[W$#U$8<8&,E#?9<FZ3G8NXRU XT&9[/5;^CB<OG'
M"EW<+#^BB\75[.IL<?4!S<[6B]^+^7_'P\TC$$9,Q;Q+>'U;[3PPM"0>I8=F
M.]>AK+"T(%&4IP.NHITTP'%E?+9<V_4 [HN,!?0V[4VND".R.+T&D6;K8]B(
M>LEY&7S47%<$%L1QC@T MX6>)T6PL1E^?;?FX'M:XI=JH%H%W;Z@'S^58/ZI
MM9%W]@VB6;# 8 HX.UJ0("AD>:GN@#I*HBBOH[B*=AC.<355'25V/8#D(F/]
M.BJJ)7VOHV3P4;-:$5@0J3DV *06>IX4P;;K*(E;<_!5UU&-HN]UE!4TZ]51
M1N'L5QW%Z?,-'EX9/*PRX7#*5'64V+69,12FCOIQ7_/ZJ<7VNUK/]QI+!J9!
M(R@F1DZ&C9C8K+$$[FS76!*WYL"LKK$:1=]K+"MHUJNQC,+9KQJ+4ZWJ30P
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M#'OJ9$$KO^+HTJ=HJ:))FR82I;G%C29*X4U*U%D.:<R/./GYLT#2*'Y-)3_
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M!I/P3JP.,+3ZLRK#&GU;6!G=$\C@!+61LEAFSREPA*BR5:Q*K:RAQMQWXD$
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M(+ V4\YSI V$TU>%!%ENU(*"H3E#UJS9:3R>=6T U)-=:6<NZE@!()N0T0*
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M>9D6:;K'V_-]0D?0BRGFXKCOXEWWVGN\[3%ZH'[#;FW]T4S7]&B6]<.<RS/
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ME?!]F$8;&-GENG*JBW3M$)WO;0*:2QT/(+G$7E#\U7N"*T"CIK<ZEB!R\\T
MJ"WS[S.Q!6N[AJIKTMO8FB]=ARY(KK$6;)#)X(_YXL-O](J)V>_SF]F'.3I;
M?ORXO$*KWV8W\Q5:?EJOUK.K\\75AU^/(PG(UH2-B?BP5,!;*S:L%,820IID
MK620_^N0"/)__.<9O:89)T]ADKU<A8^\@6N92/69^"(#"2LJE@E"*FSS""=5
M"=IO$'WEQ2"V-&0$]HF[#.!)4Y3++4V'XC@ENVA;K)0N-OQP<2P3:I#,%QJ%
M99Y)<VB66!?C6:@4=-Z5V\H\P;0T? 3ZL5E<\^0/R!9;<X=M[F2Y2DR([Y$3
MY[(BVL.X<O)<J<;'N1>3Z,I0"K&NFDP7:8CQ;F5278'X\RC!F]P4=SZ2_[+Z
MF>S+$9CNFM)%LO"@0J%I$8@YPD']S)?I2$%,B.I+=L'9E:LAR=,V&M;1LR=B
ML_"8GAZ">J0Q%<QU0(-J<BY#D5X^AO]%DK-]FI''G*6<AJ)8H/IM/($1F.R;
M,YINA.9%\!0H!/4C+YJ#DB 1R&?MPK0O6T-59,5XO(WD(;%IO6#G^:AX@9HW
M1QUT07+2C?JD2>IK]+A_Y#:!N.^:U-1Y-PJE+4NF6O(\HV)DLK)!]<B3*I(?
M!Z+X?"P$6V(']/5T)\-=%(MQQWM7XZ[[;@SNVI:,X8YC5(B[GFQ0/?(%=]PX
M$,7G8W#7%FMPU]>="G=TW'!YUTF[W&$.I5SU,R5R([ IM&H*IRH'(LS*]5HM
M-R\&.-1!)!K?NPMLH4H-<H7-J0!_G9#M?E,L[EKAY#G:8/ZXGE*N^OD2N1&
M%UHU!7B5 Q'@Y7I!];I895B]]P3[ZG@2C4_?Q;Y0I<:^PN;$V%\F52$X?7"9
M2!?QC,AXL'<,&L8YS[8"XGT5/KH]Z)Y)@T9@'YF+Z(XT V:.I:EP?$./L^"
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M,;+GS.B)7Z*[3U"2XD?V(U];J.3-)& 8 ,.V-0\#AMS(]64=&;]I,\:W"=A
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MG;,Q.Q>7E2!N6;80J;1?$21RR>*89IS)9M&?D/YJM/JX.R&KM4P>0#8%,,D
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MMH+0GQ:5TQWG/]MT0(G.IE@G&4VY"IW4I8RSD:.\0/G*SPPSD8J.E:0<._I
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MUGEBTZ.*,\@(3WM,4=*((LM[]D<4Y^$[)LG&3N0[3F$&7)ZHG'Y?FU%31BH
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M)DYMK' ;A2!:XM1,\VU'F746<M#7NKD5HHK(5)A;+FT^1QIG:6T=NYUF8VX
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M"7\4IT>9+2J/#MB4M*@BY@=N)BY?X1"!&H=C@" (>.2E0XNCTRT]&FV!>+1
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MWZ4;PC<'LEX-^$5CHIN^\M&#^ _T"UX%O[Z7#MYV0JH+Z0<)L;R*>(!.\(#
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MF:)-*_[H<2NVL/M_2S)-15GR=H_V.&,]AX**Z9PC*O_:&*80L,N.F#3M_E,
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M(PB:UU<?1KP,OV'=$NCM0@ C)HT2XUV>8&,E?:T-]X*445)8A[A&2;&%(1*
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MT4CS:UI?D'.WYL8B/8EZ29Q+ED;)>9D7>(<RX@E_17B;1?OG>+7(4"1?Q[#
M:7C'U(R3UUBV9R,XGB?5&>[1!#:=M;OA[_226K<[6&^?HH(>:9>OYDS@($E_
MK>002$YL/4N8),I6UA#P%@<\>[;#\/>=Y]#NS=@4^9F!*P4F7,9S?3TNP23<
MMF,GL_S;QG6'ZX&6V39*F^.=BW1]5N9Q2GSP!2JB.''B;OH2G9/ !R?QNA7O
MKJ=^+W/B _E%ZH^L\FP@9HFGHQ.7*X36.8VIK_.\)-*A94:3=RPWTIUN_8*'
M$YC@@@86H>"F:O[\EY]__K%2E?[R^VVY>T+9<G.71/DN.L=)@JJ7\JZB57.
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M##XP8$@7FZJ-B'DL3C;T501RH+!WS"/(1-5#[>[)X+_;5_?941;CM7(;3U:
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M>!_G?UQE"$E>K#E:?7-T1'Y]I]\1 78^<D?D2V3^L*7[COANC[-JKUI-64H
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MN^.N4MJ31:N.C8Z#6(5$\YRE.&*+\H=DR'KH])%JV((#24#KGT82A'N6U7[
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M_,.<K>>MAP J8WXEZT3OO(2XLNE@E_O#J\S=AMYZ%MW5S8]=]2,Z$LU:[>_
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MR[AC,91<HNN0W-YH>X>R%=H7\0NJZ_LG3NA#[OGU]<T==W2%%VBT@11PYAS
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MZ:EQG>;[6G#69<B)QE ;$(6();&6D\$R8!UD#JS1$NCA5NF/JDT@#JEH%VA
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M"%0G/+(2B"HJ].<NBV+]H-/C5X2W6;1_CE?MF_3\^%-$Q\:>8[JCJ52W1%\
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MO2Y]@Z(<+9^2>%OQ='EMNA)%=.Z!_[%]08/YZ'0YN1*&OTXHI6&7E(<T[O)
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MVKUCVQ<&7DI_7QK1K$OB4-IAR5YPKGI0N\ RV+#L&5BV43,&U,],>W9(-M-
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MY*0@RI/%)>_HL2)C>#M]6R<,%>D6)>;OVDE3/[E5!7BSXK$GG'*536!8H&5
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MM+#\R[8?F>CR^,#!V7S>Y*Y&#E8G7<U\D>?O^*;<DJ>B=;VTK$I/Q7$=%5H
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MY!(3(61SDR"3FNJH4@=)#\Q"PO5-LLV^0PA;T($M&^,G.5O*O7H61CM$ZFM
MA>2S.@Z-$\=T.,#$=ER&/5 1!'PQB5Y@-,+88SZQ/%OZ%28"Q :>E&);*6\
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MHE0R(PBO)T%RHTQ656J'<;\F-8-K<E;1\UBPM3IGZ9E.42)!F"@@\J0?=F>
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M50F2W;"<M\C/FGKKC5)JE-+6E9)I01M"(@#G!/G(]['/,6>.Z3++P>YSK_E
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M8DW?XI*G) @Y*XH,KJ0A@L=5!$0N;IG2TW#<FAZ[6(>2?XU::=3*"Y@?U"3
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M&SN9TLF4?<H4EW+$91 P%;C$)YCCT-<DD%XH!5:XIA78@7,I._G2R9=.OAQ
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MOGW\8LC0"->2"/L3&JR.C!!:,>*&*@P)X1&+B&O$*:4><MU(B'UG&B/2"Z!
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M,10 >5_9J0/.APJ84/!SYHR,V:C,%F<A4+S<>4@>QH.\.QTD4P_&4N4+52<
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MQ]QDG<E*F#/PC6HQAFIFE4T)W#QD/+*D-XCOXSPQMF?V!>(1?#76<$T&A5\
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M8# 1_#QZ/(GLH?C '^VHHUXQ@<G>;'-0[;RNNGE713.3'HR)BE1U <6XI<D
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M^#&B@]X60F]L LLXD\A82@SD$E(LO= 0::RIQ=LKR5B$7B)ZC) >19M/\NQ
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M$2K\+K'FN]ST:T6 #F#;![":(QL\#VR)T<0C(Q'$R%/$"5+!-ZD)(FW/!XD
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M((PBC& FM93("^X1<](35Y-X^?R 8>?4M>2L=[#4P5([86F]4\>M$!Y#YIE
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MI6 V+7\/F0&K;RQ;)2>M6DS+A7;'8;DS9[(.\:6DHM<DH@=(E^)L9?K7<0_
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M588PZ%BAF#38$ V<M$X3;CECWB@$Q#;F*CM/(8="$0((=4Q3IHF 7C,N@RT
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M66S#RW8'&NI?U:5D'_Z0D^!#I,!YMO$ X=??U$/\1)U:XU6U1J9:[2U:H\W
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MG9T&BO/DK05W]\F"5EDL=SI((RJ03.H69A;DN?195+FI?$R=NBQ"=S]67V8
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MOU5GLP&N!406",@)<$Y@9[A2"--@NT%3V^5MM?!?7'Y80IZ%-ES;VD3@L,>
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MKF]]YDDEHW[ZQUL?)YXNS,C>+^4_AX5\".NHUFI6[WJ9%)10C'7,8D1$0V4
MLMA!@H,>W:^<D\TICTYP307KPJWIZ=I;M<6H\*VR]3[RLJ99ZSGZC$B"D1Z
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M#54WS/C$'UWS+/M HTZD?^BI+,WU0KMF:W,,C4C^P_K;EM3O>'5]CX7E/<K
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M3Z9)K2/[7/.PO##G9>78G.DS$-A7EU&Y=B9/_:X]XBZJ.SJ[?J[O9.$9T#8
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M((HZE-A<<P^B'D0]B'H0W01$80(YUXKQA-A0@4A$<:QE3",. 8O1GJ.-7@B
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M)1' 2$+).(X9IQIBJ"6CH=$[2=SN2#) .B2"G9!Z[//8Y['/8]_+L(^'C&C
M,*.,X41HBAD7<:(P$4:AQ&K/@6 PZH1AW*&1+TQ["L5T6A)7=A1!I"TZ>#J-
M<X<VS;9%!TQ^<?W.]8OK=ZY?7+]S3WJV?N>>\.+ZG7O"L_4[MXTA6!M6QGVQ
MN^0]'W2'O%=T)U/=X2@SQ#Y\A;]]>S.W5<&N!>-N12V7S_S9'<G<IQ?RWZ-N
MIC]GMM+X\/ESS^S1B[ZZ,M\.["4U]RA13'%$,45)A'4<"I' & ,= A +G*S.
MDVU75-*:1TH=!,(.BIM:V7AF]NCAT6--]! APXC&&LH$8TV1T!Q@Q(F0&L0Z
M.<*XG'4!)$*@$X?$ X@'D,./^W@!!$B>0 )C@&*)A8P9@H0G"1 8,@,1?+^1
M*?NL!W="[.?WN]_O:^YW"B!-(,,P@0E.@*3&S, @(HI&,(K5JSL;K1F$T:'8
M1I1%I[N=]Q'=L+JPS;+ D#9GHUWJ06:8Q2FEKIT\?TH-#?Y3?%%VE6]/S%SK
M N/:%_UV%(%+RP&WSI0&7B]J+#GET#'(2F22<(BQ$%1(P:"D<40A5)"2$W7H
M + @NZRA*X/=IBT)M=O7SO58XK'DY5A"F5',N%":QQ!KI!A7(-;2_ 4)CLAJ
M;>U(W3LXCCM1V)!OX,'$@XD'D\W !&*>1 PR0A' F@,&(QQ'"8D81F$B40M<
M/7- $!,/ AX$/ AL#P0X%(E04"(18PX3BE7"4823!$LA\.I,Q&T=W["P T%#
M#LX);>Y]NX"VFC;49N_0?6JC=WB>ZZ&O5W04/O0WG3BY'+<O'!O7S_0AH 0Q
M) "+L824(0/24.I$"TQTR)H@^DC=1A#@#HC"#H+PA+(Q#ZGKM6"P;2>L!Z$U
M0"A6,8LI(!&E&BN)* DQC'FB;5-/&#=F;1^OOPG!3D1HAX%3JH[F8:C58_4P
MM 8,A1%(*(B,)B0P%II0$5*#2413;E0C"!;!T/X]5<3&-*,.C)IBFCV$> CQ
M$'(8" $ 21HC11$1& C)$QQ&*#)Z3,RY(HO,J>WH%2'MA$:YP.P-V#<-[J[J
MT__^7^8'+GKZ5_O)$,*2O-L?\9(2L]],[BOI,G.!6]U[,]E_V7 VI)A6D<08
M,<HU0E+@" "%0\)H>41J;M3J8KCF3=3RO.7R&7=DM62+!SRU-7J:9X[BCV//
MV3 =5#Q??E,L2/FE&:Q1>0V+O?OR^<-G_J#?99K_<6'^5=^%<VZZ<FVE4X_G
M'W(SLE*N>,HOEF4VR#FDXVWZ35M$F>S2XB+[P/%W/_P*Z"]_M6\:<WGSZ =F
M=&?"SO&,)V;L/P>\]XT_YPL(,0U%OSQFU7-$FBF=G95,'0Z^_RUHH/[/ 1Y\
M+WZMV#\,S09X+&<$W7WE%@C=/XV[H_SI!\,9RZ=7?\O<C/ZNN1GSS)1J-S<2
MOZ2SS5[L2HN%/'C,+$;]Z?KF\NK__O#K=5_I[[_\E3>,;!N/;W+/+WS;W,WF
MPD7#:>#C#<5(Q9\B[:D%W&F=6\&[Z]N/M[]=O[_K!-<W[\^#BYO+X.[W=W?7
ME]<77ZZO[E81<*\COKF]O[H+[F^#'W^_N?C]\OK^ZO*GX/VMH>O-W=6E_71W
M^_'Z\L)\'WRXOKFX>7]]\3&XNS=??+JZN6^8S.PWLW_7H=>(+8,A.NO*&6'[
M17_5!ED_9.G3U7=#@3[OO1_E!L^,E?[N^3>=/AB)\=B5%GOR>RL +/Z^ZZ7R
MCQ\F&"X%PE&L1 0XQ9&*N,)2&H &3!,"6,.9%!J?2:%"5FLCD =V4;*1;D+\
MT!8L%@+JA(0XY(QB881Z#*BM1X=C 0JU8C,90S>1,:R2,?M( "_:.V3%:N4!
ME]( 9K?_$ S3X&&\2@$WR]0QB)=K%1@"#!]U8):JH$::&&U 9]I].\A2-9+#
MH)L'^6-W,-"J8S_SW RJUTN_Y3\O%I65(E1RU*^K9?SJQ=M@Q>%K5IQMLN(@
MG%$K5M"H6<'8F$JOFG Y=J?#&;3K6<U3&@9R*K#]>\"5JOXNI''Q4R'S9#)T
MMVY>[6!>LYT5U%/"MD$'K3YO\?"UG/18AW,*Q#Y*#L;A@:(H#C;CW82-D)43
M+C7+VGP#Y]^>L7@W/%]O4A\:M('=':0;!4T'G\PMCWEP951'%7SBF7P,$.CL
MPCX]?K;:1TR'AY7VKO]:$X9MAY4??@TV=01L@#)636^.Z[)[R;D)=A+A]4:X
M[<U-^ BVUWYW%_2[JZVRO"Y9YUV)EAUAB#L!1-3\*XHV9\IU0C5WRXB_]\W
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MU\=2"!*%$A&Q6%$,.*2(*<B%P)(D* Q?4MUEYU@*.C$E'8;W$Q1__-!R:#L
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M"CF/DAC&!*O&VC,SL1=;R&S '8)8!](=YO@?/)EA1R#CH?*$=K&'RA9#):2
M<4S""!.-8QES!#%(& )* FS <!XJX1@JX1:K'$<PZK!=UNLZ&J@\E/I_:HXK
MF^EH=?P/W3[OV[,P%P1VW?]J]H']Z\(PV-?NL*OSK3NP&H#H,"Z$%67FCL5%
MLM&F/>H9;[':Y+%,N96+['?R&UADOY./?9&]RW0?+M.K?X^Z QN0'W!I/F9:
M!9E.>EH655'-MZ[@8F[+9[M )*MPF2^SD?F]5U:@,/J6=[)ZSX'W'+2%R,V>
M ZZ>^,_C#7]1[O<OU7:_[E^4F_USL=<O^NJBV.D?)QN][I*5$A.EDXAJC*'0
M0L<,RX@EL8 )B.5^7+(1"CL88>]E\+#J8=7#ZO'#JM)$ 1G%FD*.(Y@P$"54
M<J 5T7%,&V!U%^Y;T&'8 .LNF]0=#;"VRA1IGDF6?EM[DTR9&<QEV/V39X;;
MC9K?S?-1H?D;)NOK@L^_=8>/YE5#/38#%@>;MM@06$FY(Q!1+YO#GUN'_B\;
M_Q+ K3CVVC'L=?_]F%W_:;CUQC)KB;?UHHB)9*$.D0Y)A+D"Y@^,&0L3F2A"
M(-B)QIITOVMU]A^=I3_\>M: IH=&S4-M"[^;_6Y^U6X&5$.B8:)"8XA*EM#8
M6*"<J9@J0DE$]J,HL4Y$6(>$31;HR6SM!1I0_:^7%S%]XV5LIH;1P@(0DU]]
MV51?-G5)'=,)IBTMOS42N?[WR)C(5U]M:\&F EN,<,6T9I@R@4D8\TAS)0%!
M-%)")F@+!;:2!*!8:G,#$5A23*56821@&(,$Z#@"1U<@<K(KF\S1B;1I<3E(
M/%\.<M&XUR\$>30E(-_=7?U_OU_=W =7_S#_;C:M%V9PSA!N3E 7_YT3SG/5
M6!>7*5B]8S;89O 0=2 *!:=2<U:4A'@M61IK=*VZ"6VIEALZCZ,#=5ZY[0>?
M^'-05FGKN&)N[],G0^SGP&5+%^TVTX 'N=D2]CCY2?>5.X/^T5[\7W^B1CW_
MV]_Y<]+M!W?%-1?5->Y7\+>?S):WCZ[8O+SZO7EZ=QA</&1:%T_,M0ZL_1#$
M/QEUV+Q=/+LA70P&/8,@%N8_.7^8RQGBZG]&N3WZOM?94W!W^^%+\#$U,PR^
M\3PPSQZ9]0J2+'T*EA@SEUH,K_NYD4#.(3Q^4?&>NJ=7<*A8'"K"(4X48) H
M$BI@F"."$C0>H&$4EN+.?/K7>]<-,1OP;/A\8T9P\;V;_ZN@14&X,=T^:5N^
MZE\S4OC^>5#<,_-]>?4_[)J;D7_AP_(R+4>&#+<&?_L63,>!F/:*NS3)QK^X
MDDEWW_C _E(\;MK<BNOF%AJ;6V=PE;UU/N^2_HOEAFVL"$MBC92F1 ..40*,
M-<FUUC0$G":2-V:91&,%Q'QZBRM"FU;D/+@WNVS!)@[,*]+ D+$H[&CW8RJ,
M)"\@-DW<-SW[8Y;;I7WB?VCW7?F\2VTPT=QXF?'_G[TO;6X;R1+\OA'['S U
MKEE[ V*3%'65NRM"ENPJ]?A06ZZJV8\@D"11!@$6#LGL7[_OR@,@2!V6*,KF
MQ&ZU18+(S)?O/J^(0)DF_UFERMOM2G](^-VI"NF<V#12<PK\KK.BR]W7\OW6
M+H#7_6CP]/F^YRHN#P?>UJY3U_UH[QL [V](#=P:%613H:ED"87Y&,+![Q4R
MC[H0QK@DD=4L5S,0U4&2>"C[TKFF$1D0JM?(JK(H@Q3M'OA-#.QE%L!/4G<#
M)";KTOXJAA</E5=4PS]A25P1*%4%>3*7I8D7C$!"RV8#FN?K =N#]\/CS^,7
M2]BZMBKKG/VCBM1TAH^=@V:KSE6.#5J"L?HP.M?[YIG!^"1H")$[W7ZW=S *
MU7XX&/4'P=YH.#P,]L.]K@H.5%\=/03O7[I[4,RSB'Y^CH"*HP_IAQR.D.6?
MLC=Q7I3':1H#8R^"?'X7.7(_C/^@TUUD_!J'!'=FO'\';_B2 4%'YDM$M1P?
MP>:_I-=Y(SPEX(LYYK4(_SQ>)[8<]':[1\&@'QP-1H->;W"H#O9[T>&P>[2W
M!\I"J^ZV-FPYQF:?('\W!U5VVU"E@2.&^ZQ"%>IC>B<,H=35%DS35L@M4 U^
M#-BV3G0[VNMVCT;#H'LP@/\+1L.]@^"@J_;"H!MTH_;RY[6CF[QG$_"M=P-\
MNRFBW1I!EF%:.8GSV[RGXYVEFBC0[8BG\%<N/,NSRSA2!1NSJTPB%_T^HF'+
MB*FE\AM5RTD*CG:C4.WM!;OA:- ?!H'J@LUZL*> VQU&P?"Q[:(52-._.=+L
MM>%,KH%C)%.6JW&&NE";*E,@#C7U(B_(%[A<2XI-X(63(!TK^:[,LT1CB-:I
MX%HS^!M[->=@QHWCT"-=D;?+C?"KG)X - CS>,C9/*NP;#V*>^LTA>M^M/\-
M*.[K >^W *FS19)8*89=PN#$-?;M&F8)G/U*9[8)]8I705,A6D%5#F17J&N$
M^0D&83Z,)%/A0_X1?2K<%/[#B+PPE,AY M:4BE[-=4:#/.@RT]W!T: [[._W
M>Z/1(.SM'D6#P5$0#'<'W0,U/!PL8:9K9:&]NQ;][Q[U_/Y@,1G"*R; !(L&
M/T-O;N_@90$GGDXS# -DX6<<VHV&XA<047&!C!/4)?SALSO<T&MY"^E<YDMS
M+;WZO?2.=KN[:M0]&JC!80#"#4%_>' 8=H>]PTVXEUWW7@8WOI?=3G^_MSB-
MUYNA),&+\9Z+VWV5=J&!IWWPJWU\)J?T2L'[+X,$$TOQ:F>@I7R!?94*I.<U
M=ZI?<IQ&?&$?K"_"N;K1L!_N#G?[JMM7@RY<9#?<"T?]?GAX,#S:V]^(JZOE
M%^WLF;O;OTXKZ>PO7ARPX 2AA9KF)+A43#"SF".,7@3 18HQD9C=;N<&TL>1
M"ILB*5MV=H<1(LL'DYA Z5>/%7D" T7ZW14C8*\?&M(^;,2)/F_B$)&O&!_R
M@(-#&NCM_+7NW)V_VXP"V#YRU'=!"N! IE?@5+RJ*%"5 EX(!_R/G9WC-)QD
M^<Z.3!NY8:Y,:P[+NC)HOC)79G_W%KDR<.FEFGK]^TEI:4Q46)W3\L//]NJ,
M9F6OD(3%,2C%\R(F14QBA: EGX"H(XV9GOFHBBHIZ9$/H"&0B"@Z]Y%[HL]@
M<DV7,?FZ4;*_E.(^D4&.D]_0((_L66'O695[(W/$L';$W!XQ,T?T,6$VG& %
MO 0>\1430-<LQZO1O_)!9\JJ),+@!K! 72[S9Y4V+!<QU948YZ3[ NC_58&^
MH=!W\%%AJ,7+C)OG#;!J0.N=?V$ )TPJBKF(:O8Q+CY[J.YDN5;!V-,$FZS2
M )[%S 78"+6[#_ />WQ0FDJF:?H-[HXK>G"+"D,SLQFP9W)K)(6B5 D/_Q.G
M/OUBV1GO&^4T)"SF 0!+5)%@0=@$GO8X33%"9*!GP/;?GIX?.(?#R-Q -PI,
M$P-]@ L8:?A#GBF(>2H4,W834&BV(+ZSKNZB-I-5Q>*M.LB'NE6 W1.\E(0\
M/@,; ULTVDFR[#-"V5Z(SQ&XD6 ?:N-#L$<C!RWPT&!AYJA7@YH'2PMH$':A
MQL5@-.+&#9+C G<%3 4V@H8IHSVBT(A1R'$0E1,0IV/ Z1(=3(3^*L54%[QE
M\AZU8ZU%UP[H_P9R%[!!O&+*N_FHQG!L//$;@<!;@<"%@4!'0"SF^P<X+>RQ
MLA0'ZL(<  SGRS5(T'X O3*!_5#P?QF(.BVYN3?B/G7UK973WSS+[\/OKS_^
M?O;ZCU;]ZV&7]NH9A=?NH&TUO)%750$O+(JV7.<;*>Z+/%T/"8M!7H_C$"CA
M+ T[-2H41X&O&9Y\C+]K?G:EFI]4AD\"6LMG@"<FAPPGAZ;()<" V%%$2M,I
M^@L \X9Q-@/+>!J$JB+!C%^2JPEX"OR-=$:I*6F%!%4AZ_11K?VL2MV9+E*7
M*LEF1.Y,$^7<FX$F- W@NO+X$FE5'UZS+N.: M%2DB4-K"&>3JLTB]0H#F-R
M],-%,S,OA:BIX_5(?&<D%I"SUQ\0=F >K(AK*6 V18>HK@2M7.')Y/W>+)M5
MB? :%DB*]Z)V$!Q >'%!'F:XYS@"B@5S?Y)Y186DRH0)$&9TG",<^,>>/DF(
M9%V0K8!W!+^U]#U'GB:+%=5L!KP U\*#3.D*D#T$Q1(:OSM._J$T(P'>0L8U
M#Z.%TV(HH&#9]UOGH@,L+8L(V*=Y-?:.HVF<QN29QTMPT?C-Z;'!.G* 7 9)
M"]^WZS(BJ4@XO$9+^":X#.($]:F?*#_BU=GO9[\<O_.>GS%D?TFR806D#Z0$
M&[E4*=RR[_U: :*^0$FNX>M\[35_JIU!^&JS;3D^W36COYG5ZV+J>1Y/,;0%
M*P([2OC=F7/?^N7G9_K5/N>#?4ZSJQ0C&/H5"S\]961U7G%Z:O8'FSE+P>Q,
MO==YCO(--D-OB,LYJS CPC"$]14J;J$B H2K,5?"*H')@SE"M:!W9.^ A*+#
M)(H@P8A/ZAU7XZHHZ>F7G(EP?''R^OW9[S>Y%T*2'G"I(LD#$*<_>F_COZHX
MHOOR\!)N#/PS_X:G/)[E<<*^H84#4F1=PZ#MM!] @4"UAH^+/^9P^/M@&._\
M^LI[_JM"!E("?WW51"Z+B[S)N+CN4$%8@1X!,IW&LR/3'29(=Z)E(5?Y]55Q
M/+9<STMBRN+5OR%=WME3Q_L#P[KJ,WXN3!J4M5D\4R@T'2VTP:SQY<&,!$+A
M:NA#T)Q G89UIS$+!A_?)Y>FM3G24:89X E>"Y$Y7PDS7(H<<VXJ\0_BFLQG
MSOG;]UD'T,/O[QWYA_M[\);$B"%53K*(E5$#.X0'<$UT2(I)M.AG:AI4%QUK
MT,U2!42<QH$N#;,"AN++J8BEL49M*PQY5UH/)H\M:H'_)H96QL,LBOE64JQ"
M8'TZS\KYC$,$-]FGW9Z2_;$,,VR:C\]7$*++&&TBCL7B; A./<U0R%0%*<WF
MTB=@K@#&IUIJ S:A> XKN<>0#262N8O"T,AFDA,(J!N*X/N68LYU(.86C@B#
M+2$R E?8 7BJ%/;M"[*#U&8O<V!4B1EH-R.-EO!&;%HR]Y*,B19.\PK^Z7T,
M2LQ/>). M1P%.J0-5N5GS'E ;;Z -4.EUX'-A"#2$9)A,.-6*)024<WP7O:[
M71\+CN%3U&-<:8K+&8M9MF.MM%>:W+0Y(*?&S<]CE41 NF0MP)TE1L9F*0?U
M4=, P@PG>$LJG8"YZMC-N-$0MPFL)4C)V ,.5,8 FDN%#@2PW8"'*%(:@-48
M8$V"@G-/,J3DF/,;>6/*^ZM"HB K3?P6HB:-%R3R@CPVH<Q<H8:$+R?M,V7S
M"8B_XM<^@]^;N 'J4!D1@I1IF'VA[I$1P@#^/^OOV=^@05M[K?QZP#CBO  A
M]P7OEM;=[3KKCIKO(/\#.9I]E/U7"G0B^-\@G  4.>,T&P'9"WI$I&C;!#!]
M^K_8.L4%<$L=[[@4G-<+)<CG^8HPA2,,,'O,K%)SFXSSK"C$15WH](F<4C/@
M_8/NSA[(:#QTJE D R*II4_WNSN[74Z'A\T$15%Q&E7!B1O(P0D5#%X(?'@/
M?/CF6NX:3K[ELUZWN_.LYUP9_N[9'GYH[\!'HQKM8\#8!#0C!Z((N1WXSYY7
MQK#,C#*]Z"5#-<_2Z X<ZF$GPG\709O>JJ#-U\]_=X(VJX,RC9#.G:,TM4#0
MMQ"RN5X8?V('&SLOQ>5Q0BA68'I\$4<Q&#S$FZP)R(YIS/=/&Y(3 )IH18P%
M3*P,YR&%\1,*GZ%X;"@,[;M& 1KGZ/,M:$?G_-83^U:]-_.&0HTYY\9D&%:L
MWVCHX"G*0 L ,6SQY:RK:]5"]'M7,Y'GM#AC4XT,P@#]^K02[+5 P:"UI[K
MK .'Q+0\Q]: U3=8^:%4H#B/=BCN#Q O@+?@<7%[.GVNYM@!@P&U&6&<$ADP
MG%=[JH%K+UX0<Q(X%A'+\@=<GT.6L,$FJAD*+>UNS]54;)[E;T+88%ZKV 9B
M ]9,P,+U^7))U%E:2S)%CX=<#6J)UE"A9:UUN+@Z7AWG))C%R!&$V_]OD+S
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MWH1$NZ2VUCVM8LZG.R!I"T5OW1FA]#.:D_%]Q%_C EH6M3L79/BZ%]>UYM:
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M,6S@5Q4D)1^;@YD76C!J&^[77RVTW[*50I$LO$:BG9908QV>7.J[$(GDJW.
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MNDA'HTOBD4(1JM"I@I!(L&6D\VZR=HPOM@5'SDI^ZS3X$X"/^(:Q;([5 #X
MMYK20Y2IA2_S0I"(H$4UG*VS"F L$4% 573:F((#5$[A)B+8Y811*HSS'-3R
M6'@G;3K$"HK<8@8Z1@/*X]N)0.V9LM=(= EX'08Q=S"C!=@TY0+BJXQ[DK-1
M8[0XXE+GY24Z82O&IHG"V]B+6XL0ZBW8PO^![_6.CHZT%GM>B[KIQX6%4I&+
M+C?10,#36(V*7<_(_!.R\8M)/)/=V@:@C9 =Y=-P*TGX\]"OE>T%%:CPN=:N
M3!HEGDH3E19>IN-%(U8V#$HXJ7,<RK"QWT>8B1D/*XVSM22R*^6H3+7L- T
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MBJNE6!+.4$<.BVUR"BGQ0P^&(R):SV'$A*CA!!+?W9 ]D$J,_1H&>2[5GG6
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M8==IZW/644)/8@3=E&=R&J (CZK@SFUU 5_W_,PJ(,@064<>(-UELYJ>)VS
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M9%G+#V06I?,K]078O*]C 58"@1H3%R0ZJ7=!,?%&U.N@::J2N,33B']JRLD
M4FUFHK <$J^G5>FD(O,*H[_5@[=:%[_4*A]R6D9,'N-J#B,/HEUGR8D\1J;S
M;-H2'6XZX?@\M<EAKB&!RJBX_^RXCUHG!:W;WR:E%1,!-6BL(Q-'(E#66R.4
MVXJ:'="-I-V<FWIDL*F&0K7\7\=;4L,.#NI+)CA[ DO;Q<9%6N/JJ[D5-97\
MM W5/$*H9F\;JGD*H1J+E)S#CL5:!3:+2<?_^*'[ _T]PW) _3>?Y?3B_,U;
M8-Z?\$<_W &=F$YJ-^5B<J)&;;W/+<CLO_C??R_SG]W/]!-_+Z/FI1RV-"+2
MP"JCV[S%HP)&,%+TMH$%P*O)"MQ_>8NW!569+7M;_0UR:\?UD+[DA8IM2LU"
MQT&B_=?.P!J3;! F[':5_LA4R6,= 37)1/S=J%TKX44W\;?:5>A__>__!5\@
MMFPQ[DEBG)LEIIT0W.S#*&B@%!3N_-XMJGR?J'(=<S(!I)*3OL&,)08EH>94
MZ\"<+63[I0>N8Q8UQ<SI_7.3TL)%9M>H6%PZ=<PT3,>14>BURK=L<8OKB.NI
M&V+G1%?**Z1Z,NS)%\GPXD7S56.Z= !TBUY]<J<HMJA\V_#(;>S$Y?/D&"NQ
MFX[3]=)MQB*U(M;(UKD.W ^2JVGJU"E=H )*C=?N)#,XU)D0;_]/-^7TFVT#
M9L'<Y'MJAPYE>,)_'<J39I?.-INY._=.:O?J&/Q%%ZK)',-@BFDB&+Z3<4_L
M[)&8E6M/<Q=7'G8M 3T92CY"LY=38^.:9>PX5,B%PIYXIT>/*9MK+-:H,5AT
MAV0Y[;[NDVR$\&T*#+:C;77*C!UHV+[U+4Z96F16_\AVFU@L^?..4_= X@EQ
M?"\FV9<%S.*&ESEZT-^BHH)V:<]N1\Z:,+Y=/>&$=Q.I)=!E\B9VPE 5KSB@
MW(O!7*W0MK@BXG!W26U8N"?X0CE@W5N\>,*%2-SB#R1HR5+U"GW /G>I,4X@
M$*L("2[J,WEG@=MI&D<@\?.U0L2&NVK1W:6"<+*P9?)_Q9<F67OIGGV+Q8ZO
MQX0;3)&",R:L&7W1_B)G%K2N'.&POJX;L2E0-NAJ RTM.5G-=.<%1W?4A%B#
M\GBPK:4>QC9TI/Z!&?>19*L(RM%V%LBA5CI?8P6W\PL^O*O]5%<\? J^W+M[
M'8<'<S4!Q>Y;2R_T9!UG4#<F_;548I@,-%-AJ5M%,-M!+VD:8M(D_D;:Q6MM
M%T/+A+PR6G-U5KKH RW[U5A8B^7:Y#07GV*2.B1'DO@S9A=).R[M6)48IQX$
M"Q)XI <&P FXCR\?J)8_)*F<NDA7LYEE]2O(QC3.4V1(MA>T7D=<Z-"1%,.:
MNC-Q9=@$4#8)N+V<"G)\N6X*-_<78MKZ"9_9$;KY+',"RL", <F.D=(.. +W
M_Q_',I).UW40LIBNJ?APJL;,N]2E3 % =B1, 66W UL-Q3J(Z2J&[EA>RNX,
M%F!K OX6Q**MN3L,JVDE[%34T=B,3^14.;G%FJ6F)](L'*?CO7)+-@7*5ME=
MK.0VB76F2$0G%QC]K@$!HBQIN$:-79B6,H?9.;W7[J=4:NOF_VHW__[6S?\4
MW/QM:(3))_%HWBZ9/Y&6\(ZUA-=M6L*)$VZ][NG^7:5Z<ZO+FE+9NCWVGDBM
M _$46\A'T==Z&D1[QNR-=27?Z34\BK&+O,XF\FOQZ.M>IN\1877+>.7-W$5W
M=0Q=ZPOR6HD@')6T+XO^=7N\Z26R_IA+6NP?/S!3-1MONF3XZY>>G-'P8")W
MT.I+M8/@(%YUE0<SV%J>72&K^L<//62U+7Z#A]X 0,YL0&/_?6U#^)_>A=R.
M1XKFS?;4;7JXKFNDT3H!]!9L9-&?LYFWLL2E]-@H?-\8]*T@<O\A\)B8_5-!
MV*>_C<U$ E>1^<YPX)&O^Z%O]DR&+WG/3Q7_Z\53N>B'EDZBWNT/?FPUFTY.
M7K]^\V;)[J^[*:W([QQT^HX]C7KF3YY\MA!Z;!:+/\0%:9WV#F=^4$*YKWTM
MOY<%<#][2#B[])HC19HC'JWQB'O[_E%OU]_;'6QQZMO;UQ;7W2/VC_Q>=]?O
M'CVH-ONMX]2F[FN+ZS5</_ />UU_,.@]65Q?IW;7JO<_B IWDG&GFT:*SYIN
M:4/,+!=OOMIY=__;NX:$[V''MZ#D01?'MOI[@W5I:)N'(YNWHRW67B=_]E#V
M^-W!_A9K-V9'6ZR]!FM[ _]H[\@?'!T^0:S][KQAO^@^AZ.X?+):[C>XK\VP
M@'K[_EZO[Q\==;>XL=W7T\#977]_OP]*T\$69;?[>AHH"RSV<*_K'PV>KE-U
MG8K3.F.%A:)T(^Z(8Z<'ZXDG:[JO1R783:/*>R6]P[T]?W=O70[>[^P>OQ<D
MVN\/_%YOBT3?WN)K1*+^;L_O#]9E:#T!,;\1_I%SF:-*R6!.N[0U*P ;I31O
MZKXV1)GW#PZ[_F#_Z>KRVWU]9RB[ZQ\=#/R]PZ,MRF[W]310]GG?[QV!UMU?
M5VQT70>[/G'\VW2U''/#&]/7PK9NV3I9GKIITSLX] ]WUQ4/_L[N<8M$WP8H
MO]_%UXA$.YN-/NL4[:UI,QOA<[E020([\_7(-NZ<%&$'(&JI0ZUEUNM_N1=@
M;4Z*VD;M_&NSU];FV $3N=?S]_<>-1USHZ[NJ6YV2R$/0R&[_O[1D;]WL+>E
MD">^V2V%/ B%'/;Z?O=P79'B-6'<M^F0>HN)T=0XVS;VVFSKX:DNOD;[[_DA
MR*C=WN9X$>[5,_Q4$>"[P3XP(0Y[>WYW?UTFQ!8!-W_Q=?I0!WZWV_,/!IO#
M !]=H]@(E]=98W[I4PAJ;@/>:PUX[_L]$!V#PR?19&@#I<I&X=2F[FM#<!UT
M],,CO[NV:-\6U[>X_GB)3 ?]?7^PMB8/FX/KW[#?*,.Q;I@H7L7%1(]6B=1P
M737V6Q/J.\T@V"Z^V>@#:OS^_I%_M+:><D]2?]GBWX.5*FX<^CVZ VAS$Z$^
MR!!+&F7U7%Q#+WP<,?=M11"W,>L-CEGW=H%A'*ZKG<J3PK@GM=DM>3R, =_;
MW?4/>P\ZV>-!46X#];\M76WIJG^PZQ\<K:LD]1M,E6H>:;"T+^:#**_O%0\X
M?Z0+7'[:1^8+45;AP,4;[N\6!/.8'?G7?-3G^_[!X2'FTFPV=CT!T;JEDV^9
M3OI[?K=[X!_N/9;YMB64+:$\ 4+I'?K]WI'?'3R6&?<UV+5.I?+6?M'O)9M@
M4_?U@%D.WPL(M_O:HMQV7QN]KRW*V5U])_ZEX^C/JBA5Y+U^=?;I]-C[OT]0
M<]O:!1MN%_3]P?Z1?]A=5UO>S4.NS=O1%MT?SE_4Z_D'O0._?["N[K5;?]&6
M4)X@H?0&?N_PP.]N.IW<3$GD__W?_PL^# !>\CD"X.>_#W/O;_H#.:KS]?_U
M=KP+I;SW6;KSR_'QN?<F3H,TC(/$>Z>"HLI5X06SF0IR;)H>E%XY49Y*(TR'
M+R=QX45Q$59%@4T_6UZ_>G4-OE&6ECOT[Y^\N 08AB\]^NQ*(:(@/).(IKG0
MF."B92$-IV5+U-34W7U02'_X^0_EY2I$Q(N\,H-U]1SB D_W;&^_<^1-XR3!
MLT45 0!/7TYR -@4]C<I$!3PZW<T8V:WYWO];G_7]X("+G$Z"W)ZL_>L?]3I
MW>55?7A5BOF#.=R%HEWU#SJ'^E6^E^5X.WGV)9X&I4KFWM'^CQWOTT1IS#"_
MC7%((#R5Q_!4KI*@Y+WI!R*O"!(^>5;E7CR=5FDV3K)AE<2I'M1<^*#:QRF\
MX?CBY/7[L]^IL]NKL]_/?CE^I]N]X8N'<WK+JRP,O#=!&"=Q.8>?IM4H"$L^
MOVW* 7L@N/'Y=MWS 2"O%, R+6.X%]PO)E'FL4I#Y6Q]-ID7,2 M_&(6S%6.
MV](0F,$B6+\1A*&:E0'^$#==E; IVZW6/0\L@?^#!P#4!FJ%%PX1AB, MQRV
MXP'V!$F1>4,X]"@N\=34;"3PBFI8P$(E$I&%?VH!G&;Y%+XK8 78S8PG%  N
M9-5X0LO*T(*3+$E42%L\H?D%A3>LBCA51>$5:JS+4IX-.ET-LLZ=B;"-0DXM
MJH[BO"B]OZH@ISD*(\%TN)U1E8Q@<<40@Y_'.5[9=!J7M$.XM**:S0!IVL^=
MT>^ F>31#I ,((J!.@)\! P&?H3+=;QCX$: O465E+1VE,%+N>@ZI)4T"@K]
M(3>T5,W-8*I<H\9R,#LTFBM$^<@]-&,EWG 8SW QO!3@CDG";-&<+>0W VC,
M"X&%(@)GD89+EI<$ ,0K36>$E(8^6NYTU:5Y]\MT]:SV<YG5+DR8*(6'CY[7
MAH]^)5->,AK>NP*@/QMT.P/#1Q$Y[LJ/]^[PGCXRUKA8PE*#LLSC847R%]>X
MS))JJG:B/(;]-[DQL;SF"4,X>>&R9MS4[=@S<8/>7J=O#H>WU/*.5DH4IGT+
MY@-+XR:#:58)*]IU6!'*H6)!$B'M (- 2@<&"9#+1J-"E;AZX$7*LLN,DN?K
M0D-W#<6UZH(/5MXUIY9]M?*L)C+@@T4P59HL\<W>'!0>+QAG1MY%+'V N4\R
M>ALP:Y!)\--)54;95:HIOR[R8G/U;4L34MTKPWYS<YH #C8)(F_LS ]F]-GO
M[-4$<(UR=CL'"X2S%'I",+4EXBG\XU)IV=6XQ%[?T;F0Y V!:3C*13!G9L*Q
MF(78SM]H+KH$CYC61'>%HP5#V)/P=24LFY2-4HDF0&^YB@NUHV\>J ;.8.Y_
M!<[U:1MHX.!+$9Z)0A$%5D/ U/LG+%DLBK<@G,1P2-B?/C[#DOVK]/:C3O?'
M6^$[@'A_Y2_N@I(A\(SB'S^\^GC^YCP8JU=P'Y^/X3_&0@H3P DRC";&/5QF
M,["-NH[#6!M']*&UYURLUR95M_LCFDKU==]D&9SCAY_K.VPA&['3>"K4XGO>
M5].ARND /_\=;;&:T!P%@*'SG[S_\RF> M*]5U?>QPSPZ_^( "WB?X-,/<1S
MU00J,UW]$$M>^0RS9?_^-URI?>]M\#6PG<$G.T/\:"<8P7E^ DWD*I@7-;_]
MWR>Y?IZ!32:HUR4SU(&IML3EL^Y+;R+;IXS:AB'=%@'17[E7_@,@SZI+67FK
MOZH@PEMU#K.@QS1 7M=KX!(##SCBZ!\__.?9^]/7_X/]>B+UY>]_"Q9W54?N
M>[!9G0FDI\X$TM>-!MA?J3<MG73Z_+_^\[#?[[[\^%_!=/;RE/[JO7QA12F9
MOL ;GG4=WJMY^Q*UORD6NIW]&_V4="BU1(42UCX!^,$/:']17)(+PFI%^IY(
MUK(M1D?6!MP,./L.O/"S*IG1:SND8(D';/XJ+B?T^S>GQS[Z8!!J.4J-OZI8
M3C14AD^3-?O/*E6&HSXOR&,"++S7U<((;%3*L:=MCHP3!0S!DH1=\>+NDOZF
MN*8U-YYU]\',NKMG5+MN&:/%B47LVJ>KQ22B4L_:_ROE6DU::KUX5IOV1X9\
MP2^*0=O$QO.%C]B75!&;8Z@FH6<.E84@,3Z#FOE&2,T:78ST@C8<6&<I*M1@
MZ@/6B)G;]-U<*<==$:'R"%(G'L5A0+JS577QD"G)'#P(K(/:-AI!33/RMHKM
M$AH\2\VAB98U&/7YX<%P$J1C-E3P14Q12*RA6FI :/4+=#S0M+"'!AU,H8T3
MH+<%;:/+(*E4X[[B%#2Y,LOG?L.>J-\G:VWH$ IF1 ?_)I"0%TM>X!@[:% T
MM$N73;6!TCG_K4T%479E[ZB[)B!G5<W J=E_49:B>T.)NW'7FJ0^K0JTQ.XI
M!*MXF<3"L]Y$'ZY@5(ZS+&+MESPML=+/[=KG>+E2%673D,+WZ9/;Q]4L5V%L
M'&3 XIV7 4^;97D \$Y =<[KKZL]B=N[0NZ*AA1HT^2 D\?EZ;Y]FKQR1&5X
MF#\#(-LL1SZZ]!=E#BP]:6Z@5WL@+=#+PD=A'&H^I8\?1.3*+QP0+;XQ5[,
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M1&7D7<*;)6V6PC#I3A@4$T M-2V\HL)09E%WWI,/T,$55PGW-:6'[*[3 &C
MS =,R,+/.T/B/+7@!)*WY+'4E2_:42/4U(3GJEO"8$8,O"G(+;X@9H&01%5-
MHPY&?@I$#]@CKJV=6$$R+S!?F>\'/D$OH/9OB7<.N1"K@PJC4O2DA@!=8BI?
M4\I=&L$&\SG'RV1+> <6KUTDX##\$&B?W7X8LPJ&XF3K4,X]@"*[(HD3$.=-
M$:^,DQS77 $?0*:47)RH+?\-63W'SJ:8/\DT U!RLF 7R ]VE(05Q]7=?&D
M-"J$[(L/42#0@8C/_]:YZ'A(S?>;MO9*Z.T:IF+P '-^(P7,0L?J5VV5"0!^
M7E0%IH#'.D,SR.>4(B!@0)KRKP/[-)C3ZL-:AC%:((RK /,R+C&=HLE3\$H)
M[0QFN1;Y4G3S#3-J_)JV8JYPU9XIIJ)Y2XF,-L5,M$F0<BQ5OZ+$=$V];W(+
M=+R:WK]8PIN4$TI:1\P[H9T1919F#U9;M=PWXU0*;;.UR 7+Z2GDV<9E??JJ
M8E,S > 3&N,/-&,M#&-RP^[9@A.O<QW:X7V3(YT+13#^QS3B$>L= 1471G%D
M#E_8<QMZ\M',X0P4DB-#I5*'VM@CXKBAR40WNZT1>H/RJ0Q$'"H1'!/8(:%;
MJW0BQ@JWED06D=,"F*IXS4%N)8:U$Z^C>H:XK$KV[9E;POB\\^(9QD7Y)?;T
MRQD(Z=*C+ 'HD8^="$G 48A"V>2)1L$&T*RXM-M' W]J-3NOXVJ\YQ!$*99P
MP2G^\4/W!_I;JKWH[]L;S>P-<$UTK*1?-#M;[<5P5-*^K*78*!R[KU8"K1TW
MUU\ON2';N+[OZC5[VK^VRT+=7;. #6U6Q2>B@'=, :_K%/"0A8_W>2F$M _8
M$F-#$&A#MO'5>-R_+1ZWX2UQYZ>"H$]_&YMQZ2B(G\J=/S13$M%^L/]P ]]N
MW+EGF4-WC<VAO\D&4(M7\Z@=&.[Y*&MO\7S?!]C.^MSB]C+<7GM;YO4C]SHE
MW%K$V(+WRHVH;/8TM:>Z^!KGXO6 & =^K[\N@OS.;O+[0:-!K^?O'JQK</G6
M_+A#XU GF/D4Q.^FZFA/J(?O;2CX (R.W771[T9=P'9?3Q=AUS4G[<FVK"99
M=$<7WD-(H6;=PV/.N=O$+J4W=QYOX(S$>Q[9W>OM^8/#P7>+(INWHRW27H.T
MN_[NX9'?79LB];T$9QY %K7G$]>2?1_X\C9*J]O4?6V(MNGO[AWY^[OK$D8;
M=07;?3U%E'W>[_K=_J&_WUW7<+_-&<?^[4=A+I94%FRV _:I+KY65WJOU_5[
M^_O;F_SF%E\K&NT/0&DYW$9D5M@<^7@(4G+@>_W=0_C/WMZ+C?*5O5U9B?IH
M0OT>H;96C;!MWPWW &Q;7 /X<-?W\/^]V#Q6L>;#W8+O[&S1\CO>]Y:<[MT)
MOK]_Y!\->M\L63UF'.RK!Z3=J^]Q2<>!![[Q[?R^[VA^WW:NZ^;M:(ONV[FN
M#^O\Y/^]PYS+5<TG%MLE.!WDL3'3G=I,W[)SO*H-1HI-_Q<['4,ZP239E7*:
M7S5[1#5F?6G M?6(\GF@%3Q54!M [$+CR_MY'.9BKX2O;ZYXTV+ 6N,)^E&$
MS:G(-?R35^% OB1.%3H7SO[UV]GIV:?_YQV_/_5.CL_//AV_]3Z^OOCPV\>3
MUQ=WJNR_#F7*9>.TKK+\,S<5X3:<U""V?^#V]K=72HT7"M/$N;?O]KNE/NEF
M+ )UFL!;I'_@H!(@;>J40&V\CAHCWY[UG2E>A&UAB"V*<9)*J."W@"ZM;;@T
MPE 79<#$)#9-:WA*P;[;Y;J!Y<W#!Z5W"LO17 O=)U*&?-9&&*R B#O5[380
M.73/3PU@%@&@I^79<6?Z]&W]R99"Y,AND=I/48</TX<ZH,XTU50:[41J%(<R
M:6UPZ#9$+F*9:8HM:F33B%&I&G,[$+?9" VRM -4I8/<P0(.+#:V6\6Z]/%K
MK3%PWD&!XS5A#\F<.VX^VSMJ@/=9K]=OZ=6++$XOLX@*LD2OOH0%XJBB'SK=
MONBPETI:K01%Z8W4E:QBL<BTY44>J'LI(89(CUQJ?V>[176\#W8F*'8"I<;G
M!&X9"20]=W%LH8.JP+!CY+39Z*?;-%7;=@G]ZBZA1]LNH1O?)?1FS7%D^Z<7
MYV_> N/_1)UK[MPRIW8YU_;/N7V'G/H-[ V(\EPUHE6-7?Z&'MU"4QL'6G^)
MAMIAO[^_RE*KORNHRFS9NQ:U\I]1Y<0Q!]+J"[ED'EQ9]N>,=.+&8^ZW!4@E
M')"  X! [M.<"6RT1;VE0F2ZU4PW=6P=^?WRWG3_+9IM-)J]EKDERR=:;5'A
M.T$%/9F@-MC1G8>+&MNPBI,HJTINBZD'; 72%''E7#Y\&G^%*AN/OJQFXSR(
MY"OLOQFB!FBG G)'U_K(YBTZ?B?H*+-=G"E\B"7U@8-ZFMX6*;X3I#!%73)T
M!"W%[>5_)Y?_SDPT \48),=4!(>9$+=T&MP61;X3%*FI"NY\O?I44",W\*\M
M;GP?N'&2I30Z#OB'F23>G$:>Q"F^RRO9BD9U%<7,F]/C'9I$A./JX'_P/45G
MC?&QGVMM^LE=FD8[9;:C4K,AFIX[#S'.!'@CDPV6>Q"T;B\<$T>XZYF@(YQ'
M.K%'!=T\]<K@,[;$+Z^P+3;V!F<SL=?7SFJ E1F5D,R])$O'*O<%U@A=ZE,=
M\"@%'2@0+_T2UX:&&WLXZLX*>PX>19".$QXM$<4%7"O"M[C?+OA_\)3.L.3A
M"%?8,CM)=)=N'>'CT:Y@+F%C[A%&$VADAAV9+3"5^3 4Y LG-'.!8W\<OIA[
M\'R<L-&EQG&:2M"EW^T/R 4O 8\$?>9  ?$,%O4]+M2H9J(@P2O_Y-'D>CV:
M].F8>#Z=QD :?J,C*>AA]Q?#-\NB-02,H7)/#6?#&$$C0L!Q*;/[D.D2&["7
MD]RTJT?,EAFP!38:CQIS;@8^1GVN)G$X881WAE=<F=V,<7Z&<RF &7$]6D.$
M8HYO-BGCPH64,#1,_?QIZKH .4MMC_P@Y!D7[NQZ!$48RM ] JRE-CVFEIJN
M2W3%!J)M5$0S&S,T"""O9@9'Y*EX.JU2Y8V3;%@!"[._ @C-)O,"KB- N .*
MQ!R"P^D:<X4[=LCL:J*(T.!;1&I:KBBJZ8P#.QS4I9D,K:A56-PJ9!A(F.4X
MZ:+CG8WP4O"C*M648M!^\4XDF+Z ^!3'I1D/2GK]!S&0O#/LT,0V82OQB">N
MZ,]BGDP17 9Q0IO@X4_F^'$$%Y&K(/(2,[,1(YYECHH$0<T=56"F&!?F/H@Q
MA-2\GZ=0VEC7R8??STYW>D< >(#C- X164;<RA_]M-A:7_KVY\+P!*L #/-,
MJ B5W3Q+#!QX7$$&AE 28-"UPHD*";Y"X="%%'&^D'E]=104%5D?7B-D9G .
MWGFIDHQ=-3C<^U*B<6UW:0C,H?XV#G?SJZ8;O.Z:#1PB%<+M$20R.+#A)+-J
MF,0AGPKX%&Q0XHP9CMO R3.&]/7L2CTD"X>-Y/K][&\ +,"4#,#J64:G14]7
M,)2T!WP<%@/LQV,$>8Z\ J'7D9'.GQSB=LZB=Y0W Y\^8C#<.*DXE!%00RT<
MK1TG%4]@SWB@%Q;K3;($"+7@'!*:J TT@'=1\@@:G*7#<L#(:PV$484R06,V
M@"RL80YR/%Q!@QPS/.Y7QC*D^+_'I^^.C75'ZHJ, 4+9BG.6%'/ )4.B-0K0
MB))TG%&>3#K60ZR(\];'37.B#S"PQ-SHB*&U@UD[G/9 T\FKE'V:H%H!:\ A
M'*!V.G@!D /=!K:'&B2>XSZAM*C5?V@.K?6]YWC3,G3LUV .6.V=)!EAYBGL
MT$P@NV), )7-#(4#-0UX7T"Z&>$]CWQ%S#_A27'XBU] &@,7G'O'XUPQ2-O6
MY!^89^RZ"'YYZ$)/7G_[]MQ,2N/O]/-\-?R91M;FNY%Q72(/EYE-,MV.Z G9
MB,JGH)4&J1WV2Y-W[.!@JZ15,YZ(?>#.'EQ^/&UQVEF^Z#3/./G >QZ_0 0Q
MR],LWXSG>K5<C1[YU;:O9[V];F-'&AK+[]I["ZO:K>'E/8]I3R0U,.L%]6^[
MP54;Z%\#D5-YY2F^TEE89[2-6<4P4PF7[9=95?W=^'EA,>*\RHLJ8#43TW@
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M-+'=KM3W8XB[7PLHK_YU,TBYSU&)1< YZA)P"E2%R-'08H:C0816 04RIC/
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MK3-\K@ZC7'_2R4%H249I0Z35JRC0Q)%6;%*^CDZ$A8)XYHKP_(TDC6]?YT*
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M?JV?T]\+C!YY#)5C^V_4SN\T:.J^#M/&0_;WNOY>]^C)HM8C2K MG7P_=#+
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MK[2C(= 6CS(;<)9ON4XM1N*\*)LH(SF19"$M[?@9CT0^F;)R$F!4S)A@"U'
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M8%C$132%,+LN )<<J%?:IX<0KP",P##@QSQDYICV'T(6FF;Z=_PV&M=+-AJ
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M@YX +3)"N'Y[$'0RN H'B>0U:8. #$]+U[D6QQ!PF6:*-'4!LQF7=[J^="B
MJ9\HQQ@SE!%8Q 7+%[*G+.)VJ5;(N^@S6^F'.<*:()'!8=^>!#1JC=F$-BO@
M13AEH9A;>]D6*1;-N,KC\YLP 5=PR$SKJRJZ?9U2#ECCO66[*1\W>#''Y))*
MN&:*4"B2&D 0#-$-HHWF4"8?O2R?JV^ST,)4\/CER8)MT%S5&!UB@L- [FG
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MRCO'?83B4IK?U(F-PH<6%?1(,[$$&+W3UY%O20(-W21*IN;Y0QZ#J.%*A1+
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MT8?NCE6R%*Y/<.*UI<])Z+MGE"^S\7,-2L_P%/E.?1KI\='I1I8"X8=WYYW
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MX:)T6-D_;TGS#?.++"SN9%WX6DM-"WEUTA?^LCL_.Y]D>^<U:8I9ZF'H[](
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M$R-7:&+=H[#'(7]$*RP3.<15B@DTUKA=+E9#%&NZM>'M)%,HUC3PX,D*0(%
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M]O@'->]$I9 .YGILY "/1H-38NGHW3C&)EAY?YVY8VP.6K;L>5%1#@^PK<E
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M&CQ(<=.0N#E+I@G:.O0SLV&"_0"@7P1*Z,^_39=A9%JZPH!J$&(%@I$<!@8
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MD(DTOWEG^4:N@]BJ#K.O'EX;6[WYV>_A\@\259)@2B->OL?BHW-GC6PVHLB
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M#79!8@(OWBQW[\<E##'R^J\ZS+#I8_DLXQ-RJ>>8VZ!.Z,#P?0M+>).K$!]
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MUAA+KE!U<#>\! =QIZE0T&Z2;:GVA>RHA-: R5+G3!A4EQ5 7)RN)"E:H=5
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M[O+S(%@!]7[A,VD^20&Q\95/L7?''4?0:E4*0M2,&Z#U4_21,0NIL'#(0IR
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M*<UF$*A9))\2QHFNYH0%:)ND1+GN/QW+8N#<J66BH5%)1+#L:<1K'3<<*21
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MCHX!B>,#2+%;^$$<O><CXD[D$34ANT/^\\\G,7<5GCJ[-%L@"(O[]C_=Q)=
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M.K:A*,O'LKHJLE28!3C;V_,ZPT>1<YEL;!6T@9*C&E;Y1%:A0FE$TFXH.Y6
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MWADY_7UELL^&N+5,OG'7]VDRRQ:KYVJJ-X.=0&XOD =?1(/"OD6T<9'=N:]
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M<="<XL)7&<7<#?.T7MWQ4!A1T]QU=@Y7B4!!R*8P7O#=RYZA$R8#YOB^2/S
MPR0Z2)V!!U<)8'?P'?/2KP?8Y-L!=NL4M(';K4=N#U^ _+7DB$IJ5&%C#D*E
MTEC[(52IYBN4 ) E360FRR4RTS:SK;S4(LR"I]X0[HU=*R8M.[AI9CBO]!S
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M/PB24+B!PP>4^U$@XI /7#\03OB%PKHVBU__971N0&9U]94C/D3C[2';7O)
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M*'RY4>4$1VQG()S%I&B&MFJ)X\99QEE*YZOSLGU@ZP5A+XP2D06\'X51$,-
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M+3(P,C,P,S,Q+GAS9%!+ 0(4 Q0    ( !2(JE:XUBIO? \  *+3   5
M          "  :@2  !A9&UA+3(P,C,P,S,Q7V-A;"YX;6Q02P$"% ,4
M"  4B*I6B7)/MU$Y  #3W , %0              @ %7(@  861M82TR,#(S
M,#,S,5]D968N>&UL4$L! A0#%     @ %(BJ5D?ND0L@K0  67(* !4
M         ( !VUL  &%D;6$M,C R,S S,S%?;&%B+GAM;%!+ 0(4 Q0    (
M !2(JE;AB,N>J5L  (XI!@ 5              "  2X) 0!A9&UA+3(P,C,P
M,S,Q7W!R92YX;6Q02P$"% ,4    "  4B*I6[/I9>EF4 @#*I1@ %
M        @ $*90$ 8G)H8S(P,#4R-3@S7S$P<2YH=&U02P$"% ,4    "  4
MB*I6:-0M_$P)  #@+P  %P              @ &5^0, 8G)H8S(P,#4R-3@S
M7V5X,S$M,2YH=&U02P$"% ,4    "  4B*I6"DB^EE<)  #=+P  %P
M        @ $6 P0 8G)H8S(P,#4R-3@S7V5X,S$M,BYH=&U02P$"% ,4
M"  4B*I6K]]@= 8%  #Y$0  %P              @ &B# 0 8G)H8S(P,#4R
M-3@S7V5X,S(M,2YH=&U02P$"% ,4    "  4B*I6SZ7.50H%  #=$0  %P
M            @ '=$00 8G)H8S(P,#4R-3@S7V5X,S(M,BYH=&U02P4&
/  H "@"A @  '!<$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
